



# 2025 Annual Report

# This is Getinge

~12,000

Employees

SEK 35 billion

Net sales 2025

~30,000

Customers

>135

Sales to no. of countries

At some point in life, everyone needs to seek care. We have a long tradition of creating innovations that improve people's quality of life – and save lives. It is one of the most important jobs in the world.

As the world's population grows and ages, and the number of people with multiple illnesses increases, so do the challenges in healthcare. Lifestyle diseases, such as cardiovascular diseases remain among the leading causes of death globally, requiring more effective and comprehensive care solutions.

At Getinge, we work globally with a shared belief that all people and societies should have access to the best possible care, with as little impact on the environment as possible.

By offering hospitals and life science institutions advanced technological solutions and expertise, we not only contribute to improved clinical outcomes, but also more efficient workflows and reduced resource utilization.

The aim of our work is to save and improve lives by making life-saving technology accessible for more people.



# Contents



## Welcome to Getinge

2025 in brief	4
Words from the CEO	6
Getinge as an investment	8

## Business areas

Three business areas	21
Acute Care Therapies	22
Life Science	26
Surgical Workflows	30

## Other information

The Getinge share	199
Multi-year overview	201
Acquisition history	204
Reconciliation of alternative performance measures	205
Group companies	208

## Market environment

External trends	10
Growing market	12

## The Board's Operating Reports

Administration Report	35
Corporate Governance Report	56
Sustainability statement	73

Definitions	211
Annual General Meeting and Nomination Committee	213
Financial information	213
Reading guide and distribution policy	214
Contact	214

## Strategy

Global value creation	14
Strategy for sustainable growth	15
Targets 2024–2028	18
Sustainability	19

## Financial statements

Consolidated financial statements	139
Group notes	144
Parent Company financial statements	181
Parent Company notes	185
Auditor's report	191

### About the report

Getinge AB (publ)'s formal Annual Report and consolidated financial statements comprise the section Financial statements on pages 139–143, except for the Remuneration Report on pages 52–55 and have been audited by the company's auditor. The Corporate Governance Report comprises the section "Corporate Governance Report" on 56–72 and has been examined by the company's auditor. Sustainability information is integrated in the section "Strategy" on pages 14–19 and in the Sustainability statement on pages 73–137. The statutory Sustainability statement is defined on page 73. The auditor's limited assurance report on Getinge AB (publ)'s Sustainability statement is presented on pages 196–197. Getinge has used artificial intelligence (AI) as a tool to assist in text production in parts of this Annual Report. Final review and approval is carried out by company employees to ensure accuracy and relevance.

# 2025 in brief

## Q1

### FEBRUARY

Launch of DPTE®-FLEX – a manual, externally openable port that enhances safety, efficiency, and regulatory compliance in pharmaceutical manufacturing.

### MARCH

Paragonix Technologies, which was acquired in 2024, has had five of six organ transportation products approved under the EU MDR – a milestone in the ongoing expansion outside the US.




### MARCH

According to Newsweek's latest ranking, 250 of the world's best hospitals rely on our solutions to deliver world-class care.

### MARCH

Launch of Neural Pressure Support (NPS) to help clinicians to improve patient outcomes by offering lung and diaphragm-protective ventilation.



## Welcome to Getinge

→ 2025 in brief

Words from the CEO

Getinge as an investment

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

## Financial statements

## Other information

## Q2

### APRIL

The Heart Surgeon's Cookbook campaign won multiple prizes in 2025, with international awards from both The One Show, D&AD as well as Sweden's Gold Egg Award for creativity, craftsmanship, innovation and PR.



### JUNE

New rooftop solar panels on Getinge's production facility mean that 99.9% of the site's energy comes from renewable sources.

### APRIL

We won the Swecare Export Award 2025, a recognition of our international growth, innovation and profitability.



### APRIL

Ulrika Dellby elected new Board member.



### JUNE

Servo-c is extended with a neonatal option transforming the ventilator into a universal solution for all patient categories – from premature newborns to fully grown adults.



Q3

**JULY**  
 A new partnership with Zimmer Biomet means that Ambulatory Surgery Center (ASC) customers can now access Zimmer Biomet's best-in-class implants and surgical robotics and our infection control and surgical portfolio.



**JULY**  
 Our iCast covered stent system receives FDA Premarket Approval for bridging indications, increasing the potential to treat aneurysmal disease in the US.

**AUGUST**  
 EU CE mark for the Cardiosave intra-aortic balloon pump is reinstated.

**SEPTEMBER**  
 We enter into a partnership with Philips to offer hospitals integrated anesthesia workstations for operating rooms.



**Welcome to Getinge**

- 2025 in brief
- Words from the CEO
- Getinge as an investment

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**



Q4

**OCTOBER**  
 Our Advanta™ V12 is approved for major bridging indications, marking a milestone in complex aortic aneurysm treatment.

**NOVEMBER**  
 PiCCO, our minimally invasive hemodynamic monitoring system, is now included in the European Society of Intensive Care Medicine's Guideline on Circulatory Shock.

**NOVEMBER**  
 Launch of modern interface for our new generation of cGMP washers and sterilizers.

**NOVEMBER**  
 Launch of washer-disinfector Aquadis 44, which helps healthcare providers decrease their environmental impact by automatically adjusting the amount of water and detergent.


**NOVEMBER**  
 A new version of Solsus 66 Steam Sterilizer is introduced – designed to meet the evolving needs of Central Sterile Supply Departments.

**DECEMBER**  
 Launch of Automatiq, the new family of next generation automated solutions that combines smart robotics, intelligent conveyor systems and advanced software to achieve safer, more consistent and less labor-intensive sterile reprocessing.



# Words from the CEO

Interview with  
Mattias Perjos,  
President and CEO  
of Getinge



## Welcome to Getinge

2025 in brief

→ Words from the CEO

Getinge as an investment

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

## Financial statements

## Other information

# “Another record-breaking year for Getinge”

2025 was largely defined by navigating geopolitical friction, yet it was also another record-breaking year of strong growth and underlying profitability.

## 2025 was marked by significant geopolitical changes. How would you summarize the year for Getinge?

For us, it was a year in which our strategy, global footprint and our way of working were put to the test and showed their strength. Healthcare systems were under pressure from demographic changes, a shortage of resources and rising costs. In this situation, it was crucial for us to remain committed to our purpose and our long-term direction. It was gratifying to see that customers appreciate our solutions for their clinical efficacy and see us as a customer-centric partner. Internally we made significant progress on achieving regulatory milestones and productivity, and continued the sales rotation to more consumables and high-margin products. Despite a combined headwind of just over SEK 1 billion from currencies and tariffs, we delivered an unchanged adjusted EBITA margin for the full-year, confirming a strong underlying earnings trend. For example, the margin, adjusted for currencies and tariffs, would have been 16% compared with the reported 14%, which means that we are already at the start of the range we provided guidance for until 2028.

## What were the particularly important areas to focus on during the year?

We continued to focus primarily on three areas that are vital to our long-term success: quality, innovation and customer-centric partnerships. By enhancing our processes, offering high-quality solutions and continuing to develop our delivery capacity, we are building trust with our customers, which is absolutely essential in our industry. Examples of regulatory compliance milestones during the year include the CE mark being reinstated for our intra-aortic balloon pump and we also received PMA approval in the US for larger models of our iCast covered stents. Meanwhile, we have continued to invest in innovation, and launched a number of new products that improve care flows, boost productivity and contribute to better clinical outcomes.

## Healthcare solutions are in high demand all around the world, but competition is intensifying. How does this affect Getinge?

This means a greater need for us to truly understand our customers' needs. Several studies show that hospitals primarily need support in

# “We continued to focus primarily on three areas that are vital to our long-term success: quality, innovation and customer-centric partnerships.”

increasing their efficiency and productivity. This is where we already command a strong position that we can build on in both hardware and software solutions to streamline care flows and shorten waiting times. Furthermore, trade barriers and tariffs are placing higher demands on maintaining robust supply chains and a clear regional footprint, which is why we must continuously evaluate and optimize how we reach each market. In a more competitive environment, our customers are seeking out reliable partners who combine a global reach and in-depth market understanding. It is important that we succeed in applying our global customer offering and the know-how we have accumulated over 120 years, in a way that is relevant to our customers in each local market. Another key to success is establishing strong relationships and the ability to adapt to different regulatory and market conditions, without compromising quality or delivery reliability.

### What are your take-aways from last year?

A key lesson is the value of persistence and focusing on the basics. In a changing world, we need to continue to grow sustainably, simplify our work processes and optimize our productivity so that it generates tangible results. We saw during the year how well-defined priorities and a common focus create momentum in the organization. Our progress in regulatory compliance, which went according to plan, is a prime example of this.

We also learned that cooperation, both internal and external, remains vital. It is a central part of how we conduct our operations, and is key to managing uncertainty, while building stability and long-term development.

### People and culture are often mentioned as an enabler. How important do you think these two factors are?

Our employees are crucial to Getinge’s development and success. It is their commitment, skills and responsibility that make all our progress possible. Even though 2025 was challenging in many ways, it is particularly pleasing to see an increase in our KPI for employee engagement. By working together, sharing knowledge and taking clear ownership, we are continuing to develop as an organization and are well equipped to face future challenges.

### What is your view of Getinge’s role in society?

Getinge has a very important role because we operate in a sector that is essential for both the development of society and human well-being worldwide. To give just a few specific examples, more than one in four operating tables around the world, in terms of value, is manufactured by Getinge and used in more than 20 million operations every year. Our ventilators and anesthesia machines help more than 13 million

patients a year, and in Life Sciences, our new washers use a third less water and a quarter less energy. Healthcare and life science are important growth areas and yet also crucial for ensuring access to high-quality care. Our role is to be a trusted partner and provide solutions that save and improve lives. I think that is a fantastic and meaningful job.

### Looking ahead, what will characterize Getinge over the next few years?

We will continue to be defined by close cooperation with our customers, and a high degree of innovation and quality in everything that we do. When we combine this with simplified work processes and internal productivity, we create the best conditions for sustainable profitable growth. This is how we will strengthen our market position and deliver even greater value to healthcare, the life science sector and the people who are ultimately affected by our solutions.

## Welcome to Getinge

2025 in brief

→ Words from the CEO

Getinge as an investment

## Market environment

## Strategy

## Business areas

## The Board’s Operating Reports

## Financial statements

## Other information

# Getinge as an investment

## Market leading position and close customer relationships

Since the company was founded over 120 years ago, we have built-up close customer relationships and developed innovative healthcare technologies. This has resulted in leading positions in most product segments, a high level of customer loyalty and strong competitiveness.

## Growth potential in a stable market

Demographic factors suggest a rising global need for effective healthcare. Our growth strategy, focusing on the product areas that have favorable prospects and a larger share of recurring revenue at high profitability, includes both organic and acquired growth. The healthcare market is relatively unaffected by economic fluctuations, which contributes to stable underlying growth.

## Focus on improvements and sustainability

We conduct continuous improvement activities to increase customer value, sales, margins and cash flow. Sustainability, focusing on quality, business conduct, engaged employees and sustainable innovations, has top priority.

## Long-term ownership and value creation

We have a robust shareholder base with a long-term perspective, with our largest shareholder holding more than 50% of the votes. This contributes to stability and creates the conditions for continuous value creation for our shareholders, customers, patients and society as a whole.

The total return includes both price growth and dividends. An investor who bought shares for SEK 10,000 in connection with the 1993 listing and reinvested the dividends had increased the value of their investment to SEK 486,400 by the end of

the year. Our return for 2025 was higher than the cost of capital, which means that we generate added value for our owners and increase our scope for action thanks to a financially stronger position.

\* Rolling 12 months adjusted EBIT/Capital employed. Capital employed is defined as average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.



4,764%

Total return from the initial public offering in May 1993

3,363%

The total return on the Stockholm Stock Exchange over the same period

11.0%

Return on capital employed (ROCE)

## Welcome to Getinge

2025 in brief

Words from the CEO

→ Getinge as an investment

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

## Financial statements

## Other information

# Market environment

---

External trends 10

---

Growing market for our products 12

---

# External trends

**Welcome to Getinge**

**Market environment**

→ External trends

Growing market for our products

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

## Agility in a changing world

We operate globally, and although the conditions between markets may differ, many of the external influences are the same.

### Market requirements

**More cost efficient healthcare**

The need for accessible and sustainable health-care is increasing with a growing global population and longer life expectancy. Technological and digital innovations are crucial for meeting rising demand and they can be costly. Global challenges such as conflicts, trade barriers, supply chain challenges and inflation are putting further pressure on funding for the healthcare sector.

### Our solutions

We are addressing these needs to create effective care solutions in close cooperation with our customers. More patients can receive help from the clinical performance of our products. We support purchasing organizations and hospitals by offering attractive procurement terms and customized financial solutions. This facilitates improved quality of care and lower costs – without compromising patient safety. By also promoting

out-of-hospital care solutions, for example, ambulatory care centers, we are helping the healthcare system to become more efficient and increase accessibility.



## Market requirements

### Attract and retain skilled healthcare staff

The shortage of healthcare workers is growing and physical and mental health problems caused by long-term stress represent a significant challenge. Increasing focus on efficient workflows and a sustainable working environment is a prerequisite for attracting and retaining skilled staff.

### Digitalizing healthcare

Digitalization is revolutionizing healthcare with technologies such as telecare, AI, 3D printing and robotics. These innovations are paving the way for new business models and personalized care solutions that make healthcare more efficient and accessible.

### New customized drugs

Biopharmaceutical innovation is rapidly progressing towards personalized medicines, which requires specialized manufacturing processes that can be adapted to the unique needs of patients.

### Sustainable solutions in medtech

The world is facing increasing demands for resource efficiency and sustainability, and this also represents one of the most critical challenges for healthcare.

## Welcome to Getinge

### Market environment

→ External trends

Growing market for our products

### Strategy

### Business areas

### The Board's Operating Reports

### Financial statements

### Other information

## Our solutions

Our Hospital Transformational Partnerships and Digital Health Solutions initiatives includes verified solutions to increase the productivity and well-being of healthcare professionals. Our innovative products and services relieve the burden on healthcare professionals, contributing to a more sustainable work environment and a lower risk of burnout. We want to improve the conditions for healthcare professionals to work effectively and safely.

We are developing digital ecosystems together with partners, focusing on integrated solutions for advanced care. For example, we offer systems for streamlining hospital flows of equipment and patients, and have designed products that enable remote monitoring of patient vital signs.

We are contributing to this development through solutions that ensure biopharmaceutical processes and prevent contamination. Our advanced bioprocessing and cell and gene therapy technology help pharmaceutical manufacturers in meeting strict regulations and optimizing production. We aim to be a key partner in the development of the next generation of medicines.


Sustainability is integrated throughout our value chain, from research and development to recycling. Our operations are based on environmental, social and ethical responsibility, with guiding environmental, social and governance (ESG) policies. We aim to be a long-term and responsible player with sustainability as a core component in our high-quality products and solutions.

# The market is growing despite geopolitical tension and trade barriers

With a broad portfolio and a leading position in a number of product categories, we are working together with customers and partners to provide all people and societies with access to the best possible healthcare.

## Our largest sales markets 2025

Our ten largest markets represented approximately 75% of total sales in 2025.



**Welcome to Getinge**

**Market environment**

External trends

→ Growing market for our products

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

## Progressive products and continuous profitability measures

Although geopolitical instability and new trade barriers in recent years have negatively impacted hospitals and their patients in the form of higher costs, the market's annual growth is deemed to be 3–6% and the need to increase productivity and more sustainable healthcare is greater than ever.

We address these challenges with a broad portfolio in which solutions are becoming increasingly connected to facilitate the care of the future. When it comes to trade barriers such as tariffs, we are well prepared for a variety of different scenarios and are taking continuous action to counteract the negative effects on profitability.

## Available in the top ten hospitals in all markets

We have a leading position in most product categories of our three business areas. Our solutions, which reach approximately 30,000 customers in 135 countries, are represented in the top ten largest hospitals in all markets. Our unique position in many growing segments presents many opportunities to continue our expansion.

## Ambition to continue to grow in the US

Competition differs between each business area and product category. Just like us, most of these competitors have long experience in the industry, substantial size and market presence for their specific product segments. Several of them primarily operate in the US market, which is a relative strength given that the price levels and margins in general are higher, even including headwinds from current tariffs and currencies. This concentration to the US is largely due to historical reasons, since many of these competitors have their roots there. Getinge was founded in Europe, but has been growing faster in the US than in Europe for a long period of time, for example, through acquisitions, and our ambition is to continue on the established track.





# Strategy

Global value creation	14
Strategy for sustainable growth	15
Targets 2024–2028	18
Sustainability	19

# We exist to make life-saving technology accessible for more people

and create value for customers and society

At Getinge, we strive to contribute to more sustainable healthcare with optimized use of resources, improved medical results and reduced waiting times. Our ambition is for everyone to have access to the best possible care.

to conduct our business...

Own operations 

To evolve our business and achieve our financial and sustainability targets, we depend on the expertise and diverse perspectives provided by our approximately 12,000 employees. By ensuring employee engagement and an inclusive culture, we can unlock their expertise and dedication. This is a basic requirement for achieving our ambition of delivering the products that lead to improved outcomes and more efficient healthcare.

We use resources...

Resources and suppliers 

Depending on the product, we either purchase raw materials (mainly metals and minerals), processed materials (for example, plastics and electronics) or parts of products. When developing our supplier base, we evaluate a wide range of sustainability factors based on impacts, opportunities and risks.

## **E** Environmental impact

Carbon emissions arise throughout the life cycle, from raw materials and sourcing to production and use of our products. Energy consumption, water use, material extraction, material use, and waste also have negative impacts on the environment in our value chain.

Customers and society



### Healthcare

By supplying products and solutions to hospitals and life science institutions in over 135 countries, we improve efficiency and reduce the use of resources. This benefits both customers and patients.

### Patients

We want to make medical technology available to more patients, and work actively to increase the number of lives saved and the number of operations performed per day per hospital. We are also striving to reduce the time to bring new medicines to market.

### Society

Our products and service offerings support the healthcare sector's mission to save and improve people's lives, which benefits both patients and society as a whole. As a large global company, we also create jobs and develop skills of many employees and professionals. We comply with laws and regulations in the countries where we operate and tax income from our operations helps build and develop societies.

### Employees

Engaged employees are critical to our company's success. This means that we work to create the best possible conditions for coworkers to thrive and reach their highest potential. We offer skills development and have a global approach to family leave, which set out a minimum standard offering for paid parental and caregiver leave.

### For owners and lenders

It is important for us that the capital contributed by owners and lenders leads to an attractive risk-adjusted return. With good potential for growth and long-term close customer relationships, we create value for our owners and lenders.

### Environment

We work actively to reduce negative environmental impact by setting ambitious targets, carrying out improvement activities and collaborating across the value chain with suppliers, customers and other stakeholders in the pharmaceutical and healthcare industry.

## Welcome to Getinge

## Market environment

## Strategy

→ Global value creation

Strategy for sustainable growth

Targets 2024–2028

Sustainability

## Business areas


## The Board's Operating Reports

## Financial statements

## Other information

# Strategy for sustainable growth

During the year, we continued to develop our strategic focus areas to create value for all stakeholders. Our ambition is to ensure long-term profitable growth. This is only possible if our customers believe that we have an offering that enables the best possible care. Our strategy to achieve this is based on the three focus areas of quality, customers and innovation. These in turn are enabled by our people, responsible business, productivity and financial performance.



## Strategic enablers

We will achieve this thanks to our people, and by working productively and in line with our sustainability and financial ambitions. This will allow us to further strengthen our leading positions in the market.

- Employees
- Responsible business
- Productivity
- Financial performance

**Welcome to Getinge**

**Market environment**

**Strategy**

Global value creation

→ Strategy for sustainable growth

Targets 2024–2028

Sustainability

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

## Our vision beyond 2030

**Acute Care Therapies**

**>38**

lives saved per minute\*

By strengthening our leading offering in acute advanced heart & lung therapy and cardiovascular surgery.

\* Lives of critically ill patients saved.

**Life Science**

**-25%**

shorter time to market for new, complex medicines

By being a key partner to the institutions focused on developing solutions to complex and previously incurable diseases.

**Surgical Workflows**

**>1**

additional surgeries per OR per day

By strengthening our offering for the operating room and in the central sterile supply department, we help increase productivity and reduce the risk of healthcare-acquired infections.



## Quality

Achieving the highest level of quality is not merely a prerequisite for us to operate. We are conducting extensive quality efforts, concentrating on patient safety, and are convinced that it will be a competitive advantage for us in the future.

Quality beyond 2030 includes:

- We no longer have a Consent Decree with the FDA, we are continuing to deliver high-quality products that benefit patients, and we work even more closely with authorities to set the standards for the future
- Our extensive quality efforts make us one of the most reliable medtech suppliers, resulting in productivity gains and sustainability benefits for both our customers and for us



## Customers

We already hold a leading position in the majority of our product categories. Our solutions reach approximately 30,000 customers worldwide, and are represented in the top ten largest hospitals in all markets. We are endeavoring to advance our position further.

Customers beyond 2030 includes:

- We are an acknowledged and preferred partner for our customers thanks to our comprehensive offering and our first-rate service and advisory support
- We have successfully launched new offerings, leveraged our global reach, satisfied needs in our main markets and served many of the needs in emerging markets
- We help customers meet their environmental requirements by offering traceability and product-specific information. At the same time, we are continuing to reduce the negative impact of our products on the environment and surroundings



## Innovation

We remain relevant to our customers through continuous innovation. This ranges from optimizing internal processes to developing revolutionary new therapies and solutions. Historically important launches such as Servo ventilators and DPTE-BetaBag® clearly demonstrate that innovation is part of our company's DNA.

Innovation beyond 2030 includes:

- We have carried out successful launches under our innovation and sustainability strategy and are ensuring a strong roadmap moving forward
- Attractive digital solutions are an integral part of our offering and provide us with competitive advantages
- We have intensified our proactive M&A strategy to further strengthen our innovativeness
- In all innovation projects that involve the use of limited resources (such as water, electricity and minerals), we work strategically to reduce our impact and use these resources efficiently

**Welcome to Getinge**

**Market environment**

**Strategy**

Global value creation

→ Strategy for sustainable growth

Targets 2024–2028

Sustainability

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

**Welcome to Getinge**

**Market environment**

**Strategy**

Global value creation

→ Strategy for sustainable growth

Targets 2024–2028

Sustainability

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

 Enablers

**Employees**

Our approximately 12,000 employees are our most important asset. Employee well-being and engagement are the keys to our success. This is supported by a motivating work environment and competitive employment conditions, including parental leave.

Employees beyond 2030 includes:

- We continue to be regarded as an attractive workplace that successfully attracts top talent and continues to score highly in our employee surveys
- We act based on three mindsets: Team players, Forward thinkers and Game changers

**Responsible business**

Ensuring responsible business conduct throughout the value chain by implementing programs focused on anti-corruption, anti-trust and compliance with healthcare regulations is of the utmost importance to us.

Responsible business beyond 2030 includes:

- We continue to advocate for fair and transparent business practices in healthcare systems, particularly regarding public procurement processes in emerging markets
- We continue to leverage our risk-based approach to implement and improve our ethics and compliance programs
- All our employees have undergone appropriate business ethics training and state that they have the know-how and mandate to make responsible decisions

**Productivity**

Increasing productivity has been necessary to handle inflation in recent years. Our customers are under more pressure than ever to deliver more and better care with limited resources. This is where we play an important role.

Productivity beyond 2030 includes:

- Continuous improvement of our operating model and processes to become the most customer-focused and profitable business possible
- Continue to help our customers achieve more cost-efficient patient flows based on the leading clinical performance of our solutions and enabling resource savings

**Financial performance**

This is the consequence of how we manage the other elements of our strategy. If we implement it well, the results will follow.

Financial performance beyond 2030 includes:

- Having average growth and profitability at least in line with the market
- We have a balanced capital structure
- We are considered an attractive investment in both the stock and bond markets



# Targets 2024–2028

## Financial targets

### Average adjusted EPS growth

**>12%**

Adjusted earnings per share declined -3.7% during the year, mainly as a result of tariffs and currencies.

Dividend policy

**30–50%**

of net profit for the year

Dividend for  
2024 fiscal year

**SEK 4.60**  
per share

(76% of  
net profit)\*

Proposed dividend  
for 2025 fiscal year

**SEK 4.75**  
per share

(57% of  
net profit)\*

## Sustainability targets

### Engaged employees



**>70%**

Employee engagement

### Excel in quality and responsible business



**<1.5**

Audit findings/quality  
system audits



**>90%**

Percentage of employees  
who completed training  
in business ethics

### Sustainable innovation



**-90%**

Reduce Scope 1  
and 2 emissions by  
90% by 2030\*



**-25%**

Reduce Scope 3 emissions  
by 25% by 2030, and by 90%  
by 2050\*

Outcome 2025

**73%**

**1.4**

**92%**

**-54%**

**-7%**

\*Base year 2021

## Welcome to Getinge

### Market environment

### Strategy

Global value creation

Strategy for sustainable growth

→ Targets 2024–2028

Sustainability

### Business areas

### The Board's Operating Reports

### Financial statements

### Other information

\*The dividend for 2024 and the proposal for 2025 represented a departure from the policy of distributing 30–50% of net profit. The reason was the favorable cash flow generated by the operations.

# Sustainability

Sustainability is an integral part of our strategy. We want to contribute to a future in which healthcare is better, more efficient and more accessible.

Our sustainability approach, which describes our efforts to reduce our impact on people and the environment, is centered on three primary areas: **Excel in quality and responsible business** together with **Engaged employees** are the backbone of this approach. **Sustainable innovation for better health** is the driving force that lead our sustainability activities forward.



## Excel in quality and responsible business

Acting responsibly is at the core of our way of operating. We do this by ensuring a high level of quality so that our products deliver what they are meant to over their service lives. It also means that our operations are conducted in compliance with regulations and ethical principles throughout the value chain.



## Engaged employees

Engaged employees are vital to our success. For this reason, we endeavor to create the best possible conditions for our employees to develop and achieve their full potential. Besides focusing on the health and safety of our employees, we also strive to ensure that everyone feels a sense of inclusion and equal value.



## Sustainable innovation

We make life-saving technologies accessible to more people. That is how we can help improve people's lives. In practice, this means that we continuously develop new solutions and improve our offering, while also limiting our environmental impact as much as possible across the value chain.

**Welcome to Getinge**

**Market environment**

**Strategy**

Global value creation

Strategy for sustainable growth

Targets 2024–2028

→ Sustainability

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

# Business areas

Three business areas with world-leading positions	21
Acute Care Therapies	22
Life Science	26
Surgical Workflows	30

# Three business areas with world-leading positions

Our operations are organized into three business areas: Acute Care Therapies, Life Science and Surgical Workflows. Each business area has world-leading positions in most product categories, and they operate in a market with annual sales of more than SEK 200 billion.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

→ Three business areas

Acute Care Therapies

Life Science

Surgical Workflows

**The Board's Operating Reports**

**Financial statements**

**Other information**

## Acute Care Therapies

- Life support therapies for intensive care and surgery
- Cardiovascular surgery and effective management of organs for transplantation
- Comprehensive range of services, training and digital solutions

## Life Science


- Future-proofed products and systems for efficient development and manufacturing of advanced medicines
- Solutions such as washers, sterilizers, isolators and sterile transfer for reducing the risk of contamination
- Service and user support

## Surgical Workflows


- High quality operating room equipment, for example operating tables and surgical lights
- Products for sterile reprocessing of surgical instruments
- Digital solutions for increased efficiency, quality and safety before, during and after surgery
- Service and project management

## FINANCIAL PERFORMANCE


Turnover, SEK billion




Percentage distribution of turnover in 2025



Adjusted EBITA margin, %



Percentage distribution of adjusted EBITA in 2025, %<sup>1</sup>



<sup>1</sup>) Excluding Group functions and other

# Acute Care Therapies

Within Acute Care Therapies, we aspire to double the number of lives saved of critically ill patients with life-threatening conditions within the therapeutic areas of respiration, circulation of oxygenated blood and organ transplantation. The business area has a world-leading position and provides innovative products, therapies, services and training to make this possible.



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

- Three business areas
- Acute Care Therapies
- Life Science
- Surgical Workflows

**The Board's Operating Reports**

**Financial statements**

**Other information**

The addressable market amounts to approximately

**100 SEK billion**

**4–6%**

Expected growth per year

**53%**

Share of Group sales

**77%**

Share of recurring revenues

**-75%<sup>1</sup>**

Reduction of emissions in Scope 1 and 2 (vs. -72% in 2024)

← Compact, portable, and equipped with innovative monitoring features. Cardiohelp, our system for extracorporeal membrane oxygenation (ECMO), has set the standard for life saving technology for over a decade. The next product generation, Cardiohelp II, will be launched on CE markets in 2026.



**Market dynamics**

	<b>Transplant care</b>	<b>Acute Heart &amp; Lung Support</b>	<b>Cardiovascular surgery</b>	<b>Endovascular therapies</b>
<b>Products</b>	Equipment, service, and digital solutions for the preservation and transport of all major organs, such as heart, lung, liver, kidney and pancreas.	Life support therapies for intensive care and the operating room, including ECLS, ventilators, anesthesia machines, hemodynamic monitoring, intra-aortic balloon pumps and balloons, and digital solutions.	Products for advanced cardiac surgery, including products for endoscopic vessel harvesting, beating heart surgery, vascular grafts and thoracic drainage.	Products for peripheral vascular diseases, including covered stents.
<b>Share of sales</b>	6%	66% <sup>2</sup>	25%	3%
<b>Market growth per year</b>	10–14%	4–6%	1–2%	8–10%
<b>Our position</b>	2	1	1	2
<b>Our market share</b>	~10%	25–30%	45–50%	~15%

<b>Main competitors</b>	TransMedics, Terumo, XVIVO	Mindray, Medtronic, Dräger, Hamilton, Abbott, BD, Teleflex	WL Gore, Terumo, Artivion, Medtronic	WL Gore, Bentley
-------------------------	----------------------------	--	--------------------------------------	------------------

1) Reduction compared with the base year 2021.  
2) Surgical Perfusion is included in the sales figures for 2025, but excluded in other data due to an ongoing phase-out.

Welcome to Getinge

Market environment

Strategy

Business areas

Three business areas

→ Acute Care Therapies

Life Science

Surgical Workflows

The Board's Operating Reports

Financial statements

Other information



# Turning complexity into opportunity with KidneyVault technology

Kidney transplantation today is defined by expanding allocation distances, rising donor organ complexity, and persistent pressure to reduce organ nonuse. This requires organ procurement organizations and transplant centers to manage longer transport times, greater logistical uncertainty, and higher clinical risks.

Paragonix KidneyVault® Portable Renal Perfusion System is adopted to address these challenges. The feasibility was demonstrated when Donor Network of Arizona successfully transported a continuously perfused kidney on a commercial flight – an industry first for a more scalable, cost-effective alternative to private aviation.

The capability of the system was further validated in 2025 when a donor kidney traveled more than 4,800 kilometers from Arizona to Puerto Rico across two commercial flights and over 24 hours of ischemic time before being successfully transplanted.

KidneyVault has also supported the successful transplantation of high-risk kidneys that historically may have been discarded – translating advanced preservation into meaningful clinical access and patient impact.

→ Paragonix KidneyVault is an FDA approved system for preserving and transporting donated kidneys prior to transplantation.

← KidneyVault enables continuous perfusion and real time monitoring throughout the entire transport – from donor to recipient.



Our vision beyond 2030:

# Helping to double the number of lives saved among critically ill patients



Welcome to Getinge

Market environment

Strategy

Business areas

- Three business areas
- Acute Care Therapies
- Life Science
- Surgical Workflows

The Board's Operating Reports

Financial statements

Other information



Quality

Our products are essential to healthcare. Every day, medical professionals rely on our solutions to deliver life-saving care to patients when it matters most. We are developing, producing and delivering products that meet our customers' needs and comply with the strict regulations and requirements that are fundamental to the healthcare sector.

Quality is at the core of everything we do – from design to manufacturing and service. This helps us ensure that we make our life-saving technology accessible for more people.

Activities in 2025

Throughout 2025, we continued to improve our Quality Management Systems to ensure effective and compliant processes across our product life cycle. We also improved how we receive, assess, and act upon customer feedback to turn insights into action and deliver improved products and service. In the dialogue with global regulators, we adapted our approach, with emphasis on proactive alignment and focused technical discussions.

We also demonstrated progress where we have historically experienced quality challenges. For example, the CE mark was reinstated for our Cardiosave Intra-aortic Balloon pump after multiple design improvements.

We continued to adapt our portfolio to the European Medical Device Regulation (MDR). By the end of the year, more than 70% of the product portfolio was MDR certified. Several EU MDR product certifications were received in 2025.

← The Servo-c ventilator is designed to meet future needs and comply with the latest regulatory requirements for acute care.



Customers

Our customers, who work in areas such as advanced intensive care, cardiovascular surgery and organ transplantation, must be able to rely on the safety, ease of use and functionality of our solutions and services.

Activities in 2025

We continued our work to increase brand awareness and customer satisfaction. Evaluation together with our customers takes place on a regular basis and gives us a deeper understanding of specific needs. As an example, we received good feedback regarding our ventilation and catheter solutions during the year.

Our US and European customers also shared positive feedback on the usability of our solutions for life-sustaining treatment with extracorporeal membrane oxygenation (ECMO). In parallel with maintaining focus on stable deliveries to support patients and healthcare professionals across the world, we also brought new technologies and services to market.



Innovation

Our customers demand medical technologies that increase their clinical efficiency and productivity, enabling more patients to be saved in a cost-effective way. Our innovation strategy is built to create value through multiple, complementary drivers. It combines continuous portfolio enhancements that strengthen safety, compliance and competitiveness, with customer-valued functionality and expanded service offerings.

In parallel, we drive growth through external partnering and selective inorganic expansion, while investing in new growth areas that address strong and unmet clinical needs – both adjacent to and beyond our current portfolio.

Activities in 2025

In 2025, we focused on product development to drive customer value, meet regulatory requirements and accelerate our growth. As an example, we launched two new features for our renowned Servo ventilators.

A neonatal option for the Servo-c enables clinicians to treat patients in all categories, from premature newborns to adults, with a single ventilator.

We also introduced Neural Pressure Support (NPS) for both invasive and non-invasive ventilation. The two new NPS modes offer clinicians more options to provide personalized ventilation aiming to protect both the lungs and diaphragm.

During the year, the Advanta V12 covered stent system received approval for expanded use as a bridging stent in three complex procedures for aneurysm repair. This expanded approval now offers physicians a single, proven platform to treat both complex aneurysmal and occlusive disease.

 Enablers

**EMPLOYEES**

Thousands of dedicated employees in Acute Care Therapies work side by side to save lives every day. From sales and product development to production and support functions – everyone plays a crucial role in our aim to empower healthcare professionals to make a difference.

**Activities in 2025**

Our performance targets for all employees focus on strengthening key skills and increasing commitment. This is achieved through transparent communication, improved decision-making, leadership accountability and promoting a growth mindset. As a result, we've seen our Employee Engagement Index (EEI) increasing continuously year-over-year.

**RESPONSIBLE BUSINESS**

Healthcare accounts for about 5% of carbon emissions worldwide and it also generates hazardous waste. We are working intensively to reduce this impact while also improving clinical efficiency – which is positive for patients, hospital productivity and the finances of the healthcare system.

**Activities in 2025**

We continued to take action to achieve our sustainability targets, which also increases our competitiveness and ensures regulatory compliance. Alongside capitalizing on environmental effects, we place great importance on the contribution our products make to socially and economically sustainable development.

In 2025, we completed Life Cycle Assessments (LCA) for two products, enabling us to better understand their impact throughout the lifecycle and to take action accordingly to decrease our environmental footprint.

CO<sub>2</sub> emissions from our own production (Scope 1 & 2) were reduced by 75% compared with the base year 2021.

**PRODUCTIVITY**

Our responsibility to customers, investors and societies around the world includes conducting our operations with cost efficiency, as well as developing products and services that enhance productivity. In doing so, more patients can be helped without undermining the finances of the healthcare system.

**Activities in 2025**

The dedicated work to drive productivity and continuous improvements throughout the entire value chain has been more important than ever in 2025 given the macroeconomic uncertainty from tariffs and supply chain disruptions.

We've strengthened our sourcing excellence work throughout the year to equip our employees with improved tools and practices. For example, Cardiopulmonary has introduced new ways of working with upstream suppliers to eliminate backlog issues with components required in the manufacturing of ECMO disposables.

Additionally, we've maintained focus on manufacturing excellence to drive productivity in our own operations, while also increasing collaboration with our suppliers throughout the value chain to improve transparency and increase resilience. For example, the product area Cardiac Assist made manufacturing improvements to ensure the stable supply of intra-aortic balloon catheters. The on-time delivery rate increased from 71% in 2024 to 98% in 2025 with the help of improved internal processes, enhanced collaboration with suppliers, and the establishment of a cross functional team for rapid real time handling of deviations.

**FINANCIAL PERFORMANCE**


**Net sales and adjusted EBITA margin**



**Business area's share of Group sales**



**Business area's regional distribution of sales**



**PRIORITIES FOR 2026**

<b>1</b>	<b>2</b>	<b>3</b>
Strengthen our foundation by focusing on quality excellence, product upgrades and stable supply	Accelerate new avenues of growth through existing strengths and identifying future opportunities	Drive continuous improvement by simplified processes, enhanced root cause analysis, increased productivity and strengthened sourcing management

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

Three business areas

→ Acute Care Therapies

Life Science

Surgical Workflows

**The Board's Operating Reports**

**Financial statements**

**Other information**

# Life Science

In Life Science, we partner with scientists and engineers to develop and manufacture better and new medicines. The focus is on bioprocesses and reducing the risk of contamination through tailored, compliant and effective solutions to prevent, mitigate and cure diseases – and save lives.



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

- Three business areas
- Acute Care Therapies
- Life Science
- Surgical Workflows

**The Board's Operating Reports**

**Financial statements**

**Other information**

The addressable market amounts to approximately

**40 SEK billion**

**6–10%**

Expected growth per year

**13%**

Share of Group sales

**58%**

Share of recurring revenues

**-87%<sup>1</sup>**

Reduction of emissions in Scope 1 and 2 (vs. -59% in 2024)

← Getinge's Applikon Bio is a range of modular glass bioreactors that can be safely sterilized in a sterilizer. The system supports smooth upscaling from laboratory level to production volumes, helping users reduce risks and time to market.



**Market dynamics**

	Pharma production	Medical research
<b>Products</b>	Solutions for aseptic/sterile transfers, GMP sterilizers, GMP washers, bioreactors, automated logistics, isolators, disposables for liquid handling and pumps.	Lab washers, sterilizers and bioreactors, as well as cage washers and logistic automation.
<b>Share of sales</b>	76%	24%
<b>Market growth per year</b>	10–12%	6–8%
<b>Our position</b>	1–4	2–3
<b>Our market share</b>	10–15%	10–15%
<b>Main competitors</b>	Fedegari, Steris, Steelco, Sartorius, GE, Thermo Fisher	Steris, Steelco/Miele, IWT, Sartorius, Eppendorf

1) Reduction compared with the base year 2021.



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

Three business areas

Acute Care Therapies

→ Life Science

Surgical Workflows

**The Board's Operating Reports**

**Financial statements**

**Other information**

# Enhancing safety and efficiency in sterile transfer

The new DPTE®-FLEX Alpha port enables secure, gloveless transfers that minimize human intervention and contamination risks in pharmaceutical production. The system contributes to safety, efficiency and regulatory compliance, which supports more efficient and ergonomic manufacturing, reduced waste and improved reliability.

The intuitive design enhances workflow efficiency while improving operator ergonomics. The external handles perform dual functions – and the fully mechanical, interlocked system supports a safe and user-friendly connection and disconnection of the DPTE® Beta part.



← The manually operated, externally openable DPTE® FLEX Alpha port improves safety, efficiency, and regulatory compliance in pharmaceutical manufacturing by enabling safe, glove free transfers. This helps reduce human intervention and the risk of contamination.

Our vision beyond 2030:

# Enabling 25% more rapid development of advanced medicines



Welcome to Getinge

Market environment

Strategy

Business areas

- Three business areas
- Acute Care Therapies
- Life Science
- Surgical Workflows

The Board's Operating Reports

Financial statements

Other information



Quality

Our life science customers are engaged in the development and production of medicines, which means that they are subject to very strict quality requirements. As a supplier and partner, we are indirectly subject to the same high standards.

Activities in 2025

We define and monitor key performance indicators for all quality processes and manage continuous improvement in our products and systems. We have restructured our quality organization by adopting a holistic approach to quality throughout the entire product life cycle. This is a cultural shift towards a more proactive approach for identifying potential shortcomings. For example, we have increased the number of tests in our production and our focus on preventive maintenance.

← When it was launched 60 years ago, Getinge's DPTE® system revolutionized sterile transfer technology. The latest version, DPTE® FLEX, offers even greater flexibility and improved safety in the manufacturing of sterile products.



Customers

Life Science partners with leading pharmaceutical and biopharma companies worldwide – ranging from established global players to fast-growing innovators – to support the development, manufacturing, and distribution of life-saving medicines.

Activities in 2025

In 2025, our solutions for sterile goods management, including washers and sterilizers, achieved significant net sales growth. Additionally, sterile transfer solutions experienced a robust recovery, particularly in the Americas and Europe, following a prolonged period of customer destocking.

Moving into 2026, we expect continued investments in biopharma and pharma capacity, driven by innovation in biologics, GMP (Good Manufacturing Practice) guidelines and manufacturing of GLP1 products for treatment of type 2 diabetes and obesity.

Our focus will remain on delivering scalable, compliant solutions, enabling customers to meet stringent regulatory requirements and accelerate time-to-market.



Innovation

Our customers demand technologies and services that provide safer, faster and more economically efficient development, production and distribution of medicines. Our ongoing development efforts are aligned to meet these demands by providing the next generation of products to our customers.

Activities in 2025

Within the sterile transfer area, the introduction of the new DPTE®-FLEX Alpha port, minimizing human intervention and contamination risks in pharmaceutical production, is one example of our aim to cover evolving customer needs.

Meeting the digitalization challenges in the pharmaceutical industry is one of our top priorities. To achieve this, we have partnered with leading control system suppliers to develop new user-friendly interfaces that enable superior monitoring of our equipment. These solutions can be seamlessly integrated into customers' IT infrastructures.

 Enablers

**EMPLOYEES**

Customers greatly appreciate our commitment to customer focus, innovation and collaboration. These aspects are fully embedded in how we develop our employees and the organization.

**Activities in 2025**

We strengthened leadership capabilities by fostering skills that enable clear direction and accountability. We increased talent awareness to better recognize and develop individual potential, with focus on promoting a culture of constructive feedback to support continuous growth and collaboration.

**RESPONSIBLE BUSINESS**

Our customers' commitment to sustainable development and manufacturing of medicines has increased considerably in recent years. This presents new opportunities that inspire us to evolve.

**Activities in 2025**

We continued to identify and take sustainability actions to strengthen our competitiveness and achieve our sustainability targets.

Innovation and sustainability in product development remain a key priority, especially in our capital equipment segment. This helps customers reduce their environmental impact and lower the total cost of ownership.

During the year, we introduced the Ultima 1600LXP/HE-HD washer, which delivers efficient use of water, detergents, and rinsing agents, combined with energy saving features.

Emissions from our own production (Scope 1 & 2) decreased by 87% compared with the base year 2021.

In our manufacturing site in Getinge, Sweden, 99.9% of the energy comes from renewable sources, and overall energy use at the site dropped by 10% during the year.

**PRODUCTIVITY**

To enhance our competitiveness, we are striving to work cost-effectively and create products and services that improve productivity for our customers.

**Activities in 2025**

Our focus on productivity improvements continued in 2025. Initiatives included consolidating the supplier base, reducing the cost of existing products and improving the quality of production. For example, the lead time for GSS/GEV sterilizers has been reduced by more than 20% and the Cost of Goods Sold (COGS) for certain capital goods in the product area Washers, Isolators and Sterilizers has decreased by about 10%.

**FINANCIAL PERFORMANCE**


**Net sales and adjusted EBITA margin**



**Business area's share of Group sales**



**Business area's regional distribution of sales**



**PRIORITIES FOR 2026**

- 1** Drive growth through continued focus on innovation, sales structure and acquisitions
- 2** Integration and expansion of the acquired companies HPNE and Getinge Aseptic Solutions
- 3** Manufacturing Excellence that drives productivity and profitability
- 4** Release capital for investments in value-adding growth
- 5** Drive operations toward our sustainability targets
- 6** Create high engagement among employees

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

Three business areas

Acute Care Therapies

→ Life Science

Surgical Workflows

**The Board's Operating Reports**

**Financial statements**

**Other information**

# Surgical Workflows

In Surgical Workflows, we have a leading position in the global market for products and services for hospital operating rooms and central sterile supply departments.



The addressable market amounts to approximately

**70 SEK billion**

**4–6%**

Expected growth per year

**34%**

Share of Group sales

**51%**

Share of recurring revenues

**-54%<sup>1</sup>**

Reduction of emissions in Scope 1 and 2 (vs. -55% in 2024)

← Torin OR Management uses artificial intelligence (AI) to streamline the hospital's daily and long term scheduling of surgeries.



## Market dynamics

	<b>Sterile reprocessing department</b>	<b>Operating room equipment</b>	<b>Digital solutions for increased efficiency</b>
<b>Products</b>	Complete solutions for sterile reprocessing of instruments and endoscopes including steam- and low-temperature sterilizers, washer-disinfectors, endoscope cleaners, automation solutions and consumables, as well as service and clinical training.	Complete operating room solutions, including modern hybrid operating rooms in cooperation with imaging partners, advanced operating tables, surgical lights, ceiling supply units and fluorescence imaging, as well as consulting on planning, workflows and technical service.	Advanced digital solutions for optimizing hospital workflows and ensuring efficiency in sterile supply chains, operating room integration and management.
<b>Share of sales</b>	<b>52%</b>	<b>42%</b>	<b>6%</b>
<b>Market growth per year</b>	<b>3–5%</b>	<b>4–6%</b>	<b>7–15%</b>
<b>Our position</b>	<b>1–2</b>	<b>1</b>	<b>1–5</b>
<b>Our market share</b>	<b>20–25%</b>	<b>15–20%</b>	<b>5–10%</b>
<b>Main competitors</b>	Steris, SteelcoBelimed, Shinva, ASP	Baxter, Steris, Stryker, Mindray, Dräger	Steris, Karl Storz, Teletracking, Censis and local IT companies

<sup>1</sup>) Reduction compared with the base year 2021.

**Welcome to Getinge**

**Market environment**

**Strategy**


**Business areas**

- Three business areas
- Acute Care Therapies
- Life Science
- Surgical Workflows

**The Board's Operating Reports**

**Financial statements**

**Other information**



**Welcome to Getinge**  
**Market environment**  
**Strategy**

**Business areas**

- Three business areas
- Acute Care Therapies
- Life Science
- Surgical Workflows

**The Board's Operating Reports**

**Financial statements**

**Other information**

# A revolution in sterile reprocessing

Getinge's Automatiq marks a new era in automation for Central Sterile Supply Departments (CSSD).

The system, which consists of a range of logistical automation modules, helps hospitals deliver safer and more efficient care with limited resources by transforming how logistics are managed in sterile reprocessing.

The combination of smart robotics, intelligent transport systems, and advanced software is

designed to automate manual processes that often involve ergonomic strain and repetitive tasks for CSSD staff. The system improves reliability, saves valuable time, and enables staff to focus on other value creating activities.

Automatiq is built with a modular design and integrated digital solutions, enabling it to evolve in line with future technological advancements and hospital needs.



→ The launch of Automatiq brings the automation of the CSSD into a new era. The system is designed to optimize the handling of sterile goods and to improve efficiency in every step of the workflow.

← Automatiq Envoy is a self navigating mobile robot for transporting instruments between workstations.

Our vision beyond 2030:

# One more surgery per day per OR

↓ Maquet Corin is an intuitive, safe, smart and connected OR table, designed to streamline the daily routines in surgical departments.



Welcome to Getinge

Market environment

Strategy

Business areas

- Three business areas
- Acute Care Therapies
- Life Science
- Surgical Workflows

The Board's Operating Reports

Financial statements

Other information



Quality

Our Surgical Workflows products and services are the backbone of a hospital's surgical operations. It is essential that they are of the highest quality. Otherwise, the operations risk coming to a standstill.

Activities in 2025

During the year, we continued to strengthen our Quality Value Engineering efforts, with focus on raising development quality and reducing development costs.

We completed 22 external audits with no major findings, achieving an Audit Ratio of 0.95.

During 2025, we eliminated a slight complaint backlog and improved the handling efficiency, with focus on faster resolutions and improved customer satisfaction. We also implemented initiatives to reduce the number of customer complaints through product quality improvements.



Customers

Our customers are hospitals and clinics offering surgery and sterilization of surgical instruments. High utilization rates, productivity and quality in these operations are essential to their financial performance.

We partner with our customers to drive efficient workflows and high productivity by providing comprehensive solutions including infrastructure, machinery, consumables, service, and digital tools.

Activities in 2025

We entered into a partnership with Zimmer Biomet, who will include Getinge Surgical Workflows products in their comprehensive solutions for orthopedic Ambulatory Surgery Centers (ASC) in the US.

In 2025, we saw a continued demand for infection control equipment and consumables, driven by our renewed portfolio and an accelerated consumables growth strategy.



Innovation

Our customers want technology and services that make surgical workflows safer, faster and more cost effective. Our aim is to meet these needs with innovative solutions.

Activities in 2025

During 2025, we launched new products as well as new features to existing offerings and services.

The new version of the Solsus 66 Steam Sterilizer offers new features as well as enhanced usability and operational efficiency, while reducing the environmental impact. The Aquadis 44 Washer-Disinfector is designed to minimize resource use and lower operating costs.

The new Automatiq offers customers a brand new control system and a new automation module. During the year, we also launched the digital systems Tegriss V8 and FleetView.

Xen Chemistry was introduced to the US market. This results in significant profitability improvements and strong revenue growth for consumables, while providing our customers with next generation chemistry products.

 Enablers

**EMPLOYEES**

Meeting customer needs requires strong customer focus, innovation and collaboration. This is why we are prioritizing the development of both our employees and the entire organization.

**Activities in 2025**

During the year, we continued to invest in leadership development. We also strengthened our product management capabilities and began our important upskilling journey in Artificial Intelligence.

**RESPONSIBLE BUSINESS**

Our customers demand products and services that minimize the negative impact on the environment from sterile reprocessing and surgery. We have been working on this for a long time and have a leading position in the area.

**Activities in 2025**

During the year, we continued to map the impact of raw material and component sourcing. We also accelerated our product development with the aim to reduce electricity and water consumption. We remain well on track to meet our Scope 1 and 2 emissions reduction targets. Our ongoing investments in energy efficiency and renewable energy across our production facilities continued to deliver measurable progress, positioning us to achieve our commitments on schedule. CO<sub>2</sub> emissions from our own production (Scope 1 & 2) was reduced by 54% compared with the base year 2021.

**PRODUCTIVITY**

To enhance our competitiveness, we conduct cost efficient operations and develop products and services that increase customer productivity.

**Activities in 2025**

We are continuing to focus intensely on reducing product costs through more efficient manufacturing and procurement. Our focus on efficient procurement and Quality Value Engineering, which involves redesigning and replacing components, continued in 2025, resulting in a net material cost saving of approximately 1%. Our extensive efforts to improve our supply chain productivity with structure simplification, purchasing activities and digitalization also continued. Activities improving the effectiveness of our supply chain included a new warehouse management software for our US operations and a digital order system enabling global tracking of customer orders.

**FINANCIAL PERFORMANCE**

**Net sales and adjusted EBITA margin**



**Business area's share of Group sales**



**Business area's regional distribution of sales**



**PRIORITIES FOR 2026**

- 1** Continue the structured efforts to ensure high quality in products and processes
- 2** Further strengthen our position in Infection Control and become a leading full-service supplier with the global launch of a comprehensive consumables portfolio
- 3** Launch new products and assume a stronger position in fast-growing segments, such as Digital Health Solutions, endoscope reprocessing and low temperature sterilization
- 4** Increase productivity through efficient manufacturing, procurement and service processes
- 5** Improvements in line with our sustainability targets

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

- Three business areas
- Acute Care Therapies
- Life Science
- Surgical Workflows

**The Board's Operating Reports**

**Financial statements**

**Other information**

# The Board's Operating Reports

Administration Report	35
Corporate Governance Report	56
Sustainability statement	73

# Administration Report

Administration Report	35
Risk overview	39
Getinge's primary risks	40
Proposed appropriation of profit	45
Guidelines for remuneration	47
Remuneration report 2025	52

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**Ownership and Legal form**

Getinge AB (publ) with corporate identity no 556408-5032 is a limited liability company and its Class B shares are listed on Nasdaq Stockholm. Getinge AB (publ) with registered office at Box 8861, 402 72 Gothenburg, Sweden, is the Parent Company of the Getinge Group and is headquartered in Gothenburg, Sweden. The largest shareholder in Getinge AB (publ) is Carl Bennet AB, which is also the ultimate Parent Company of the Group that includes the Getinge Group.

**Operation and structure**

Getinge is a global provider of products and solutions for operating rooms, intensive-care units and sterilization departments serving 40 countries and with proprietary production in nine countries. Operations are conducted in three business areas – Acute Care Therapies, Life Science and Surgical Workflows. Sales take place through our own subsidiaries and distributors in more than 135 countries. 69% of the sales are conducted through the Group's sales companies and the remaining 31% are sold by agents and distributors in markets where Getinge often lacks its own representation. Americas represented the Group's largest market, accounting for 45% (45) of sales, followed by EMEA at 35% (35). APAC accounted for 20% (20) of sales. Production is conducted at a total of 25 facilities in France, China, the Netherlands, Poland, the UK, Sweden, Türkiye, Germany and the US.

**Financial overview**

**Net sales**

Net sales increased 0.6% during the year to SEK 34,969 M (34,759). Organically, sales increased by 4.9%. In Acute Care Therapies, sales amounted to SEK 18,675 M (17,948), corresponding to an organic

increase of 7.0%. Life Science's sales amounted to SEK 4,498 M (4,552), an organic increase of 4.1%. Surgical Workflows' sales in 2025 amounted to SEK 11,796 M (12,258). Sales increased organically by 2.1%.

**Adjusted EBITA**

EBITA adjusted for restructuring and acquisition costs and other items affecting comparability amounted to SEK 4,880 M (4,869).

**Operating profit**

The Group's operating profit amounted to SEK 3,789 M (2,854). Adjusted for restructuring and acquisition costs and other items affecting comparability, operating profit amounted to SEK 4,494 M (4,549), corresponding to 12.9% (13.1) of net sales. The Group's adjusted EBITDA amounted to SEK 6,581 M (6,646), corresponding to 18.8% (19.1) of net sales.

**Net financial items**

Net financial items amounted to SEK -644 M (-571), of which net interest items comprised SEK -588 M (-539).

**Profit before tax**

The Group's profit before tax amounted to SEK 3,145 M (2,282).

**Taxes**

The Group's tax expense amounted to SEK 869 M (-628), entailing a tax rate of 27.6% (27.5).

**Tied-up capital**

Inventories amounted to SEK 6,018 M (6,590) and accounts receivable to SEK 5,782 M (6,348). The return on equity was 7.5% (5.2). Goodwill totaled SEK 25,775 M (30,088) at the end of the fiscal year.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**Investments**

Investments in intangible assets and tangible assets amounted to SEK 1,345 M (1,309). Investments primarily pertained to product development, production facilities, production tools and IT projects.

**Financial position and equity/assets ratio**

Consolidated net interest-bearing debt declined to SEK 9,840 M (10,467). The equity/assets ratio amounted to 52.2% (52.0) and the net debt/equity ratio to 0.33 (0.32). The Group's leverage (net debt in relation to adjusted EBITDA) amounted to 1.5 (1.6). Equity at year-end amounted to SEK 29,494 M (33,210).

**Cash flow**

Cash flow from operating activities amounted to SEK 3,949 M (4,577).

**Restructuring activities**

In 2025, restructuring costs amounted to SEK 374 M (848), which were mainly attributable to personnel-related costs linked to the communicated phase-out of the Surgical Perfusion product category.

**Class of shares and share data**

Net profit for 2025 amounted to SEK 2,276 M (1,654). Earnings per share, before and after dilution, amounted to SEK 8.29 (6.01).

For information regarding trading of shares in the company, the number of shares, shareholders, classes of shares and the rights associated with these classes, refer to Note 17 Supplementary disclosures equity, Getinge as an investment on page 8 and Other information on pages 199–201.

**Significant events during the year**

**Governance of quality**

During the year, work continued on the improved global quality management system implemented in 2023. The aim of the system is to enhance focus and establish a well-defined Group-wide quality strategy in order to deliver an even higher level of quality. The system defines the processes, controls and documentation necessary to meet regulatory requirements, manage risks and deliver high-quality products to customers.

**Adjustments to EU Medical Device Regulation**

Work on meeting the requirements of the new EU Medical Device Regulation (EU MDR) continued during the year. All but one of the production facilities where this is a requirement had received an EU MDR certificate by the end of 2025.

**CE mark for Cardiosave**

At the beginning of August 2025, the notified body TÜV SÜD reinstated Getinge's CE mark for Getinge's Cardiosave Intra-Aortic Balloon Pump, which had been temporarily suspended since March 2024. The reinstatement of the CE mark was subject to certain conditions, which Getinge actively worked on to fulfill.

**Tariffs**

On April 2, 2025, US President Trump announced an extensive program of tariffs. Getinge is monitoring and actively adapting its operations based on current developments. The Group has a good overview of its supply chain and thus also the impact of tariffs and other trade barriers. With a geographically diversified purchasing and manufacturing strategy, Getinge can partially limit any potential negative impacts. More than 60% of

sales in the US are manufactured in the US. The remainder is mainly imported from Europe, which is the flow that is most affected by the tariffs.

Getinge is primarily working on price adjustments, cost efficiencies and structural measures to minimize the negative consequences of these tariffs.

**Acquired operations**

Additional purchase prices of SEK 1,580 M were paid in 2025, of which SEK 1,555 M for Paragonix Technologies and SEK 44 M related to the acquisition of Irasun GmbH. All shares outstanding in the subsidiary Pulsion Medical Systems SE were acquired during the year from non-controlling interests for SEK 83 M. For further information, refer to Note 19 Financial instruments and Note 27 Acquisition of operations.

**Dispute**

**Settlement agreements with authorities in Brazil – ongoing**

As a consequence of ongoing government investigations regarding anti-competitive practices relating to the sale of medical devices between 2004 and 2017, mainly to public hospitals, Getinge has previously entered into settlement agreements with the Brazilian Federal Prosecutor's Office (Ministério Público Federal) and the competition authority, the Administrative Council for Economic Defense (CADE). The negotiations with the federal agency for internal control, public transparency and counter-corruption, Comptroller General of the Union (CGU), were still pending at the end of 2025. In 2024, Getinge made a provision of SEK 482 M related to these negotiations. The final and definitive costs will be determined once the negotiations have been concluded, and such an amount could both be

lower and higher than the provision that has now been made (see Note 15 Other provisions for further information).

**Consent Decree with FDA – ongoing**

In February 2015, Getinge signed a Consent Decree with the US Food & Drug Administration (FDA), which encompassed four production units in the US and Germany and pertained to certain identified quality concerns. In addition, Getinge's production units in Fairfield and Mahwah received warning letters from the FDA in 2018–2019, resulting from observations from inspections in 2018. These observations, which Getinge had also identified, pertain to procedures and processes linked to demands for supplier checks, processes for the approval of design changes and incident reporting. Getinge has subsequently worked to remedy these concerns and submitted an action plan to the FDA and improvements are proceeding according to this plan. In October 2022, the FDA expanded the Consent Decree to include Getinge's subsidiary Datascope due to observations made at inspections between 2021 and 2022 at the site in Wayne, New Jersey. These observations pertained to Datascope failing to fully comply with the Quality Management System and related processes. Datascope is enforcing the ongoing actions to address the findings and to ensure full compliance with the Quality Management System, including via the new quality organization. A work plan has been submitted to the FDA and dialogue and improvements are continuing.

Under the Consent Decree, Getinge has committed to implement a remediation program with the support of third-party auditors to ensure long-term compliance based on the Quality

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

Management System and related processes. Audits were carried out by the FDA and third-party auditors in 2024 and 2025. The relevant production units have prepared comprehensive remediation plans through which they will share and implement best practices across product areas. They are actively cooperating with the FDA and auditors to execute these plans and achieve compliance, with the overall goal of implementing lasting, systemic quality improvements.

**Getinge's financial targets 2024–2028 and dividend policy**

Getinge updated its financial targets in May 2024 as follows:

- Average adjusted earnings per share growth: >12%
- Getinge's dividend policy is to pay dividends of 30–50% of net profit to shareholders

**Innovation and product development**

Innovation and product development are cornerstones of the Group's strategy to strengthen the customer offering and ensure future organic growth. The Group uses innovation and product renewal to manufacture products, systems and solutions with a documented ability to deliver high-quality clinical results and economic benefits. The Group's research and development costs amounted to SEK 2,096 M (2,091) in 2025. Of this amount, SEK 643 M (660) was capitalized as intangible assets.

**New products during the year**

*Surgical Workflows*

- Aquadis 44 – the utility-efficient washer-disinfector, which helps hospitals reduce costs and meet environmental targets
- Automatiq – the new family of next generation automated solutions that combines smart robotics, intelligent conveyor systems and advanced software to achieve safer, more consistent and less labor-intensive sterile reprocessing

*Acute Care Therapies*

- Servo-c – the ventilator was expanded with a neonatal option in targeted markets
- Neural Pressure Support (NPS) – for Servo-u ventilator systems, available for both invasive and non-invasive ventilation
- Integrated anesthesia workstation – hospitals are offered an integrated anesthesia workstation for the operating room through a collaboration between Getinge and Philips
- KidneyVault – a portable system to optimize the protection of donor kidneys during transport

*Life Science*

- DPTE[®]-FLEX Alpha port – a manual, externally openable port that enables gloveless component transfer, which reduces human intervention and contamination risks in pharmaceutical production
- Ultima 1600 LXP/HE-HD heavy duty washer – a powerful addition to the Lancer Ultima product line launched in France and the US
- cGMP washers and sterilizers – a modern interface was introduced for an open and flexible visualization system

**Approvals and certifications**

In the third quarter, Getinge had the CE mark for the Cardiosave Intra-Aortic Balloon Pump reinstated, subject to certain conditions. In the same quarter, the Advanta V12 balloon expandable covered stent received EU MDR approval for three additional indications, an important factor in strengthening its position in the European market.

**Personnel**

At December 31, 2025, there were 11,670 (11,791) employees (full time equivalents), of whom 1,327 (1,296) were employed in Sweden. In 2025, Getinge continued its extensive efforts to strengthen the Group's personnel and management development. The Group also carried out activities intended to further strengthen the commitment of its employees and implemented digital tools for personnel development. Since early 2023, all Getinge entities offer at least 16 weeks paid parental leave and four weeks paid caregiver leave to care for a close family member. In 2025, the Group also continued its long-term endeavors to increase diversity and collaboration. Getinge has a previously implemented policy to ensure that all employees are given equal opportunity to develop and receive equal pay for equal work, regardless of such factors as gender, ethnicity or religion.

The Getinge Group relies on several intangible resources that are not recognised as assets in the balance sheet but are central to the value creation model. These include, among others, our technology, our brands, as well as the expertise and know-how possessed by our employees. Management actively works to develop and protect these resources through investments in

research and development, skills enhancement, and system improvements. The significance of these resources for future cash flows means they constitute an important part of the Group's long-term competitiveness.

**Remuneration to Senior Executives**

The guidelines for remuneration to Senior Executives adopted at the 2023 Annual General Meeting are presented on pages 47–49. During 2025, the company complied with these guidelines. No deviations from the guidelines nor any derogations from the procedure for resolution on remuneration, established by the remuneration guidelines, have been made. Total remuneration to Senior Executives amounted to SEK 136 M (144) in 2025, see Note 22 for more information. The total cost for remuneration and benefits to the Getinge Executive Team amounted to SEK 178 M (165) and pertains to base salaries, variable short-term and long-term remuneration, other benefits and pensions. It also includes social security expenses on salaries and benefits and special payroll tax on pensions.

**Sustainability statement**

Getinge's 2025 Sustainability statement, which is part of the Administration Report, has been prepared in accordance with the Swedish Annual Accounts Act and applies the rules on sustainability reporting according to the European Sustainability Reporting Standards (ESRS). The statutory Sustainability statement in accordance with the Annual Accounts Act can be found on pages 73–137. For Getinge's EU Taxonomy reporting, see pages 102–105.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**Risks and uncertainties**

Getinge actively and systematically manages the risks that the Group is exposed to. In accordance with this, the Getinge Executive Team conducts an annual evaluation of material risks and effects, and decides and acts on measures to reduce these. The risk evaluation is reported to the Board of Directors and serves as a key starting point in determining the focus areas for Corporate Internal Audit.

Getinge is exposed to risk related to other external events, such as geopolitical risks, natural disasters, terrorism, pandemics, etc. Active business intelligence can detect some of these risks at an early stage and the Group will then have the chance to adapt to the new situation. In 2025, Getinge was exposed to trade sanctions resulting from the dynamic geopolitical situation, and Getinge is actively monitoring the ongoing debate on increased trade barriers such as tariffs. Getinge has a geographically diversified purchasing and manufacturing strategy, which can partially limit any potential negative consequences.

Technological advances are currently being made at a very fast pace, which is affecting the competitive situation in the market. The Group assigns considerable resources to developing its customer offering, such as in the form of a higher degree of connected products. In this way, information about how the products are used clinically can be transferred from the customers back to Getinge, and this information will then form the basis of the next stage of product development. There is a certain risk that new, or existing, players could develop transformative technology more successfully than Getinge and thus gain an advantage in the market.

Cyber-related risks are a focal point for the Group in terms of both IT infrastructure and connected equipment with customers. In both of these areas, Getinge carries out active and extensive measures to manage these risks. A circumstance that reduces exposure related to infrastructure is that this can be considered to be decentralized. In addition, the Group also closely monitors critical systems to prevent these risks. In relation to the cyber security of the Group's customer offering, the company works diligently to ensure the integrity of its equipment that is connected to the Internet. Comprehensive access testing and other measures are also carried out before these solutions are offered to the Group's customers.

Furthermore, Getinge is also exposed to risks related to non-compliance with laws and regulations, mainly pertaining to business ethics. Corruption in particular remains a risk in some of the markets in which Getinge operates and has ambitions to grow. The Group has a zero tolerance policy when it comes to deviations in this area and takes extensive action in business ethics such as the responsible leadership training program and other training courses. Further information about the Group's financial risk management can be found on pages 39–43.

**Financial risk management**

Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to risks related to currency risks, interest-rate risks, financing and liquidity risks and credit and counterparty risks. Risk management is regulated by the finance policy adopted by the Board and a Treasury directive decided by the Getinge Executive Team that supplements the finance

policy. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the finance function. For more detailed information concerning these risks, refer to Note 18 Financial risk management.

**Sensitivity analysis**

Getinge's earnings are affected by a series of external factors. The following table shows how changes to some of the key factors that are important to Getinge could have affected the Group's profit before tax in 2025.

<b>Change in profit before tax</b>	<b>SEK M</b>	
Price change	+/- 1%	+/-350
Cost of goods sold	+/- 1%	+/-183
Salary costs	+/- 1%	+/-131

**Outlook**

Organic sales growth is expected to be in the range of 3–5% for the full-year 2026.

**Significant events after the end of the reporting period**

Geopolitical debate and the turbulent global environment continue to dominate the market. It is too early to draw any conclusions regarding the effects of the geopolitical developments in the Middle East and related circumstances.

# Risk landscape and risks

Getinge operates in a global market and has a strong presence in a large number of countries. The global footprint means that Getinge navigates in a comprehensive risk universe. The Group's risk management strategy is integrated into its business processes and the company's strategy work, which is fostering a risk culture that encourages engagement and accountability. Getinge has an Enterprise Risk Management (ERM)-process covering all business areas, the global sales and service organization and the corporate and Group support functions, see page 71. Active risk management at all levels is important in order for Getinge to successfully continue to create innovative products that improve people's quality of life.

**The Group's risks are divided into three categories:**

- External – risks that cannot be controlled, but that are monitored and prepared for in order to optimize outcomes and turn risks into opportunities;
- Operational – risks that are largely controllable and preventable, mainly related to processes, assets and employees.
- Strategic – risks that make it more difficult to achieve the strategic targets. These risks are managed by balancing risks and the potential for maximizing advantages.

The most relevant risks are presented on the following pages, but the list does not constitute a complete account of all of the risks to which the Group is exposed.

## External risks

Risks that cannot be controlled, but that are monitored and prepared for in order to optimize outcomes and turn risks into opportunities;

**Read more on page 40.**

## Operational risks

Risks that are largely controllable and preventable, mainly related to processes, assets and employees.

**Read more on pages 41–42.**

## Strategic risks

Risks that make it more difficult to achieve the strategic targets. These risks are managed by balancing risks and the potential for maximizing advantages.

**Read more on page 43.**

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**GETINGE'S PRIMARY RISKS, CONSEQUENCES AND MANAGEMENT**

EXTERNAL RISKS	Description	Potential consequences	Management
<b>Unforeseen events</b>	Rapidly emerging situations, such as geopolitical risks, trade barriers, natural disasters, war, terrorism, pandemics, fires, etc. which could affect a specific facility, a region, a single country or large geographical areas.	Employees could be injured. In addition, operations can be disrupted, which could have a negative impact on sales and earnings. Price increases to customers and a higher risk premium in the capital market are other scenarios.	Some of these risks can be identified at an early stage through active monitoring, which enables the Group to adapt to the changed circumstances. Getinge is monitoring and actively adapting its operations based on the escalating developments during 2025 regarding geopolitical friction and higher trade barriers, such as tariffs and increased volatility in currency markets. The Group has a solid process for funding and has a good overview of its supply chain and thus also the impact of tariffs and other trade barriers. Getinge has a geographically diversified purchasing and manufacturing strategy that could be beneficial if an unforeseen event arises. It also enables the Group to act quickly in the event that the risk occurs. Getinge takes continuous preventive action at the Group's production sites, such as regular inspections performed by external experts. The Group also actively conducts business continuity planning, which aims to restore operations quickly in the event of interruptions.
<b>Dependence on external suppliers</b>	Critical components manufactured by external suppliers are a vital part of Getinge's supply chain.	The operations could be disrupted, which may have a negative impact on sales and earnings.	Getinge actively monitors critical suppliers, starting when the partnership is established and continuing with continuous evaluations. The purchasing organization has tools for assessing risk and receives regular training in this area. The Group has intensified its collaborations with suppliers throughout the value chain to improve transparency and its ability to manage resilience. Interruptions related to critical suppliers are managed as an important part of the Group's business continuity planning. The Group works on ensuring that it has adequate levels of critical components in stock, in its own operations or with the relevant supplier. Geopolitical turbulence created several challenges in terms of component availability during the year. These were successfully handled through systematic risk management and increased transparency in our value chains.
<b>Changes in healthcare reimbursement systems</b>	Political decisions can change the conditions for healthcare through changed reimbursement models for healthcare providers.	Changes in reimbursement systems could have significant effects on specific markets, with budget cuts or deferred funding potentially impacting the operations.	Getinge operates in a large number of markets, which reduces the overall impact of individual changes.
<b>New competitors and new technologies</b>	Certain markets and product segments have niche players who offer solutions outside customary market behavior.	Niche players could capture market shares from established companies, including Getinge, which could have negative effects on earnings.	Through continuous innovative development and market analysis, Getinge strives to be at the forefront, identify potential competitors and adapt to technological changes. The industry is also considered to have high barriers to entry since medical devices are subject to extensive regulatory requirements.
<b>Increased expectations and new rules and regulations related to sustainability</b>	Sustainability requirements and expectations on Getinge as a company are changing at a rapid pace.	If Getinge fails to meet the ever-changing environmental, social and governance requirements it could have negative consequences on the company's reputation, operations and financial earnings. It may impact the company's ability to recruit and retain competent employees, and risk disqualifying the company from participating in tenders with specific requirements.	By engaging with stakeholders and improving its materiality assessment, Getinge increases its understanding of the expectations placed on the company. It also helps the company to adopt the focus areas that are to be prioritized moving forward. In addition, the company has developed its sustainability framework, focusing on the products and solutions placed on the market to ensure quality and corporate responsibility. This also leads to employee engagement. The company reports annually on its performance in sustainability in a transparent manner and complies with the reporting requirements of the Swedish Annual Accounts Act.
<b>Increasing competition for public funds</b>	Reduced public budgets for investing in medical devices impacts the total market potential.	Increased competition for limited public funds may lead to reduced funding for medical device investments, which in turn could negatively impact Getinge's sales figures.	Through continued innovative development and active work on offering solutions that improve the efficiency of healthcare, the assessment is that Getinge can generate demand even where budgets are constrained. Activities to enhance manufacturing productivity are another important focus area for strengthening competitiveness.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

OPERATIONAL RISKS	Description	Potential consequences	Management
<b>Quality risks from a regulatory perspective</b>	A large part of Getinge’s product range is subject to strict legislation requiring extensive assessments, quality controls and detailed documentation.	Getinge’s operations, financial position and earnings may be negatively impacted if the company is unable to comply with regulatory requirements.	<p>Getinge conducts extensive quality and regulatory activities. The Quality Compliance, Regulatory &amp; Medical Affairs function is represented in the Getinge Executive Team and also in the management teams of each business area, and in all R&amp;D and production units.</p> <p>In 2025, work continued on the improved global quality management system implemented in 2023, which supports a well-defined Group-wide strategy on quality.</p> <p>Getinge conducts extensive work within Research and Development to ensure that the product portfolio meets all existing and future quality and regulatory requirements. These efforts include adjustments to the EU Medical Device Regulation (EU MDR), which improves the company’s long-term ability to meet future regulatory requirements. All but one of the production facilities where the EU MDR is a requirement had received an EU MDR certificate by the end of 2025.</p> <p>All production sites manufacturing medical devices have ISO 13485 certification and all sales and service entities have ISO 13485 and ISO 9001 certification.</p> <p>A new, digital quality training course, available in 15 languages, was launched in 2025. The program uses real-life scenarios and practical insights to highlight how each role contributes to the Group’s common target of delivering safe, efficient and customer-focused solutions. In addition, Getinge’s sales force and service technicians receive training in products and in Getinge’s quality management system, which is a requirement for representing Getinge.</p> <p>Getinge’s Quality, Compliance, Regulatory &amp; Medical Affairs function has a department that performs audits based on international standards, see page 71.</p> <p>In summary, Getinge invests significant resources in quality and regulatory matters, which is a top priority of the Group’s strategy.</p>
<b>Product quality from a customer perspective</b>	Products do not meet customer expectations.	Product quality shortcomings could lead to customers seeking alternative suppliers, which in turn could negatively impact sales and profitability over time.	<p>Getinge conducts comprehensive and systematic quality activities that extend over the entire product life cycle. To ensure high and consistent quality, the company continuously monitors product performance and customer experience by following a well-established post-market surveillance program. Such monitoring allows for early identification of deviations and trends, which forms the basis for structured improvements based on a root cause analysis.</p> <p>In the event of quality failures, it is essential to rapidly rectify the fault, ideally during the first service visit. For this reason, Getinge closely monitors the “first-time fix” factor and works actively to make improvements based on analyses and targeted measures. The Group’s quality efforts comprise a continuous improvement process that enhances both product reliability and customer confidence.</p>
<b>Product liability risks</b>	Healthcare suppliers run a risk, like other players in the healthcare industry, of being subject to product liability claims.	Product liability claims could involve large amounts and entail significant legal expenses, which could impact the Group’s financial position and earnings.	Getinge conducts extensive quality and regulatory activities. Sources of potential future liability claims are monitored through active incident reporting. Corrective and protective action (CAPA) is initiated when necessary to investigate the underlying cause, after which the product design may be corrected to remedy the fault.
<b>Deficiencies in information security and cyber security in IT infrastructure</b>	Leaks of confidential information or intrusions into the Group’s IT system resulting in restricted availability or interruptions of business-critical systems. In this context, extortion or sabotage cannot be excluded.	IT system intrusions could lead to business interruptions. A loss of sensitive information may adversely affect confidence in the company. Leaks of personal data could lead to high fines.	Getinge has global IT services that ensure efficiency, coordination and security. Getinge’s IT structure in production is largely decentralized, which reduces the consequences of certain cyber risks by spreading the risks across different systems. Getinge has centralized identity management and conducts extensive surveillance and monitoring of the central infrastructure to quickly detect and counteract security threats via its security operations center (SOC). Getinge regularly trains all employees to reduce cyber risks based on human factors.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

OPERATIONAL RISKS	Description	Potential consequences	Management
<b>Deficiencies in cyber security related to products</b>	Security deficiencies in the Group's digital offering, such as connected equipment at customer sites and stricter legal requirements for processing personal data. In this context, extortion or sabotage cannot be excluded.	Restricted availability of Getinge's equipment for its customers, which could result in interruptions to the hospital operations and that patients cannot be offered sufficient care.	Getinge works diligently and systematically, following a risk-based approach, to ensure the integrity of its connected equipment. By continuously evaluating and prioritizing security risks, Getinge can effectively protect both systems and customer data. Comprehensive penetration testing is carried out before these solutions are offered to the Group's customers to identify and rectify potential vulnerabilities.
<b>Non-compliance with laws and regulations</b>	Breaches of laws and regulations related to, for example, business ethics, competition, anti-corruption, AI, cyber security, data protection or trade restrictions.	Breaches of these regulations could lead to fines, sanctions and have a negative impact on the Getinge brand.	The EVP Sustainability, Legal & Compliance represents the Ethics & Compliance function in the Getinge Executive Team, which highlights the importance of these topics. Training and communication are pillars of the company's global ethics and compliance programs. The programs are based on risk assessments and include targeted training in relevant areas for employees in high-risk regions and roles. The Board and all members of the Getinge Executive Team receive annual training, and the global Ethics & Compliance function monitors to ensure that all employees complete their assigned courses.  Getinge's governance model for compliance was further developed in 2025 to meet regulatory requirements. A global workshop on Getinge's Code of Conduct was also launched during the year with the aim of embedding shared values, strengthening accountability and giving employees the tools to manage complex situations. This initiative helps teams handle real-life challenges and fosters trust and accountability. The training course is conducted as interactive workshops led by managers, using authentic case studies from the operations to ensure practical relevance.
<b>Dependence on meeting climate targets</b>	Getinge is dependent on meeting the climate targets set, which have been approved by the SBTi. For more information about the targets, see page 95. Getinge's analysis shows that the majority of emissions come from the purchases of goods, logistics and the use of sold products. As a result, the company does not have full control over its emissions and cannot therefore directly control its reduction.	If Getinge does not meet its climate targets, it could have a significant negative impact on the company's reputation and operations, in addition to negative climate impacts.	The company has gradually reduced the emissions that it can control (Scope 1 & 2) and aims to achieve net zero by 2030 for these. In terms of emissions from the value chain, the company has made progress in reducing emissions from freight transport. For more information about the company's efforts to reduce emissions, see pages 92–93.
<b>Lack of future skills</b>	Risk of dependency on key people including lack of succession planning and ineffective processes to identify and spread critical know-how within the organization. Also the risk of being unable to attract and retain the right talent and skills.	Could lead to higher employee turnover, operational disruptions and damage the Getinge brand. In the future, it may have a negative impact on Getinge's long-term sustainability and growth, and affect Getinge's ability to attract and retain talent.	Getinge is continuously improving the succession planning process to ensure the global development of talent. The company is focusing on talent mobility and knowledge sharing and strives to create a culture and leadership that attracts both new and existing talent. Getinge's aim is to be a company where everyone can thrive and grow.  The Group is concerned with ensuring access to the right skills, retaining key individuals, being an attractive employer to recruit talent externally, and identifying and developing talent within the organization.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

STRATEGIC RISKS	Description	Potential consequences	Management
<b>Digitalization and innovation</b>	Getinge's future growth depends on successful product development, particularly in digitalization. Innovation is crucial for maintaining and strengthening the company's leading position.	Innovation efforts are costly and it is not possible to guarantee that developed products will be commercially successful, which could result in impairment. In the long term, the Group's market position could be negatively affected if Getinge is unsuccessful in this area.	As means of maximizing the return on investments in research and development, the Group applies a structured selection and planning process that includes careful analyses of the market, technological progress, choice of production method and selection of subcontractors. The actual development work is also conducted in a structured manner and each project undergoes a number of fixed controls.
<b>Fragmented product portfolio</b>	Getinge's product portfolio consists, to a certain extent, of a large number of acquisitions that were made throughout the years within a variety of product categories.	An offering to Getinge's customers that, in certain parts, is too diverse could lead to the Group lacking the critical mass needed to conduct fully efficient operations in all product categories.	Efforts are being made to enhance the efficiency of the customer offering under the framework of the ongoing strategic activities in each business area. The introduction of the EU Medical Device Regulation (EU MDR) means priorities need to be made regarding the certification of products under the new regulatory framework. Products that will be a part of the customer offering long term, are selected, which will lead to increased concentration as well as streamlining.
<b>Risks related to intellectual property rights</b>	Getinge's leading positions in many product segments are based on patent and trademark rights, which could lead to disputes with competitors.	Costly disputes over intellectual property rights could reduce the return on investment in research and development. It cannot be ruled out that the costs that could arise associated with this could be material.	Getinge closely monitors the activities of its competitors and actively defends its intellectual property rights through legal processes if necessary.
<b>Financial risks</b>	Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to risks related to currency risks, interest-rate risks, financing and liquidity risks and credit and counterparty risks.	Financial risks could adversely affect the Group's income statement and balance sheet.	Financial risk management is regulated by the finance policy adopted by the Board and a supplementary Treasury directive. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the treasury function. For more detailed information concerning these risks, refer to Note 18 Financial risk management.
<b>Profitability dependent on certain products and markets</b>	Some products and markets contribute more to overall profitability.	If sales volumes of these products and in these markets were to decrease, it could have a negative impact on the Group's profitability.	Getinge works actively to monitor profitability per product and market in order to ensure profitability over time. To reduce the sensitivity of profitability, the Group actively works on ensuring that it has the right cost level in relation to the current price levels in the market. Activities to enhance manufacturing productivity are another important focus area for strengthening competitiveness. Getinge is also working to introduce selected products in new markets where the Group is already present.
<b>Delayed transition to more sustainable products and packaging solutions</b>	Long lead times in research and development due to comprehensive regulations and long validation processes are hampering rapid development to more sustainable product and packaging solutions. The medical device market is strictly regulated, partly to ensure patient safety, which can affect how quickly Getinge's products can become more sustainable.	If it is not possible to transfer Getinge's product and packaging solutions to more sustainable solutions quickly enough, there is a risk that Getinge's reputation and competitiveness could be negatively affected.	Getinge will always prioritize patient safety and follow applicable regulations. Without impacting our fundamental approach, the company has expanded the implementation of eco-design principles in its development process and has increased the number of products with life cycle assessments to ensure that the environmental properties of the products are gradually improved.

Sustainability-related risks are reported in more detail on page 78.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**Getinge's insurance program**

**Strategy**

Getinge works actively with loss prevention activities, for example, through its extensive quality activities and by preventing interruption risks in the operations. The starting point is for Getinge to act as if the Group is uninsured. That means that Getinge continuously considers risk factors and manage them as part of the daily work. Actively monitoring incidents and correcting underlying causes means that incidents can be prevented.

**Group-wide insurance program**

Getinge has a Group-wide insurance program that covers the entire global operations. The program aims to protect the assets in the consolidated balance sheet and to counteract fluctuations in earnings. The aim is to cover insurable risks with adequate limits based on current risk exposure levels. Insurance contracts are entered into with insurance companies with high credit ratings and a proven ability to manage claims. The insurance program generates economies of scale, ensures standardized insurance coverage for the Group's global operations and adds customer value since insurance is often required in tender and procurement processes and when commercial contracts are signed.



# Proposed appropriation of profit

Getinge AB (publ), Corp. ID No. 556408-5032

**The following non-restricted equity in the Parent Company is at the disposal of the Annual General Meeting, SEK M:**

Share premium reserve	4,264
Retained earnings	17,491
Net profit for the year	1,956
<b>Total</b>	<b>23,711</b>

The Board and CEO propose that a dividend of SEK 4.75 per share shall be distributed to shareholders	1,294
to be carried forward	22,417
<b>Total</b>	<b>23,711</b>

The Board of Directors deems the proposed dividend to be justified in relation to requirements that the nature of the business, scope and risks impose on consolidated equity and the Group's consolidation requirements, liquidity and financial position.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

# Assurance of the Board of Directors and the CEO

The Board of Directors and the CEO affirm that the consolidated financial statements have been prepared in accordance with international financial reporting standards IFRS, as adopted by the EU, and provide a true and fair view of the Group's financial position and profit. These financial statements were prepared in accordance with generally accepted accounting policies and provides a true and fair view of the Parent Company's financial position and profit. The Board of Directors and the CEO also certify that the consolidated accounts and the annual accounts have been prepared in accordance with the European Sustainability Reporting Standards (ESRS) and the specifications adopted under the EU Taxonomy Regulation.

The Administration Report for the Group and Parent Company provides a fair and accurate overview of the performance of the Parent Company and the Group's operations, financial position and earnings and describes the material risks and uncertainties faced by the Parent Company and companies belonging to the Group.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**Date of adoption and signing of the Annual Report, Gothenburg, March 25, 2026**

**Johan Malmquist**  
Chairman  
AGM-elected Board member

**Carl Bennet**  
Vice Chairman  
AGM-elected Board member

**Johan Bygge**  
AGM-elected Board member

**Cecilia Daun Wennborg**  
AGM-elected Board member

**Ulrika Dellby**  
AGM-elected Board member

**Dan Frohm**  
AGM-elected Board member

**Mattias Perjos**  
President & CEO,  
AGM-elected Board member

**Malin Persson**  
AGM-elected Board member

**Kristian Samuelsson**  
AGM-elected Board member

**Fredrik Brattborn**  
Board member  
Representative of the Swedish  
Metalworkers' Union

**Åke Larsson**  
Board member  
Representative of the Swedish  
Association of Graduate Engineers

**Our auditor's report on the annual report and the consolidated financial statements was submitted on March 25, 2026.  
Our limited assurance report regarding the statutory sustainability statement was submitted on March 25, 2026.**

**Fredrik Norrman**  
Authorized Public Accountant  
Auditor in Charge

# Current guidelines for remuneration to Senior Executives

## Adopted at the 2023 Annual General Meeting

### 1. Scope of the guidelines, etc.

These guidelines cover the individuals who, during the validity period of the guidelines, are included in the group management of Getinge AB (publ), below referred to as "Senior Executives". The guidelines shall apply for remuneration agreed and amendments in any remunerations already agreed, as of the adoption of the guidelines by the 2023 Annual General Meeting. The guidelines are not applicable on any remuneration resolved by the General Meeting.

### 2. Promotion of Getinge's business strategy, long-term interests and sustainability, etc.

A prerequisite for successful implementation of the company's business strategy and safeguarding the company's long-term interests is that the company is able to recruit and retain qualified personnel. The main principle is that remuneration and other employment conditions for Senior Executives, shall be in line with market terms and competitive on every market where Getinge operates, to ensure that competent and skilled personnel can be attracted, motivated and retained. Individual levels of remuneration shall be based on experience, competence, level of

responsibility and performance, and also the country where the Senior Executive is employed. These guidelines promote the company's business strategy, long-term interests and sustainability as described in the below section regarding criteria for variable remuneration, and contribute to the company's ability to, on a long-term basis, retain qualified personnel.

For information regarding Getinge's business strategy, please see the company's annual reports and the website (<https://www.getinge.com>).

### 3. Principles for various types of remuneration, etc.

The total remuneration to Senior Executives shall be in line with market terms and consist of base salary (fixed cash remuneration), variable cash remuneration, any other variable remuneration, pension benefits and other benefits. In addition, the General Meeting may – irrespective of these guidelines – resolve on, for instance, share- or share price-related remunerations.

#### Fixed remuneration

The fixed remuneration, meaning the base salary, shall be based on the individual employee's area of responsibility, authority, competence, experience and performance.

#### Variable remuneration

The allocation between base salary and variable remuneration shall be in proportion with the area of responsibility and authority of the executive. The variable remuneration shall always be pre-limited to a maximum amount and related to predetermined and measurable criteria, designed to contribute to the business strategy and long-term added value of the company.

The annual variable remuneration is designed to promote the company's strategy to produce and offer products that can support in making health care more efficient in the long-term and to provide better health care for the people who need Getinge's products. If the above-mentioned activities are performed in an efficient and sustainable way, one outcome is improved financial results and increased capital efficiency, which constitutes the foundation of the variable remuneration. The sustainability work is integrated in the company's day-to-day operations. If the company's principles for sustainability or ethical guidelines are not complied with, the company has the possibility to withhold any variable remuneration or reclaim already awarded remuneration.

#### Annual variable remuneration

For Senior Executives, the annual variable remuneration (annual bonus) shall be capped at 70% and, in specific cases, where the nature of the position, the competitive situation and the country of employment so require, capped at 90% of the fixed annual base salary. The variable remuneration shall be based on objectives set by the Board of Directors. These objectives are related to (i) earnings, (ii) organic growth, (iii) working capital and cash flow, and (iv) sustainability. In order to promote the interest of the shareholders', the company's values and collectively strive to achieve the business strategy, long-term interests and sustainable development of the company, all members of the group management have the same targets for annual variable remuneration.

#### Variable long-term cash bonus (LTI-bonus)

In addition to base salary and annual variable remuneration as described above, Senior Executives can obtain a variable long-term bonus (LTI-bonus) The target that forms the basis for the LTI-bonus is adjusted earnings per share for a three-year period, adjusted for the category of adjustment items decided at implementation of the program by the Board of Directors at the recommendation by the Remuneration Committee.

## Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board's Operating Reports

→ Administration Report

Corporate Governance Report

Sustainability statement

### Financial statements

### Other information

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

By connecting the performance target to the shareholders' objective, a common interest to promote Getinge's business strategy, long-term interests and value creation is created. Payment is subject to continued employment at the end of the vesting period for the LTI-bonus (with some customary exceptions).

The vesting period for the LTI-bonus shall be not less than three financial years. The payment of LTI bonus per each three-year program shall be capped to 33% of one year's base salary. A new LTI-bonus program can be set up every year with a duration period of three years. Senior Executives of the group management shall invest not less than 50% of the received LTI-bonus (net, after taxes paid) in Getinge shares, until the Senior Executive's own total holdings of shares correspond to one year's salary (gross). The Senior Executive shall keep these shares for at least three years.

*Limitation of total variable remuneration for the CEO*

For the CEO, the total payment of variable remuneration (annual variable remuneration and LTI-bonus), in addition to what is previously mentioned, annually be limited so that the total variable remuneration does not exceed 100% of the fixed salary. This applies to variable remuneration that is paid 2022 or later.

*Determination of result for variable remuneration, etc.*

When the measuring period for achievement of the criteria for payment of the variable remuneration has expired, the Board of Directors shall, based on proposal by the Remuneration Committee, establish to which extent the criteria are achieved. In their assessment on whether the criteria are achieved or not, the Board of Directors may, in accordance with proposal by the Remuneration Committee, allow exception from the established targets on the conditions set out

in the below item 5. The assessment of achievement of the financial targets shall be based on the company's most recent published financial information, with any adjustments predetermined by the Board of Directors when implementing the program. Variable cash payment can be awarded after the expiration of the measuring period (annual variable remuneration) or be subject to postponed payment (LTI-bonus).

Getinge is actively working to ensure that the company is managed in the most sustainable, responsible and efficient way possible, and that applicable legislations and regulations are complied with. Getinge also apply internal rules, including a code of conduct and different group-wide steering documents (policies, instructions and guidelines) within a range of different areas. Variable remuneration shall not be awarded, and can be reclaimed, if the Senior Executive has acted contrary to these rules, principles or the company's code of conduct. Variable remuneration shall not be awarded if the earnings before tax is negative. The Board of Directors shall also have the possibility to, in accordance with legislation or agreement, in whole or partly, reclaim any variable wrongly awarded remuneration.

*Other variable remuneration*

Additional variable cash remuneration can be awarded in case of extraordinary circumstances, provided such extraordinary arrangements are only conducted for the purpose of recruiting or retaining executives. Such remuneration may not exceed an amount corresponding to 100% of the base salary and only be awarded once a year per individual. Resolution on such remuneration shall be made by the Board of Directors and based on a proposal by the Remuneration Committee. In addition to variable remuneration, resolutions on share- or share price related incentive programs, in accordance with the above, can from time to time be made.

**Pension and insurance**

The CEO has right to retire from the age of 62 and other Senior Executives has right to retire in accordance with applicable local regulations.

Pension contributions for the CEO shall amount to no more than 40% of the fixed base salary on a defined contribution basis. Variable cash remuneration shall not qualify for pension benefits.

Pension contributions for other Senior Executives shall amount to a maximum of 40%<sup>1</sup> of the pensionable salary and shall be on a defined contribution basis. Variable cash remuneration shall not qualify for pension benefits in general, except where mandatory by collective bargaining agreement provisions applicable for the executive. In such case, this shall be considered when creating the total benefits package. In addition to the above, Senior Executives may be covered by an additional health income insurance (sw. *sjukinkomstförsäkring*).

For employments governed by other than Swedish regulations, pension benefits and other insurances may be duly amended to comply with mandatory rules or established local regulations, taking into consideration, to the extent possible, the overall purpose of these guidelines.

**Other benefits**

Other benefits such as company car, additional medical insurance (sw. *sjukvårdsförsäkring*) and company health care (sw. *företagshälsovård*), may be provided to the extent this is considered to be in line with market terms for Senior Executives on similar positions on that local market. The total value of such benefits may not exceed 10% of the fixed base salary.

**Conditions for termination**

Senior Executives shall have a permanent employment. If the company terminates the employment, the notice period shall not exceed twelve months. Upon termination of employment, the total of the

fixed salary during the notice period together with severance pay may not exceed an amount equivalent to two years fixed base salary for the CEO, and one year for other executives. If the executive terminates the employment, the notice period shall not exceed six months and be without any right to severance pay.

Senior Executives may be entitled to compensation for any competition restrictions after the termination of employment, however, only to the extent severance pay for the corresponding period is not awarded. The purpose of such compensation is to compensate the executive for any gap between the monthly base salary at the notice of termination and (lower) monthly income received, or that could be received, by a new employment, assignment or own business. The compensation can be awarded during the period of the competition restriction, however, not more than for 12 months after the termination of employment.

**Salary and employment conditions for employees**

When preparing the Board of Director's proposal for these remuneration guidelines, salary and employment conditions for the company's employees have been considered. This have been made by including information of the total income of the employees, the components of the remuneration and the increase and growth rate over time, as part of the Remuneration Committee's and the Board of Directors' basis for decision when evaluating whether the guidelines and the limitations set out herein are reasonable. The development of the gap between the remuneration to Senior Executives and remuneration to other employees will be disclosed in the remuneration report.

**4. The resolution process to determine, review and implement the guidelines**

The Board of Directors has established a Remuneration Committee. The Committee's tasks include preparing the Board of Directors' decision

<sup>1</sup>) Pension contributions may, exceptionally, exceed this limit if required to comply with mandatory law, collective bargaining agreements or other applicable rules or established local practice, taking into consideration, to the extent possible, the overall purpose of these guidelines.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

to propose guidelines for Senior Executive remuneration. These are reviewed annually and new proposals for guidelines shall be drafted by the Board at least every fourth year and presented to the Annual General Meeting for resolution. The guidelines shall be in force until new guidelines are adopted by the Annual General Meeting.

The Remuneration Committee shall also monitor and evaluate programs for variable remuneration to Senior Executives, the guidelines for remuneration to Senior Executives, as well as the current remuneration structures and compensation levels in the company, and provide recommendations to the Board of Directors in relation to remuneration to the CEO. Regarding resolution on remuneration to other Senior Executives in accordance with the guidelines (other than the specifically regulated above) the CEO shall consult with the Remuneration Committee.

The CEO and other members of the group management do not participate in the Board of Directors' processing of, and resolutions on, remuneration-related matters when such matters concern them.

The Board of Directors shall annually draw up a remuneration report that shall be presented to the Annual General Meeting for approval.

**5. Deviations from the guidelines**

The Board of Directors may temporarily resolve to deviate from the guidelines, entirely or partly, if in a specific case there is special cause for the deviation and a deviation is necessary to serve the company's long-term interests, a sustainable development of the company or to ensure the company's financial viability. As set out above, the Remuneration Committee's tasks include preparing the Board of Directors' resolutions in remuneration-related matters. This includes any resolutions to deviate from the guidelines.

# The Board of Directors' proposal to guidelines for remuneration to Senior Executives

**The Board of Directors of Getinge AB (publ) proposes that the 2026 Annual General Meeting resolves on the following guidelines for remuneration to Senior Executives.**

The currently applicable guidelines for remuneration to Senior Executives were adopted at the 2023 Annual General Meeting. In relation to the currently applicable guidelines, the guidelines that are now proposed for adoption by the 2026 Annual General Meeting mean that the payment of LTI-bonus in exceptional cases, were the nature of the position, the competitive situation and the country of employment so require, may be capped at 50% of the fixed annual base salary. Furthermore, the expectations on Senior Executives' holdings of Getinge AB shares are being changed and clarified. The proposed amendments also include a changed decision-making process for remuneration in accordance with the guidelines to other Senior Executives (other than the CEO), where the Remuneration Committee is delegated decision-making authority and the introduction of a possibility for the CEO and the Chairman of the Board to, in urgent or extraordinary cases, jointly decide on certain variable remuneration to other Senior Executives in accordance with the dual approval principle. Certain clarifications and editorial changes have also been made.

No remarks on the remuneration guidelines have emerged in connection with dealings at General Meetings.

**1. Scope of the guidelines, etc.**

These guidelines cover the individuals who, during the validity period of the guidelines, are included in the group management of Getinge AB (publ), below referred to as "Senior Executives". The guidelines shall apply to remuneration agreed and amendments in any remunerations already agreed, as of the adoption of the guidelines by the 2026 Annual General Meeting. The guidelines are not applicable on any remuneration resolved by the General Meeting.

**2. Promotion of Getinge's business strategy, long-term interests and sustainability, etc.**

A prerequisite for successful implementation of the company's business strategy and safeguarding the company's long-term interests is that the company is able to recruit and retain qualified personnel. The main principle is that remuneration and other employment conditions for Senior Executives shall be in line with market terms and competitive on every market where Getinge operates, to ensure that competent and skilled personnel can be attracted, motivated and retained. Individual levels of remuneration shall be based on experience, competence, level of responsibility and performance, and also the country where the Senior Executive is employed. These guidelines promote the company's business strategy, long-term interests and sustainability as described in the below section regarding criteria for variable remuneration, and contribute to the

company's ability to, on a long-term basis, retain qualified personnel.

For information regarding Getinge's business strategy, please see the company's annual reports and the website (<https://www.getinge.com>).

**3. Principles for various types of remuneration, etc.**

The total remuneration to Senior Executives shall be in line with market terms and consist of base salary (fixed cash remuneration), any variable cash remuneration and any other variable remuneration, pension benefits and other benefits.

In addition, the General Meeting may – irrespective of these guidelines – resolve on, for instance, share- or share price-related remunerations.

*Fixed remuneration*

The fixed remuneration, meaning the base salary, shall be based on the individual employee's area of responsibility, authority, competence, experience and performance.

*Variable remuneration*

The allocation between base salary and variable remuneration shall be in proportion with the area of responsibility and authority of the executive. The variable remuneration shall always be pre-limited to a maximum amount and related to predetermined and measurable criteria, designed to contribute to the business strategy and long-term added value of the company.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

The variable remuneration is designed to promote the company's strategy to produce and offer products that can support in making health care more efficient in the long-term and to provide better health care for the people who need Getinge's products. If the above-mentioned activities are performed in an efficient and sustainable way, one outcome is improved financial results and increased capital efficiency, which constitutes the foundation of the variable remuneration. The sustainability work is integrated in the company's day-to-day operations. If the company's principles for sustainability or ethical guidelines are not complied with, the company has the possibility to withhold any variable remuneration or reclaim already awarded remuneration.

The variable remuneration may consist of a short-term incentive program (STI) and a long-term incentive program (LTI).

*Short-term incentive program (STI)*

The STI may consist of annual variable cash remuneration (STI bonus). For Senior Executives, the STI bonus shall be capped at 70% and, in specific cases, were the nature of the position, the competitive situation and the country of employment so require, capped at 90% of the fixed annual base salary. The STI bonus shall be based on objectives set by the Board of Directors. These objectives shall be related to (i) earnings, (ii) organic sales growth, (iii) working capital, and (iv) sustainability. In order to promote the interest of the shareholders', the company's values and collectively strive to achieve the business strategy, long-term interests and sustainable development of the company, all members of the group management shall have the same targets for STI bonus.

*Long-term incentive program (LTI):*

*Long-term variable cash remuneration (LTI-bonus)*

The LTI may consist of long-term variable cash remuneration (LTI bonus). The target that forms the basis for the LTI-bonus is adjusted earnings per share for a three-year period, adjusted for the category of adjustment items decided by the Board of Directors at implementation of the program, on the recommendation of the Remuneration Committee. By connecting the performance target to the shareholders' objective, a common interest to promote Getinge's business strategy, long-term interests and value creation is created. Payment is subject to continued employment at the end of the vesting period for the LTI-bonus (with some customary exceptions).

The vesting period for the LTI-bonus shall be not less than three financial years. The payment of LTI-bonus per each three-year program shall be capped at 33% of one year's base salary or, in exceptional cases were the nature of the position, the competitive situation and the country of employment so require, at 50% of the fixed annual base salary. A new LTI program can be set up every year with a duration period of three years.

*Senior Executives' holdings of Getinge shares*

Senior Executives of the group management are expected to acquire Getinge shares corresponding to at least one year's salary (gross), calculated based on the share price prevailing from time to time, and maintain the holding for the duration of their employment. To ensure that this objective is achieved, Senior Executives who have not reached this holding shall invest not less than 50% of each received LTI-bonus (net, after taxes paid) in Getinge shares. The calculation of the total holding includes all shares acquired by the Senior Executive themselves, regardless of when or how they were acquired.

*Limitation of total variable remuneration for the CEO*

For the CEO, the total payment of variable remuneration (STI bonus and LTI bonus) shall, in addition to what is previously stated, annually be limited so that the total variable remuneration does not exceed 100% of the fixed salary.

*Determination of result for variable remuneration, etc.*

When the measuring period for achievement of the criteria for payment of the variable remuneration has expired, the Board of Directors shall, based on proposal by the Remuneration Committee, establish to which extent the criteria are achieved. In their assessment on whether the criteria are achieved or not, the Board of Directors may, in accordance with proposal by the Remuneration Committee, allow exception from the established targets in the event of significant unforeseen events. The assessment of achievement of the financial targets shall be based on the company's most recent published financial information, with any adjustments predetermined by the Board of Directors on the recommendation of the Remuneration Committee. Variable payment can be awarded after the expiration of the measuring period (STI bonus) or be subject to postponed payment (LTI-bonus).

Getinge is actively working to ensure that the company is managed in the most sustainable, responsible and efficient way possible, and that applicable legislations and regulations are complied with. Getinge also apply internal rules, including a code of conduct and different group-wide steering documents (policies, instructions and guidelines) within a range of different areas. Variable remuneration shall not be awarded, or can be reclaimed, if the Senior Executive has acted contrary to these rules, principles or the company's code of conduct.

Variable remuneration shall not be awarded if the earnings before tax is negative. The Board of Directors shall also have the possibility to, in accordance with legislation or agreement, in whole or partly, reclaim any wrongly awarded variable remuneration.

*Other variable remuneration*

Other variable remuneration than STI- and LTI-bonus can be awarded in case of extraordinary circumstances, provided such extraordinary arrangements are only conducted for the purpose of recruiting or retaining Senior Executives in the Executive Management Team. Such remuneration may not exceed an amount corresponding to 100% of the base salary and only be awarded once a year per individual. For resolutions on such other variable remuneration to the CEO, the Remuneration Committee is preparatory, and the Board of Directors is decision-making. For resolutions on such other variable remuneration to other Senior Executives than the CEO, the Remuneration Committee is the decision-making body. In urgent cases however – if a resolution by the Remuneration Committee cannot be awaited – the CEO shall be able to make such decisions regarding other Senior Executives jointly with the Chairman of the board in accordance with the dual approval principle, but only if the total amount does not exceed 50 % of the fixed annual base salary. Such decision shall be reported back to the Remuneration Committee as soon as possible.

In addition to the variable remuneration above (STI, LTI and other variable remuneration), resolutions by the general meeting on share- or share price related incentive programs, in accordance with item 3 above, can be made from time to time.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

*Pension and insurance*

The CEO has right to retire from the age of 62 and other Senior Executives has right to retire in accordance with applicable local regulations. Pension contributions for the CEO shall amount to no more than 40% of the fixed base salary on a defined contribution basis. Variable cash remuneration shall not qualify for pension benefits.

Pension contributions for other Senior Executives shall amount to a maximum of 40%<sup>1</sup> of the pensionable salary and shall be on a defined contribution basis. Variable remuneration shall not qualify for pension benefits in general, except where mandatory by collective bargaining agreement provisions applicable to the executive. In such case, this shall be considered when creating the total benefit package. In addition to the above, Senior Executives may be covered by an additional health income insurance (sw. *sjukinkomstförsäkring*).

For employments governed by other than Swedish regulations, pension benefits and other insurances may be duly amended to comply with mandatory rules or established local practice, taking into consideration, to the extent possible, the overall purpose of these guidelines.

*Other benefits*

Other benefits such as company car, additional medical insurance (sw. *sjukvårdsförsäkring*) and company health care (sw. *företagshälsovård*), may be provided to the extent this is considered to be in line with market terms for Senior Executives on similar positions on that local market. The total value of such benefits may not exceed 10% of the fixed base salary.

*Conditions for termination*

Senior Executives shall have a permanent employment. If the company terminates the employment, the notice period shall not exceed twelve months. Upon termination of employment, the total of the fixed salary during the notice period together with severance pay may not exceed an amount equivalent to two years fixed base salary for the CEO, and one years fixed base salary for other executives. If the executive terminates the employment, the notice period shall not exceed six months and be without any right to severance pay.

Senior Executives may be entitled to compensation for any competition restrictions after the termination of employment, however, only to the extent severance pay for the corresponding period is not awarded. The purpose of such compensation is to compensate the executive for any gap between the monthly base salary at the notice of termination and (lower) monthly income received, or that could be received, by a new employment, assignment or own business. The compensation can be awarded during the period of the competition restriction, however, not more than for 12 months after the termination of employment.

*Salary and employment conditions for employees*

When preparing the Board of Director's proposal for these remuneration guidelines, salary and employment conditions for the company's employees have been considered, by including information of the total income of the employees, the components of the remuneration and the increase and growth rate over time as part of the Remuneration Committee's and the Board of Directors' basis for decision when evaluating whether the guidelines and the limitations set out herein are reasonable. The development of the gap between the remuneration to Senior Executives and remuneration to other employees will be disclosed in the remuneration report.

**4. The resolution process to determine, review and implement the guidelines**

The Board of Directors has established a Remuneration Committee. The Committee's tasks include preparing the Board of Directors' decision to propose guidelines for Senior Executive remuneration. These are reviewed annually, and the Board shall draft new proposals for guidelines at least every fourth year, which shall be presented to the Annual General Meeting for resolution. The guidelines shall be in force until new guidelines are adopted by the Annual General Meeting.

The Remuneration Committee shall also monitor and evaluate programs for variable remuneration to Senior Executives, the application of the guidelines for remuneration to Senior Executives, as well as the current remuneration structures and compensation levels in the company, and provide recommendations to the Board of Directors for resolutions on remuneration to the CEO. Regarding resolution on remuneration to other Senior Executives in accordance with the guidelines (other than the specifically regulated above regarding other variable remuneration in case of extraordinary circumstances) resolutions shall be made by the Remuneration Committee.

The CEO and other members of the group management do not participate in the Board of Directors' or the Remuneration Committees' processing of, and resolutions on, remuneration-related matters when such matters concern them.

The Board of Directors shall annually draw up a remuneration report that shall be presented to the Annual General Meeting for approval.

**5. Deviations from the guidelines**

The Board of Directors may temporarily resolve to deviate from the guidelines, entirely or partly, if in a specific case there is special cause for the deviation and a deviation is necessary to serve the company's long-term interests, a sustainable development of the company or to ensure the company's financial viability. As set out above, the Remuneration Committee's tasks include preparing the Board of Directors' resolutions in remuneration-related matters. This includes any resolutions to deviate from the guidelines.

**6. Other**

Information regarding remuneration, etc. to Senior Executives during the financial year 2025 is set out in note 22 of the Annual Report 2025, including any previously resolved remuneration that has not yet become due for payment, and in the remuneration report.

Gothenburg in March 2026

**The Board of Directors of Getinge AB (publ)**

<sup>1</sup>) Pension contributions may, exceptionally, exceed this limit if required to comply with mandatory law, collective bargaining agreements or other applicable rules or established local practice, taking into consideration, to the extent possible, the overall purpose of these guidelines.

# Remuneration Report 2025

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**Introduction**

This report reflects how the guidelines for remuneration to Senior Executives, adopted at the 2023 Annual General Meeting ("AGM"), have been implemented and applied during 2025. The report also provide details on the remuneration to the President & CEO, how the performance targets for variable remuneration have been applied, and information that the company has not implemented any share- or share price-related incentive programs. This report has been prepared in compliance with the Swedish Companies Act and the *Rules on remuneration of the Board and Executive Management and Incentive programs issued by the Stock Market Self-Regulation Committee* (the Remuneration Rules).

Further information on remuneration to Senior Executives is available in Note 22 on pages 175–176 of the 2025 Annual Report. Information on the work by the Remuneration Committee in 2025 is set out in the Corporate Governance Report, which can be found on pages 56–72 of the 2025 Annual Report.

Remuneration of the Board of Directors is not covered by this report, but is resolved annually by the AGM. Information about remuneration to the Board of Directors is disclosed in Note 22 on page 175 and the Corporate Governance Report on pages 56–72 of the 2025 Annual Report.

The company has not received any comments on the 2024 Remuneration Report.

**The Group's overall performance 2025**

The President & CEO summarizes the Group's result and overall performance in his statement, which is included on pages 6–7 of the 2025 Annual Report.

**The company's remuneration guidelines**

A prerequisite for successful implementation of the company's business strategy and safeguarding of its long-term interests and sustainability is that the company is able to recruit, motivate and retain qualified personnel. By offering Senior Executives a competitive total compensation, the remuneration guidelines enable the company, on a long-term basis, to attract qualified personnel to the business.

The total remuneration to Senior Executives shall be in line with market terms and consist of base salary (fixed cash remuneration), variable cash remuneration, any other variable remuneration, pension benefits and other benefits. Remuneration and other employment terms and conditions are to be market-based and competitive in every market where Getinge is active. In addition, the General Meeting can decide on share- or share price-related remuneration.

The current guidelines for remuneration, adopted at the 2023 AGM, are presented on pages 47–49 of the 2025 Annual Report.

**Application and deviations from the remuneration guidelines**

In 2025, the company has complied with the guidelines adopted at the 2023 AGM. No deviations have been made from the guidelines nor any derogations from the procedure for resolution on remuneration, established by the remuneration guidelines.

The auditors' statement regarding the company's compliance with the guidelines is available on [www.getinge.com/int/company/corporate-governance/general-meetings/](http://www.getinge.com/int/company/corporate-governance/general-meetings/) under the tab 2026 Annual General Meeting. No paid remuneration has been reclaimed during 2025.

**Share based remuneration**

The General Meeting has not resolved on implementation of any share- or share price-related incentive program.


**Total remuneration to the President & CEO during 2025**

SEK 000s

Executive	Fixed remuneration		Variable remuneration			Total	Share of fixed and variable remuneration (%) <sup>6</sup>
	Fixed salary <sup>1</sup>	Other benefits <sup>2</sup>	Short-term variable remuneration <sup>3</sup>	Long-term variable remuneration <sup>4</sup>	Pension expenses <sup>5</sup>		
Mattias Perjos, President & CEO	28,436	456	18,761	–	11,176	58,829	68/32

- 1) Fixed salary refer to base salary, including holiday pay.
- 2) Other benefits refer to benefits such as company car, medical insurance (sw: sjukvårdsförsäkring), health income insurance (sw: sjukinkomstförsäkring) etc.
- 3) Short-term variable remuneration refers to bonus accrued during the 2025 fiscal year and to be paid during 2026.
- 4) Long-term variable remuneration refers to bonus accrued for expired long-term incentive program. During 2025, the program for 2023–2025 expired without reaching the performance target, why no long-term bonus has been accrued.
- 5) Pension expense for the President & CEO is based on a defined contribution basis and amounts to 40% of the base salary.
- 6) The pension expense for the President & CEO is based on the fixed base salary and is included in its entirety in the fixed remuneration.

**Total remuneration to the President & CEO in 2025**



**Percentage of fixed and variable remuneration in 2025**



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

→ Administration Report

Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**Principles for the application of performance targets for variable remuneration**

Selection of performance targets and resolution to determine the variable remuneration has been prepared by the Remuneration Committee and resolved by the Board of Directors. The variable remuneration is pre-limited to a maximum amount and related to predetermined and measurable criteria, designed to contribute to the interests of shareholders and the company's core values and

creates an incentive for joint efforts to achieve the company's business strategy, long-term added value and the sustainable development of the company. Getinge's sustainability work is integrated in the company's day-to-day operations. If Getinge's principles for sustainability or ethical guidelines are not complied with, the company has the possibility to withhold any variable remuneration or reclaim already awarded remuneration.

After the end of the fiscal year and based on a proposal by the Remuneration Committee, the Board of Directors has resolved to which extent the criteria for payment of the short- and long-term variable remuneration have been fulfilled. The assessment if the financial targets have been reached has been based on the company's most recent published financial information, with any adjustments approved by the Board of Directors at the proposal of the Remuneration Committee.

**Application of the performance targets for short-term variable remuneration**

The variable short-term remuneration to the President & CEO is limited to 80% of the fixed annual base salary. The targets for the 2025 fiscal

year were related to earnings, organic growth, tied-up working capital and sustainability. All five performance targets were fully or partly achieved in 2025, resulting in a degree of target fulfillment of 84 % and a corresponding bonus payout.

**The performance by the President & CEO during the reported fiscal year: short-term variable cash remuneration**

**Criteria for determination of short-term variable remuneration for the President & CEO and outcome**


Executive	Performance target	Weighting of performance target	Outcome of performance target	Variable remuneration per performance target (SEK 000s)
Mattias Perjos, President & CEO				
	Adjusted EBITA (SEK M) <sup>1</sup>	55%	SEK 5,460 M	10,319
	Net sales – organic growth (%) <sup>2</sup>	20%	4.9%	3,752
	Tied-up working capital – no. of days	15%	88.8 days	2,814
	Sustainability – reduction of CO <sub>2</sub> emissions in Scope 1 & Scope 2 <sup>3</sup>	5%	-13.4%	938
	Sustainability – ESG risk assessment and audit of suppliers	5%	Achieved	938
				<b>18,761</b>

1) Adjusted EBITA refers to the operating profit adjusted for exchange rate changes, acquisitions, divestments, restructuring costs and other material items affecting comparability.


2) Refers to the Group's organic net sales growth.

3) Scope 1 includes emissions from the consumption of oil and gas, and Scope 2 includes emissions from the consumption of electricity, heating and cooling.

**Distribution of outcome of short-term variable remuneration per performance target 2025**



**Set performance target**



Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

→ Administration Report

Corporate Governance Report

Sustainability statement

Financial statements

Other information

**Application of the performance targets for the variable long-term remuneration**

The long-term variable remuneration (“LTI bonus”) for the President & CEO is capped at an amount corresponding to one year’s base salary for a three-year period and is subject to continued employment at the end of the vesting period (with

some customary exceptions). The vesting period for the LTI bonus is three fiscal years.

The performance target for LTI 2023–2025, LTI 2024–2026 and LTI 2025–2027 is development of earnings per share over a three-year period, adjusted for the categories of adjustment items that the Board of Directors determines at the

implementation of each program based on recommendation of the Remuneration Committee.

The incentive program LTI 2023–2025 expired at the end of the 2025 fiscal year and the performance target was not achieved, which means that there will be no payout of long-term variable remuneration.

**The performance by the President & CEO during the reported fiscal year – long-term variable remuneration**

**Criteria for determination of long-term variable remuneration for the President & CEO and outcome**

Executive	Long-term incentive program (LTI)	Performance target <sup>1</sup>	Outcome of performance target	Variable remuneration per performance target (SEK 000s)
Mattias Perjos, President & CEO	LTI 2023–2025	Development of adjusted earnings per share 2023–2025	SEK 11.29 (adjusted earnings per share 2025)	– <sup>2</sup>
	LTI 2024–2026	Development of adjusted earnings per share 2024–2026	–	– <sup>3</sup>
	LTI 2025–2027	Development of adjusted earnings per share 2025–2027	–	– <sup>4</sup>

1) The performance targets in the group’s long-term variable remuneration schemes are earnings per share, adjusted for acquisitions, divestments, restructuring costs and other material non-recurrent costs.

2) At the end of the year, there was no provision for earned LTI bonus to the President & CEO as LTI 2023–2025 has expired and the performance target was not met. The vesting period for the Group’s long-term incentive scheme is three years and the remuneration is conditioned by the President & CEO remaining an employee at the end of the vesting period.

3) Since the three-year performance period for the performance target for the incentive program LTI 2024–2026 has not ended, there is no earned compensation for the incentive program and therefore no outcome for the performance target is reported.

4) Since the three-year performance period for the performance target for the incentive program LTI 2025–2027 has not ended, there is no earned compensation for the incentive program and therefore no outcome for the performance target is reported.

**Comparative information regarding the company’s result and changes in remuneration**

**Changes in remuneration and company performance over the last five reported fiscal years<sup>1</sup>**

	2025 <sup>4</sup>	2025 compared with 2024	2024 compared with 2023	2023 compared with 2022	2022 compared with 2021	2021 compared with 2020
Changes in remuneration to the President & CEO, SEK 000s <sup>2</sup>	58,829	-1,015 (-1.7%)	13,457 (29.0%)	3,143 (7.3%)	-16,378 (-27.5%)	-7,082 (-10.6%)
Changes in average remuneration to employees of Getinge AB, SEK 000s <sup>3</sup>	1,540	188 (13.9%)	-34 (-2.4%)	356 (34.6%)	-244 (-19.2%)	-340 (-21.1%)
Changes in operating profit for the group, SEK M	3,789	935 (32.8%)	-882 (-23.6%)	110 (3.0%)	-745 (-17.0%)	-413 (-8.6%)

1) In the above table, changes in remuneration and result between the years are presented. The changes are presented in both absolute terms and as a percentage.

2) Remuneration to the President & CEO relates to the total remuneration including fixed salary, short- and long-term variable remuneration, pension expenses and other benefits.

3) Remuneration to the Senior Executives excluded.

4) Refers to the outcome for year 2025.

Gothenburg in March 2026

**The Board of Directors of Getinge AB (publ)**

**Relative changes in remuneration and profit**



Welcome to Getinge

Market environment

Strategy

Business areas

The Board’s Operating Reports

→ Administration Report

Corporate Governance Report

Sustainability statement

Financial statements

Other information

# Corporate Governance Report

Corporate governance structure	57
Board of Directors	59
President & CEO and the Getinge Executive Team	65
Getinge’s Corporate Governance Framework	68
Assurance framework and risk management	70
Internal control over the financial reporting	71

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other information**

**About the report**

This Corporate Governance Report has been prepared and adopted by Getinge AB (publ)’s Board of Directors in accordance with the provisions of the Swedish Annual Accounts Act and the Swedish Corporate Governance Code. The Corporate Governance Report presents an overview of Getinge’s corporate governance, including a description of the system for internal control over the financial reporting. Information on Getinge’s corporate governance is also available at [www.getinge.com/int/company/corporate-governance/overview/](http://www.getinge.com/int/company/corporate-governance/overview/). Information on the website does not comprise part of this Corporate Governance Report.

## Enhanced corporate governance for long-term value creation

Over the past year, Getinge has continued to refine the Group’s corporate governance in order to create long-term value and bolster its ability to act quickly, responsibly and sustainably in a changing global context. By carrying out specific initiatives in business ethics, compliance and quality management, the Group has enhanced its ability to act proactively and adapt to new regulations. The aim of this work was to help strengthen risk management and improve operational efficiency.

During the year, the company has focused particularly on:

- **The Code of Conduct as a basis for learning**  
A global workshop was launched with the aim of embedding shared values, strengthening accountability and giving employees the tools to manage complex situations.
- **Refined governance model for compliance**  
Getinge’s governance model was further developed to meet regulatory requirements and geopolitical challenges, focusing specifically on AI regulations, cyber security, trade barriers such as tariffs and sustainability regulations.

- **Enhanced quality management**  
Work included refining the quality regulatory compliance function, improving quality management systems and clarifying process ownership to ensure a high level of product quality and pursue operational excellence.
- **Effective M&A integration**  
The Group has improved the integration process for acquisitions.
- **Change of auditor**  
Getinge conducted a structured introduction of the Group’s new auditor.

Getinge AB (publ) hereby submits its 2025 Corporate Governance Report that summarizes how corporate governance is structured, as well as how it has been carried out and developed in the Group during the 2025 fiscal year. This Corporate Governance Report is reviewed by the company’s auditors. The auditor’s examination of the Corporate Governance Report is provided on page 195.

## Corporate governance structure

### Getinge as a company

Getinge is a Swedish public limited liability company with the business name Getinge AB (publ), whose Class B shares are listed on Nasdaq Stockholm. The Board of Directors is domiciled in the municipality of Gothenburg, Västra Götaland County, Sweden. The objects of the company's operations shall be to, directly or indirectly through subsidiaries, engage in the manufacturing and sale of medical technical equipment, and in any other activities compatible therewith.


The Articles of Association contain no specific provisions for the appointment or dismissal of Board members or on amendments to the Articles of Association. The complete Articles of Association are available on [www.getinge.com](http://www.getinge.com).

### External regulations

Getinge's corporate governance is based on applicable laws, regulations, good practice on the stock market and the Nasdaq Rulebook for Issuers. In addition, the Group's corporate governance is based on the Swedish Corporate Governance Code (the "Code"). Getinge follows the Code's "comply or explain" principle.

Getinge's only deviation from the Code's regulations in 2025 was from the Code's rule 2.4, that the Chairman of the Board or any other Board member is not to be Chairman of the Nomination Committee. The Nomination Committee appointed Carl Bennet (Board member and owner of Getinge's largest shareholder, Carl Bennet AB) as Chairman of the Nomination Committee, since the Nomination Committee found it important to have

### Main governing bodies within Getinge



a representative of the company's largest shareholder to serve as Chairman.

There were no violations of the stock market rules and no violations of good practice on the stock market reported by Nasdaq Stockholm's Disciplinary Committee or the Swedish Securities Council during the year.

### A SHARES AND SHAREHOLDERS

The total number of shares in the company amounts to 272,369,573, of which 18,217,200 are Class A shares, each share carrying entitlement to ten votes and 254,152,373 are Class B shares, each share carrying entitlement to one vote. All shares carry the same dividend entitlement, and the Articles of Association contain no limitation on the number of votes each shareholder can cast at a General Meeting of Shareholders. The 2025 Annual General Meeting ("AGM") resolved to authorize the Board to, on one or several occasions until the 2026 AGM, resolve on repurchase of as many own Class B shares that the shares held by Getinge at any point in time does not exceed ten (10) percent of all shares in the company. No shares were repurchased in 2025.

Getinge's largest shareholder, Carl Bennet AB, held 20.20% of the shares outstanding and 50.19% of all votes in the company at the end of the 2025 fiscal year, making him the only direct or indirect shareholder with a holding in the company representing over one tenth of the number of votes for all of the shares in the company.

For information about the Getinge share and the company's shareholders, see pages 199–200 and [www.getinge.com](http://www.getinge.com).

### Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board's Operating Reports

Administration Report

→ Corporate Governance Report

Sustainability statement

### Financial statements

### Other

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other**

**B GENERAL MEETING OF SHAREHOLDERS**

The General Meeting of Shareholders is Getinge's highest decision-making body. Shareholders can exert their influence at the AGM and, when applicable, at an Extraordinary General Meeting. The AGM, where shareholders exercise their voting rights in key issues for the company, is held within six months of the end of the fiscal year.

General Meetings of Shareholders are convened by publishing of a notice in the Swedish Official Gazette (*sw. Post- och Inrikes Tidningar*) and on the company's website. An announcement is to be made in the newspaper Svenska Dagbladet that the notice of the Meeting has been published. Shareholders who want to participate in the discussions at the Meeting must give notice of attendance to the company not later than the date provided in the notice of the Meeting. The Articles of Association also prescribe a possibility for the Board of Directors to resolve on collection of powers of attorney and to resolve that shareholders can exercise their voting rights by postal voting. A shareholder who wishes to have a matter put forward at the General Meeting of Shareholders must submit a written proposal to the Board in a timely manner so that the proposal can be included in the notice of the Meeting.

**2025 Annual General Meeting**

The 2025 AGM was held on April 22 in Halmstad, Sweden, both physically and through postal voting. All of the members of the Board, the Nomination Committee's representatives and the auditor in charge attended the AGM. A total of 725 shareholders were represented at the AGM, representing approximately 83.5% of the votes in the company.

The decisions made by the AGM include:

- Dividend of SEK 4.60 per share for the 2024 fiscal year
- Re-election of all Board members available for re-election and the Chairman, and election of Ulrika Dellby as a new Board member
- Election of Ernst & Young AB as the company's new auditor
- Approval of the remuneration report
- Authorization for the Board to resolve on repurchase of own shares

The minutes from the AGM are available at: [www.getinge.com](http://www.getinge.com).

**2026 Annual General Meeting**

The AGM will be held on April 21, 2026 at Kongresshallen at Hotel Tylösand in Halmstad, Sweden. Shareholders are also offered the possibility of taking part through postal voting. Information about how shareholders can register their attendance at the AGM is available at [www.getinge.com](http://www.getinge.com). The notice of the AGM is also available on the website, together with proposals and other relevant documentation for the AGM.

**C NOMINATION COMMITTEE**

The Nomination Committee's task is to put forward proposals ahead of the AGM regarding the election of the Chairman of the AGM, the Chairman of the Board and other members of the Board, election of auditors, as well as fees for Board members and auditors.

At the 2020 AGM, principles were adopted for the appointment of the Nomination Committee and the instruction for the Nomination Committee, to apply until further notice. Ahead of each AGM, the Nomination Committee shall be composed of members appointed by the four largest shareholders in terms of voting rights as of August 31 of each year, and the Chairman of the Board. In addition, if the Chairman of the Board in consultation with the member appointed by the largest shareholder in terms of voting rights deems it appropriate, it shall include an, in relation to the company and its major shareholders, independent representative of the minority shareholders. The complete instruction for the Nomination Committee is available on [www.getinge.com/int/company/corporate-governance/overview/](http://www.getinge.com/int/company/corporate-governance/overview/).

**Nomination Committee ahead of the 2026 Annual General Meeting**

The Nomination Committee ahead of the 2026 AGM comprises the company's Chairman of the Board Johan Malmquist, and representatives from the following four owners, listed by size:

- Carl Bennet AB: Carl Bennet
- Fourth Swedish National Pension Fund: Jannis Kitsakis
- AMF Pension & Fonder: Sophie Larsén
- Carnegie fonder: Anna Strömberg

Carl Bennet was appointed Chairman of the Nomination Committee ahead of the 2026 AGM (see the section "External regulations" above for information about deviation from the Code). No remuneration is paid to members of the Nomination Committee, and the members have affirmed that there are no conflicts of interest that affect their assignment on the Committee.

The Nomination Committee has addressed all the matters that the Nomination Committee must address in accordance with the Code. As a basis for its work, the Nomination Committee studied the financial statements for the company's operations in 2025, the completed Board evaluation and proposals received. When preparing its proposals on the composition of the Board, the Nomination Committee takes into account the individual expertise and experience of the proposed Board members, how well the Board will work as a whole and whether it possesses the necessary breadth in terms of background and expertise. The Nomination Committee paid particular attention to the balance between the need for renewal and continuity in the Board, and the value of diversity. In its efforts to achieve diversity, the Nomination Committee gives special consideration to the importance of gender balance. The Nomination Committee applies rule 4.1 of the Code as its diversity policy in preparing proposals of Board members. The aim of the policy is that the Board is to have a composition appropriate to the company's operations, phase of development and other relevant circumstances and to exhibit diversity and breadth of qualifications, experience and background, and strive for gender balance. Ahead of the 2025 AGM, the Nomination Committee noted that the gender balance was not satisfactory and at the AGM,

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other**

the Board was expanded by one female member, in accordance with the Nomination Committee's proposal. The Nomination Committee has, in its own assessment, concluded that the current Board is well functioning and that the Board members together hold the diversity and extensive competence, experience and background required, and are suitable with respect to the company's operations, phase of development and other circumstances, including sustainability aspects. In its assessment of the future composition of the Board, the Nomination Committee specifically considered the need to supplement the Board's overall skills by adding additional experience of international business operations and in-depth expertise of the US market. The Nomination Committee announced in a press release on December 18, 2025 that it proposes to the 2026 AGM that the number of Board members elected by the AGM remain at nine, that Malin Persson has declined re-election and that Camilla Sylvest is proposed by the Nomination Committee as a new Board member.

The proposals of the Nomination Committee ahead of the 2026 AGM are submitted in the notice of the Meeting.

**D EXTERNAL AUDITOR**

Getinge AB (publ)'s auditor is elected by the AGM. The auditor performs an audit of the Annual Report, financial statements and the consolidated financial statements as well as the management by the Board and President and CEO in accordance with generally accepted auditing standards. After each fiscal year an auditor's report for the Parent Company and a Group auditor's report are presented to the General Meeting. The auditor also reviews Getinge's nine-months report.

The Auditor in Charge participates in all of the Audit and Risk Committee meetings, as well as relevant Ethics and Sustainability Committee meetings, and reports to the relevant committees and Board of Directors on their audit.

**External auditors in 2025**

The registered auditing firm Öhrlings PricewaterhouseCoopers AB was the auditor until the 2025 AGM, at which the registered auditing firm Ernst & Young AB was elected as the new auditor until the 2026 AGM. The Authorized Public Accountant Fredrik Norrman has been Auditor in Charge since the 2025 AGM.

In addition to standard audit assignments, Ernst & Young AB provides advisory services and performs assessments. Such assignments take place in accordance with the regulations determined by the Audit and Risk Committee for approval of the nature and scope of the services and the fees for such services. The performed assignments are not deemed to have given rise to any conflict of interest. Details about the amounts of remuneration paid to auditors are presented in Note 5 of the Annual Report.

**E BOARD OF DIRECTORS**

**Composition of the Board of Directors**

Since the 2025 Annual General Meeting, Getinge AB (publ)'s Board has comprised nine members elected by the AGM, of whom one is Getinge's President and CEO, as well as two members appointed by employee representative organizations and two deputy members for the employee representatives. Out of the Board members elected by the AGM, three are women and six are men (corresponding to 33% and 67%, respectively).

**Independence of Board members**

The Nomination Committee deemed that the composition of the Board during 2025 met the requirements for independence as stipulated by the Code. The Nomination Committee has observed that Mattias Perjos, in his capacity as President and CEO, is to be regarded as dependent in relation to the company and executive management, and that Carl Bennet and Dan Frohm, as Board members of Getinge's principal owner Carl Bennet AB, are to be regarded as dependent in relation to the major shareholders. Other Board members are deemed to be independent in relation to the company, executive management and major shareholders. A total of eight out of nine Board members are deemed to be independent in relation to the company and executive management (89%) and seven out of nine are deemed to be independent in relation to major shareholders (78%).

**Expertise of the Board**

Ahead of the 2026 AGM, the Nomination Committee concluded that the Board functions well and that the Board members possess broad expertise and solid industry knowledge. For example, the Board members jointly possess solid financial background and extensive financial know-how, such as through Board members' previous operative assignments within fields of economics and finance and other Board assignments, including work in Audit Committees. The Board also jointly possess competence and experience from the sustainability field, for example through one Board member's previous assignment as chairman of a Sustainability Committee in another company but also through other Board members' operational assignments in

**The Board of Directors of Getinge AB (publ) is responsible for, among other things:**

- Overall strategy, targets and organization
- That procedures are in place for financial reporting and that financial reporting is conducted in accordance with applicable rules and regulations
- An overview of the financial plan, earnings, forecasts and forward-looking statements as well as the adoption of the financial statements
- Ensuring that there are effective systems for follow-ups and control of operations, financial position and risks, and well-functioning internal control
- Identifying how sustainability issues affect risks and business opportunities
- Approving guidelines and general policies for conduct in society with the aim of securing long-term value creation
- Ensuring that there are sufficient control mechanisms in place for compliance with applicable rules and regulations, as well as with internal policies and guidelines
- Ensuring that external disclosures (incl. financial reporting and sustainability reporting) are characterized by openness and objectivity, and are correct, reliable and have a high level of relevance, and that there are appropriate processes, controls and systems in place

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other**

executive positions. Through certain Board members' previous and/or current operational assignments for Getinge and other companies, the Board members jointly possess sound knowledge of the industry and market where the company operates and of areas of relevance for the operations, such as acquisitions, company development and artificial intelligence. Within the Board, there is also competence and experience from operational work within hospitals and clinical activity. In addition, the Board has solid experience from international relations and Board work, in broad sense, through Board members' previous and current operational assignments as well as Board assignments in other companies.

**Responsibilities and work of the Board of Directors**

Primarily, the Board is responsible for the organization of the company and the management of its affairs. In carrying out its duties, the Board must safeguard the interest of all its shareholders. The Board of Directors is to maintain and promote a good corporate culture and ensure that Getinge – on behalf of its shareholders – is led in the most sustainable, responsible and effective manner possible.

The guidelines for the Board's work are described in greater detail in the Board's rules of procedure and annual plan, which are reviewed and adopted each year. The rules of procedure include provisions on preventing disqualification and conflicts of interests for Board members, and a process for handling any transactions between Getinge and related parties.<sup>1</sup>

The Chairman is responsible for leading and managing the Board's work and ensuring that it is conducted in an organized and efficient manner. The President and CEO acts as rapporteur at the Board's meetings. In addition, the Group's Chief Financial Officer serves as rapporteur and the Group's Head of Corporate Legal serves as Secretary of the Board, with the exception of instances where it is inappropriate for them to attend. Other senior executives also participate when needed. The rules of procedure also contain guidelines for the work of the Board's committees. The Board decides on the members of the committees, with the aim of the committee members possessing the relevant experience and skills for the committees' work.

**Board of Directors' work in 2025**

In 2025, the Board held a total of 10 meetings, with an attendance rate of 100% of the members elected by the AGM.

At its ordinary meetings, the Board has addressed fixed agenda items in accordance with the Board's rules of procedure and annual plan. Accordingly, the Board has addressed the Group's long-term objectives and strategy, risks and risk management, sustainability matters, financial plan and investment plan, financial reports and corporate governance documents. The Board has continuously addressed its business situation and financial matters, ethics and compliance, quality and regulatory matters, succession planning and talent development, as well as organizational matters. During the year, the Board also addressed legal proceedings and acquisitions.

During the year, the Board worked in particular on matters related to:

- quality work and remediation of the communicated challenges in the area and implementation of robust processes and systems;
- sustainability efforts and ensuring that these are integrated throughout operations;
- the Group's acquisition agenda and integration of previous acquisitions;
- trade barriers, such as tariffs;
- business intelligence, geopolitical challenges and scenario simulations.

At one of its meetings, the Board met with the company's auditor without the presence of the President and CEO or any other individual from executive management. The Board also continuously evaluated the work of the President and CEO and addressed to this matter at one meeting without the presence of executive management.

**Board of Directors' evaluation of its work**

The Board carries out an annual evaluation of its work for the purpose of developing its methods and effectiveness. The evaluation in 2025 was, as in previous years, based on a survey and a tool provided by an external party. Additionally, the Chairman of the Board carried out individual interviews with the Board members. The results and analysis of this have been reported to the Board and followed up on with discussions and identification of focus areas moving forward. The Nomination Committee has taken part of the evaluation in its entirety as well as the Board's conclusions.

<sup>1</sup>) Board member's shareholdings and other assignments can be found on pages 62–64. Getinge does not collect shareholding information from suppliers or other stakeholders. Information on any transactions with related parties are presented in Note 28.

## BOARD COMMITTEES

The Board has established three committees – to focus on remuneration, audit and risk and ethics and sustainability

### F REMUNERATION COMMITTEE

#### Responsibilities and work

The Remuneration Committee is responsible for:

- preparing the Board’s resolutions concerning remuneration principles, remuneration and other employment terms and conditions for executive management;
- monitoring and evaluating variable remuneration programs for executive management;
- assisting in the preparation of the company’s remuneration report;
- preparing proposals on guidelines for the remuneration to senior executives that the Board will propose to the AGM;
- monitoring and evaluating the application of the guidelines for remuneration;
- evaluating the current remuneration structures and levels in the company; and
- preparing resolutions related to succession planning and talent development.

The Committee held three meetings in 2025, and remained in contact as required. A particular area of focus was evaluating and ensuring that current remuneration levels and structures are in line with market terms.

#### Composition

In 2025, the Committee comprised the Board members Johan Malmquist (Chairman), Carl Bennet and Dan Frohm. The members of the Remuneration Committee are independent in relation to the company and executive management, and Johan Malmquist is also independent in relation to the company’s major shareholders.

### G AUDIT AND RISK COMMITTEE

#### Responsibilities and work

The Audit and Risk Committee is responsible for:

- meeting the requirements of the Swedish Companies Act, the Code and the EU Audit Regulation;
- manage contact between the Board and the auditors;
- preparing matters relating to the election of auditors and remuneration;
- monitoring the company’s accounting;
- preparing the company’s financial statements;
- preparing the company’s finance policy;
- monitoring the effectiveness of the company’s internal control, financial risk management and internal audit;
- monitoring legal disputes, internal investigations and whistle-blowing cases;
- monitoring the Group’s work on information and cyber security matters; and
- monitoring sustainability reporting matters that have been delegated to the Ethics and Sustainability Committee.

The Committee held six meetings in 2025, and remained in contact as required. The company’s auditors participated in all meetings. Particular focus areas were the Group’s digital compliance program, trade barriers, financial capital structure and the introduction of the new auditor.

#### Composition

Since the 2025 AGM, the Committee comprised the Board members Johan Bygge (Chairman), Cecilia Daun Wennborg, Dan Frohm, Kristian Samuelsson and Ulrika Dellby. The members of the Committee are independent in relation to the company, executive management and the company’s major shareholders, with the exception of Dan Frohm, who is not considered to be independent in relation to the company’s major shareholders. The composition of the Committee meets the qualification criteria that is placed on accounting or auditing expertise.

### H ETHICS AND SUSTAINABILITY COMMITTEE

#### Responsibilities and work

The Ethics and Sustainability Committee is responsible for:

- preparing strategic matters regarding the work on key areas for sustainable development as defined by Getinge and the sustainability-related matters that the Board is required to address under the Code;
- monitoring the reporting and presentation of sustainability information in the financial statements and following up on the auditor’s review of the annual Sustainability statement;
- monitoring the work of the Sustainability function;
- monitoring the work of the Ethics & Compliance function and monitoring the implementation of an effective Ethics & Compliance program; and
- monitoring the work of the Quality Compliance, Regulatory & Medical Affairs function, and monitoring the implementation of the quality organization.

The Committee held seven meetings in 2025, and remained in contact as required. Particular focus areas for the year were the work on the Group’s materiality assessment and sustainability strategy, monitoring the process of sustainability reporting and product quality activities. In addition, the Committee has specifically monitored the Group’s implementation of and compliance with sustainability regulations affecting products and intra-Group processes and worked on the Group’s due diligence process for sustainable supply chains.

#### Composition

In 2025, the Committee comprised the Board members Cecilia Daun Wennborg (Chairman), Malin Persson and Dan Frohm. The members of the Committee are independent in relation to the company, executive management and the company’s major shareholders, with the exception of Dan Frohm, who is not considered to be independent in relation to the company’s major shareholders.

## Welcome to Getinge

## Market environment

## Strategy

## Business areas

## The Board’s Operating Reports

Administration Report

→ Corporate Governance Report

Sustainability statement

## Financial statements

## Other

# Board of Directors



Name	Johan Malmquist	Carl Bennet	Johan Bygge	Cecilia Daun Wennborg	Ulrika Dellby
<b>Position</b>	Board member elected by the AGM, Chairman of the Board. Board member since 2016. Chairman of the Remuneration Committee.	Board member elected by the AGM, Vice Chairman of the Board. Board member since 1989. Member of the Remuneration Committee.	Board member elected by the AGM. Board member since 2007. Chairman of the Audit and Risk Committee.	Board member elected by the AGM. Board member since 2010. Chairman of the Ethics and Sustainability Committee. Member of the Audit and Risk Committee.	Board member elected by the AGM. Board member since 2025. Member of the Audit and Risk Committee.
<b>Year of birth, education and nationality</b>	1961, B.Sc. in Business Administration, Swedish.	1951, B.Sc. in Business Administration, med. Dr. h.c., tech. Dr. h.c., honorary doctorate in economics, Swedish.	1956, B.Sc. in Business Administration, Swedish.	1963, B.Sc. in Business Administration, Swedish.	1966, B.Sc. in Business Administration, Swedish.
<b>Core expertise</b>	Industry know-how, Business management, International industry	Industry know-how, Business management, International industry	Business management, Mergers and acquisitions, Finance	Medical and healthcare, Business management, Sustainability	Acquisitions, Strategy, Business development.
<b>Board assignments</b>	Chairman of Arjo AB (publ) and Trelleborg AB (publ). Board member of Mölnlycke Health Care AB, Stena Adactum AB and Chalmers University of Technology Foundation.	Chairman of Lifco AB (publ). Vice Chairman of Arjo AB (publ) and Elanders AB (publ). Board member of L E Lundbergsföretagen AB (publ).	Chairman of Scandi Standard AB (publ), Guard Therapeutics AB (publ), Arevo AB, AB Regin and Q-Linea AB. Vice Chairman of Third Swedish Pension Fund (AP3). Board member of Lantmännen Ek.För, CapMan OYJ and Riksbankens Jubileumsfond Foundation.	Chairman of Almi AB. Board member of Loomis AB (publ), Bravida Holding AB (publ), Atvexa AB, Social Initiative Norden AB, Gränges AB (publ), and member of the Swedish Securities Council.	Board member of Arjo AB (publ), Elanders AB (publ), Lifco AB (publ), Linc AB (publ), Werksta Holdco AB and the Royal Dramatic Theatre.
<b>Professional experience, previous assignments and other information</b>	President & CEO of Getinge 1997–2015. Former Business Area Director within Getinge, President of Getinge's French subsidiary, President of subsidiaries in the Electrolux Group. Former Chairman of the Board of Tingstad Pappers AB, and Board member of Elekta AB (publ), SCA AB (publ) and the Dunker Foundations.	CEO and Chairman of Carl Bennet AB. Former President & CEO of Getinge 1989–1997. Chairman of Getinge's Board of Directors 1997–2019. Former Board member of Holmen AB (publ).	Former Chairman of PSM International China, Nobina AB (publ) and Yangi AB, Chairman of EQT Asia Pacific, Venture Partner of Prorum AG Venture Fund, COO of EQT, Board member of Anticimex, I-Med Ltd and Praktikertjänst AB, CFO of Investor AB, Executive Vice President of Electrolux and CFO of Electrolux.	Former deputy CEO of Ambea AB, CEO of Skandiabanken, Head of Swedish Operations at Skandia, President of Skandia Link, and Board member of Atos Medical Holding AB (publ), Hoist Finance AB (publ), Sophiahemmet, ICA Gruppen AB (publ), Hotell Diplomat AB, Eleda TopCo AB, Oncopeptides AB (publ) and the Oxfam Sweden Foundation.	Former partner of the Boston Consulting Group and Fagerberg & Dellby Fond I AB, CEO of Brindfors Enterprise IG (now Brand Union), Chairman of Fasadgruppen Group AB (publ), Vice Chairman of BICO Group AB (publ) and Norrporten and Board member of Cybercom Group AB, Kavli Holding AS, SJ AB and Business Executives Council of the Royal Swedish Academy of Engineering Sciences.
<b>Attendance at meetings*</b>					
Board meetings	10/10	10/10	10/10	10/10	6/6
Remuneration Committee	3/3	3/3	–	–	–
Audit and Risk Committee	–	–	6/6	6/6	4/4
Ethics and Sustainability Committee	–	–	–	7/7	–
<b>Independence<sup>1</sup></b>					
Dependent/independent in relation to the company and executive management and in relation to major shareholders	Independent in relation to the company, executive management and major shareholders.	Dependent in relation to major shareholders, owner and Chairman of Getinge's principal owner Carl Bennet AB. Independent in relation to the company and executive management.	Independent in relation to the company, executive management and major shareholders.	Independent in relation to the company, executive management and major shareholders.	Independent in relation to the company, executive management and major shareholders.
<b>Remuneration and holdings</b>					
Total remuneration in 2025, SEK	1,878,500, of which 163,100 comprises fees for the Remuneration Committee.	849,300, of which 118,200 comprises fees for the Remuneration Committee.	1,057,400, of which 326,300 comprises fees for the Audit and Risk Committee.	1,054,000, of which 159,800 comprises fees for the Audit and Risk Committee and 163,100 comprises fees for the Ethics and Sustainability Committee.	890,900, of which 159,800 comprises fees for the Audit and Risk Committee.
Holdings in Getinge AB (publ) <sup>2</sup>	160,000 Class B shares.	Holds 18,217,200 Class A shares and 36,802,969 Class B shares through companies.	33,200 Class B shares.	18,500 Class B shares.	3,000 Class B shares.

\* Ulrika Dellby was elected as Board member at the 2025 AGM and subsequently attended 6/6 Board meetings and 4/4 Audit and Risk Committee meetings.

1) See further on the independence of the Board on page 59.

2) Holdings are stated as of December 31, 2025 and include, where applicable, holdings of related natural persons and legal entities. See definition of related parties on page 64.

## Welcome to Getinge

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

Administration Report

→ Corporate Governance Report

Sustainability statement

## Financial statements

## Other

## Board of Directors, cont.



Name	Dan Frohm	Mattias Perjos	Malin Persson	Kristian Samuelsson
<b>Position</b>	Board member elected by the AGM. Board member since 2017. Member of the Audit and Risk Committee, the Remuneration Committee and the Ethics and Sustainability Committee.	Board member elected by the AGM. Board member since 2017. President & CEO.	Board member elected by the AGM. Board member since 2014. Member of the Ethics and Sustainability Committee.	Board member elected by the AGM. Board member since 2021. Member of the Audit and Risk Committee.
<b>Year of birth, education and nationality</b>	1981, M.Sc. in Industrial Engineering and Management, Swedish.	1972, M.Sc. in Industrial Engineering and Management, Swedish.	1968, M.Sc. in Industrial Engineering and Management, Swedish.	1977, Professor, M.D., PhD., Swedish.
<b>Core expertise</b>	International industry, Strategy and business development	Industry know-how, Business management, International industry	Business management, Sustainability, Technological development, R&D, Strategy and business development	Medical and healthcare, Technological development, R&D, AI/Digitalization
<b>Board assignments</b>	Chairman of Elanders AB (publ). Vice Chairman of Carl Bennet AB and Lifco AB (publ). Board member of Arjo AB (publ) and the Swedish-American Chamber of Commerce, Inc.	Board member of EUROAPI S.A. Member of the International Chamber of Commerce (ICC) Sweden's Board.	Chairman of Universeum AB. Board member of Hexpol AB (publ), Peab AB (publ), Beckers Group, Hydroscand Group AB, Stena Sessan AB, Absolent Air Care Group AB (publ) and AB Sigrid Rudebecks Skola.	Member of the Faculty Board of Sahlgrenska Academy, University of Gothenburg.
<b>Professional experience, previous assignments and other information</b>	CEO of DF Advisory LLC. Former management consultant at Applied Value LLC in New York.	President & CEO of Getinge. Former CEO of Coesia Industrial Process Solutions (IPS) and head of Coesia International. Senior positions at FlexLink AB including the role of CEO.	CEO and owner of Accuracy AB. Former CEO of the Chalmers University of Technology Foundation and many years' experience in major Swedish industrial enterprises such as the Volvo Group. Former Board member of Hexatronic Group AB (publ), EVERY ASA, OX2 AB (publ), Oddwork Sweden AB and Ricardo PLC.	Professor of orthopaedic surgery at the University of Gothenburg and senior consultant in orthopaedic surgery at Sahlgrenska University Hospital. Experience from healthcare with evidence-based medical research and interdisciplinary research in areas such as artificial intelligence (AI) and digitization.
<b>Attendance at meetings*</b>				
Board meetings	10/10	10/10	10/10	10/10
Remuneration Committee	3/3	–	–	–
Audit and Risk Committee	6/6	–	–	6/6
Ethics and Sustainability Committee	7/7	–	6/7	–
<b>Independence<sup>1</sup></b>				
Dependent/independent in relation to the company and executive management and in relation to major shareholders	Dependent in relation to major shareholders, board member of Getinge's principal owner Carl Bennet AB. Independent in relation to the company and executive management.	Dependent in relation to the company and executive management in his capacity as President & CEO of Getinge. Independent in relation to major shareholders.	Independent in relation to the company, executive management and major shareholders.	Independent in relation to the company, executive management and major shareholders.
<b>Remuneration and holdings</b>				
Total remuneration in 2025, SEK	1,127,300, of which 118,200 comprises fees for the Remuneration Committee, 159,800 comprises fees for the Audit and Risk Committee and 118,200 comprises fees for the Ethics and Sustainability Committee.	–	849,300, of which 118,200 comprises fees for the Ethics and Sustainability Committee.	890,900, of which 159,800 comprises fees for the Audit and Risk Committee.
Holdings in Getinge AB (publ) <sup>2</sup>	154,999 Class B shares.	200,000 Class B shares.	18,112 Class B shares.	5,000 Class B shares.

1) See further on the independence of the Board on page 59.

2) Holdings are stated as of December 31, 2025 and include, where applicable, holdings of related natural persons and legal entities. See definition of related parties on page 64.

### Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board's Operating Reports

Administration Report

→ Corporate Governance Report

Sustainability statement

### Financial statements

### Other

## Board of Directors, cont.



Name	Åke Larsson	Fredrik Brattborn	Ida Ekman	Pontus Käll
<b>Position</b>	Ordinary Board member appointed by employee organization	Ordinary Board member appointed by employee organization	Deputy appointed by employee organization	Deputy appointed by employee organization
<b>Year of birth, education and nationality</b>	1966, M.Sc. in Electrical engineering, Swedish.	1976, Swedish.	1985, B.Eng. in Chemical engineering, Swedish.	1991, Swedish.
<b>Core expertise</b>	R&D, Industry know-how, Business know-how	Manufacturing, Industry know-how, Business know-how	Digitalization/IT, Industry know-how, Business know-how	Manufacturing, Industry know-how, Business know-how
<b>Board assignments</b>	–	–	–	–
<b>Professional experience, previous assignments and other information</b>	Specialist, Research & Development at Maquet Critical Care AB. Assignments on Getinge's Board: Ordinary Board member 2016–2018, 2020–2022 and from October 2022. Deputy 2014–2016, 2018–2020 and 2022.	Workshop technician, Manufacturing at Getinge Disinfection AB. Assignments on Getinge's Board: Deputy 2020–2021. Ordinary member from April 2022.	Manager Data Foundation and Operations, IT at Getinge Business Support Services. Assignments on Getinge's Board: Deputy representative since 2022.	Functional tester at Getinge Sterilization AB. Assignments on Getinge's Board: Deputy representative since 2022.
<b>Attendance at meetings*</b>				
Board meetings	10/10	10/10	10/10	10/10
Remuneration Committee	–	–	–	–
Audit and Risk Committee	–	–	–	–
Ethics and Sustainability Committee	–	–	–	–
<b>Independence<sup>1</sup></b>				
Dependent/independent in relation to the company and executive management and in relation to major shareholders	–	–	–	–
<b>Remuneration and holdings</b>				
Total remuneration in 2025, SEK	–	–	–	–
Holdings in Getinge AB (publ) <sup>2</sup>	100 Class B shares.	Holds no shares.	45 Class B shares.	Holds no shares.

1) See further on the independence of the Board on page 59.

2) Holdings are stated as of December 31, 2025 and include, where applicable, holdings of related natural persons and legal entities. See also the definition of related parties below.

Definition of related parties, linked to shareholdings:

Related parties are legal entities directly or indirectly controlled by the Board member or President & CEO or by his or her related parties.

In the case of physical relatives, the spouse/cohabiting partner, children under custody and other relatives with whom households have been shared for at least one year are covered.

### Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board's Operating Reports

Administration Report

→ Corporate Governance Report

Sustainability statement

### Financial statements

### Other

**I PRESIDENT & CEO AND THE GETINGE EXECUTIVE TEAM**

**President & CEO**

The Board of Directors has delegated the day-to-day management of Getinge and the overall management of the Group's operations to the President & CEO, including an authorization to make decisions and govern all matters that are not exclusively under the authority of the Board of Directors.

It is the President & CEO's responsibility to implement and ensure that the strategies, business plans and operational objectives that the Board adopts are carried out and that effective internal governance and control are maintained. The President & CEO also reports at Board meetings and keeps the Board of Directors and its Chairman up to date on Getinge's financial position, development, risks and opportunities, and the progress of sustainability activities. The President & CEO's role, areas of responsibility and authorizations are described in more detail in the instruction for the CEO and for financial reporting.

**Executive Team**

The President & CEO is supported by the Getinge Executive Team in conducting Getinge's operations. The Getinge Executive Team comprises the business area presidents, the head of the Global Sales and Service organization, the CFO and heads of the Group support functions.

The President & CEO delegates roles and responsibilities to the Executive Team, which then structures its own management teams and ensures that strategic matters, leadership, product quality, ethics and compliance, and sustainability matters are integrated into the business.

**Forum at Getinge Executive Team level – structured governance for greater transparency and control**

Getinge has a number of forums at the Executive Team level with clearly defined areas of responsibilities so as to ensure effective, accountable and transparent governance at the company. These forums provide important support structures for strategic decision-making, risk management and compliance, and ensure that the Group acts in line with external requirements and internal values.

*Sustainability and ethics*

- The Sustainability Board is responsible for the governance of all sustainability-related areas, including preparing initiatives and policies for the Executive Team, the Ethics and Sustainability Committee and the Board.
- The Ethics Committee monitors internal investigations and compliance issues, and decides on business relationships for which specific risks have been identified.

*Financial communication and information management*

- The Disclosure Committee examines proposed disclosures in financial reports, and makes recommendations to the Audit and Risk Committee and the Board.
- The Insider Committee assists the President & CEO in managing inside information and related disclosures.

*IT and digitalization*

- The IT Board prioritizes and coordinates the Group's IT activities and prepares investment proposals for the Executive Team.

*Sponsoring and remuneration*

- The Sponsorship & Donations Committee is responsible for the pre-approval of sponsorships and donations.
- The STIP Steering Committee prepares the process for annual variable remuneration, including performance targets and any deviations from current guidelines, for employees who are not members of the Executive Team.

**Getinge Executive Team 2025**

At year-end 2025, the Getinge Executive Team comprised ten individuals. The Executive Team held six ordinary meetings during the year and remained in continuous contact and alignment between meetings. The primary focus of the meetings was the Group's strategic and operational performance and monitoring of results. During the year the Getinge Executive Team addressed topics such as sustainability, the acquisition agenda, the changing global landscape and financial situation, challenges in the supply chain and other external factors. One of the major focus areas in 2025 was trade barriers, and the Executive Team also continued to focus on the Group's quality measures.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other**

# Executive Team



	<b>Mattias Perjos (1972)</b>	<b>Agneta Palmér (1978)</b>	<b>Carsten Blecker (1966)</b>	<b>Elin Frostehav (1982)</b>	<b>Stéphane Le Roy (1977)</b>
<b>Position</b>	President & CEO	Chief Financial Officer	Chief Commercial Officer	President, Acute Care Therapies	President, Surgical Workflows
<b>Education</b>	M.Sc. in Industrial Engineering and Management	M.Sc. in Economics	PhD in Dentistry; Doctorate in Business Administration, Bachelor in Medicine	M.Sc. in Industrial Engineering and Management	M.Sc. in Industrial Engineering
<b>Nationality</b>	Swedish citizen	Swedish citizen	German citizen	Swedish citizen	French citizen
<b>Employed at Getinge since</b>	2017	2018	2014	2019	2012
<b>Holdings in Getinge AB (publ)<sup>1)</sup></b>	200,000 Class B shares	3,800 Class B shares	7,200 Class B shares	5,000 Class B shares	6,650 Class B shares
<b>Previous experience and other assignments</b>	<p>Mattias Perjos has held senior positions at Coesia 2012–2017, including CEO of Coesia IPS Division and Coesia International. Previously he was CEO of Flexlink 2006–2016 where he started his career in 1998 and served as business area manager 2003–2006.</p> <p>Board member of EUROAPI S.A. Member of International Chamber of Commerce (ICC) Sweden’s Board.</p>	<p>Until March 2024, Agneta Palmér held the position of Executive Vice President Operational Services and prior to that was Vice President Corporate Control at Getinge. She has previously held leading positions in finance in the Volvo Group and before that worked as a management consultant with a focus on business development, process optimization and financial control.</p>	<p>Carsten Blecker previously served as President EMEA, responsible for all of Getinge’s country organizations in the region. Before that, he was Head of Biomet’s Dental business for EMEA. Prior to that, Carsten was with Palex Medical as Business Unit Director. Carsten also worked for McKinsey &amp; Company, Kimberly-Clark Healthcare EMEA and Medtronic EMEA.</p>	<p>Until March 2022, Elin Frostehav was Vice President of Critical Care, a product segment in Acute Care Therapies at Getinge. She has previously held leading global positions within Semcon in the areas of product development and digitalization. Prior to Semcon, Elin held various positions at FlexLink.</p>	<p>Stéphane Le Roy most recently served as the Regional President of South West Europe in Getinge’s Global Sales organization. He joined Getinge in 2012 as country manager for Infection Control in France. Between 2006 and 2012, he was business unit manager for CT Scanners for Siemens Healthcare in France. Before that, he held several product management positions and supply chain assignments within the field of medical imaging at GE Healthcare.</p>

1) Holdings are stated as of December 31, 2025 and include, where applicable, holdings of related natural persons and legal entities.

Definition of related parties, linked to shareholdings:  
Related parties are legal entities directly or indirectly controlled by the Board member or President & CEO or by his or her related parties.  
In the case of physical relatives, the spouse/cohabiting partner, children under custody and other relatives with whom households have been shared for at least one year are covered.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other**

## Getinge Executive Team cont.



	<b>Eric Honroth (1971)</b>	<b>Joanna Engelke (1960)</b>	<b>Magnus Lundbäck (1969)</b>	<b>Anna Romberg (1979)</b>	<b>Alexandra Holland (1986)</b>
<b>Position</b>	President, Life Science	Executive Vice President, Quality Compliance, Regulatory & Medical Affairs	Executive Vice President, Human Resources	Executive Vice President, Sustainability, Legal & Compliance	Executive Vice President, Brand & Communications
<b>Education</b>	B.Sc. in Business and Marketing	MBA, B.A. in Political Science	PhD in Strategy and Organization and Technology Licentiate	PhD in Corporate Governance and Compliance, M.Sc. in Economics and Business Administration	Bachelor of Science in Communications
<b>Nationality</b>	US citizen	US citizen	Swedish citizen	Finnish citizen	US citizen
<b>Employed at Getinge since</b>	2018	2022	2017	2020	2024
<b>Holdings in Getinge AB (publ)<sup>1</sup></b>	1,025 Class B shares	Holds no shares.	7,842 Class B shares	7,100 Class B shares	Holds no shares.
<b>Previous experience and other assignments</b>	Until March 2022, Eric Honroth was President of the North America sales region in Getinge's Global Sales organization. He has more than 20 years of experience in global leadership roles in the medical devices industry, including roles at Becton Dickinson, CareFusion and Abbott Vascular.	Joanna Engelke has solid experience from areas of regulatory healthcare in international companies. She has previously held leading positions as Head of New Ventures & Chief Quality Officer for JUUL Labs, Senior Vice President Global Quality & Regulatory Affairs at Boston Scientific Corporation, Managing Director at Holloran Consulting Group and Portfolio CEO, Biospecific at PureTech Ventures among others.	Magnus Lundbäck was previously SVP Human Resources & Sustainability at Gunnebo Group. He has previously served as Executive Vice President Human Resources and Sustainability at Getinge and as Vice President Human Resources at Volvo Car Corporation.	Anna Romberg has served as VP Ethics and Compliance for Cargotec Oyj, and in various governance and compliance roles at Telia Company AB. She has also supported numerous global companies, with regards to governance and compliance matters, on a consultancy basis. She is one of the founders of the Nordic Business Ethics Initiative.  Chairman of the Board of North House AB.	Until November 2024, Alexandra Holland was Vice President, Business and Culture Communications at Johnson & Johnson MedTech. She has more than 15 years of leadership experience in healthcare communications working across the consumer, medtech and corporate sectors.

1) Holdings are stated as of December 31, 2025 and include, where applicable, holdings of related natural persons and legal entities.

Definition of related parties, linked to shareholdings:

Related parties are legal entities directly or indirectly controlled by the Board member or President & CEO or by his or her related parties.

In the case of physical relatives, the spouse/cohabiting partner, children under custody and other relatives with whom households have been shared for at least one year are covered.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other**

## Getinge's Corporate Governance Framework

Getinge's operational corporate governance model consists of three main components: (A) guiding principles and steering documents, (B) operational governance and (C) legal entity governance. These components aim to facilitate the achievement of targets, ensure effective control and monitoring, and support the work of the Board, and in combination they form the basis of governance at the company.


### A Getinge guiding principles and steering documents

#### Guiding principles

Getinge's vision, purpose, goals, brand promise and cultural core values serve as the central guiding principles for the company's operations. The Board is responsible for setting the overall long-term strategy, which is the basis of both the future direction of the company and the annual operational and financial targets. Once a year, the Board also reviews the strategy for all business areas and the Global Sales and Service organization. The President and CEO subsequently establishes the operational targets for the business, in accordance with decisions and guidance from the Board.

#### Steering documents – framework

At the heart of Getinge's steering documents is the Code of Conduct, which sets out guidelines for how the operations are to be conducted in accordance with the company's values. The Code of Conduct is summarized in six guiding principles (see figure). Based on these principles, the Board of Getinge adopts global policies, which are revised at least once every two years, that set out the company's



### Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board's Operating Reports

Administration Report

→ Corporate Governance Report

Sustainability statement

### Financial statements

### Other

approach in key areas. The Board assumes overall responsibility for ensuring that the policies are implemented appropriately. The implementation process has been delegated in the global organization. Where necessary, the policies are supplemented with more detailed directives and instructions, which are decided by the President

and CEO or the responsible member of the Executive Team. The Ethics & Compliance function is responsible for the global Ethics & Compliance program, including establishing related standards and processes, and for monitoring compliance within the organization. For more information on the Ethics & Compliance function, see page 71.

The company's quality steering documents are available to all employees and are implemented in the Group's day-to-day operations and work, for example, through Getinge's Responsible Leadership Program. The Code of Conduct and eight of Getinge's global policies are also available on Getinge's external website.

**B Operational governance**

Getinge’s operating model is designed to ensure a clear structure and distribution of responsibilities, and to create a strategic and operational focus in the Group. The model is based on the company’s product and service offering to customers, considering the various needs and conditions in each business area and geographical market. The governance is based on decentralized decision-making under the framework of the Group-wide strategies, principles and steering documents, thus enabling management close to the operations and local customization.

**Business areas**

Operationally, the business is organized into the business areas Acute Care Therapies, Life Science and Surgical Workflows. Each business area is responsible for (i) their daily operations and integrated financial results, (ii) developing their product portfolios and offerings, and (iii) their strategic agendas. They are also responsible for ensuring that the operations are conducted in accordance with rules and regulations, and for ensuring that quality and regulatory requirements are met and that sustainability topics are integrated into operations.

**Global Sales and Service organization**

The operational business also includes a Group-wide Global Sales and Service organization to

capitalize on synergies in sales. The function coordinates larger strategic decisions with the business areas and assumes the ultimate responsibility for ensuring that sales are conducted in accordance with laws and rules and that quality and regulatory requirements are met.

**Competence and support functions**

Getinge has certain shared competence and support functions that are organized into two categories. Corporate functions provide steering in areas at Group level and are responsible for developing policies, guidance, processes and structures. The corporate functions also include separate supervisory functions. For more information about these supervisory functions, see page 70. The Group support functions are


competence and support functions for coordination of a variety of areas and are more active operationally in daily activities.

**C Legal entity governance**

Getinge comprises a large number of separate legal entities globally. Each legal entity within Getinge functions as part of an operational business area, the Global Sales and Service organization, the corporate functions or the Group support functions.

Governance of the legal entities must be effective and designed to ensure compliance with local rules and regulations and intra-Group requirements.

- Welcome to Getinge
- Market environment
- Strategy
- Business areas
- The Board’s Operating Reports
  - Administration Report
  - Corporate Governance Report
  - Sustainability statement
- Financial statements
- Other



1) Includes Strategy, M&A and Investor Relations  
 2) Also includes Treasury, Tax, Corporate Control, Group Business Control, Risk Management, IT and Supply Chain Services.  
 3) Reports directly to the Audit and Risk Committee.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other**

## Assurance framework and risk management


### Getinge's risk management framework

Getinge's three business areas and the Global Sales and Service organization are responsible for identifying and managing risks in their respective areas. The corporate and Group support functions support these units by providing governance, developing processes and promoting synergies in their specific areas of competence. In addition, several forums and groups have been established that focus on certain areas and identify and monitor specific types of risks. For more information on Getinge's forums at the Executive Team level, see page 65.

The established forums and groups conduct regular evaluations and monitoring to ensure correct coordination and management from a Group perspective. Examples of these forums are the Ethics Committee and Sustainability Board. The Group's financial risks are monitored and managed by the Group's Treasury function.

To manage cyber risks, Getinge also has a Chief Information Security Officer (CISO) who coordinates this work via, inter alia, a Security Advisory Board and a Getinge Centre of Excellence for cyber security, which evaluates and improves secure product life cycles for the Group's products.

## GETINGE'S GOVERNANCE AND ASSURANCE FRAMEWORK



1) The first pillar's control activities include: quality systems audit (at certificate level), management control self-assessment and remediation of audit and investigations findings.  
 2) The second pillar's control activities include: The Ethics & Compliance function's risk monitoring and risk assessment, internal controls (for more information about the control activities related to the company's internal control over the financial reporting, see page 71 and Corporate Quality Audit.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other**

**Enterprise Risk Management (ERM)**

Getinge applies a structured method for identifying, assessing and managing the risks to which the Group is exposed to ensure that the Group achieves its targets. In 2025, Getinge continued its efforts to strengthen the process for risk identification, preventive action and risk management. The three business areas, the global sales and service organization and the corporate and Group support functions report risks to the Executive Team every year after performing a risk evaluation following the Group's ERM process.

Both financial risks and opportunities, as well as the actual and potential impacts of the Group's operations on people and the environment, are identified and evaluated under the framework of Getinge's double materiality assessment (DMA). The DMA is performed in accordance with the requirements of the CSRD and serves as an important foundation for the company's sustainability reporting. The results of the DMA are integrated into the Group's ERM process, which ensures that sustainability-related factors are considered in the overall risk management. The Executive Team evaluates the material risks identified in the ERM process and its potential impacts, and decides on actions to mitigate risks and their consequences. The results of the ERM process serve as a key basis in determining the focus areas for Corporate Internal Audit. Most of the risks are regularly addressed by the Executive Team throughout the year. For more information about Getinge's primary risks, consequences and management, see page 39.

**Ethics & Compliance**

The risk identification system and management process for this work is conducted by the Ethics & Compliance function. The function is responsible for the global Ethics & Compliance program, sets standards and processes, and monitors the use and implementation of these. The function also manages the Group's Speak-Up Line (whistleblower function) and performs risk assessments and internal investigations. Internal investigations and whistleblowing cases are reported to the Audit and Risk Committee, other work is reported to the Ethics and Sustainability Committee. An update is also presented to the Board in its entirety once a year. More information on the Ethics & Compliance function is presented in the Sustainability statement on page 80.

**Corporate Internal Audit**

Getinge's internal audit function, Corporate Internal Audit, aims to provide independent audit of operational governance in selected areas, with a focus on effectiveness and risk management. The Corporate Internal Audit function is led by the Head of Internal Audit who reports directly to the Audit and Risk Committee, but belongs to the management team for Sustainability, Legal & Compliance. The annual internal audit plan is based on identified risks and function-specific and industry-related risk assessments. Each year, priority is assigned to a number of units, Group-wide processes or thematic areas for auditing, in which improvement areas are identified and graded based on their potential business impact. The areas are based on the annual plan but can also be adapted to issues that arise during the year. For all observations, an action plan is prepared in collaboration with each business

owner. The Corporate Internal Audit function follows up on and ensures that action plans are conducted within defined time periods.

The organization was reviewed in 2025 and, based on a voluntary initiative, an external evaluation was carried out of the work on developing the internal Corporate Internal Audit function to identify potential improvements.

**Corporate Quality Audit**

Getinge's Corporate Quality Audit function is part of the Quality Compliance, Regulatory & Medical Affairs support function, which is Getinge's global quality organization (for more information about the QCRM, see page 80). Corporate Quality Audit conducts risk-based audits in accordance with international regulatory standards, such as ISO 13485, FDA 21 CFR Part 820 and the EU MDR, and internal quality requirements, to ensure quality-related compliance and promote operational excellence among the Group's business units.

The function is led by the Head of Corporate Quality Audit who reports to the QCRM management team. The results of the audits are reported to the business areas and analyzed at various levels of the organization, up to the Executive Team level. The annual audit plan follows a risk-based approach that draws on regulatory requirements, operational priorities and the external environment. Corporate Quality Audit monitors to ensure that all observations are managed and followed up within set timeframes. By providing early insight into systemic risks, driving sustainable improvements and promoting shared best practices, the function can strengthen Getinge's quality culture and support management in its decision-making.

In 2025, the function initiated the implementation of a global inspection management process across all Group companies, with the aim of improving inspection performance so as to ensure regulatory robustness.

**Internal control over the financial reporting**

At Getinge, internal control over the financial reporting is an integrated part of the corporate governance. It comprises processes and methods to safeguard the accuracy in the financial reporting, and in this manner, is aimed to protect the shareholders' investment in the company.

**Control environment**

The basis of the internal control over the financial reporting comprises the control environment, including the organization, decision-making channels, authorities and the responsibilities that are documented and communicated in steering documents. The Audit and Risk Committee's responsibilities include monitoring the effectiveness of the company's internal control, financial reporting and risk management. Each business area and the Global Sales and Service organization are responsible for continuous transaction management and accounting. Getinge's Shared Service Center in Krakow, Poland, conducts this management on behalf of the business areas and the Global Sales and Service organization for most of the companies in Europe and North America, primarily regarding customer invoicing, supplier invoices and payment and work duties in the annual accounting process. Each business area and the Global Sales and Service organization has

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

→ Corporate Governance Report

Sustainability statement

**Financial statements**

**Other**

a financial manager, who is responsible for the financial control and for ensuring that the financial statements are accurate, complete and submitted in good time prior to consolidated reporting. The change process that commenced in 2024 continued in 2025, with the finance functions for the larger countries divided into a financial and a business-oriented function with the aim of streamlining work in accounting and in the business organization. The financial control function is divided into the geographic areas of responsibility of France, the Nordic region, North America, DACH/BNL and East Asia.

**Control activities**

The most material risks identified relating to financial reporting are handled by the company's control activities. For example, there are automated controls in IT-based systems that manage authority levels and attestation rights, as well as key control elements, such as duality in the day-to-day accounting and closing entries. Detailed financial analyses of results and follow-ups against plan and forecasts supplement the operation-specific controls and provide overall confirmation of the quality of the financial reporting. The Group follows standardized templates and models to document controls.

An internal framework for general IT controls in systems and applications that have the greatest impact on the financial reporting was implemented in 2024. These controls include maintenance, development and authorization management processes. System and application owners have carried out self-assessments of the control environment, which were then evaluated internally and subsequently by the external auditors. The process is similar to the annual assessment of financial controls.

**Information and communication**

The Group has information and communication procedures to promote completeness and accuracy in the financial reporting. Steering documents and work descriptions are available on the company's internal digital platform. Information regarding the efficiency of the internal controls in the Group is regularly reported to the relevant financial manager for the Global Sales and Service organization and the business areas, as well as to the internal control function, the finance function, the Getinge Executive Team and the Audit and Risk Committee.

**Follow-up and monitoring**

Each financial manager and the Getinge Executive Team perform monthly analyses of the financial reporting at a detailed level. The registered auditing firm Ernst & Young AB was elected as the company's new auditor at Getinge's AGM in April 2025. Information about Getinge's internal control environment, processes and work methods has since been transferred to the auditor. The Audit and Risk Committee follows up the financial reporting at its meetings and the company's auditors report on their observations and provide recommendations. The Board of Directors receives financial reports on a monthly basis and the company's financial position is discussed at every Board meeting. The efficiency of the internal control activities for the financial reporting is followed up by the internal control function every year using a risk-based random sampling model. This comprises an assessment of the formulation and operative function of key control elements that have been identified and documented. The external auditors perform an annual evaluation of a selection of key controls in the internal

assurance framework and report the results to the Audit and Risk Committee.

**Self-assessment and validation**

Getinge has worked for several years with a formalized process for the follow-up and evaluation of the documentation of key control elements. The internal assurance framework is revised every year based on the results of, for example, self-assessments and auditing activities. The validations are performed by each financial manager and the person with the main responsibility for the geographic financial controller function, or the person delegated in the Global Sales and Service organization or the business area, supported by the central internal control function.

The purpose of self-assessment is to proactively identify any weaknesses in the internal control environment, jointly develop improvement measures, but also to ensure the maintenance of the achieved good internal control environment. Another purpose is to enhance the efficiency of the local control activities in Group companies by identifying shared work methods and transferring knowledge between the companies to raise the general quality of the control environment.

In 2025, just over two-thirds of the active companies, jointly totaling just over 90% of the sales in the Group, conducted a self-assessment. In conjunction with the standard Group audit, the auditors conducted an in-depth validation of the internal control environment. The self-assessment includes the following business processes: corporate governance (such as assignment of authority for financial IT systems), financial reporting, production and inventories, tangible

and intangible assets, sourcing of and revenues from products and services, procedures for salary payments and remuneration as well as tax management. The auditors' assessment includes a defined sample of these processes.

**Outcome 2025**

The follow-up of the internal control in 2025 indicated that documentation and control activities over the financial reporting were, in all material respects, established at the validated companies. An area identified as having the largest potential for improvement is further training for the organization in internal control with a focus on documenting controls and their outcomes.

**Ongoing work**

The focus in 2026 will be on continuing to harmonize ways of working in the business processes, thus optimizing the use of the common system environment. Uniform business processes also allow for a higher degree of standardized and automated controls, and enhance efficiency. The outcome from the year's validation and evaluation, and from the various company audits, will be used as a basis for the continuous improvement work on internal control via financial reporting.

# Sustainability statement

General disclosures	73
Environment	84
Social	106
Governance	123
Appendix	129

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

→ Sustainability statement

General disclosures

Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

## General disclosures

### Basis for preparation

The Sustainability statement in the Board of Directors' Report constitute Getinge's statutory sustainability statement according to the requirements of the Swedish Annual Accounts Act. The report has been prepared according to the European Sustainability Reporting Standards (ESRS).

The sustainability statement covers all subsidiaries in the Getinge Group (see pages 208–210), including those subsidiaries owned directly or indirectly by Getinge AB (publ). The scope of consolidation is the same as for the financial statements. The reporting approach across all material topics and disclosures is consistent for all subsidiaries. All subsidiaries are included in Scope 1, 2 and 3 reporting.

Getinge is using the same time horizons as set out in the ESRS 1. Measurement uncertainty and inherent assumptions exist, and for each metric where estimations are used, Getinge will disclose the estimations made, and any action to improve accuracy. Unless otherwise stated in the respective material topic section, no changes in targets, metrics and measurement methodologies have occurred during the year.

Value chain estimations and planned actions to improve accuracy are described under the respective KPI or in the Reporting principles section. The entire value chain was considered during the double materiality assessment. The sustainability statement covers value chain information relating to the Group's direct and indirect business relationships in the upstream and downstream value chain.

In 2025, restatements of Scope 1, 2 and 3 data were made for the acquisitions Paragonix, Quadralene, Ultra Clean and Healthmark for the period 2021–2024, for more information see section E1 Climate Change. It was discovered in the reporting process that data for Work Related Accident Rate (WRAR) had been incorrectly reported which has now been corrected, for more information see page 111.

Getinge uses phase in provision for anticipated financial effect for ESRS 2, E1, E3 and E5. Getinge has also implemented the Quick Fix provisions for S2 and S4. Regarding the EU Taxonomy, Getinge has utilized the simplified tables, and is applying the 10% materiality threshold, where feasible.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
    - Environment
    - Social
    - Governance
    - Appendix

**Financial statements**

**Other information**

## Strategy

**Getinge's Sustainability approach**

Sustainability is an integral part of the company's strategy (see pages 13–19) to shape a future where healthcare is better, more efficient, and accessible. Getinge's sustainability approach is anchored in the strategic pillars of innovation, quality, responsibility, and employee engagement. Innovation means that the company works continually to develop innovative solutions for better health which includes minimizing the environmental impact from products. Getinge does not breakdown its sustainability goals by products, services, markets, or customer groups because of the diversified nature of the company's product portfolio. Ensuring quality is the highest priority in all steps of a product's life cycle and conducting business in compliance with regulations and ethical principles is fundamental to sustainable business. Employee engagement is critical to Getinge's success. This means that the company strives to create the best possible conditions for coworkers to thrive and reach their highest potential. Health and safety and ensuring employees feel included and equally valued are at the core of this engagement.

The following pages describe how impacts are identified through the double materiality assessment. Detailed information about each material topic, the related policies, strategic direction, actions, targets, key figures, results, and performance data, including impacts, risks and opportunities can be found in the topical sections under the respective areas 'Environment', 'Social' and 'Governance'.



Excel in quality and responsible business



Engaged employees



Sustainable innovations

**Stakeholder groups and stakeholder dialogue**

Maintaining an open dialogue with stakeholders is important to ensure that Getinge continues to integrate relevant sustainability aspects into its business model, strategy, policies and daily operations. Input on stakeholder expectations and requirements is gathered through various channels such as: customer meetings and surveys, investor meetings, industry forums, supplier follow-ups and in dialogues and surveys with company employees. This engagement directly informs Getinge’s strategic priorities and materiality assessment, and thereby shapes focus areas, policies, targets and decision making. Getinge’s main stakeholders, their ESG expectations, and the way in which the company engages with them are listed in the table below.

Employees	Customers	Business partners	Investors and owners	Governments and regulators	Affected communities and nature
<p>Getinge’s employees play a key role in enabling the company to successfully deliver on its business strategy. Employee representatives are also important stakeholders as they can give voice to employee groups, particularly vulnerable groups.</p>	<p>Getinge has a close relationship and a continuous dialogue with its customers. By actively listening to their feedback, the company ensures the delivery of valuable products and services.</p>	<p>Collaboration and dialogue with external experts are essential to enable a positive contribution to society.</p>	<p>As owners of Getinge, investors are important stakeholders. Getinge informs and educates the capital market through regular and transparent dialogue with investors.</p>	<p>Getinge is committed to complying with applicable regulations in the markets and in the geographic locations where it operates. A strong regulatory framework is vital to the company’s success.</p>	<p>Getinge acknowledges nature and communities as important silent stakeholders. By minimizing environmental impacts and supporting community well-being, the company wants to contribute to sustainable ecosystems and resilient societies.</p>
<p><b>ESG expectations</b></p> <p>Employee surveys show that the expectations are: fair and safe treatment, meaningful work, fair wages, a sense of belonging and good development opportunities.</p>	<p><b>ESG expectations</b></p> <p>Getinge continues to experience an increase in ESG-related questions from customers. Beyond quality and safety of products, customers place high importance on environmental aspects related to management, climate as well as product specific topics and value chain due diligence.</p>	<p><b>ESG expectations</b></p> <p>Responsible business practices and partnership on strategic issues.</p>	<p><b>ESG expectations</b></p> <p>Beyond the company’s financial performance (profitability) and economic efficiency as well as tangible and intangible assets, investors rank quality and governance-related aspects the highest.</p>	<p><b>ESG expectations</b></p> <p>Compliance with regulations and leadership in product quality.</p>	<p><b>ESG expectations</b></p> <p>There are implicit expectations that Getinge will act responsibly across environmental, social, and governance dimensions. This includes reducing environmental footprint, fostering social equity and community well-being, and maintaining ethical and transparent governance practices that prioritize long-term sustainability.</p>
<p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Daily interactions between managers and employees</li> <li>• Digital town hall held bi-annually (DigiTalk)</li> <li>• Regular digital live chat with the executive team (GetinTouch)</li> <li>• Meetings, interviews and workshops</li> <li>• Education and training</li> <li>• Employee Engagement Survey</li> <li>• GetNet (internal digital platform)</li> <li>• Speak-Up Line</li> </ul>	<p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Meetings and interviews</li> <li>• Tradeshows</li> <li>• Analysis of tender specifications and requirements of purchasing organizations</li> <li>• Product-related information and customer trainings</li> <li>• Customer involvement in product development such as clinical trials and Factory Acceptance Tests</li> <li>• Speak-Up Line</li> <li>• Getinge.com</li> </ul>	<p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Meetings and interviews with suppliers and financial stakeholders</li> <li>• ESG rating agencies</li> <li>• Communication and training on Supplier Code of Conduct and Business Partner Code of Conduct</li> <li>• Speak-Up Line</li> <li>• Getinge.com</li> </ul>	<p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Meetings and interviews</li> <li>• Financial and non-financial reporting including Getinge Capital Markets Day</li> <li>• Quarterly teleconferences and dedicated meetings with Sustainability analysts</li> </ul>	<p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Memberships in UN Global Compact and local Swedish Associations</li> <li>• Industry associations AdvaMed and MedTech Europe</li> <li>• Ongoing dialogues with regulators on certification/registration of products</li> </ul>	<p><b>Engagement channels</b></p> <ul style="list-style-type: none"> <li>• Scientific reports and tools. Examples of which are Encore, World Resource Institute Aqueduct, ILOSTAT, environment at a glance indicator (OECD), WASH, Forced Labor Observatory</li> </ul>

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

→ General disclosures

Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

## Description of the process to identify and assess material impacts, risks and opportunities

Both actual and potential impacts of Getinge’s operations on the environment and society across the value chain have been analyzed. Moreover, Getinge has conducted an assessment of both impacts and sustainability-related risks and opportunities that could affect its business. Where possible, these risks were quantified and supplemented with qualitative analysis. The financial assessment methodology has been aligned with the company Enterprise Risk Management (ERM) methodology, is part of the base for the double materiality assessment, and follows the same principles as for previous years.

Stakeholder involvement is carried out both directly through meetings and surveys, and indirectly by consulting internal experts and analyzing stakeholders requests and documentation. More information can be found on page 75.

The process to determine the material topics included four steps:



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

→ General disclosures

Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

## Material impacts, risks and opportunities

The following impacts, risks and opportunities (IROs) have been deemed material for Getinge as a result of the double materiality assessment. In response to the identified IROs listed below, Getinge has adopted a sustainability approach and incorporates sustainability aspects into its business model and strategy to remain resilient and to capitalise on opportunities. The sustainability approach together with the company strategy aims to address the identified IROs.

E ENVIRONMENT			
Topic	Value chain location		
<b>E1 Climate change:</b> Mitigation, page 85–94	Upstream Own operations Downstream	–	R O
<b>E1 Climate change:</b> Energy, page 85–94	Upstream Own operations Downstream	–	R O
<b>E1 Climate change:</b> Adaptation, page 85–94	Upstream Own operations Downstream	–	R
<b>E3 Water and marine resources:</b> Water consumption, page 95–97	Upstream Own operations Downstream	–	R O
<b>E5 Resource use &amp; circular economy:</b> Resource inflows, including resource use, page 98–101	Upstream Own operations	–	
<b>E5 Resource use &amp; circular economy:</b> Resource outflows and waste, page 98–101	Own operations Downstream	–	

S SOCIAL			
Topic	Value chain location		
<b>S1 Own workforce:</b> Occupational health & safety, page 107–115	Own operations	–	
<b>S1 Own workforce:</b> Diversity, equity, inclusion & belonging (DEIB), page 107–115	Own operations	–	+
<b>S2 Workers in the value chain:</b> Responsible sourcing, page 116–118	Upstream	–	
<b>S4 Consumers and end-users:</b> Patient safety & quality, page 119–122	Upstream Own operations Downstream	–	+ R O

G GOVERNANCE			
Topic	Value chain location		
<b>G1 Governance:</b> Anti-corruption and business conduct, page 124–128	Upstream Own operations Downstream	–	R

- + Positive impact
- Negative impact
- O Financial opportunity
- R Financial risk

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
    - Environment
    - Social
    - Governance
    - Appendix

Financial statements

Other information

### Considerations in materiality assessment and scoring

**Scale and thresholds:** When developing the assessment criteria, Getinge sought alignment with internal risk assessment tools to ensure a coherent approach. Both impact and financial materiality were assessed qualitatively on a scale ranging from 0 (insignificant) to 5 (very high). A sustainability matter was classified as material if it achieved a score of 3 or above in either impact or financial materiality.

**Positive/negative impacts:** Both positive and negative impacts have been assessed.

**Actual/potential impacts:** Impacts have been identified as actual or potential. For actual negative impacts, scale, scope, and remediability have been the focus of the assessment. For potential negative

impacts, likelihood has also been assessed. For positive impacts, scale, scope, and likelihood have been assessed.

**Own operations/value chain:** Impacts and risks were assessed for Getinge's own operations, and for the value chain where relevant and possible.

**Risks/opportunities:** An assessment of risks and opportunities was carried out aligned with the Enterprise Risk Management process.

**Time horizons** (short, medium and long term) have been used as described in the ESRS standards.

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

→ General disclosures

Environment

Social

Governance

Appendix

Financial statements

Other information

## Material impacts, risks and opportunities and their interaction with strategy and business model

Material impacts across the company's own operations and its value chain are illustrated to the right. The intention of the illustration is to provide an overview of the material impacts from the company's activities and it is not exhaustive. More detailed information on each material topic and where impacts occur in the value chain, as well as policies, strategic direction and actions, targets, key figures, results, and performance data, can be found in the topical sections under 'Environment', 'Social' and 'Governance'. Data on number of employees is found under S1 on page 114, and total revenue is presented in the yearly summary on page 139.

Being dependent on distributors to increase customer reach also means that the potential risk of **bribery and corruption** increases.

Upstream: Suppliers of goods and services



Raw materials used to manufacture Getinge products include oil, minerals and metals. These raw material industries are associated with high **carbon emissions** and entail potential risks of **human rights** violations and **poor working conditions**.



Transporting products to manufacturing sites and customers results in **carbon emissions** and potential breaches to workers' **human rights**.

Own operations



Product development relies on the **inflow of materials** such as minerals for electronic equipment, many of which are scarce resources.

The company's manufacturing processes uses water and energy, resulting in **carbon emissions**. Employee **health and safety** is a top priority with key focus on poor ergonomics as the primary cause of injury. Being a global employer puts emphasis on the importance of ensuring a culture of **inclusion and belonging** free from discrimination.



Downstream: Distributors, customers & end-users



As a provider of equipment for acute care, ensuring **product quality** is the primary priority as it directly impacts **patient safety**. Being involved in public procurement highlights the importance of working to reduce the risks of **corruption and bribery**.

Some Getinge products require significant amounts of **energy** and **water** during use. The **carbon emissions** generated can be significant depending on the source of energy used to run the products. In regions facing water scarcity, the use of water-intensive products can have a substantial impact. Anesthesia gas, used in Getinge anesthesia machines is also a potent **greenhouse gas**.

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

Financial statements

Other information

## Governance

### The role of and information provided to the administrative, management and supervisory bodies


Getinge's main governing bodies who oversee sustainability matters are the Board of Directors, the Ethics and Sustainability Committee, the Executive Team and the Sustainability Board.

#### Board of Directors

In 2025, Getinge's Board of Directors consisted of nine members elected by the Annual General Meeting, one of whom is Getinge's president and CEO, two members appointed by employee organizations and two deputies. In the Board, 67% of the members are independent, and the gender diversity ratio (male:female) is 2:1. Getinge's Board of Directors holds the ultimate responsibility for material matters within the group, including sustainability and quality. It sets Getinge's sustainability targets, oversees the group's goals and strategies, risk management, M&A strategy, how the customer offering should be designed and the policy implementation – with the overall sustainability and quality approach integrated into all decisions. Parts of the preparatory work has been delegated by the Board to relevant Board committees. Furthermore, the Board establishes the general long-term strategy, which sets the direction for the coming years, and based on Getinge's Code of Conduct the Board adopts and revises Getinge's global policies. For more information about Getinge's global policies, see the table on pages 82–83.

The Board of Directors also approves the group's annual materiality assessment which guides sustainability efforts, and is accountable for the group's reporting, including the sustainability statement and its assurance by the auditors.

Sustainability Governance organization chart



The Board's primary role is supervisory, ensuring the governance and work of the Getinge Executive Team, monitoring, managing and overseeing impacts, risks and opportunities. This includes incorporating sustainability and quality into all decisions it makes on major acquisitions of companies and in the risk management process.

Through the Board members' previous and current operational assignments for Getinge and other companies, the Board collectively possesses sound knowledge of the sectors and markets where the company operates and of areas of relevance for the operations. Within the Board, there is competence and experience from operational work within hospitals and clinical activity, providing valuable insight into Getinge's products and their applications. In addition, the Board has

solid experience from international relations and governance, through Board members' previous and current operational assignments and Board assignments in Getinge as well as in other companies.

The members of the Board of Directors are also considered, by the Nomination Committee, to possess competence and experience from the sustainability field, for example through one Board member's previous assignment as chairman of a Sustainability Committee, but also through other Board members' operational assignments in executive positions. In 2025, the Board participated in a new internal Code of Conduct training.

#### Board Committees responsible for sustainability

The Ethics and Sustainability Committee is comprised by the Board members Cecilia Daun Wennborg (Chairman), Malin Persson and Dan Frohm. The members of the Committee are independent in relation to the company, executive management and the company's major shareholders, with the exception of Dan Frohm, who is not considered to be independent in relation to the company's major shareholders. Two of the Committee members have previous experience from similar committees at other companies. The Committee receives relevant training from internal and external experts as deemed necessary. The facilitation of access to training and sustainability-related expertise for the Ethics and Sustainability Committee supports Getinges'

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

oversight and achievement of its sustainability goals, including the management of risks, addressing of material impacts, and identifying of sustainability-related opportunities.

The Ethics and Sustainability Committee works with ensuring a more in-depth follow-up on the strategic integration of sustainability, including quality, and prepares policies, actions and targets, for decisions to be made by the Board of Directors. Additionally, as delegated by the Audit and Risk Committee, the Committee monitors reported sustainability information in both quarterly reports and the annual report and follows up on the auditor's review of the yearly Sustainability statement.

**Executive Team and the Sustainability Board**

Getinge's Executive Team consists of ten executive members, including Getinge's president and CEO. The gender diversity ratio (male:female) is 1:1. The CEO has the ultimate responsibility for the ongoing management and leadership of the Group and is supported in this work by the Getinge Executive Team (GET), who holds the operational responsibility for integration of sustainability and quality into the company's strategy, business model and operations. Based on the global policies adopted by the Board, the CEO or the member of the Executive Team responsible for the area issues more detailed and guiding directives and instructions (where appropriate).

Within the Getinge Executive Team, the ultimate responsibility for Getinge's sustainability approach, including monitoring, managing and overseeing impacts, risks and opportunities, rests with the Executive Vice President (EVP) Sustainability, Legal & Compliance. Progress on implementation is reviewed as part of the recurring business and functional reviews. In addition, a quarterly meeting is held with the Sustainability

Board, consisting of all members of the Getinge Executive Team, to enable focus on key topics.

The members of GET are considered to possess competence and experience from the sustainability field, for example through one member's previous experience in various governance and compliance roles. The sustainability-related skills and expertise within GET supports the Groups identification, oversight and achievement of its' sustainability related targets. In 2025, GET participated in a new internal Code of Conduct training.

Getinge's administrative, management and supervisory bodies who oversee sustainability matters are regularly provided information and address different sustainability matters, with the support of different functions within the organization.

**Sustainability function**

The Corporate Sustainability function, which is part of the overall Sustainability, Legal & Compliance team, is responsible for advancing the sustainability approach on an operational level. The Corporate Sustainability function is the subject matter expert of environmental matters as well as driver of key cross functional projects.

The EVP Sustainability, Legal & Compliance oversees the work of the Corporate Sustainability function on material impacts, risks and opportunities, and follows up on its execution of the strategy. The outcome of this work is also reported by the EVP Sustainability, Legal & Compliance to the Ethics and Sustainability Committee and reported to the Board of Directors at least once a year. Dedicated controls and procedures to follow up on the implementation are also ensured through a Sustainability Controller, integrated in the Finance function.

Sustainability targets are prepared by the Corporate Sustainability function, as instructed



by the Ethics and Sustainability Committee, and ultimately decided upon by the Board of Directors. The responsibility to follow up on these targets and monitor Getinge's progress lies with the Ethics and Sustainability Committee.

**Ethics and Compliance function**

The governance of ethics and compliance is led by the Ethics & Compliance function, which is also part of the Sustainability, Legal & Compliance team. This function has adopted a risk-based approach to ensure that compliance programs are designed and implemented addressing relevant risk areas such as anti-bribery & corruption, healthcare compliance, human rights and trade sanctions. While the function provides day-to-day support for implementation, ultimate responsibility for implementation of the compliance programs lies with each respective business area and function. The Chief Ethics & Compliance Officer reports to the Board's Audit & Risk Committee, Ethics & Sustainability Committee as well as the Getinge Executive Team on a periodic basis.

**Quality Compliance, Regulatory and Medical Affairs function**

Quality and patient safety is a critical material topic for the company. A function for Quality Compliance, Regulatory & Medical Affairs has

been established at group level, led by the Executive Vice President (EVP) Quality Compliance, Regulatory & Medical Affairs.

The function develops relevant policies, processes, and monitoring mechanisms to ensure the effectiveness of the quality management system as well as compliance with regulatory requirements. The ultimate operational responsibility for product quality and regulatory compliance lies with business area and functional management. Quality system audits are also carried out by each certificate holder in operations to ensure that the quality system meets the applicable external requirements. The responsibility to follow up and monitor Getinge's progress within quality related matters lies with the Ethics and Sustainability Committee.

**Business areas and functions**

Each of the business areas and functions within Getinge, including the global sales and service organization and corporate and group competence and support functions, are ultimately responsible for implementing policies, targets and actions. On an operational level sustainability-related risks, opportunities and progress are regularly evaluated and aligned, as part of this work. The business areas and functions are also responsible for integrating sustainability related

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

considerations into their respective strategy and operational plan, which is presented to GET as well as the Board of Directors.

**Policies and steering documents**

The mandates and responsibilities of the Board of Directors and its Committees related to sustainability, including quality, as outlined in this section, are defined in the rules of procedure. Sustainability governance at Getinge is ultimately regulated by a sustainability policy adopted by the Board of Directors. The sustainability policy is part of Getinge's global policy framework.

**Policy commitments**

The global policy framework comprises 16 global policies approved by Getinge's Board, and related global directives. Getinge's global policies and directives are reviewed and updated at least every two years in response to the continuously evolving regulatory environment and stakeholder expectations. These documents provide additional guidance on specific areas and emphasize the company's commitment to responsible business ethics.

Externally, the company is involved in several global initiatives related to responsible business ethics. Getinge is a signatory of the United Nations (UN) Global Compact and supports the ten principles on human rights, labor, environment, and anti-corruption.

Getinge also supports the 17 UN Sustainable Development Goals (SDGs) and Getinge's 2025 Annual Report identifies and describes those SDGs that best correspond to the company's impact on its business environment. In addition, Getinge has been a supporting member of the Swedish Anti-Corruption Institute since 2022 and actively participates in related networks.

**Embedding policy commitments**

All corporate functions and production units are responsible for complying with the Code of Conduct and achieving the sustainability targets in their line organizations. They are also responsible for evaluating sustainability-related risks in their operations, including but not limited to supplier responsibility, environment, occupational health & safety, anti-corruption, and labor & diversity. The corporate functions provide support, supervision and monitoring.

**Integration of sustainability-related performance in incentive schemes**

Sustainability work is integrated in Getinge's day-to-day operations, and Getinge's guidelines for remuneration to senior executives aim to promote Getinge's business strategy, long-term interests and sustainability. If the company's principles for sustainability or ethical guidelines are not complied with, the company has the possibility to withhold any variable remuneration or reclaim already awarded remuneration.

The selection of performance targets in incentive schemes and resolution to determine the variable remuneration is prepared by the Remuneration Committee and resolved by the Board of Directors. In 2025, two out of five performance targets for the short-term variable remuneration for the President and CEO were sustainability related. One target was related to the reduction of CO<sub>2</sub> emissions in Scope 1 and Scope 2, and the other target was related to a responsible supply chain. Each target is weighted 5 %, and the percentage of the remuneration recognized in the current period that is linked to climate related considerations is 5 %.

Statement on due diligence

Core elements of due diligence	Disclosure Requirement
a) Embedding due diligence in governance, strategy and business model	GOV-2, GOV-3, SBM-3
b) Engaging with affected stakeholders in all key steps of the due diligence	SBM-2, IRO-1, S1, S2, S4
c) Identifying and assessing adverse impact	IRO-1, SBM-3, S1, S2, S4, G1
d) Taking actions to address those adverse impacts	S1, S2, S4, G1
e) Tracking the effectiveness of these efforts and communication	S1, S2, S4, G1

Getinge's Human Rights Policy states that all people should be treated with dignity and respect. The policy and due diligence procedure is based on the Universal Declaration of Human Rights, the United Nations Guiding Principles on Business and Human Rights, and the International Labor Organization's (ILO) Declaration on Fundamental Principles and Rights at Work and applies to all employees and business relationships on behalf of Getinge.

Risk management and internal controls over sustainability reporting

Getinge does not have a full set of internal controls in place for ESRS reporting. The first part of the internal control framework over sustainability reporting focuses on environmental measures and has been rolled out during 2025. The framework will be further developed during 2026. The risk management process aligns with Getinge's ERM process.

## Overview of Getinge’s policies, directives and standard operating procedures

(As applicable from a sustainability perspective)

News on updated policies are presented on Getinge’s intranet page. At the same time, all employees with an e-mail address receive information on updated policies. Employees who need to know about the changes get trained by the document owner. Regional Ethics & Compliance officers communicate updates in their respective

regions. Input on stakeholder expectations and requirements is gathered through various channels such as customer meetings and surveys, investor meetings, industry forums, supplier follow-ups and in dialogues and surveys with company employees. This engagement directly informs policy setting at Getinge.

Policies and directives	ESRS standard	Description and key contents	Scope	Third party initiatives included	Most senior person overseeing policy	Availability
<b>Code of Conduct</b>	S1, S2	Getinge’s Code of Conduct provides the foundation for how the company conducts business. It describes the main principles for conducting business in line with both laws and stakeholder expectations	Getinge Group	• The UN Global Compact and the ten principles on human rights, labor, environment, and anti-corruption.	Anna Romberg, Executive Vice President, Sustainability, Legal & Compliance	Internal
<b>Environmental Policy</b>	E1, E3, E5, S1, S2, S4	The policy outlines Getinge’s commitment to reducing its environmental impact both within its own operations and throughout the entire value chain, and it details the company’s key initiatives and guiding principles	Getinge Group, business partners		Mattias Perjos, President and CEO Getinge	Public
<b>Sustainability Policy</b>	E1, E3, E5, S1, S2, S4	The policy provides a framework for employees to understand Getinge’s sustainability commitments and supports them in aligning with the company’s values, rules, and expectations.	Getinge Group		Anna Romberg, Executive Vice President, Sustainability, Legal & Compliance	Public
<b>People Policy</b>	S1	The policy outlines Getinge’s commitment to fostering a fair, responsible and sustainable working environment for all employees. It defines the company’s approach to supporting its people, reflecting the company’s human rights values both internally by ensuring Getinge is a great place to work and externally in all business and stakeholder interactions.	Getinge Group	• International human rights standards as defined in UN Global Compact.	Magnus Lundbäck, Executive Vice President, Human Resources	Public
<b>Human Rights policy</b>	S1, S2, S4	The policy outlines the company’s position on Human Rights, including forced labor, compulsory labor and child labor. Getinge is committed to respecting Human Rights and upholding the dignity and equal treatment of all individuals. The company works to identify, mitigate and prevent Human Rights risks and abuses within its operations, supply chain and the communities in which it operates.	Getinge Group	• The Universal Declaration of Human Rights • The United Nations Guiding Principles on Business and Human Rights • The International Labour Organization’s Declaration on Fundamental Principles and Rights at Work.	Anna Romberg, Executive Vice President, Sustainability, Legal & Compliance	Public
<b>Business Partner Code of Conduct</b>	S2, S4	The Code of Conduct for Business Partners sets out Getinge’s commitment to responsible business practices and defines the principles that all Business Partners are expected to follow throughout their relationship with the company. The Code of Conduct is made available through Getinge’s website	Business partners	• The UN Global Compact and the ten principles on human rights, labor, environment, and anti-corruption. • The Universal Declaration of Human Rights • The UN Guiding Principles on Business and Human Rights • ILO’s Declaration on Fundamental Principles and Rights at Work • The UK Modern Slavery Act	Anna Romberg, Executive Vice President, Sustainability, Legal & Compliance	Public

Welcome to Getinge

Market environment

Strategy

Business areas

The Board’s Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

→ General disclosures

Environment

Social

Governance

Appendix

Financial statements

Other information

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

→ General disclosures

Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

<b>Policies and directives</b>	<b>ESRS standard</b>	<b>Description and key contents</b>	<b>Scope</b>	<b>Third party initiatives included</b>	<b>Most senior person overseeing policy</b>	<b>Availability</b>
<b>Health and Safety directive</b>	S1, S2	The directive outlines the structure and purpose of Getinge's Occupational Health and Safety Management System. It sets out the requirements necessary for building a high-performing organization that ensures a safe, healthy and sustainable workplace for all employees.	Getinge Group	–	Magnus Lundbäck, Executive Vice President, Human Resources	Internal
<b>Diversity and Inclusion directive</b>	S1	The directive outlines the company's commitment to fostering a diverse and inclusive workplace. It sets forth the expectation that all employment practices provide equal opportunities without any form of unlawful discrimination. The directive applies to all external and internal recruitment, ongoing employment, promotions, development opportunities and all other personnel-related decisions. It is aligned with the Getinge Code of Conduct, which defines how the company conducts its business and the collective responsibilities upheld toward its stakeholders.	Getinge Group	–	Magnus Lundbäck, Executive Vice President, Human Resources	Internal
<b>Quality Policy</b>	S1, S4	The policy outlines the company's commitment to delivering safe, effective and high-quality solutions that meet the expectations of patients, customers and regulators. It further establishes the company's way of working, which is grounded in maintaining an effective and compliant quality management system, continuously improving through customer insights and fostering a collaborative culture where quality and compliance are integrated into everyday work to ensure reliable outcomes.	Getinge Group	–	Mattias Perjos, President and CEO Getinge	Public
<b>Anti-Bribery and Corruption Policy</b>	S1, S2, S4	The policy outlines the company's commitment to the highest standards of responsible business conduct. It establishes that Getinge does not accept bribery or corruption in any form and will act proactively to uphold ethical business practices. The policy also affirms that Getinge must comply with all applicable anti-bribery and corruption legislation.	Getinge Group, business partners	<ul style="list-style-type: none"> <li>• The US Foreign Corrupt Practices Act</li> <li>• UK Bribery Act</li> <li>• The Brazil Clean Company Act</li> <li>• Equivalent laws worldwide</li> </ul>	Anna Romberg, Executive Vice President, Sustainability, Legal & Compliance	Public
<b>Getinge Knowledge Sharing Document for EcoDesign</b>	E1, E3, E5, S1, S4	The procedure is part of Getinge's Design Controls and Risk Management Directive and outlines the company's commitment to preventing and minimizing the environmental impact of its products throughout their entire life cycle, while maintaining essential product requirements such as safety and performance. It affirms that sustainability is an integral part of all design and development activities and reflects the increasing expectations from society and customers. The procedure focuses on ensuring environmentally sustainable product development, with the overarching objective of reducing environmental impact at every stage of the product life cycle.	All levels within Getinge where products are designed and manufactured	–	N/A	Internal



Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

→ Environment

Social

Governance

Appendix

Financial statements

Other information

E

# Environment

The environmental challenges facing society today are deeply interconnected and increasingly urgent. For the healthcare sector, this means navigating a landscape where environmental performance and patient well-being are closely linked.

As a global medtech company, Getinge works to understand and manage its environmental impacts across the value chain, aiming to reduce impact while supporting safe, high-quality care.

**E1 Climate change** →

**E3 Water & marine resources** →

**E5 Resource use & circular economy** →

**EU Taxonomy** →

### Relevant Sustainability Development Goals



# Climate change

The healthcare sector accounts for about 5% of global carbon emissions<sup>1</sup>. Climate change is directly linked to health, with rising temperatures and extreme weather contributing to the spread of diseases, respiratory conditions, and heat-related illnesses. This means that the healthcare sector needs to be involved in a systematic approach to deliver better health outcomes with a reduced carbon footprint.

Getinge is committed to reaching net-zero emissions in line with its targets validated by the Science Based Targets initiative. The Group is not excluded from EU Paris-aligned Benchmarks.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

1) Source: [https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196\(20\)30121-2/fulltext](https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(20)30121-2/fulltext)



## Getinge's targets

**20%**  
reduction in energy consumption by 2030

**Energy**  
The company target is to reduce energy consumption by 20% by 2030 compared to the base year 2021.

**90%**  
reduction in Scope 1 & 2 emissions by 2030


**Net-zero emissions by 2050**  
In 2020, Getinge committed to establish a science-based climate target. The company's near- and long-term targets were validated by the Science Based Targets initiative in 2023.

**25%**  
reduction in Scope 3 emissions by 2030

The long-term target is net-zero emissions by 2050. The near-term targets are to reduce Scope 1 & 2 emissions by at least 90% and Scope 3 emissions by at least 25% by 2030 compared to the base year 2021. Stakeholder involvement in target setting is explained on page 75.

## Outcome

### Scope 1 & 2 emissions and total energy consumption



## Overview of Getinge’s material impacts, risks and opportunities related to climate change

-  Positive impact
-  Financial opportunity
-  Negative impact
-  Financial risk

### Climate change mitigation

#### Actual negative impact

Carbon emissions are prevalent at most stages of Getinge's value chain, with the majority of emissions arising from purchased goods and services, use of sold products and transportation of goods to and from production sites.

**Upstream:** Materials used in manufacturing that have high energy demands for extraction, refinement, or production (e.g., metals, electronics, plastics) increase the overall carbon footprint. Certain suppliers rely on carbon-intensive energy sources, contributing significantly to Scope 3 emissions. Transporting materials between suppliers and manufacturers results in carbon emissions, with air freight representing the majority of these emissions.

**Own operations:** Energy used for manufacturing and heating of production facilities and offices lead to carbon emissions in sites where fossil fuels are used. Manufacturing generates waste (e.g., production scrap), some of which requires energy-intensive disposal or end up in landfills, which often entails increased emissions.

**Downstream:** Transporting finished products from Getinge manufacturing sites to customers results in carbon emissions, particularly when air freight is used. Products that require energy to operate, particularly sterilizers, contribute to increased energy demand and emissions, especially when customers rely on fossil-based electricity to generate steam. Many of Getinge's products are incinerated at the end of their lifecycle due to safety regulations, leading to emissions and pollution. The absence of take-back programs or recycling systems further exacerbates these challenges.

#### Where

Upstream  
Own operations  
Downstream

#### Time frame: Impact

Medium- and long-term

#### Time frame: Risk and opportunity

Medium- and long-term

### Financial risk

If Getinge or its supply chain fails to transition in line with market and regulatory requirements, this could entail a risk of Getinge losing market share in markets where low-carbon operations are prioritized by customers and regulators. If carbon pricing and related compliance costs increase significantly across several markets, this could also affect Getinge negatively throughout the value chain.

### Financial opportunity

Under the assumption that certain markets still use fossil fuels in the electricity grid, putting more energy efficient products on the market is a competitive advantage for Getinge as these will reduce carbon emissions.

### Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board’s Operating Reports

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

### Financial statements

### Other information

## Overview of Getinge’s material impacts, risks and opportunities related to climate change, cont.

- + Positive impact
- Negative impact
- O Financial opportunity
- R Financial risk

### Energy

#### Actual negative impact

**Upstream:** Certain manufacturing processes in the supply chain require a significant amount of energy. This is true primarily in Tier 2-n of the value chain as these tiers involve mining, oil extraction and chemical processes.

**Own operations:** Energy used for manufacturing and heating of production facilities and offices lead to carbon emissions in sites were fossil fuels are used.

**Downstream:** Some of Getinge's products consume significant amounts of energy when used (this is particularly true for sterilizers and washers).

#### Financial risk

If Getinge products are found to be less energy efficient than competitor's this could entail risk of Getinge losing competitive advantage in markets where energy efficient products are prioritised by customers and regulators. If energy prices increase significantly this could also affect Getinge negatively across the full value chain.

#### Financial opportunity

Putting more energy efficient products on the market is deemed to represent an opportunity due to assumed competitive advantage with these products.

- R O

#### Where

Upstream  
Own operations  
Downstream

#### Time frame: Impact

All

#### Time frame:

**Risk and opportunity**  
Medium- and long-term

### Climate change adaptation

#### Potential negative impact

**Upstream:** When new materials are required to adapt to climate change there may be impacts such as loss of reliability in a value chain that is designed for stability and compliance. Adapting to changes in supply may also lead to increased logistics or changed logistics routes.

**Own operations:** If higher demand for electricity is required to power equipment used for climate change adaptation, such as HVAC, cleanrooms and dehumidification systems, Getinge's energy consumption could increase.

**Downstream:** Extreme temperatures in hospitals can expose medical devices to heat stress beyond their designed tolerance levels, while elevated humidity increases the likelihood of product failures. In addition, water scarcity can disrupt sterilization processes, and the risk of unreliable power supply may further compromise safe and continuous operations.

#### Financial risk

Persistent extreme weather conditions could disrupt production at sites located in climate-sensitive areas, affecting Getinge's ability to manufacture and deliver products. Additionally, downstream adaptation may be required, such as designing products to withstand increased humidity or addressing reduced water availability, particularly critical for sterilization processes. These adaptations could lead to higher production costs.

#### Financial opportunity

There are potential market opportunities if the company develops products that can withstand greater climate fluctuations, reduce energy and water demand, and offer preventive maintenance services.

- R O

#### Where

Upstream  
Own operations  
Downstream

#### Time frame: Impact

Medium- and long-term

#### Time frame:

**Risk and opportunity**  
Long-term

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Climate related risk and scenario analysis

During 2025, Getinge conducted a climate scenario analysis to understand risks and impact across the value chain in line with ESRS E1-1. The company’s risks and opportunities were evaluated using both a low-emission scenario (SSP1-1.9) and a high-emission scenario (SSP5-8.5) reflecting different potential future outcomes. The analysis had a focus on regions exposed to acute physical risks (flooding, extreme heat) and transition risks (regulatory changes, shifts in market demand

toward low carbon solutions). Resilience analysis has only been made for Getinge’s own operations during 2025.

An assessment of the locations of Getinge’s production sites and key supplier locations was conducted using publicly available geospatial climate tools. Temperature rise, precipitation changes, and drought risk were assessed using the Probable Futures platform, a non-profit initiative visualizing climate risks through the


CORDEX-CORE regional climate model framework. The following risk thresholds were applied and considered high risk:

- Temperature: Areas with >31–90 days above 35°C.
- Precipitation: Areas with 3-4 times higher frequency of rare storms.
- Dryness: Areas with >51% annual likelihood of a year-long drought.

One major focus area was water given its importance for operations across the value chain. Using the World Resources Institute’s tool Aqueduct Water Risk Atlas. For medium- and long-term projections, the “pessimistic scenario,” aligned with the SSP5-8.5 high-emission pathway was used.

### Getinge production sites located in areas of physical risk in a high carbon scenario

- Effects of Climate change already entail a high risk
- Effects of Climate change will be a high risk in a medium timeframe (5 years)
- Effects of Climate change will be a high risk in a long timeframe (+5 years)



\*Source: probablefutures.org/maps  
 \*\*Source: Aqueduct Water Risk Atlas

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

Most transition risks relate to market and reputation-based factors. These risks were analyzed using geospatial coordinates based on Getinge’s geographic locations, as well as local regulatory developments concerning carbon trading, carbon pricing, the transition to a low-carbon economy, energy supply security and raw material costs under different scenarios and global warming models.

Physical and transition climate risks have been assessed using a time-horizon of up to 2050. The following time horizons have been used and are aligned with the company’s ERM framework:

- Short-term – one to three years tied to strategic and financial timeframe
- Medium-term – five years (2030), tied to long-term strategic goals
- Long-term – five years and beyond (2050)

The chart to the right is a summary of the scenarios analyzed, risks and the actions to be taken to mitigate or adapt to the assessed risks. However, the resilience analysis for the full value chain has not been finalized during 2025. An assessment of whether the scenarios are compatible with critical climate-related assumptions made in financial statements as well as continued analysis of all risks will be developed during 2026.

As most of the emissions stem from the up- and downstream value chain (Scope 3 emissions) the company is dependent on its partners both in relation to climate change adaptation and mitigation.

Scenario	Risks	Response	Action	Description
<b>Low-emission scenario</b>	Policy and legal	Climate mitigation	Getinge invests in actions to reduce carbon emissions	Short term perspective (0-5 years): invest in energy efficiency and decarbonizing energy used in production.
	Technological			Medium-long term perspective (more than 5 years): Innovation to improve energy and resource efficiency of products.
	Market	Reputational		
	SSP1-1.9			
<b>High-emission scenario</b>	Acute physical risk	Climate adaptation	Getinge keeps track of and invests in minimizing exposure to potential physical risks	Track risk exposure upstream and in production.
	Chronic physical risk			Invest in adaptation measures in own production sites if necessary.
SSP5-8.5				Preparedness in case of increasing non-communicable diseases and ability to respond in event of global pandemics.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

Financial statements

Other information

## Climate transition plan

Getinge understands the role that healthcare has on climate change and has set science based targets which have been validated by Science Based Target Initiative to mitigate its emissions across the value chain. The development of an ESRS-aligned transition plan started during 2025 with the aim to reach the targets, adapt to climate change and remain resilient. The plan encompasses GHG emissions from Getinge's own operations and its value chain. Getinge has carried out a scenario analysis and identified transition risks and opportunities, set targets and key performance indicators and started the analysis of the implications on the business strategy. The company has yet to analyse the compatibility of assets and the business plan with the implications of a carbon transition. The ambition is to continue developing the plan during 2026.


The work with the transition plan to date has shown that the emissions for which the company has full impact (Scope 1 and 2 emissions from production facilities) have reduced significantly since the target was set in 2021 and the target to reach net-zero by 2030 remains. However, reaching the near-term reduction of 25% Scope 3 emissions will be more challenging. Emissions from purchased goods and services and from energy consumed in product use represent the majority of the company's Scope 3 emissions.

The company has identified the main levers for reducing emissions and their impact on emissions as well as Getinge's potential to influence the reduction, dependencies and uncertainties. To further strengthen resilience Getinge has identified actions and main levers for reducing emissions (see pages 91–92).

### Continuous improvement of data and calculation methods

Improvements in the quality of data inputs, emission factors and/or calculation methods will have an impact on the reduction plan. Getinge has been working on emissions calculations for Scope 1, 2 and 3 since 2021, constantly seeking to improve the measurements and calculations where Scope 3 emissions from purchased goods and use of sold products are still to a high degree based on assumptions. The base year for all reported carbon emissions is 2021 as it was the first year in which the company established a complete Scope 1, 2, and 3 inventory and the closest year to the year when the submission of the science based targets was done (2022). The baseline figures have been updated for the 2025 years' report and is adjusted to the base year of SBTi.


### Emission distribution



### Scope 3 emission distribution



### Progress on Scope 1 & 2 emissions towards Net Zero target



**Emissions 2025 and decarbonization approach\***

Scope	Source of emissions	Share of total emissions	Decarbonization approach	Impact of approach	Level of control/influence	Dependencies
Scope 1	Fuel used in production	<1%	Energy efficiency	Medium	Direct control	Weather (fuel is mostly used for heating).
			Switch to renewable fuels	High	Medium influence	The majority of fuel used in sites is gas. Alternatives such as biogas is not available in all sites which is a limiting factor to emission reduction.
Scope 1	Fuel used in vehicles	1%	Switch to electrical vehicles	High	High influence	Infrastructure for electrical vehicles.
Scope 2	Electricity used in production	<1%	Energy efficiency	Low-medium	High influence	Production volume and weather (heating plays an important role in energy used).
			Switch to renewable sources of electricity	High	High influence	Availability of renewable sources of energy and viability of solar power.
Scope 2	Electricity used in leased offices	<1%	Switch to renewable sources of electricity	High	Intermediate influence	Many offices are leased and thus dependent on owner decisions.
Scope 3	Purchased goods and services	31%	Choice of materials	Medium to high	Intermediate influence	Medtech is highly regulated and changing materials needs to give priority to patient safety. Changing materials takes time for this reason.
			Supplier Scope 1 & 2 emissions	Medium	Low-intermediate influence	Suppliers reducing their GHG emissions in line with targets reported to Getinge. Influence on supplier varies dependent on share of business.
Scope 3	Goods transportation (Up- and downstream)	6%	Choice of transport mode	Medium	High level of influence	Getinge is dependent on being able to transport equipment quickly in certain circumstances (e.g. transplant care) and the only choice is then air freight.
			Decarbonization of aviation, ocean and road transport	High	Low level of influence	Getinge is dependent on the decarbonization of the air, road and ocean freight industries.
Scope 3	Use of sold products	53%	Energy efficiency of products put on the market	Medium	Direct control	Getinge can work to develop more efficient products over time but market penetration of new products may take time. Servicing products regularly and using them in an optimal way will impact emission reduction.
			Decarbonization of energy used by customers (renewable electricity)	High	Low level of influence	Continued decarbonization of the global electricity grid in particular in markets such as US, China and India will have a significant impact on emission reduction.
Scope 3	Business travel	1%	Choice of transport mode	High	Medium influence	Due to the nature of the business, speed is sometimes critical in reaching customers and this has an impact on business travel choice of transport mode.
			Decarbonization of aviation	High	Low level of influence	Getinge is dependent on the decarbonization of aviation and has low influence on this change.
Scope 3	Other Scope 3 emissions	~5%	–	–	–	–

\*Work to calculate the exact emission reduction potential for each lever is still under development.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

→ Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

→ Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

Policies

Getinge's Global Environmental Policy states the company's commitment to reducing its environmental impact across the value chain. The reduction of greenhouse gases is a primary focus in this policy. Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units). The local ISO 14001 certification provides a framework for local implementation and follow-up of energy management and emission reduction.

Getinge's EcoDesign procedure applies to hardware, accessories, spare parts, service, after-market, packaging and manuals. The procedure describes how the company addresses the environmental considerations in the Design Controls and Risk Management Process for Medical Devices and non-Medical Devices (local procedure), by using a standardized Life Cycle Assessment (LCA) methodology. This methodology contributes to the reduction of the environmental impact by providing information on the environmental footprint and the emission hotspots in the lifecycle of a product (including extraction of material, production, transport, product use and end-of-life treatment). Relevant employees are trained in using the LCA tool to ensure correct and consistent application.

Strategic direction and actions

Getinge is determined to measure and track carbon emissions across its full value chain, focusing on areas where the company has direct influence. These areas include energy used in production, product development which impacts choice of materials and energy efficiency of the products when in use as well as choice of transport mode.

 **Actions Upstream**  
Scope 3 emissions

**Reducing emissions from purchased goods and services**

Reducing emissions from purchased goods and services is challenging in the medtech industry due to the regulated nature of the industry. Despite this, Getinge is taking steps to reduce emissions with a focus on direct suppliers of goods that have a relatively high emission impact, such as metals, plastics and electronics. The aim is to obtain primary environmental data on products and alternatives, and to partner with existing suppliers to support their carbon emission reduction journeys.

Significant impact will come from the work that has started in the three business areas to identify key EcoDesign opportunities by systematically challenging design, material and component selection as well as continuously aiming to reduce material flows. This includes replacing materials with lower-emission alternatives, e.g. bio-based plastics that can replace fossil-based plastics. During 2025, the company has primarily focused on improving the data from suppliers by sending a questionnaire to the 70 largest suppliers of direct material by spend. It can be concluded that more than two thirds of the suppliers in scope have carbon emission targets but availability of supplier specific carbon data on purchased goods is still low and development of weight and supply chain specific based emission calculations moves slowly. This means the company continues to rely on spend data for purchased goods- and services emission calculations (Scope 3 category 3.1: Purchased goods and services).

**Decrease in emissions from goods transportation**

Goods transportation emissions have continued to decrease during 2025 as a result of shifting transport modes from air freight to sea freight on several logistics' routes most notably between Europe and US. This modal shift has resulted in a decrease of more than 39% since the base year.

 **Actions Own Operations**  
Scope 1 and 2 emissions

**Reducing emissions from production**

Scope 1 and 2 represented 2.5% of the total carbon emissions in 2025. The emissions from energy used in manufacturing and heating of premises are the company's priority as they are directly controllable by the company. During 2025, the focus has been on improving energy efficiency, switching to alternative sources of energy and electricity and reducing the use of fossil-fuels to the greatest extent possible. Two sites in Europe have, for example, invested in boiler optimization as well as implementing measures to improve operational control.

**Electrifying the car fleet**

The electrification of the company's vehicle fleet continued in 2025 even though challenges regarding the charging infrastructure in some parts of the world still impacts the transition.

 **Actions Downstream**  
Scope 3 emissions

**Energy consumption during use of sold products**

For products such as sterilizers and washer-disinfectors with high carbon emissions in the use phase, Getinge continuously explores ways to improve energy efficiency. A key approach is applying EcoDesign principles in product development.

Reducing emissions during use also depends on the rate at which customers transition from fossil-based to renewable sources of electricity. Getinge provides improved usage instructions and engages in active dialogue with customers to support emission reduction. During 2025 a questionnaire has been sent to 35 of the customers using sterilizers in an effort to improve data on the electricity used. The results were that the majority of the customers in scope use electricity from the grid which supports the hypothesis made in Getinge calculations for category 3.11: Use of sold products.

## Targets, key figures and results

### Energy consumption and mix

During 2025 Getinge has continued to reduce its energy consumption in line with the target of a 20% reduction of energy consumption compared with the base year 2021.

For 2025, the energy consumption for production sites amounted to 80 887 MWh, a 19% reduction compared with the base year 2021.

The share of renewable energy amounts to 69% for 2025 (66% in 2024).

For Getinge's reporting principles related to energy consumption see page 129.

### Energy consumption within the organization\*

Energy consumption and mix	2025	2024	Base year 2021
Fuel consumption from coal and coal products (MWh)	–	–	–
Fuel consumption from crude oil and petroleum products (MWh)	430	297	345
Fuel consumption from natural gas (MWh)	22,827	22,934	32,253
Fuel consumption from other fossil sources (MWh)	–	–	–
Consumption of purchased or acquired electricity, heat, steam, and cooling from fossil sources (MWh)	1,836	4,976	29,220
<b>Total non-renewable fossil energy consumption (MWh)</b>	<b>25,093</b>	<b>28,207</b>	<b>61,819</b>
<b>Share of fossil sources in total energy consumption (%)</b>	<b>31%</b>	<b>34%</b>	<b>62%</b>
Fuel consumption for renewable sources, including biomass (also comprising industrial and municipal waste of biologic origin, biogas, renewable hydrogen, etc.) (MWh)	8,034	8,984	6,837
Consumption of purchased or acquired electricity, heat, steam, and cooling from renewable sources (MWh)	47,760	45,242	30,879
The consumption of self-generated non-fuel renewable energy (MWh)	–	–	–
<b>Total renewable energy consumption (MWh)</b>	<b>55,794</b>	<b>54,226</b>	<b>37,716</b>
<b>Share of renewable sources in total energy consumption (%)</b>	<b>69%</b>	<b>66%</b>	<b>38%</b>
<b>Total energy consumption (MWh)</b>	<b>80,887</b>	<b>82,433</b>	<b>99,536</b>

\* Four legal entities, Healthmark, Ultra Clean, Quadralene and Paragonix have been added through acquisition and data is updated for the period 2021–2024. In 2025, Getinge is unable to report energy consumption from nuclear sources due to a lack of available data. The company aims to establish the necessary processes to report this information from 2026 onwards.

### Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board's Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

→ Environment

Social

Governance

Appendix

### Financial statements

### Other information

**Net-zero emissions by 2050**

The long-term target is net-zero emissions by 2050. The near-term targets are to reduce Scope 1 and 2 emissions by at least 90% and Scope 3 emissions by at least 25% by 2030 (base year 2021).

The targets encompass all Scope 1 direct emissions from the operations and Getinge includes leased vehicles in its Scope 1 emissions. Scope 2 includes indirect emissions generated during the production of purchased electricity, district heating, cooling, and process steam. Getinge includes leased office spaces in its Scope 2 emissions.

Scope 3 comprises other indirect emissions, both upstream and downstream in the value chain, arising from activities such as purchased travel, transportation, production of purchased goods and services, and commuting trips of employees.

Scope 1 and 2 emissions in own production decreased with 11% during 2025 compared to 2024. The main contribution being the transfer to renewable electricity, optimization and improved operational control in the production sites, leading to reduction in gas consumption and partly also conversion to bio-gas. To reflect its renewable electricity procurement, Getinge applies contractual instruments such as I-RECs and other renewable energy certificates in its Scope 2 reporting. For total Scope 1 and 2 emissions, the transition from fossil fuel company vehicles to electric and hybrid vehicles accounts for the majority of the reduction.

Regarding emissions from the value chain (Scope 3), it is primarily in outbound transportation that the company can draw conclusions from changes in emissions.

For Getinge’s reporting principles related to GHG emissions see page 129.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

**Emissions, ton CO<sub>2</sub>eq\***

Metric	2025	Retrospective				Milestones and target years			
		2024	2021	% Change from last year	% Change from base year	2030	2050	Annual % target / base year	
<b>Scope 1 GHG emissions</b>									
Gross Scope 1 greenhouse gas emissions (tCO <sub>2</sub> eq)	11,650	13,186	18,483	-12%	-37%				
Percentage of Scope 1 GHG emissions from regulated emission trading schemes (%)	–	–	–	–	–				
<b>Scope 2 GHG emissions</b>									
Gross location-based Scope 2 greenhouse gas emissions (tCO <sub>2</sub> eq)	14,344	–	–	–	–				
Gross market-based Scope 2 greenhouse gas emissions (tCO <sub>2</sub> eq)	3,480	3,926	14,765	-11%	-76%				
<b>Total Scope 1 &amp; 2 GHG emissions (location-based) (tCO<sub>2</sub>eq)</b>	<b>25,994</b>								
<b>Total Scope 1 &amp; 2 GHG emissions (market-based) (tCO<sub>2</sub>eq)</b>	<b>15,130</b>	<b>17,112</b>	<b>33,247</b>	<b>-12%</b>	<b>-54%</b>	<b>-90% (3,325)</b>	<b>-90% (3,325)</b>	<b>10%</b>	
<b>Metric</b>		<b>2025</b>	<b>2024</b>	<b>2021</b>					
		(like for like)**	(like for like)**	(like for like)**					
<b>Significant Scope 3 GHG emissions</b>									
<b>Total Gross indirect (Scope 3) GHG emissions (tCO<sub>2</sub>eq)</b>	<b>594,982</b>	<b>567,571</b>	<b>585,026</b>	<b>610,757</b>	<b>-3%</b>	<b>-7%</b>	<b>-25% (458,068)</b>	<b>-90% (61,076)</b>	<b>3%</b>
3.1 Purchased goods and services (tCO <sub>2</sub> eq)	187,265	165,837	166,387	163,616					
3.2 Capital goods (tCO <sub>2</sub> eq)	23,225	23,225	20,897	22,542					
3.3 Fuel and energy-related activities (tCO <sub>2</sub> eq)	4,110	705	3,615	2,645					
3.4 Upstream transportation and distribution (tCO <sub>2</sub> eq)	37,015	34,761	39,675	58,772					
3.5 Waste generated in operations (tCO <sub>2</sub> eq)	122	114	111	113					
3.6 Business travel (tCO <sub>2</sub> eq)	6,222	6,222	7,138	1,502					
3.7 Employee commuting (tCO <sub>2</sub> eq)	8,142	8,142	7,922	7,200					
3.8 Upstream leased assets (tCO <sub>2</sub> eq)	N/A	N/A	N/A	N/A					
3.9 Downstream transportation (tCO <sub>2</sub> eq)	1,446	1,388	1,594	2,400					
3.10 Processing of sold products (tCO <sub>2</sub> eq)	N/A	N/A	N/A	N/A					
3.11 Use of sold products (tCO <sub>2</sub> eq)	326,012	326,012	336,489	350,558					
3.12 End-of-life treatment of sold products (tCO <sub>2</sub> eq)	1,423	1,165	1,199	1,409					
3.13 Downstream leased assets (tCO <sub>2</sub> eq)	N/A	N/A	N/A	N/A					
3.14 Franchises (tCO <sub>2</sub> eq)	N/A	N/A	N/A	N/A					
3.15 Investments (tCO <sub>2</sub> eq)	N/A	N/A	N/A	N/A					
<b>Total GHG emissions</b>									
<b>Total GHG emissions (location-based) (tCO<sub>2</sub>eq)</b>	<b>620,976</b>	–	–	–	–	–	–	–	
<b>Total GHG emissions (market-based) (tCO<sub>2</sub>eq)</b>	<b>610,112</b>	<b>582,701</b>	<b>602,138</b>	<b>644,004</b>	<b>-3%</b>	<b>-10%</b>	<b>N/A</b>	<b>-90% (64,400)</b>	<b>3%</b>
<b>GHG intensity per net revenue</b>									
<b>Total GHG emissions (location-based) per net revenue (tCO<sub>2</sub>eq/SEK M)</b>	<b>18</b>	–	–	–					
<b>Total GHG emissions (market-based) per net revenue (tCO<sub>2</sub>eq/SEK M)</b>	<b>17</b>	<b>17</b>	<b>17</b>	<b>24</b>					

\* Four legal entities, Healthmark, Ultra Clean, Quadralene and Paragonix have been added through acquisition and data is updated for the period 2021–2024. An error was found where the emission factor for historical years (2021–2024) for one site had the wrong unit for emissions from electricity: tonnes CO<sub>2</sub>e/kWh instead of tonnes CO<sub>2</sub>e/MWh in the Q4 report 2025. This has now been corrected, and the data has been updated accordingly. Getinge reports on location-based GHG emissions for the first year in 2025, therefore historical data is not available.

\*\* 2025 like-for-like are the Scope 3 emission without new acquisitions included. This is to facilitate comparison with Scope 3 2024 and the base year as these have not been re-calculated. Note that all reductions that include Scope 3 in the table have been calculated using the like-for-like numbers.

# Water & marine resources

Globally, nearly four billion people experience severe water scarcity for at least one month each year<sup>1</sup>. Addressing water scarcity is not only crucial to secure access to water, but also essential for improving public health worldwide. The value of water in hospitals and the life science industry cannot be underestimated, as it directly impacts health outcomes and scientific progress. Water is an indispensable resource, serving as the backbone for patient care, medical processes, and scientific research. In hospitals, it ensures hygiene, for example, by supporting instrument reprocessing, and maintaining a safe environment for patients and staff.

Furthermore, in the life science industry, access to high-quality water is crucial for laboratory accuracy, pharmaceutical production, biotechnology processes, and research and development, ensuring the integrity and reliability of scientific work. Water is also necessary in the production and testing of Getinge equipment and in the upstream supply chain.

1) Source: Water scarcity | UNICEF  
2) Source: WRI Water Risk Atlas tool Aqeduct



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**


## Getinge's target

**20%**  
reduced water consumption in sites located in water scarce areas by 2030

The target is to reduce water consumption in sites located in water scarce areas by 20% by 2030 compared to the base year 2021. The sites in scope for the target are those located in areas of high water-stress defined as extremely high and high according to Aqeduct.<sup>2</sup> Stakeholder involvement in target setting is explained on page 75.

## Outcome

**Water consumption development, m<sup>3</sup>**



\* High according to Aqeduct  
\*\* Extremely high to high according to Aqeduct

## Overview of Getinge’s material impacts, risks and opportunities related to water & marine resources

 Positive impact

 Financial opportunity

 Negative impact

 Financial risk

### Water consumption

#### Actual negative impact

**Upstream:** Water is necessary in producing several materials purchased by Getinge, such as electronics, metals, and plastics. Increased consumption of these materials results in increased consumption of water, potentially in areas with high water stress.

**Own operations:** Getinge consumes water in larger amounts in the sites that manufacture sterilizers and washers. Consumption of water in areas classified to have high water stress can put pressure on ecosystems and community access to water. Seven of the company’s manufacturing sites are located in high water-stressed areas.

**Downstream:** Water is needed to use some of the products Getinge puts on the market such as sterilizers and washers. If these products are used in customer sites located in high water-stressed areas the impact could be significant.

#### Financial opportunity

By putting more water efficient sterilizers and washers on the market Getinge could gain a competitive advantage. Moreover, water efficient products could lead to reduced water consumption for customers, improving the cost of ownership, which also could benefit Getinge’s competitive advantage.

#### Where

Upstream  
Own operations  
Downstream

#### Time frame: Impact

Medium- and long-term

#### Time frame:

#### Risk and opportunity

Medium- and long-term

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

→ Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

→ Environment

Social

Governance

Appendix

Financial statements

Other information

## Policies

Getinge actively promotes resource efficiency in its entire value chain. The management of water follows the principles set out in both the sustainability and environmental policies and local environmental management systems.

The Sustainability policy describes sustainable innovations for better health which includes making products with reduced environmental impact.

Getinge's Global Environmental policy includes the company's commitment to ensuring resource efficiency in all Getinge sites. The policy outlines the importance to continuously work to make manufacturing processes resource and water efficient, minimizing risk of pollution with the goal to optimize resource use throughout the company operations. The policy does not include water treatment or prevention of water pollution, nor does it specifically address sites with material water risks.

Getinge's process for EcoDesign includes requirements and criteria that shall be considered in the design phase such as selection of materials to be used and their environmental impact.

Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units) in order to comply with local regulations including safeguarding the use of water where relevant.

## Strategic direction and actions

The company uses the World Resources Institute tool Acqueduct to understand which sites are located in water stressed areas. The targets to reduce water consumption are related to the identified sites. In the sites located in water scarce areas actions during 2025 have included to map the major sources of water consumption in order to understand better what action can be taken to reduce the use of water.

With regards to the impact from use of products continuous work is done in the product development of sterilizers and washers to find solutions to reduce water consumption when these products are used. One example of this work is the launch of Getinge Aquadis 44, a washer disinfectant which has unique systems that automatically adjust the amount of water and detergent needed based on the load. This ensures optimal cleaning and resource efficiency and can reduce water consumption by up to 50%.

## Targets, key figures and results

Getinge's target is to reduce water consumption in sites located in water scarce areas<sup>1</sup> by 20% by 2030 (base year 2021). Getinge has used the tool Acqueduct to identify sites in areas of high- and extremely high water stress. Data is compiled monthly via a data management system and is sourced from direct measurements, either via supplier invoices or via local measuring equipment or meters. Getinge does not disclose on water recycled, reused or stored in 2025. In 2026 Getinge will investigate possibilities of recycling

and reusing water. For sites in areas of high water stress, the 2025 result shows a 17% increase compared to last year. Water consumption is mainly related to facilities management and testing in production of washers and sterilizers and varies over time depending on production volume. The result for 2025 is mainly due to a higher degree of testing in production and increase in water for facilities at one of Getinge's sites. For Getinge's reporting principles related to water, see page 132.

Water consumption in own operations*	2025	2024	2021
<b>Total water consumption, m<sup>3</sup></b>	<b>215,414</b>	<b>205,964</b>	<b>213,301</b>
Total water consumption in areas of water stress (m <sup>3</sup> )			
Water risk (high according to Aqueduct)	57,617	40,547	54,384
High water stress (extremely high and high according to Aqueduct)	114,691	97,692	104,673
Water intensity ratio (m <sup>3</sup> /mSEK) total revenue	6	6	8

\* In 2025 the method to calculate water intensity ratio was changed from net revenue in own operations to total revenue in accordance with ESRS requirements. Four legal entities, Healthmark, Ultra Clean, Quadralene and Paragonix have been added through acquisition and data is updated for the period 2021–2024.

### Getinge sites located in water stressed areas

Suzhou	China
Rastatt	Germany
Tournefeuille	France
La Ciotat	France
Poznan	Poland
Antalya	Turkey
Englewood	US



1) Source: WRI Water Risk Atlas tool Acqueduct

# Resource use & circular economy

Globally, the rate of circularity is decreasing. In 2025, only 11% of materials in the world were recycled<sup>1</sup>. Changing the way products are made and how materials are used will have an important role in reusing and recycling, as well as reducing carbon emissions.

One example is that by eliminating waste and pollution, greenhouse gas emissions can be reduced across the value chain<sup>2</sup>. According to the World Health Organization, high income hospitals generate around 0.5 kg of hazardous waste per bed per day and in high income countries the majority of waste (not including food waste) is plastic-based<sup>3</sup>.

Working to reduce waste streams and improve material efficiency is therefore a priority for Getinge.

1) Source: <https://www.circularity-gap.world/2025>  
 2) Source: Ellen McArthur foundation  
 3) Source: <https://www.who.int/news-room/fact-sheets/detail/health-care-waste>



- Welcome to Getinge**
- Market environment**
- Strategy**
- Business areas**
- The Board's Operating Reports**
  - Administration Report
  - Corporate Governance Report
  - Sustainability statement
    - General disclosures
    - Environment
    - Social
    - Governance
    - Appendix
- Financial statements**
- Other information**

## Getinge's target

**No waste to landfill by 2030**  
 The target for the company towards 2030 is zero waste to landfill, excluding material required by local regulations to be landfilled. Stakeholder involvement in targets setting is explained on page 75.

## Outcome

**Waste to landfill 2025**  
**344 tons**

## Overview of Getinge’s material impacts, risks and opportunities related to resource use & circular economy

**+** Positive impact

**O** Financial opportunity

**-** Negative impact

**R** Financial risk

### Resource inflows, including resource use

#### Actual negative impact

**Upstream:** Production of single-use plastic consumables increases the demand for high-volume raw materials that strain ecosystems and contribute to waste after disposal.

**Own operations:** Getinge is a manufacturer of both capital goods and consumables. Manufacturing requires energy and resource inputs, which contributes to emissions and resource depletion.

**-**

#### Where

Upstream  
Own operations

#### Time frame: Impact

Medium- and long-term

### Resource outflows and waste

#### Actual negative impact

**Own operations:** Getinge’s production sites produce waste which is partly recycled, partly incinerated and when legally obliging sent to landfill. Waste handling requires energy and contributes to emissions and pollution. Packaging is often made of materials such as wood, paper and plastics and the majority of the packaging becomes waste after being used for transporting goods.

**Downstream:** Getinge contributes to the generation of hospital waste as some of the products put on the market are disposable products. Single-use plastic consumables generate significant waste which often ends up in incineration due to their contamination in use in hospitals, classifying them as hazardous waste, contributing to pollution and emissions. Packaging that is needed to transport products and to maintain the necessary sterility in certain products prior to their use, becomes waste after the product is used.

**-**

#### Where

Own operations  
Downstream

#### Time frame: Impact

Short-, medium- and long-term

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Policies

Getinge’s Global Environmental Policy states the company’s commitment to ensure resource efficiency. The policy outlines the importance to continuously work to make manufacturing processes resource and energy efficient, minimizing risk of pollution, emissions and waste with the goal to optimize resource use throughout the company operations. The policy also includes Getinge’s ambition to work with circularity.

The company is dedicated to the principles of circularity and actively promotes resource efficiency, avoiding hazardous substances and waste in its entire value chain. The policy further commits to sustainable sourcing and the responsible use of renewable resources by working closely with business partners to identify environmentally preferable alternatives, including sourcing sustainable materials and implementing efficient production methods across the value chain. In developing the policy, input from key

stakeholders has been considered through customer requests, along with recognizing the company’s impact on nature as a silent stakeholder.

The management of waste follows the principles set out in local environmental management systems. Getinge’s process for EcoDesign includes requirements and criteria that shall be considered in the design phase. Examples include selection of materials to be used, reduction of material usage and the use of packaging materials as well as designing products with end of life in mind enabling reuse or recycling of material.

Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units) and all have management processes in place to comply with local regulation connected to waste handling.

## Strategic direction and actions

### Waste from own operations

Getinge’s production facilities are mainly limited to assembly, which means that material inflows and outflows are largely balanced, with packaging being the main exception. Getinge can only directly influence waste management from its own operations. However, it also influences the amount of waste generated by customers downstream through the use of packaging and sale of single-use items, which are mainly made of plastic. The ambition is to follow the waste hierarchy aiming for prevention of waste. When this is not possible, reuse and recycling are seen as the preferred alternatives and the last alternative is incineration. In some cases legislation rules that certain waste is to be landfilled. The company works together with waste handling companies globally, treating the waste from operations to continuously find the best alternatives.

### Waste from packaging

Product safety and clinical performance can never be compromised. This means that changing materials in the primary packaging is not an option unless the same level of safety and sterility can be maintained.

### Product resource efficiency

Getinge has implemented Life Cycle Assessments (LCA) for products and conducted more than 12 full studies up to date. In addition, the EcoDesign SOP mandates that all new products are to be assessed according to this LCA methodology before they are put on the market. Getinge has two major product categories which are consumables and hardware. Consumables consist of single-use products that are not possible to repair or reuse. Getinge’s hardware products have a life-time of at least 10 years and are fully repairable, their expected life-time may vary depending on service intervals for example.

The result from the studies aids in communicating the product’s environmental impact, identifies the focus areas, optimizes resource use, provides a data-driven basis for informed decision making in product development and supports the EcoDesign process. The life cycle assessments show that materials used in the products are mainly metals, primarily steel and aluminum, and plastics. With regards to packaging the primary materials used are wood, cardboard and plastics depending on the product in scope.

Getinge’s main waste streams include plastic packaging and electronics as well as hazardous waste including chemically contaminated waste and soiled materials.



### Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board’s Operating Reports

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

### Financial statements

### Other information

## Targets, key figures and results

### No waste to landfill by 2030

Responsible resource use and waste management are priorities across the company. By monitoring waste handling the company ensures the best options are chosen to ensure material efficiency. By 2030, the company aims to achieve zero waste to landfill from own operations for all production sites globally, except for materials required by local regulations to be landfilled. Getinge's policy commitment to resource efficiency supports the target by reducing material use, minimizing waste generation, and promoting circular practices across operations. Moreover, the target aligns with the waste hierarchy by prioritizing waste prevention, reuse and recycling over disposal. In 2025 Getinge's total waste sent to landfill was 344 (205) tons. The result for non-hazardous waste sent to landfill is mainly explained by increases in waste at one of Getinge's sites. There are two main reasons for the increase. The site has improved their waste management system during the year which has made it possible to report on more granular waste data which was previously not captured. The increase is also partly attributable to higher product disposals which have occurred due to transport damage and shelf-life obsolescence. The total amount of generated waste for 2025 increased compared to 2024 and summed up to 3,262 (3,159) tons. The increase mainly relates to the above mentioned site.

For Getinge's reporting principles related to waste see page 132.

	2025	2024
<b>Resource outflows – waste from own operations*</b>		
<b>Total waste generated</b>	<b>3,262</b>	<b>3,159</b>
<b>Total hazardous waste generated</b>	<b>270</b>	<b>244</b>

<b>Hazardous waste diverted from disposal due to</b>	2025	2024
Preparation for reuse	7	–
Recycling	30	62
Other recovery operations	127	129

<b>Non-hazardous waste diverted from disposal due to</b>	2025	2024
Preparation for reuse	104	–
Recycling	1,555	1,452
Other recovery operations	910	1,065

<b>Hazardous waste directed to disposal by</b>	2025	2024
Incineration	5	–
Landfilling	4	–
Other disposal operations	96	53

<b>Non-hazardous waste directed to disposal by</b>	2025	2024
Incineration	26	132
Landfilling	340	205
Other disposal operations	57	62

<b>Non-recycled waste</b>	2025	2024
<b>Total non-recycled waste</b>	<b>528</b>	<b>451</b>
Percentage of non-recycled waste (%)	16%	14%

\*2025 is the first year in which Getinge reports on waste according to the criteria as specified in E5-5. To report comparative data for 2024 assumptions have been made regarding the proportions allocated to each waste category. Getinge does not generate any radioactive waste from its own operations. Four legal entities, Healthmark, Ultra Clean, Quadralene and Paragonix have been added through acquisition and data is updated for 2024. Getinge does not disclose on rates of recyclable content in products and in products packaging in 2025.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

→ Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

# EU Taxonomy

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

→ Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

The EU Taxonomy Regulation (EU) 2020/852 is a classification system for environmentally sustainable economic activities. Which is part of EU's climate and energy targets. The taxonomy regulation consists of six environmental objectives and provides certain conditions for taxonomy-alignment. One condition is that the relevant economic activity must substantially contribute to one or more of the following six environmental objectives, and Do No Significant Harm (DNSH) to the remaining objectives:

- Climate change mitigation
- Climate change adaptation
- Transition to a circular economy
- Pollution prevention and control
- Protection and restoration of biodiversity and ecosystems
- Sustainable use and protection of water and marine resources

To qualify as Taxonomy aligned, Getinge must also comply with the minimum safeguards, which ensure adherence to standards related to human and labour rights as well as responsible business conduct.

**Taxonomy-eligibility**

To identify taxonomy-eligible economic activities, an internal working group, supported by external expertise, has assessed the company's economic activities and investments against the EU Taxonomy Regulation and its delegated acts. So far, the taxonomy regulation has focused on sectors and economic activities that have the greatest impact on the climate and environment. Medical technology is not listed as one of these areas and Getinge's core business is not included in the taxonomy with eligible economic activities. However, there are economic activities listed in the EU Taxonomy that Getinge are eligible to report on.

In 2025, Getinge reports on taxonomy-eligible turnover for the following economic activity: Circular Economy (CE) 1.2 Manufacture of electrical and electronic equipment. Getinge's eligibility stems from products and product groups that use electricity. Moreover, taxonomy-eligible CapEx is reported for the following economic activities: Climate Change Mitigation (CCM) 6.5 Transport by motorbikes, passenger cars and light commercial vehicles and CCM 7.7 Acquisition and ownership of buildings. Eligibility for CCM 6.5 relates to Getinge's leased vehicles and eligibility for CCM 7.7 relates to Getinge's leased offices. In 2024, the company reported on eligible capital expenditures related to five

additional economic activities<sup>1</sup> which have been determined to be below the newly applicable thresholds for taxonomy-eligibility as defined by the EU Commission.

Getinge does not report on taxonomy-eligible OpEx as the KPI has been deemed not material to the company's business model. Getinge has made this assessment as the company's core activities are not covered by the taxonomy with eligible economic activities to report on, which makes the potential eligible OpEx negligible. Moreover, Getinge's total OpEx according to the taxonomy definition constitutes only a small proportion of the company's operating expenditures.

**Taxonomy-alignment**

The technical screening criteria for Getinge's taxonomy-eligible economic activities include detailed requirements to make a substantial contribution to the respective environmental objective as well as to DNSH to the remaining environmental objectives.

As Getinge's core business is not eligible and there has been some reporting uncertainty related to the EU Taxonomy Regulation Getinge has not prioritized investigating taxonomy alignment during the year. Thus, it is assumed that the company does not comply with the alignment criteria for these economic activities and the

company reports 0% taxonomy-alignment. In 2026, Getinge aims to carry out the necessary assessments to determine alignment for the three economic activities.

**Minimum safeguards**

Compliance with minimum safeguards must also be met, and Getinge's position is that the group essentially meets these requirements. During 2025 Getinge carried out a Human Rights impact assessment in one of its key markets. The learnings from this assessment will be included in the company's human rights due diligence process implementation which is still ongoing. This means that Getinge is not yet claiming that it meets the Minimum Safeguards.

**Reporting principles**

As reporting data for turnover, CapEx and OpEx are based on separate account structures, the risk for double counting is deemed low. Getinge is applying the International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board, as adopted by the EU.

Total turnover corresponds to net sales in the consolidated income statement. See Note 2 on page 146. Getinge allocates eligible turnover to the economic activity CE 1.2.

1) CCM 7.2/ CE 3.2 Renovation of existing buildings, CCM 7.3 Installation, maintenance and repair of energy efficiency equipment, CCM 7.4 Installation, maintenance and repair of charging stations for electric vehicles in buildings (and parking spaces attached to buildings), CCM 7.5 Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings and CCM 7.6 Installation, maintenance and repair of renewable energy technologies.

Total capital expenditures include investments in tangible assets, right-of-use assets, and intangible assets before depreciation, amortization, and any revaluations. It also includes additions to tangible and intangible assets resulting from business combinations. Accounting principles for items reported as capital expenditures are found in Notes 9, 10 and 11 on pages 152–157. Getinge allocates eligible CapEx to the economic activities CCM 6.5 and CCM 7.7.

Total operational expenditures include direct non-capitalised costs that relate to research and development, building renovation measures, short-term lease, maintenance and repair, and any other direct expenditures relating to the day-to-day servicing of assets of property, plant and equipment. Getinge does not report on taxonomy-eligible OpEx as the KPI has been deemed not material to the company's business model.

Getinge has not developed a CapEx plan under the Taxonomy Regulation.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Proportion of turnover, CapEx, OpEx from products or services associated with Taxonomy-eligible or Taxonomy-aligned economic activities – disclosure covering year 2025 (summary KPIs)**

**Financial Year 2025**

KPI	Total MSEK	Proportion of Taxonomy eligible activities %	Taxonomy aligned activities MSEK	Proportion of Taxonomy aligned activities %	Breakdown by environmental objectives of Taxonomy aligned activities						Proportion of enabling activities %	Proportion of transitional activities %	Not assessed activities considered non-material %	Taxonomy aligned activities in previous financial year 2024 MSEK	Proportion of Taxonomy aligned activities in previous financial year 2024 %
					Climate change mitigation %	Climate change adaptation %	Water %	Circular Economy %	Pollution %	Biodiversity %					
Turnover	34,969	21%	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0	0%
CapEx	1,716	21%	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	2%	0	0%
OpEx	1,495	0%												0	0%

**Financial statements**

**Other information**

**Proportion of turnover from products or services associated with Taxonomy-eligible or Taxonomy-aligned economic activities – disclosure covering year 2025 (activity breakdown)**

**Reported KPI (Turnover) – Financial Year 2025**

Economic activities	Code	Taxonomy eligible KPI (Proportion of Taxonomy eligible Turnover)	Taxonomy aligned KPI (monetary value of Turnover)	Taxonomy aligned KPI (Proportion of Taxonomy aligned Turnover)	Breakdown by environmental objectives of Taxonomy aligned activities						Enabling activity (E)	Transitional activity (T)	Proportion of Taxonomy aligned in Taxonomy eligible (%)
					Climate change mitigation (%)	Climate change adaptation (%)	Water (%)	Circular Economy (%)	Pollution (%)	Biodiversity (%)			
Manufacture of electrical and electronic equipment	CE 1.2	21%	0 MSEK	0%	0%	0%	0%	0%	0%	0%	N/A	N/A	0%
<b>Sum of alignment per objective</b>					0%	0%	0%	0%	0%	0%			
<b>Total KPI (Turnover)</b>		21%	0	0%	0%	0%	0%	0%	0%	0%	N/A	N/A	0%

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

**Proportion of CapEx from products or services associated with Taxonomy-eligible or Taxonomy-aligned economic activities – disclosure covering year 2025 (activity breakdown)**

**Reported KPI (CapEx) – Financial Year 2025**

Economic activities	Code	Taxonomy eligible KPI (Proportion of Taxonomy eligible CapEx) %	Taxonomy aligned KPI (monetary value of CapEx) MSEK	Taxonomy aligned KPI (Proportion of Taxonomy aligned CapEx) %	Breakdown by environmental objectives of Taxonomy aligned activities						Enabling activity (E)	Transitional activity (T)	Proportion of Taxonomy aligned in Taxonomy eligible %
					Climate change mitigation %	Climate change adaptation %	Water %	Circular Economy %	Pollution %	Biodiversity %			
Transport by motorbikes, passenger cars and light commercial vehicles	CCM 6.5	13%	0	0%	0%	0%	0%	0%	0%	0%	-	T	0%
Acquisition and ownership of buildings	CCM 7.7	8%	0	0%	0%	0%	0%	0%	0%	0%	N/A	N/A	0%
<b>Sum of alignment per objective</b>					0%	0%	0%	0%	0%	0%			
<b>Total KPI (CapEx)</b>		21%	0	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

→ Environment

Social

Governance

Appendix

**Financial statements**

**Other information**

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

→ Social

Governance

Appendix

Financial statements

Other information



# Social

Employee engagement is the foundation for working with other material topics such as quality, inclusion and belonging, and health and safety. Engaged employees find a greater sense of meaning in what they do, see a stronger connection between their strengths and their role, and expend discretionary effort in their performance. These positive behaviors make a difference to the business in terms of reputation, productivity, and profitability.

Getinge aims to build an organization with engaged and performance driven people by nurturing a culture in which everyone feels included and can perform, improve, and develop.

**S1 Own Workforce** →

**S2 Workers in the Value Chain** →

**S4 Consumers and End-users** →

## Relevant Sustainability Development Goals



# Own workforce

For the company’s business to evolve and to achieve financial and sustainability targets, the expertise and diverse perspectives provided by the Getinge employees worldwide are essential. By ensuring employee engagement and an inclusive culture, the company aims to unlock their expertise and dedication to continue delivering the products that lead to improved outcomes and resource efficiency within the healthcare sector.

All of Getinge’s own employees are included in the activities to ensure a healthy, safe and inclusive workplace described in this chapter. This means that the company works to understand areas where different people in the organization are exposed to risks. Getinge’s Speak-up line and complaints handling mechanism are described under G1. Employee representatives have been consulted with regards to the material topics, policies, actions, targets and other aspects related to sustainable practices two times during 2025 and input has been taken into account in all these areas. Getinge has made the assessment that the demanding nature of the company’s industrial operations carries a very small risk of forced labor, compulsory labor, and child labor within the company’s own workforce.



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

Getinge’s target

**Employee engagement**

The target for employee engagement is to reach an employee index score >70% measured through employee surveys. Stakeholder involvement in target setting is explained on page 75.

Outcome

**Employee engagement 2025**

**73%**



## Overview of Getinge’s material impacts, risks and opportunities related to own workforce

**+** Positive impact

**O** Financial opportunity

**-** Negative impact

**R** Financial risk

### Occupational health & safety



#### Actual negative impact

**Own operations:** Despite continuous work to reduce risks, safety-related incidents do occur in the company, mostly related to ergonomics, falls and material handling. If the company or managers would neglect health and safety measures, the potential negative impact of workplace accidents, injuries, and occupational illnesses could increase.

#### Where

Own operations

#### Time frame: Impact

Short-, medium- and long-term

### Diversity, equity, inclusion & belonging (DEIB)



#### Actual positive impact

**Own operations:** Getinge’s culture promotes inclusive behavior with the ambition that all people are able to thrive in the workplace. Diverse perspectives in the company foster innovative thinking and enhanced problem-solving by leveraging diverse skills and experiences. Training programs, development initiatives and regular individual development meetings between employees and managers help ensure that career progression aligns with individual ambitions and demonstrated competence.

#### Where

Own operations

#### Time frame: Impact

Short- and medium-term

#### Potential negative impact

**Own operations:** Lack of diversity may result in unconscious bias in recruitment, promotion, or performance reviews. In addition, a lack of diverse perspectives can lead to an inflexible culture that is unable to account for the interests of all stakeholders. If existing policies are not enforced, discrimination or harassment could occur.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

# Occupational health and safety

Safety at work is a basic human right. Ensuring a safe working environment protects employees from workplace hazards, enables improved productivity and reduces absenteeism. Getinge prioritizes health and safety measures that can have a positive impact on the well-being of its employees. Employees who feel cared for are more likely to be engaged, productive, and committed.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Getinge's target



Getinge's target is to reduce the Work Related Accident Rate (WRAR), which describes work-related accidents in relation to working hours, to less than 1 by 2025.

<1

Work-related accident rate (WRAR)

## Outcome

**Rate of recordable work-related accidents for own workforce (per 200,000 worked hours)**



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Policies

Getinge's Code of Conduct mandates that all employees take responsibility for their own safety and the safety of others. All employees, temporary workers and consultants must also comply with the mandatory requirements of Getinge's global policies, as well as adhering to local occupational health and safety standards.

Getinge's global Human Rights Policy, which aligns with the International Bill of Human Rights and Code of Conduct, encourages every employee to report, give feedback and avoid any hazardous situation. A dedicated Speak-Up Line enables employees to report health and safety risks confidentially. Getinge's Business Partner Code of conduct applies to suppliers and includes providing and maintaining a safe working environment.

Health and safety are managed globally under Getinge's Health and Safety directive, with each workplace expected to follow the standards outlined by the directive.

Each production site prepares and documents its own Occupational Health and Safety Policy in accordance with Getinge's directive. Employee consultation forums, such as safety committees, are set up in compliance with local laws. Getinge's management system was implemented in 2021 when the global directive came into effect. The management system guides how work is managed to reduce risks and is adapted locally but is not certified according to ISO or other standards.

The risk assessment process, guided by the Global Occupational Health and Safety Risk Assessment procedure, involves identifying hazards and assessing risks. It provides guidance for employees on how to identify potential risks and a method for evaluating the level of criticality. The assessment is reviewed annually or whenever there are organizational changes.

Getinge's incident management process requires that a thorough investigation of incidents, corrective and preventive actions are carried out, and that insights are shared across the organization. Local occupational health services carry out risk analyses regularly. After any incident, risk analyses are reviewed to ensure proactive risk management. Work-related hazards posing a risk of high-consequence injuries are monitored through risk analysis and tracked in local management systems.

To ensure up-to-date competence and a thorough understanding of health and safety risks, Getinge's global curriculum for training and development covers health and safety awareness training.

## Strategic direction and actions

Getinge aims to be an incident-free workplace. An important part of the approach is to have a safety-focused culture, as this enables employees to take ownership of their own and other employees' safety.

In 2025, the company continued to enhance its reporting system to maintain a structured and preventive approach to occupational health and safety. Conducted actions are part of Getinge's continuous work related to the topic.

As part of this effort, initiatives addressing ergonomics included the Safety Champion program, job rotation schemes, and more frequent breaks to reduce ergonomics-related injuries. Several sites also implemented stretch-and-flex warm-up programs, provided cushioned footwear for employees who stand for extended periods, and improved charging areas for handheld electric tools to reduce strain. Monitoring of ergonomic risk factors and maintaining surveillance records remained key components of the preventive program.

Beyond ergonomics, Getinge carried out annual health examinations, regular risk identification and control activities, safety inspections, incident response exercises, and safety training for new employees and contractors as part of its systematic health and safety approach.

Activities to strengthen leadership capabilities included safety training for managers and supervisors, clarifying roles and responsibilities, and monthly safety meetings to reinforce accountability.

The company also continued to improve processes aimed at preventing recurring injury types, such as reducing incidents of cuts through blade safety training and introducing operational controls in departments using blades frequently.

## Targets, key figures & results

### Health and safety

Getinge’s target is to reduce the work-related accident rate (WRAR) to less than 1 by 2025. The target is set based on industry benchmarks (Occupational Health and Safety Association) which indicate that keeping a work related accident rate of less than 1 for the manufacturing industry is ambitious but achievable.

Getinge does not have a global Health and Safety Management System but instead has an Occupational Health and Safety Directive. This directive covers all entities and employees.

In 2025, the WRAR was 0.59 (0.98) for employees and 0.35 (0.92) for contractors. Accidents reported are similar between the years, mainly related to ergonomics.

For Getinge's reporting principles related to Health and Safety see page 133.

### Employee engagement

Employee engagement is evaluated by regular feedback mechanisms, such as the global bi-annual employee survey. The target for employee engagement is to reach an employee index score over 70 in the surveys. In 2025, the engagement score was 73% (71%). The company remains committed to maintaining or exceeding this level in future surveys. Aligned with employee needs and the company’s strategic goals, Getinge’s training programs are continuously monitored and improved. Getinge conducted 62,757 (71,132) hours of training globally in 2025.

### Health and safety metrics\*

	2025		2024	
	Employees	Non-employees	Employees	Non-employees
Number of fatalities in own workforce as result of work-related injuries and work-related ill health	0	0	0	0
Number of recordable work-related accidents for own workforce	69	4	115	10
Rate of recordable work-related accidents for own workforce (per 200 000 worked hours)	0.59	0.35	0.98	0.92
Rate of recordable work-related accidents for own workforce (per 1 000 000 worked hours)	2.97	1.73	4.89	4.60
Number of cases of recordable work-related ill health of own workforce, subject to legal restrictions on the collection of data	13	–	11	–
Number of days lost to work-related injuries and fatalities from work-related accidents, work-related ill health and fatalities from ill health	697	45	1,100	105

\* Four legal entities, Healthmark, Ultra Clean, Quadralene and Paragonix have been added through acquisition and data is updated for the 2024. Getinge’s WRAR target has been set per 200,000 worked hours. Errors have been corrected in the 2024 WRAR calculation for employees and non-employees which were previously reported as 0.92 and 0.84 respectively. Action has been taken to reduce the risk of errors occurring in the future. Getinge does not disclose on work related ill-health related to non-employees.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

# Diversity, equity, inclusion and belonging (DEIB)

A diverse and inclusive environment ensures that different perspectives are considered in decision-making, allowing the company to serve its customers better and remain competitive. It fosters innovation, creativity and a positive workplace culture. A lack of diversity can lead to discriminatory practices, reduce employee well-being, and deprive employees of equal employment opportunities.

Diversity has a wide scope. In addition to differences in gender and gender identity, diversity includes differences in race, ethnicity, religion, age, marital or parental status, disability, sexual orientation, nationality, or other protected characteristics, backgrounds, experiences, perspectives, thoughts, interests and ideas. Getinge strictly complies with all non-discrimination requirements, including in the administration of DEIB.



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Getinge's ambition

Getinge's ambition is to ensure equal employment opportunity and non-discrimination across all levels of the organization.

## Outcome

**Reported discrimination cases 2025**

**10 cases**

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Policies

Getinge's commitment to equal employment opportunities and an inclusive workplace is underscored by the company's Code of Conduct and Human Rights Policy, which affirm principles of diversity, inclusion, freedom of association, and workplace safety. These policies provide a clear framework for the company's zero-tolerance stance on discrimination and harassment.

Building on the policy framework, the People Policy and Diversity Directive outline specific expectations and practices to ensure fairness, respect, and dignity for all employees, regardless of gender, gender identity, race, ethnicity, religion, age, marital or parental status, disability, sexual orientation, nationality, or other protected characteristics.

Additionally, employees have access to a Diversity Behavior Instruction, offering guidance on fostering conscious inclusion, reducing discrimination risk, and intervening as bystanders when necessary. Processes for unbiased recruitment are in place to secure equal opportunities and non-discrimination in recruitment. The Getinge Speak-Up Line enables employees, as well as suppliers and partners, to report behavior that deviates from these guidelines.

## Strategic direction and actions

**Diversity**

Recognizing the importance of diverse perspectives in leadership, the company has implemented initiatives to ensure equal employment opportunity by recruiting from a broad pool of diverse talent. By focusing on mentorship, leadership development, and individual development plans between managers and employees, the company ensures that a wide range of thoughts and ideas shape its future leadership.

**Equity**

Global paid family leave is a cornerstone of Getinge's commitment to equity. Introduced in 2022, the company offers at least 16 weeks of paid parental leave and 4 weeks of paid caregiver leave to all employees with over one year of service, regardless of gender. Local regulations may provide more generous terms.

Eliminating pay disparities based on gender promotes an inclusive workplace where all employees are valued equally for their contributions, regardless of their gender. Gender pay equity analyses were conducted in several countries, including the UK, the US, Australia, France, Sweden, and Germany, ensuring compliance with local legislation and corporate guidelines.

**Inclusion and belonging**

In 2025, Getinge strengthened its commitment to inclusion and belonging by establishing a comprehensive Employee Resource Group (ERG) framework designed to foster belonging and amplify employee voices from across the organization. Building on the success of Getinge's North America ERG program (where 8 groups already exist), Getinge has extended this initiative

globally, supporting opportunities for employees worldwide to connect, support one another, and drive meaningful cultural change.

The ERG framework provides a structure and resources for employee-led groups centered on shared identities, experiences, or affinities. The global ERG framework is supported by a steering committee composed of global functional leaders, ensuring strategic alignment and executive commitment to these employee-led initiatives. This governance structure provides ERGs with the guidance and organizational support needed to create meaningful impact.

By empowering local employee communities to shape their own ERG structures whilst maintaining alignment with Getinge's core values, Getinge continues to build an inclusive workplace where every employee can bring their whole self to work.

In 2025 Getinge launched GetMentor, a global mentoring program designed to accelerate talent development and deepen the understanding of the company's core values across the organization. The program connects experienced leaders with emerging talents, creating meaningful relationships that foster trust, openness, and knowledge-sharing across different teams, functions and levels of the organization.

The program strengthens Getinge's commitment to developing its people by providing structured opportunities for employees to elevate their Game changer, Team player and Forward thinker potential through one-on-one mentoring relationships. Selected mentors participate in comprehensive training on mentoring, coaching, feedback and value alignment before beginning their 12-month mentoring journey. This

investment in both mentor and mentee development ensures that participants build community and a sense of belonging across the organization, enhance self-awareness, and embody Getinge's values while advancing their professional growth.

Diversity and inclusive leadership are integrated into the company's Leading Leaders and Leading People training programs. Diversity and inclusion have also been included in the Aspiring Leaders program attended by employees who are expected to take up managerial roles in the near future. More than 160 employees attended this training during 2025.

Getinge has developed an e-learning course on unconscious bias. Available to all employees, it has a specific focus on managers. This course aims to raise awareness of the biases that can influence decision-making and interpersonal interactions, often unconsciously. By helping managers recognize how these biases can affect team dynamics, recruitment, and leadership decisions, the training promotes greater accountability and awareness. This initiative is a vital part of the company's broader efforts to create a more inclusive and equitable culture where every voice is heard, and everyone can thrive.

In addition, Getinge measured employee sentiment around DEIB through its employee surveys. This listening approach enables Getinge to better understand employee experiences, identify opportunities for improvement, and ensure that efforts are informed by the voices of employees across the organization as well as their effectiveness. This serves as a control mechanism for assessing and addressing gaps in inclusion.

# Employee metrics

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

→ Social

Governance

Appendix

**Financial statements**

**Other information**

The metric head count has been used representing a snapshot of the end of the reporting period. This metric counts the number of personnel irrespective of whether the person is working full time or part time or whether the person is currently actively working or on either unpaid/paid leave. The number of employees at Getinge was 12,118 at the end of the reporting period (December 31, 2025).

**Workers who are not employees**

Non-employees at Getinge are hired via a third-party vendor (or self-employed) and hence their contract and payment is either handled via the third party or in conjunction with the third party. Workers who are not employees at Getinge accounted for 846 full-time equivalents (FTEs) or 1,697 workers by head count in 2025.

**Employee turnover**

Turnover is calculated as all employees who had their last day at Getinge during 2025 divided by the average head count during the reporting period.

**Remuneration metrics**

During 2025, Getinge is not able to disclose information related to gender pay gap or the annual total remuneration ratio. This is because the necessary internal processes to compile and validate these data points are not yet in place. In 2026, Getinge will work to establish the required processes.

Employees by gender (head count)	Number of employees
Male	7,370
Female	4,738
Other	10
Not reported	N/A
<b>Total</b>	<b>12,118</b>

Employees by contract type, broken down by region (head count)*	Americas	APAC	EMEA	Total
Number of employees	3,375	1,580	7,163	<b>12,118</b>
Number of permanent employees	3,321	1,524	6,822	<b>11,667</b>
Number of temporary employees	54	56	341	<b>451</b>
Number of full-time employees	3,348	1,565	6,510	<b>11,423</b>
Number of part-time employees	27	15	653	<b>695</b>

\* Getinge did not employ any non-guaranteed hours employees in 2025.

Employees by contract type, broken down by gender*	Female	Male	Other	Total
Number of employees	4,738	7,370	10	<b>12,118</b>
Number of permanent employees	4,526	7,131	10	<b>11,667</b>
Number of temporary employees	212	239	0	<b>451</b>
Number of full-time employees	4,311	7,103	9	<b>11,423</b>
Number of part-time employees	427	267	1	<b>695</b>

\* Getinge did not employ any non-guaranteed hours employees in 2025.

**Employees by country (head count)\***

Country	Total
United States	3,090
Germany	1,879
Sweden	1,382
France	1,316
Other*	4,451
<b>Total employees by head count</b>	<b>12,118</b>

\* Countries with less than 50 employees or of less than 10% of total population.

Employee turnover	Total leavers
Employee turnover	1,611
Employee turnover rate	13%

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

**Collective bargaining coverage and social dialogue**

Coverage of collective bargaining agreements varies by region, and Getinge monitors participation levels and negotiation progress across all locations. The Group annually monitors the number of employees covered by collective bargaining agreements in every market where the Group operates. In 2025, 40% of Getinge's employees were covered by collective bargaining agreements.

**Wages and social protection**

Getinge's employees are paid more than minimum wage in all countries. Employees are covered by social protection against loss of income whereas Getinge at a minimum follows applicable law in all countries.

**Work-life balance**

Entitlement to parental leave is governed by local rules, regulations and individual contracts, and there is no data recorded centrally to provide an overview. In 2023 Getinge introduced a new global policy, which ensures 16 weeks of paid parental leave to all employees with at least one year's service. To calculate the entitlement to take parental leave in 2025, all employees that had a seniority of one year or more at the end of the period were included as entitled which is considered a lower bound estimate of employees entitled to take leave. In 2025, 90% of Getinge's employees (head count) were entitled to take parental leave. The percentage of employees that took parental leave was 3% during the year. Out of female and male employees entitled to take leave the percentage was 4% and 2% respectively.

**Collective bargaining coverage and social dialogue\***

Coverage rate	Collective bargaining coverage		Social dialogue
	Employees – EEA (for countries with >50 empl.)	Employees – Non-EEA (est. for regions with >50 empl.)	Workplace representation (EEA only) (for countries with >50 empl.)
0–19%	Poland, Denmark	EMEA excl EEA, Americas, APAC	Belgium, Denmark
20–39%			
40–59%	Netherlands		Netherlands
60–79%	Germany		
80–100%	Italy, France, Spain, Sweden, Belgium		Italy, France, Germany, Poland, Spain, Sweden


\*In 2025 Getinge reports on the overall percentage of employees covered by collective bargaining agreements for each country in which Getinge has significant employment defined as at least 50 employees by head count. Due to uncertainty in reporting requirements related to calculating what constitutes 10% of total employees this is not considered in the calculation.

For Getinge's reporting principles related to employee data see pages 132–133. Getinge reports on number of full time employees (FTE) in Note 23 of the financial report.

**Confirmed incidents of discrimination and actions taken**

In 2025, 10 cases of discrimination or harassment were reported through Getinge's speak-up line and through direct contact with Ethics and Compliance. During 2025, Getinge did not record any cases of discrimination that would be found substantiated as of the date of this reporting and incidents did not result in any fines or penalties.

**Gender representation**



Managers are defined as employees with at least one person reporting directly to them. Top managers refer to members of the Executive Team (see pages 66-67). In 2025 the Executive Team consisted of 5 men and 5 women.

Age intervals all employees (head count)	Female	Male	Other	Total
< 30 years old	671	747	0	<b>1,418</b>
30–50 years old	2,811	4,142	5	<b>6,958</b>
>50 years old	1,242	2,441	4	<b>3,687</b>
Invalid	14	40	1	<b>55</b>
<b>Total</b>	<b>4,738</b>	<b>7,370</b>	<b>10</b>	<b>12,118</b>

# Workers in the value chain

Ensuring good working conditions and protecting worker rights throughout the entire value chain is important for safeguarding the well-being of individuals. Factors that may impact workers' quality of life include unsafe environments, excessive working hours, and unfair treatment.

By prioritizing fair labor practices, workers can get access to better working conditions that lead to a healthier and more equitable workforce.<sup>1</sup>

## Getinge's ambition

Getinge's ambition is to minimize ESG-related risks through a structured and responsible approach in working with suppliers. By strengthening requirements, follow-up, and transparency within the supplier base, the company strives to ensure a socially, ethically, and environmentally sustainable supply chain

## Outcome

**Number of ESG supplier audits 2025**

**37 audits**

<sup>1)</sup> <https://www.ilo.org/publications/value-chain-development-decent-work-0>



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**



## Overview of Getinge’s material impacts, risks and opportunities related to workers in the value chain

 Positive impact

 Financial opportunity

 Negative impact

 Financial risk

### Responsible sourcing

#### Potential negative impact

**Upstream:** Responsible sourcing is a material topic for Getinge, as the company recognizes its potential impact on working conditions throughout the value chain. Getinge recognizes that actual risks of negative impact are present in the company's value chain related to workers rights, including excessive working hours, inadequate health and safety measures, unfair wages, and poor employment terms. Furthermore, fundamental labor rights such as freedom of association and the right to collective bargaining risk being compromised. There is also a potential risk of modern slavery and child labor.



#### Where

Upstream

#### Time frame:

#### Impact

Short- and medium-term

### Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board’s Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

→ Social

Governance

Appendix

### Financial statements

### Other information

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Policies

The Business Partner Code of Conduct defines ethical principles and requirements that stakeholders doing business with Getinge must comply with, comprising for example areas as occupational safety, human rights, including child and forced labor. The Business Partner Code of Conduct applies to suppliers, partners, contractors, and subcontractors. It outlines the company's demands on ethical business and responsible leadership, which are prerequisites for a sustainable collaboration. For more information about consideration given to interests of key stakeholders in setting policies see page 75.

As responsible leadership is about daily decisions, it is critical that the Business Partner Code of Conduct is applied, that compliance is monitored, and that the business partners work with continuous improvements. We monitor compliance and improvements by auditing our suppliers.

## Strategic direction and actions

To address potential negative impacts on workers in the value chain Getinge continues take action on responsible sourcing. Getinge launched a comprehensive ESG due diligence program across its supply chain in 2024. In 2025, this work has advanced and is expected to continue over the coming years. Consequently, Getinge has not defined a specific timeframe for these actions. The process includes a thorough assessment of ESG risks related to the supplier's country of origin, such as human rights and anti-corruption concerns, as well as risks linked to the specific products, services, or processes provided, including health, safety, and environmental impacts. Suppliers identified as potentially high or medium risk are required to complete a self-assessment questionnaire. Those who fail to meet the standards outlined in the Getinge Business Partner Code of Conduct undergo an audit. The assessment primarily focuses on first-tier suppliers, and risk classification is an ongoing process with the goal of auditing all suppliers deemed high risk. Getinge's supplier due diligence involves classifying suppliers by risk level, verifying whether identified risks are actual, and implementing measures to mitigate them.

## Targets, key figures and results

After onboarding a majority of the company's legal entities on this due diligence process in 2024, including training of more than 300 employees tasked with implementing and overseeing the due diligence activities, the 2025 efforts have focused on continuing to implement the process across the organization.

A total of 37 ESG supplier audits have been performed, resulting in the identification of diverse types of risks in our value chain. The risks are primarily related to Health and Safety, Environment, Human Rights and Governance. Risk mitigation regarding breaches of our Business Partner Code of Conduct is currently being put in place.

Work is still ongoing to establish targets related to responsible sourcing. Getinge does not yet have a processes in place to track the effectiveness of its actions. At this stage, there is no defined timeframe for setting such targets.

**Audit finding categories**



# Consumers and end-users

Getinge’s offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. This means most of the company’s products contribute directly or indirectly to public health.

Product quality is by consequence an essential aspect in ensuring the safety of patients. Regulatory conformance of all products is mandatory in the highly regulated health-care and life science industry. While the ESRS S4 standard covers impacts on consumers and end users more broadly, Getinge interprets it in the healthcare context, where ensuring product quality is the most material way to safeguard patient safety and wellbeing.



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Getinge’s ambition

**Regulatory compliance**

Getinge tracks two focused KPIs that reflect the company’s commitment to quality: audit findings per audit (targeting regulatory compliance) and field actions per billion SEK net sales (assessing product quality). While field actions are safety-related measures with no defined target, Getinge’s ambition is that the number of audit findings per audit made for quality systems is 1.5 or less.

## Outcome

**Number of audit findings per audit for quality systems 2025**

1.4



## Overview of Getinge’s material impacts, risks and opportunities related to consumers and end-users

**+** Positive impact

**O** Financial opportunity

**-** Negative impact

**R** Financial risk

### Patient safety & quality

#### Potential negative impact

**Downstream:** Poor quality can have severe operational, financial, legal, and reputational consequences. The most significant impact would be harm to patients as defective medical devices can lead to adverse health consequences. When product quality fails, already manufactured products and parts are at risk of becoming obsolete, which would result in unnecessary use of materials and natural resources, as well as increased waste streams with negative environmental consequences.

#### Actual positive impact

**Downstream:** Getinge's products have an actual positive impact as their life-supporting medical technology plays a crucial role in saving lives and improving patient outcomes. For instance, Getinge's products for Acute Care Therapies and the operating room are vital for treating patients in critical conditions, and Life Science products help minimize contamination risks during drug production. These contributions enhance patient care and support the broader healthcare system by ensuring the availability of reliable and effective medical solutions.

#### Financial risk

Delivering safe, high-quality products is critical for Getinge, as patient safety and regulatory compliance are non-negotiable. Any quality failure can lead to severe consequences such as recalls, legal liabilities, and reputational damage, making the financial risk significant. High standards ensure trust, market access, and long-term competitiveness.

#### Financial opportunity

Maintaining the highest standards in product quality and patient safety is not only a regulatory requirement but also a strategic advantage. Consistently delivering reliable, safe products strengthens customer trust, enhances brand reputation, and differentiates Getinge in a competitive medtech market. This commitment to excellence can open doors to new partnerships, attract investment, and secure long-term contracts with healthcare providers.

**- + R O**

#### Where

Downstream

#### Time frame: Impact

Short-, medium- and long-term

#### Time frame:

#### Risk and opportunity

Medium- and long-term

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

→ Social

Governance

Appendix

**Financial statements**

**Other information**

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Policies

Getinge is committed to delivering safe, high-quality products for its customers and patients. The Quality policy states that quality is a measurement of the company's performance in providing solutions that are safe and effective and satisfy customers' and patients' expectations. The Quality policy applies to patients, customers and regulators. For more information about consideration given to interests of key stakeholders in setting policies see page 75.

QMS implementation is based on a unified Quality Policy and a global framework consisting of nine Quality Directives. This ensures alignment with regulatory standards across all locations, supporting both product quality and regulatory compliance.

The Quality Management Systems (QMS) at all sites are certified according to ISO 9001 or ISO 13485 standards. Depending on market requirements, there is also additional compliance with national standards like 21 CFR 820. All sites have certified quality systems audited by external certified bodies. Getinge uses a structured corporate approach to continuously monitor the compliance and the effectiveness of local QMS implementations, enabling the company to conduct targeted improvements across all areas.

Comprehensive training ensures that all employees understand quality principles, their significance, and Getinge's unified approach toward achieving quality. The company's commitment includes regular audits, with the purpose of ensuring the correct implementation of the QMS across the company.

## Strategic direction and actions

During 2025, Getinge continued to work on important initiatives to optimize the QMS and deliver improved end-to-end quality outcomes. These initiatives and the associated investments in the QMS have been prioritized to support the company's operations-related commitments to the FDA in the United States and other competent authorities worldwide. This work is expected to continue over the coming years. Consequently, Getinge has not defined a specific timeframe for these actions.

In 2025, Getinge sustained previous transformation of key QMS processes including management review, complaint handling, and field actions. This has resulted in better detection of potential problem areas, improved patient and user safety, and reduced business risks, while also continuing to nurture a learning organization. These processes apply across the entire organization, supporting a consistent and unified approach to quality management.

In 2025, the company worked on continuous improvement of end-to-end processes supporting field service, logistics, and use of data. A global 'Let's Talk Quality' interactive training was launched to all employees to bring basic quality principles to life. Some of these initiatives started over the past year will continue into 2026. Additionally, Getinge will be starting new Priority Projects to bring about company-wide changes, including continuous improvement of the audit and inspection management processes to make internal audits more effective, implementation of a global regulatory information management system to ensure an efficient and compliant product registration process, and the release of new CAPA training and site-specific assessments to advance our investigative and problem-solving capabilities.

From mid-2024 to mid-2025, a majority of KPIs show sustained improvement and the others remained stable.



## Targets, key figures and results

Getinge tracks two KPIs that reflect its commitment to quality: audit findings per audit (targeting regulatory compliance) and field actions per billion SEK net sales (assessing product quality), where the KPI is based on number of initiated field actions. While field actions are safety-related measures with no defined target, Getinge aims for findings per audit to remain below or equal to 1.5.

External stakeholders have not been involved in the establishment of these KPIs. However, the company makes the assessment that they drive the necessary change to ensure continuous and sustained quality of products.

**Getinge’s performance in 2025 included:**

- Field actions per billion SEK (assessing product quality): 1.0 (1.2)
- Audit findings per audit for quality systems: 1.4 (2.5)
- Online customer trainings: 53,238 (48,486)

As product quality and reliability are directly linked to the safety of caregivers and patients, field actions, which include recalls, corrections, and safety notifications, are essential for ensuring patient safety and regulatory compliance. In 2025, we see a decrease in number of field actions per billion SEK.

Audit findings are documented observations of nonconformance identified during an external audit against regulatory, quality, or procedural requirements. Getinge undergoes audits in accordance with industry practices and the requirements set by the FDA and equivalent governmental oversight bodies worldwide. The KPI for compliance metric decreased in 2025 which is mainly due to the fact that the first quarters of 2024 included a number of intensive quality audits. An error was identified in the full-year 2025 quarterly report, where the KPI was incorrectly reported as 1.3. This has now been corrected in the annual report

Online customer training includes various activities designed to train hospital staff in the proper and safe use of Getinge equipment. The KPI shows the number of times a customer has finalized an eLearning course or joined a training webinar, held by Getinge. In addition, the company offers extensive online training opportunities via [getinge.com](https://getinge.com), simulations, workshops, and user training at customer sites. Respiratory Week was organized in October and resulted in a higher number of webinars, which had a positive impact on the 2025 result.

**Incidents reported**

In 2025, Getinge reported 0 (zero) incidents of regulatory non-compliance concerning the health and safety impacts of products and services resulting in penalties or fines and 0 (zero) incidents resulting in warnings. Compliance with CE certification ensures that all relevant products are evaluated for health and safety impacts.

All Getinge products are evaluated regarding requirements for product and service information and labeling by either being subject to medical device market regulations or managed in Getinge’s QMS. In 2025, Getinge reported 0 (zero) incidents of non-compliance concerning product and service information and labeling resulting in penalties or fines and 0 (zero) incidents resulting in warnings.

Getinge did not have any incidents of non-compliance with regulations and/or voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship in 2025.

Customer privacy remains a priority, and during 2025, Getinge received four complaints concerning breaches of customer privacy. These cases were primarily due to human error and local non-conformities, and corrective actions have been implemented to prevent recurrence.

No leaks, theft, or loss of customer data were detected in 2025.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

→ Social

Governance

Appendix

**Financial statements**

**Other information**

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

Social

→ Governance

Appendix

Financial statements

Other information



# Governance

Strong governance is the foundation for responsible and sustainable business conduct. In a rapidly evolving regulatory landscape, companies are expected to demonstrate transparency, accountability, and robust oversight of risks and opportunities across their operations and value chains. For the healthcare industry, governance plays a critical role in safeguarding patient safety, ensuring ethical practices, and maintaining trust among stakeholders.

Getinge works continuously to ensure strong governance frameworks, supporting sound decision-making, compliance, and long-term value creation.

**G1 Anti-corruption and Business conduct**



## Relevant Sustainability Development Goals



# Anti-corruption and Business conduct

Corruption can divert financial resources away from healthcare services, leading to inadequate care and even loss of life<sup>1</sup>. Corruption increases inequalities in healthcare access and leads to inefficient use of public funds. As marginalized communities rely heavily on public health services, they often suffer the most when resources are used wrongly. Corruption erodes trust in healthcare systems, making individuals less likely to seek care or follow medical advice. When patients believe that healthcare providers are corrupt, they may avoid necessary treatments, which can lead to worse health outcomes.

This chapter describes Getinge’s interpretation of the ESRS G1 category focusing on Business conduct.

1) <https://www.ilo.org/publications/value-chain-development-decent-work-0>



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

Getinge’s target

**Training in business ethics**  
Getinge's target is that all employees are properly trained in business ethics including anti-corruption.

Outcome

**Employees who conducted the training 2025**

**92%**

## Overview of Getinge’s material impacts, risks and opportunities related to anti-corruption & business conduct

 Positive impact

 Financial opportunity

 Negative impact

 Financial risk

### Anti-corruption and business conduct

#### Actual negative impact

**Upstream:** Corruption among Getinge’s upstream suppliers can lead to disruptions in the supply chain, including loss of access to critical components and materials required for production. Such incidents may result in production delays and increased procurement costs.

**Own operations:** Corruption leads to inefficiencies in healthcare delivery, inflating costs, and reduced quality of services. Given that many healthcare providers are publicly owned institutions, Getinge engages in public procurement as part of standard commercial practice. The risk of corruption is significant, especially in public procurement processes in emerging markets or markets where less mature tendering processes involve several business partners and intermediaries. Distorted public procurement, which could be a result of corrupt practices, may lead to negative impact on the welfare of societies, potential misuse of public funds and potential negative impact on health equity.

**Downstream:** Corruption or unethical practices among distributors, sales agents, or other partners in the value chain can have a direct negative impact on stakeholders. For healthcare providers and patients, this may result in inflated costs, reduced access to essential medical products, or compromised trust in the healthcare system. Ultimately, these impacts can harm patient care quality and equity, while damaging relationships with hospitals, governments, and communities that rely on transparent and ethical business conduct.

#### Financial risk

Corruption within Getinge’s upstream supply chain can pose significant financial risks by driving inflated costs and causing disruptions due to reduced availability of critical components. Such issues may ultimately lead to production delays and loss of sales. In addition, Getinge’s global operations face financial exposure related to anti-corruption and business conduct. Compliance with anti-corruption laws and regulations is essential to safeguard the company’s reputation and avoid substantial fines or legal penalties. Failure to uphold these standards could result in financial losses, reputational damage, and diminished investor confidence. Similarly, corruption among downstream distributors can negatively impact Getinge’s brand integrity, erode customer trust, and lead to lost sales opportunities.

#### Where

Upstream  
Own operations  
Downstream

#### Time frame: Impact

Short-term

#### Time frame:

#### Risk and opportunity

Short-term

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

## Policies

Responsible business is at the heart of Getinge’s corporate culture. Getinge employees meet stakeholder expectations and mitigate risk by building and maintaining a strong quality and ethical business culture. This includes promoting the approach to responsible business throughout the supply and value chain.

Implementing anti-corruption, anti-trust and healthcare compliance programs is important to ensure that Getinge advocates fair, transparent business practices and a culture of accountability in healthcare systems.

Getinge’s Code of Conduct applies to all employees and provides the foundation for how the company conducts business. It describes the main principles for conducting business in line with both laws and stakeholder expectations. One of the principles in Getinge’s Code of Conduct, which applies to all employees, is to always act with honesty, fairness, and integrity. The principle states that employees should never act in a way that could manipulate the market or unfairly disadvantage colleagues, business partners, or competitors. It also states that there must be no bribes, no corruption, and no insider trading, without exceptions.

Getinge’s Global Anti-Bribery & Corruption Policy provides an overview of the company’s commitment to work against bribery and corruption. The policy applies to all employees, board


members, executive team, and business partners acting on behalf of Getinge. The Anti-Bribery and Corruption Policy is communicated to business partners during contracting and onboarding processes. The policy and the Business Partner Code of Conduct, which defines ethical principles and requirements stakeholders doing business with Getinge must comply with, are also referred to in contract templates.

The Code of Conduct and the Anti-Bribery and Corruption policy are made available to all employees through trainings and internal communication channels. For more information about consideration given to interests of key stakeholders in setting the above policies see page 75. The implementation is driven by global and local management, supported by the global Ethics & Compliance function.

Getinge is a member of the UN Global Compact, and committed to abiding all applicable Anti-Bribery and Corruption laws in every country the company operates in.

Getinge’s policy framework includes specific directives on Interaction with Healthcare Professionals and Healthcare Organizations, Conflicts of Interest, Third-party Engagement, Global Gifts and Hospitality, Sponsorship and Donations and Speak-Up and Non Retaliation.

A policy regarding animal welfare is being developed.



## Strategic direction and actions

Getinge uses a risk-based methodology in implementing its ethics and compliance programs and concentrates its efforts on high-risk areas. Actions related to anti-corruption and business ethics are carried out continuously. One of the high-risk areas is the interaction with healthcare professionals and participation in public procurement. Getinge has developed a formal protocol for conducting risk assessments and uses forensic expertise when necessary.

The risk assessment process includes an evaluation of various criteria and risk factors such as those related to location, business activity, third-party interactions, products or services, internal control, and audit outcomes. The risk investigation committee is separated from Getinge’s management teams. For more information on the process to report outcomes to the administrative, management, and supervisory body, see pages 79–81.

Regional risk assessments are conducted periodically, encompassing a thorough review of country risk analysis, past audits, investigation findings, and risk assessments from site visits and stakeholder interviews. Findings from the last regional risk assessment indicate that a continued focus is necessary on interactions with healthcare professionals and organizations, and also third-party management.

In response to these findings, a detailed plan at each regional level has been developed to advance the implementation of identified mitigation actions. This includes updating relevant policies and delivering training on interactions with healthcare professionals and organizations.

The Global Anti-Bribery & Corruption (ABC) program serves as a method and tool for ensuring

that Getinge has adequate procedures in place for preventing the company from taking part in any corrupt business practices and ensuring that the company adheres to applicable laws and regulations, as well as relevant ethical norms including the Code of Conduct, global policies and directives.

As a key mitigation action, a global tool has been introduced to register all engagements with healthcare professionals and organizations. Comprehensive guidance, tools, and training have been provided to ensure that all interactions, including speaking engagements, consultancy agreements, and usability testing with third-party vendors, are conducted ethically and transparently, and compliance with global regulations.

A Global Educational Grants portal has also been launched where requests for Education Grants are submitted by qualifying organizations for funding or product support for independent education or research, with no commercial influence. All requests are reviewed by the Educational Grants Review Committee.

In addition, specific Ethics & Compliance programs have been designed for Healthcare Compliance and Anti-Trust to provide a risk-based framework for managing the risk of undue influence and unfair business practices.

Internal Controls, relevant for the Ethics & Compliance programs, have been integrated into the Getinge Internal Controls framework. The Corporate Internal Audit function conducts risk-based audits on the local implementation and provides recommendations for improving the effectiveness of the Ethics & Compliance programs.

### Speak-Up Line

Getinge is dedicated to providing open and transparent communication, internally and externally. All employees are encouraged to report any suspected or observed violations of the law or the corporate Code of Conduct. In this regard, Getinge encourages reporting to managers, Human Resources (HR and the global Ethics & Compliance team.

Getinge’s whistle-blower hotline – the Getinge Speak-Up Line – is available both internally and externally via the company’s internal communication platform GetNet and the public website [getinge.com](https://getinge.com). The platform for Getinge’s Speak-Up Line has access to over 340 languages, and Getinge currently uses around 60 different languages. Getinge provides information and training to its own employees on how to use the Speak-Up line as part of the mandatory Ethics and Compliance training.

Access to Speak-Up reports is restricted to designated employees within the Global Ethics and Compliance team who are bound by an agreement stating that all cases must be handled confidentially.

Getinge also has a strict non-retaliation policy with clear responsibilities for monitoring and reacting to any attempt to impose a sanction, disadvantage or discrimination against any person who raises a concern or cooperates in a company investigation.

The status of internal investigations is reported to senior executives on a regular basis in various forums, such as the Ethics Committee, Audit & Risk Committee, during Business Area management meetings or regional Global Sales management meetings.

By using these mechanisms, Getinge endeavors to identify, trace and take corrective action on complaints, following established routines and processes. Getinge is committed to investigating potential business conduct incidents promptly, independently and objectively. Intended users of the Speak-Up Line are not involved in the design, review, and operation of the hotline.

### Risk-based training programs

Training and communication are essential components of Getinge’s global ethics and compliance programs. Based on risk assessments, the programs include training for Anti-bribery and corruption for employees in high-risk regions and roles. The Board and all members of the Getinge Executive Team are trained annually. The global Ethics and Compliance team monitors all training to ensure that employees complete their assigned training programs.

A specialized program, titled Responsible Leadership #ItStartsWithMe, was deployed in 2022 aiming to enhance business ethics awareness and a culture of compliance at all levels in Getinge. In 2024, the program was complemented with modules aimed at colleagues working in the factories.

In 2025, Getinge introduced a global Code of Conduct training initiative aimed at strengthening the company’s shared values and the collective commitment to doing the right things, helping teams navigate real-world challenges, and building trust and accountability. The training covers topics such as anti-corruption and bribery and is delivered through interactive workshops led by managers, incorporating real company case studies to ensure applicability

### Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board’s Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

Social

→ Governance

Appendix

### Financial statements

### Other information

and relevance. The Code of Conduct training is mandatory for all employees, with the ambition that all employees have completed it in 2026.

The company has an ethics ambassador program with around 70 Ethics Ambassadors globally promoting business ethics and Responsible Leadership. The ethics ambassador program is a key initiative with the aim of spreading knowledge and supporting the organization in business ethics and compliance including Anti-Bribery and Corruption.

**Approach to remedies**

Getinge is committed to fulfilling its obligations when it comes to respecting human rights across its operations and business relationships. In line with the UN Guiding Principles on Business and Human Rights (UNGPs), and aligned with internationally recognized human rights standards, Getinge seeks to prevent and address adverse human rights impacts connected to its activities and, where appropriate, to provide for or cooperate in their remediation.

Targets, key figures and results

**Business Ethics & Responsible Leadership**

Getinge's target, which is set by the Getinge Executive Management Team, is that all employees are properly trained in business ethics. The percentage of employees who completed the online training in business ethics in 2025 was 92% (90%). These metrics are extracted from Getinge's SAP system and revised by the Corporate Internal Audit function. From 2026, Getinge will track a new KPI in business ethics regarding the percentage of employees who have completed the Code of Conduct workshop which was launched in 2025.

**Confirmed incidents of corruption and bribery and actions taken**

During 2025, Getinge recorded one case of corruption as well as one case in which one of the company's own workers was dismissed for a corruption related incident. No public corruption cases were brought against the company or its employees and the company has no related convictions.

**Legal actions for anti-competitive behavior, antitrust, and monopoly practices**

No legal actions for anti-competitive behavior, antitrust, and monopoly practices arose in 2025.



**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
  - Appendix

**Financial statements**

**Other information**

# Reporting principles

## Environment

### Climate and Energy

Boundaries: All greenhouse gas emissions are consolidated from entities over which Getinge has operational control.

The base year for calculation has been set to 2021 emission values, if not stated otherwise. The base year is updated for the 2025 report and is aligned with the baseline year in SBTi. Apart from adding four acquired units and restatements presented in page 94, no changes in calculation method have been made.

Carbon dioxide (CO<sub>2</sub>) is the predominant greenhouse gas included in the calculations. Emission factors applied to energy consumption for different energy resources are converted to MWh/CO<sub>2</sub>eq. Getinge uses CO<sub>2</sub>eq emission factors that may include small amounts of converted methane (CH<sub>4</sub>) and N<sub>2</sub>O, where applicable. Getinge does not report on other ozone depleting substances or greenhouse gases, neither on biogenic CO<sub>2</sub> emissions.

Getinge strives to reach its targets to reduce GHG emissions without offsetting mechanisms to the extent possible. Getinge acknowledges that reducing CO<sub>2</sub> emissions with CO<sub>2</sub> offsetting is accepted by the GHG Protocol, but not by the SBTi.

### Scope 1 and 2

GHG emissions are calculated based on the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition).

#### Scope 1 Fuel combustion

Global Scope 1 emission factor for fuel combustion is from the Department for Business, Energy and Industrial Strategy 2021 Government GHG Conversion Factors for Company Reporting, in line with IPCC 2006 Guidelines for National Greenhouse Gas Inventories.

#### Calculation of emissions from vehicles

Except for a very small share, Getinge's fleet consists of leased vehicles. Emissions from leased vehicles under the operational control of Getinge are calculated by multiplying annual mileage in km with CO<sub>2</sub>eq emission factors per vehicle. Annual mileage per car is based on the assumption that each car has an annual mileage of 30 000 km. The emission factors used are DEFRA's "UK Government Conversion Factors for Company Reporting" for the respective years 2021–2025.

### Scope 2

#### Market-based

Scope 2 Country-specific (market-based) factors are sourced for electricity from a third party and using market-based emission factors. In addition, supplier specific factors have been analyzed locally to report emissions based on the market-based methodology. The most recent and internationally recognized schemes are preferred.

#### Location-based

Scope 2 Country-specific (location-based) factors are sourced for electricity from a third party and using location-based emission factors. In addition, supplier specific factors have been analyzed locally to report emissions based on the location-based methodology. The most recent and internationally recognized schemes are preferred.

### Calculation of emissions from offices and warehouses

Emissions from owned and leased offices and warehouses are calculated by multiplying workplace area in m<sup>2</sup> with an average factor of energy consumption per year (kWh/m<sup>2</sup> per yr). For offices, this factor is 242.19 kWh/yr and for warehouses 96.88 kWh/yr<sup>1</sup>. In the few cases in which data for consumption per office or warehouse is available, this has been used. The sum of calculated annual energy consumption per office/warehouse is then multiplied by country specific emission factors for the respective site. Emission factors: (IEA 2019) CO<sub>2</sub>eq emissions per kWh of electricity and heat (gCO<sub>2</sub>eq /kWh).

## Welcome to Getinge

### Market environment

### Strategy

### Business areas

### The Board's Operating Reports

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

Social

Governance

→ Appendix

### Financial statements

### Other information

1) <https://www.altenergymag.com/article/2019/07/benchmarking-commercial-building-energy-use-per-square-foot/31381>, [https://www.betterbuildingspartnership.co.uk/sites/default/files/media/attachment/REEB%202023%20Benchmarks\\_0.pdf](https://www.betterbuildingspartnership.co.uk/sites/default/files/media/attachment/REEB%202023%20Benchmarks_0.pdf)

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
- Appendix

**Financial statements**

**Other information**

**Scope 3**

**Scope 3.1 – Purchased goods and services**

The emissions represented in category 3.1 are based on the services and products Getinge has purchased during the year. These purchases were divided into five different categories:

- Plastics
- Metals
- Electronics and Electrical
- Other
- Purchased services

For plastics, metals and electronics, the calculations are based on both spend data and weight of the materials where available. Material emission factors used are the following: US commodities and Industries v1.1, DEFRA UK database, EPA database, the Zero carbon product database and Ecolnvent.

**3.1 – Plastics**

There are 10 different types of plastic in the calculations, which are based on the same methodology. The description below is applicable for all plastic types.

*Activity data:*

- Spend data from plastic supplier is collected and then divided into type of plastic and weight.

*Emission factors:*

- Plastic emission factors from the Zero carbon product database.
- Plastic emission factors from the DEFRA database.
- Plastic emission factors from the Ecolnvent database.
- Each factor is increased with 20% to include the last processing step of each material.

*Assumptions:*

- Assumed value on the type of plastic(s) each supplier delivers to Getinge.
- Assumed value on price per kg to calculate the total weight of each plastic type.
- A scale-up factor based on spend was used to cover all plastic goods.

**3.1 – Metals**

There are 5 different types of metals in the calculations, which are based on the same methodology. The following description is applicable for all metal types.

*Activity data:*

- Spend and weight data is collected for each purchase of metals, which is categorized based on type of metal. If metals can not be categorized an assumed mix is applied.

*Emission factors:*

- Metal emission factors are from the Zero carbon product database. The emission factors have values based on the origin countries of the metal and are then weighed to a general factor depending on the share of where the metals are bought and share of recycled (secondary) metals.

*Assumptions:*

- To include emissions from further processing of metals after production, each factor is increased with 20%.
- The emission factors are based on the mix of origin of countries 2021.

**3.1 – Electronics and electrical**

This category is based on weight data, which is allocated into every business area and divided into the different categories below.

*Activity data:*

- Spend and weight data is collected for each purchase of electronics, which is categorized based on type of electronic product. Each type of product is then assumed to include a specific mix of materials.

*Emission factors:*

- Material emission factors from the Zero carbon product database.
- Material emission factors from the DEFRA database.

*Assumptions:*

- The categorization of different products into a product group.
- The specific mix of materials included in the emission factors applied to the product groups.

**3.1 – Other**

This category is only based on spend data. All data are recalculated each year based on the exchange rate between the currency paid with and SEK, to match the values from 2021 (and the emission factors).

*Activity data:*

- Spend data for each purchase of products that cannot be categorized in the previously mentioned categories is collected. The spend data is then categorized into different categories of products which are then assumed to include a specific mix of materials.

*Emission factors:*

- Material emission factors from Supply Chain GHG Emission Factors for US Commodities and Industries v1.1.
- Material emission factors from the DEFRA UK database.

- Material emission factors from the EPA database
- Material emission factors from the Zero carbon product database.

*Assumptions:*

- The categorization into specific purchase types.
- The specific mix of emission factors to build the specific emission factors to the purchase types.

**3.1 – Purchased services**

This category is only based on spend data. All data are recalculated each year based on the exchange rate between the currency paid with and SEK, to match the values from 2021 (and the emission factors).

*Activity data:*

- Spend data for each purchase of services is collected. The spend data is then categorized into different service types.

*Emission factors:*

- Material emission factors built from CDP data from relevant IT companies.
- Material emission factors from the Trucost database.
- Material emission factors from the EPA database.
- Material emission factors from Supply Chain GHG Emission Factors for US Commodities and Industries v1.1.

*Assumptions:*

- The categorization into specific service types.
- The mapping of specific emission factors to specific service types.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

Social

Governance

→ Appendix

**Financial statements**

**Other information**

**Scope 3.2 – Capital goods**

This category is only based on spend data of larger investments that Getinge has made over the measurement period.

*Activity data:*

- Spend data for each purchase is collected. The spend data is then categorized into different types of investments.

*Emission factors:*

- Material emission factors based on CDP data from relevant companies.

*Assumptions:*

- USD to SEK factor used is the same year on year.

**Scope 3.3 – Fuel- and energy related activities**

The emissions represented in category 3.3 are based on calculations in Scope 1 and 2 (including leased assets).

**Scope 3.4 – Upstream transportation and distribution**

The emissions represented in category 3.4 are based on the transportation services that Getinge has purchased during the year. The inbound and outbound transports in the value chain have been separated in the calculations.

*Activity data:*

- Inbound: Getinge gather and estimate weight for each product bought. In addition, information about the geographic origin and destination of the order is used in the calculation.
- Outbound: Getinge receive emission or transport reports from forwarders.

*Emission factors:*

- Transportation mode emission factors from

the DEFRA UK database.

*Assumptions:*

- Inbound: The distance of each transport is estimated based on the region which the goods are transported from and the region where the goods are transported to.
- Inbound: The type of transport mode used is estimated based on whether it is a domestic, inter-continental or intra-continental transport.
- Outbound: To cover the forwarders that could not provide an emission or transport report, Getinge scales up the results based on spend.

**Scope 3.5 – Waste generated in operations**

This category is only based on weight data of waste produced at Getinge production sites.

*Activity data:*

- Weight data is collected from each production site and categorized into specific waste types.
- Emission factors:
- Material emission factors are from the DEFRA UK database.

**Scope 3.6 – Business travel**

The emissions represented in this category are based on data supplied from global supplier BCD, which gives an emission report that lists emissions from Getinge.

*Activity data:*

- Getinge collects emission data from a global travel supplier that summarizes trips made during the measurement period.

*Emission factors:*

- The emission factors used by the global supplier is based on DEFRA UK and EPA database. Note that these are not used directly by Getinge.

*Assumptions:*

- All business travel is covered in travel agency data.

**Scope 3.7 – Employee commuting**

The emissions represented in category 3.7 are based on the number of Getinge's employees and estimations on travel behavior.

*Activity data:*

- Number of full-time employees during the measurement period.
- Assumption on travel behavior based on Getinge's best knowledge.

*Emission factors:*

- Factors representing public transport and car travel from Tremod database.

*Assumptions:*

- It is assumed that individual coworkers travel either by car or public transport and the mix between these modes is also assumed.
- Assumed average length of distance travelled.
- Assumed number of average working days per year.

**Scope 3.8 – Upstream leased assets**

The emissions represented in category 3.8 are based on Getinge's leased vehicles and leased spaces during the year. Note: Since Getinge uses an operational control approach, these emissions will be included in Scope 1 and 2 emissions when reporting.

**3.8 – Leased vehicles (incl. in Scope 1 and 3.3)**

*Activity data:*

- Distance traveled on average by each leased vehicle.
- In a few cases, precompiled emission report from leasing suppliers.

*Emission factors:*

- Vehicle manufacturer WLTP emission factors,

based on type of engine/vehicle.

- Vehicle emission factors are from DEFRA database.
- DEFRA's "UK Government Conversion Factors for Company Reporting" for the respective years 2021-2024 was applied in estimates.

*Assumptions:*

- To calculate the WTT emission factors, an assumed value of 15% is added to the calculations. Based on the fact that most of the leased vehicles use diesel as fuel.
- For the vehicles with no specific data on WLTP emissions, an average WLTP factor representing traditional diesel engine was used.

**3.8 – Leased spaces (incl. in Scope 2 and 3.3)**

*Activity data:*

- Area of the leased spaces (m<sup>2</sup>), divided into offices or warehouse and country.

*Emission factors:*

- Energy consumption-based factors from the IEA database.

*Assumptions:*

- The energy consumption is based on average consumption factors per area from CREEM.

**Scope 3.9 – Downstream transportation and distribution**

The emissions represented in category 3.9 should be based on the transportation of products that Getinge does not purchase or have control over. Data for this type of transportation was not readily available, and this category has therefore been based on a calculation that the transportation that is paid for by customers is around 5% of all total outbound transports.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

- Administration Report
- Corporate Governance Report
- Sustainability statement
  - General disclosures
  - Environment
  - Social
  - Governance
- Appendix

**Financial statements**

**Other information**

**Scope 3.10 – Processing of sold products**

Not applicable for Getinge.

**Scope 3.11 – Use of sold products**

The emissions represented in category 3.11 are based on the expected energy consumption from Getinge's sold products during their lifetime.

*Activity data:*

- Number of sold products that consume direct energy, sold during the measurement period.
- Estimated energy profile for the sold products during its lifetime.
- Lifetime expectancy is calculated to be on average 10 years

*Emission factors:*

- Global electricity emission factor from "Our world data" database.
- Steam factor from DEFRA UK.

*Assumptions:*

- The expected energy profile is not available for every type of product sold, therefore an average energy profile for a category of products has been applied.
- Since Getinge does not have availability over the type of electricity or steam their customers will use, global emission factors for the electricity and steam consumption have been applied.

**Scope 3.12 – End-of-life treatment of sold products**

The emissions represented in category 3.12 should be based on the total weight of the products sold by Getinge during the year. This data was not readily available for the calculated year and is thus correlated to the materials purchased for the products that are produced.

*Activity data:*

- Weight data.
- Spend data (used to calculate an estimated weight).

*Emission factors:*

- Material economics report "Industrial transformation 2050".
- Waste handling factors from DEFRA UK.

*Assumptions:*

- Material bought is the same as material sold.

**Scope 3.13 – Downstream leased assets**

Not applicable for Getinge.

**Scope 3.14 – Franchises**

Not applicable for Getinge.

**Scope 3.15 - Investments**

Not applicable for Getinge.

**Waste**

Responsible use of resources and waste handling is in focus in all locations of operation. Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units) to comply with all local regulation in this area and has set targets to increase recycling of its waste. The management of waste follows the principles set out in the environmental and sustainability policies and local environmental management systems. Waste data is measured bi-annually and is based on invoices from suppliers or local data bases. The development of generated waste volumes from production and modes of recycling are gathered in a central data management system for all production units.

**Water**

Water data is compiled monthly, either via supplier invoices or via local measuring equipment or meters. For assessing water risk and water stress level, the WRI Aqueduct database has been used.

Methodologies to report employee data

**Employees and non-employees**

Employee data is extracted from the HR Business Intelligence Solution which collects data from Getinge's Global Human Resource Information System (HRIS). Data is reported as a snapshot of the end of the reporting period (31st of December 2025). Getinge differentiates between internal personnel (employees) and external personnel (non-employees). Head count counts the number of personnel irrespective of whether the person is working full-time or part-time or whether the person is currently actively working or on either unpaid/paid leave. Full-Time Equivalent (FTE) expresses the total hours worked by employees, regardless of whether they work full-time, part-time, or on temporary contracts, as a standardized number of full-time positions. The calculation is based on converting each employee's contracted or actual working hours into a proportion of a full-time schedule and then aggregating these values. Non-employees are hired via a third party vendor, or self-employed, and hence their contract and payment is either handled via the third party or in conjunction with the third party.

**Gender**

Gender data allows for classifications beyond "Male" and "Female," such as "Unknown" or "Undeclared." Due to the very small number of employees in these categories, these have been aggregated and reported collectively under "Other." In line with Getinge's governance on gender classification, gender is recorded in the HR system exactly as stated in the employee's passport.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

Social

Governance

→ Appendix

**Financial statements**

**Other information**

**Employee turnover**

Employee data is extracted from the HR Business Intelligence Solution which collects data from Getinge's Global Human Resource Information System (HRIS). Turnover is calculated as all employees who had their last day at Getinge during 2025 divided by the average headcount during the reporting period.

**Collective bargaining coverage and social dialogue**

In 2025 Getinge reports on the overall percentage of employees (head count) covered by collective bargaining agreements for each country in which Getinge has significant employment defined as at least 50 employees by head count. Due to uncertainty in reporting requirements related to calculating what constitutes 10% of total employees this is not considered in the calculation.

**Work-life balance**

The data is extracted from Getinge's HRIS and is reported over the period of a year for people going on leave or returning from leave. To calculate the entitlement to take parental leave in 2025, all employees that had a seniority of one year or more at the end of the period were included as entitled which is considered a lower bound estimate of employees entitled to take leave. In 2025, 90% of Getinge's employees (head count) were entitled to take parental leave.

**Age intervals**

The data is extracted from the HR Business Intelligence Solution which collects data from Getinge's Global Human Resource Information System (HRIS). For age group reporting, the recorded date of birth is used to calculate each employee's age at the end of the reporting period. If the date of birth is missing or if the calculated age falls outside the valid range the entry is classified as invalid in the reporting.

**Health & Safety**

High consequence work-related accident is defined as a work-related accident that results in an injury from which the worker cannot, does not, or is not expected to recover fully to pre-injury health status within six months. Work-related ill health is defined as any negative impact, such as abnormal conditions or disorders with a clear causal relationship between the ill health and the specific work environment or activity, other than one resulting from occupational health injuries arising from exposure to hazards at work. Getinge does not collect data on work-related ill health related to non-employees. Recordable injury is defined as any occupational injury that requires medical treatment more than simple first aid and occurs within a Getinge site perimeter, or while on business travel and which includes an employee, or a contractor normally based at that site. Work-related accident rate (WRAR) represents the number of accidents that resulted in absence of more than one day per 200,000 hours worked and 1,000,000 hours worked respectively.

## Appendix - ESRS index

### Disclosure requirements covered by the Sustainability statement (IRO-2)

Standard	Disclosure requirement	Title	Page number	Additional information	Data points from other EU legislation and related ESRS datapoint(s)
<b>ESRS 2</b>		<b>GENERAL DISCLOSURES</b>			
	BP-1	General basis for preparation of sustainability statement	73		
	BP-2	Disclosures in relation to specific circumstances	73		
	GOV-1	The role of the administrative, management and supervisory bodies	79–81		SFDR and Benchmark Regulation ESRS: Paragraph 21 (d)
	GOV-2	Information provided to and sustainability matters addressed by the undertaking's administrative, management and supervisory bodies	79–81		
	GOV-3	Integration of sustainability-related performance in incentive schemes	81		
	GOV-4	Statement on due diligence	81		SFDR, Paragraph 30
	GOV-5	Risk management and internal controls over sustainability reporting	81		
	SBM-1	Strategy, business model and value chain	74		SFDR, Pillar 3 and Benchmark Regulation ESRS: Paragraph 40 (d) i-iv
	SBM-2	Interests and views of stakeholders	75		
	SBM-3	Material impacts, risks and opportunities and their interaction with strategy and business model	77–78		
	IRO-1	Description of the process to identify and assess material impacts, risks and opportunities	76		
	IRO-2	Disclosure requirements in ESRS covered by the undertaking's sustainability statement	134–137		

Blue text = Material topic  
 Grey text = Not material topic

Standard	Disclosure requirement	Title	Page number	Additional information	Data points from other EU legislation and related ESRS datapoint(s)
<b>ESRS 2</b>		<b>GENERAL DISCLOSURES</b>			
	E1 ESRS 2 GOV-3	Integration of sustainability-related performance in incentive schemes	81		
	E1 ESRS 2 SBM-3	Material impacts, risks and opportunities and their interaction with strategy and business model	77–78, 86–89		
	E1 ESRS 2 IRO-1	Description of the processes to identify and assess material climate-related impacts, risks and opportunities	76		
	E3 ESRS 2 IRO-1	Description of the processes to identify and assess material water and marine resources-related impacts, risks and opportunities	76		
	E5 ESRS 2 IRO-1	Description of the processes to identify and assess material resource use and circular economy-related impacts, risks and opportunities	76		
	S1 ESRS 2 SBM-2	Interests and views of stakeholders	75		
	S1 ESRS 2 SBM-3	Material impacts, risks and opportunities and their interaction with strategy and business model	108		SFDR, Paragraph 14 (f-g)
	S2 ESRS 2 SBM-2	Interests and views of stakeholders	75		
	S2 ESRS 2 SBM-3	Material impacts, risks and opportunities and their interaction with strategy and business model	117		SFDR, Paragraph 11 (b)
	S4 ESRS 2 SBM-2	Interests and views of stakeholders	75		
	S4 ESRS 2 SBM-3	Material impacts, risks and opportunities and their interaction with strategy and business model	120		
	G1 ESRS 2 GOV-1	The role of the administrative, supervisory and management bodies	79–81		
	G1 ESRS 2 IRO-1	Description of the processes to identify and assess material impacts, risks and opportunities	76		

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

Social

Governance

→ Appendix

**Financial statements**

**Other information**

## Appendix - ESRS index

Standard	Disclosure requirement	Title	Page number	Additional information	Data points from other EU legislation and related ESRS datapoint(s)
<b>E1</b>		<b>CLIMATE CHANGE</b>			
	E1-1	Transition plan for climate change mitigation	90		EU Climate Law, Paragraph 14. Pillar 3 and Benchmark Regulation, Paragraph 16 (g)
	E1-2	Policies related to climate change mitigation and adaptation	92		
	E1-3	Actions and resources in relation to climate change policies	92		
	E1-4	Targets related to climate change mitigation and adaptation	93–94		SFDR, Pillar 3 and Benchmark Regulation, Paragraph 34
	E1-5	Energy consumption and mix	93		SFDR, Paragraph 37, 38, 40-43
	E1-6	Gross Scopes 1, 2, 3 and Total GHG emissions	94		SFDR, Pillar 3 and Benchmark Regulation, Paragraph 40, 53-55
	E1-7	GHG removals and GHG mitigation projects financed through carbon credits	–	Not material topic	N/A EU Climate Law, Paragraph 56
	E1-8	Internal carbon pricing	–	Not material topic	N/A
	E1-9	Anticipated financial effects from material physical and transition risks and potential climate-related opportunities	–	Phase-in	N/A Benchmark Regulation, Paragraph 66, 69. Pillar 3, Paragraph, 66 (a)(c), 67 (c)
		Disclosures pursuant to Article 8 of Regulation (EU) 2020/85 (Taxonomy Regulation)	102–105		

Standard	Disclosure requirement	Title	Page number	Additional information	Data points from other EU legislation and related ESRS datapoint(s)
<b>E3</b>		<b>WATER AND MARINE RESOURCES</b>			
	E3-1	Policies related to water and marine resources	97		SFDR, Paragraph 13-14
	E3-2	Actions and resources related to water and marine resources	97		
	E3-3	Targets related to water and marine resources	97		
	E3-4	Water consumption	97		SFDR, Paragraph 28 (c), 29
	E3-5	Anticipated financial effects from water and marine resources-related impacts, risks and opportunities	–	Phase-in	
<b>E5</b>		<b>RESOURCE USE &amp; CIRCULAR ECONOMY</b>			
	E5-1	Policies related to resource use and circular economy	100		
	E5-2	Actions and resources related to resource use and circular economy	100		
	E5-3	Targets related to resource use and circular economy	101		
	E5-4	Resource inflows	–	Data not available to disclose on DR 2025	
	E5-5	Resource outflows (waste)	101		SFDR, Paragraph 37 (d), 39
	E5-6	Anticipated financial effects from resource use and circular economy-related impacts, risks and opportunities	–	Phase in	

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

Social

Governance

→ Appendix

**Financial statements**

**Other information**

Blue text = Material topic

Grey text = Not material topic

## Appendix - ESRS index

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

Social

Governance

→ Appendix

**Financial statements**

**Other information**

Standard	Disclosure requirement	Title	Page number	Additional information	Data points from other EU legislation and related ESRS datapoint(s)
<b>S1</b>		<b>OWN WORKFORCE</b>			
	S1-1	Policies related to own workforce	110, 113		SFDR, Paragraph 20, 22-23. Benchmark Regulation, Paragraph 21
	S1-2	Processes for engaging with own workers and workers' representatives about impacts	75		
	S1-3	Processes to remediate negative impacts and channels for own workers to raise concerns	110, 113, 127-128		SFDR, Paragraph 32 (c)
	S1-4	Taking action on material impacts on own workforce, and approaches to managing material risks and pursuing material opportunities related to own workforce, and effectiveness of those actions	110, 113		
	S1-5	Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities	111		
	S1-6	Characteristics of the undertaking's employees	114		
	S1-7	Characteristics of non-employee workers	114		
	S1-8	Collective bargaining coverage and social dialogue	115		
	S1-9	Diversity metrics	115		
	S1-10	Adequate wages	115		
	S1-11	Social protection	115		
	S1-12	Persons with disabilities	–	Not material topic	
	S1-13	Training and skills development metrics	–	Not material topic	
	S1-14	Health and safety metrics	111		SFDR and Benchmark Regulation, Paragraph 88 (b-c), 88 (e)

Blue text = Material topic

Grey text = Not material topic

Standard	Disclosure requirement	Title	Page number	Additional information	Data points from other EU legislation and related ESRS datapoint(s)
<b>S1</b>		<b>OWN WORKFORCE</b>			
	S1-15	Work-life balance metrics	115		
	S1-16	Remuneration metrics (pay gap and total remuneration)	114	Data not available to disclose on DR 2025	SFDR, Paragraph 97 (a-b), Benchmark Regulation, Paragraph 97 (a)
	S1-17	Incidents, complaints and severe human rights impacts	115		SFDR, Paragraph 103 (a), 104 (a), Benchmark Regulation, Paragraph 104 (a)
<b>S2</b>		<b>WORKERS IN THE VALUE CHAIN</b>			
	S2-1	Policies related to value chain workers	118		SFDR, Paragraph 17-19, Benchmark Regulation, Paragraph 19
	S2-2	Processes for engaging with value chain workers about impacts	75		
	S2-3	Processes to remediate negative impacts and channels for value chain workers to raise concerns	127-128		
	S2-4	Taking action on material impacts on value chain workers, and approaches to managing material risks and pursuing material opportunities related to value chain workers, and effectiveness of those action	118		SFDR, Paragraph 36
	S2-5	Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities	118		

## Appendix - ESRS index

Standard	Disclosure requirement	Title	Page number	Additional information	Data points from other EU legislation and related ESRS datapoint(s)
<b>S4</b>		<b>CONSUMERS AND END-USERS</b>			
	S4-1	Policies related to consumers and end-users	121		SFDR, Paragraph 16-17, Benchmark Regulation, Paragraph 17
	S4-2	Processes for engaging with consumers and end-users about impacts	75		
	S4-3	Processes to remediate negative impacts and channels for consumers and end-users to raise concerns	127–128		
	S4-4	Taking action on material impacts on consumers and end-users, and approaches to managing material risks and pursuing material opportunities related to consumers and end-users, and effectiveness of those actions	121		SFDR, Paragraph 35
	S4-5	Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities	122		

Standard	Disclosure requirement	Title	Page number	Additional information	Data points from other EU legislation and related ESRS datapoint(s)
<b>G1</b>		<b>BUSINESS CONDUCT</b>			
	G1-1	Business conduct policies and corporate culture	126		SFDR, Paragraph 10 (b), 10 (d)
	G1-2	Management of relationships with suppliers	–	Not material topic	
	G1-3	Prevention and detection of corruption and bribery	127		
	G1-4	Incidents of corruption or bribery	128		SFDR, Paragraph 24 (a-b), Benchmark Regulation, Paragraph 24 (a)
	G1-5	Political influence and lobbying activities	–	Not material topic	
	G1-6	Payment practices	–	Not material topic	

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

Administration Report

Corporate Governance Report

Sustainability statement

General disclosures

Environment

Social

Governance

→ Appendix

**Financial statements**

**Other information**

Blue text = Material topic

Grey text = Not material topic

# Financial statements

Consolidated financial statements	139
Group notes	144
Parent Company financial statements	181
Parent Company notes	185
Auditor's report	191

# Consolidated income statement

SEK M	Note	2025	2024
Net sales	2, 3	34,969	34,759
Cost of goods sold	4	-18,315	-18,606
<b>Gross profit</b>		<b>16,654</b>	<b>16,153</b>
Selling expenses	4	-6,050	-5,979
Administrative expenses	4	-4,587	-4,654
Research and development costs	4, 9	-1,452	-1,431
Acquisition expenses	4	-24	-50
Restructuring costs	4	-374	-848
Other operating income	4	604	672
Other operating expenses	4	-982	-1,008
<b>Operating profit (EBIT)</b>	3, 4, 5, 6	<b>3,789</b>	<b>2,854</b>
Interest income and other similar income	6, 7	75	107
Interest expenses and other similar expenses	6, 7	-719	-678
<b>Profit after financial items</b>		<b>3,145</b>	<b>2,282</b>
Taxes	8	-869	-628
<b>Net profit for the year</b>		<b>2,276</b>	<b>1,654</b>
<b>Net profit for the year attributable to:</b>			
Parent Company's shareholders		2,258	1,638
Non-controlling interests		17	16
<b>Earnings per share, SEK<sup>1</sup></b>	17	<b>8.29</b>	<b>6.01</b>
Weighted average number of outstanding shares for calculation of earnings per share (000s)	17	272,370	272,370

1) Before and after dilution.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

→ Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

# Consolidated statement of comprehensive income

SEK M	Note	2025	2024
<b>Net profit for the year</b>		<b>2,276</b>	<b>1,654</b>
<b>Other comprehensive income</b>			
<b>Items that cannot be restated in profit</b>			
Actuarial gains/losses pertaining to defined-benefit pension plans		165	31
Tax attributable to items that cannot be restated in profit		-45	-3
<b>Items that can later be restated in profit</b>			
Translation differences		-4,160	2,063
Hedging of net investments		-754	393
Cash flow hedges	19	-5	12
Tax attributable to items that can be restated in profit		156	-83
<b>Other comprehensive income for the year, net after tax</b>		<b>-4,643</b>	<b>2,412</b>
<b>Comprehensive income for the year</b>		<b>-2,367</b>	<b>4,066</b>
<b>Comprehensive income for the year attributable to:</b>			
Parent Company's shareholders		-2,373	4,038
Non-controlling interests		6	28

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

→ Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

# Consolidated balance sheet

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

→ Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

SEK M	Note	2025	2024
<b>ASSETS</b>			
<b>Non-current assets</b>			
Intangible assets	3, 9	33,513	39,242
Tangible assets	3, 10	3,469	3,902
Right-of-use assets	11	1,470	1,795
Financial instruments, long-term	19	10	15
Financial receivables, long-term	19	24	33
Deferred tax assets	8	792	770
<b>Total non-current assets</b>		<b>39,278</b>	<b>45,757</b>
<b>Current assets</b>			
Inventories	12	6,018	6,590
Accounts receivable	13, 19	5,782	6,348
Contract assets	14	850	926
Current tax assets		35	73
Financial instruments, current	19	22	3
Other receivables	19	723	806
Prepaid expenses and accrued income	16	396	455
Cash and cash equivalents	19, 20, 26	3,401	2,961
<b>Total current assets</b>		<b>17,227</b>	<b>18,162</b>
<b>TOTAL ASSETS</b>		<b>56,505</b>	<b>63,918</b>

SEK M	Note	2025	2024
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Share capital	17	136	136
Other capital provided		6,789	6,789
Other reserves		1,000	5,752
Retained earnings		21,504	20,328
<b>Equity attributable to the Parent Company's shareholders</b>		<b>29,430</b>	<b>33,005</b>
Non-controlling interests		64	205
<b>Total equity</b>		<b>29,494</b>	<b>33,210</b>
<b>Long-term liabilities</b>			
Interest-bearing long-term liabilities	19, 20	7,893	6,971
Other long-term liabilities	19	452	1,892
Provisions for pensions and similar obligations, interest-bearing	20, 21	2,358	2,700
Provisions for pensions and similar obligations, non-interest-bearing	21	60	86
Leasing liabilities, long-term	11, 19, 20	1,029	1,309
Deferred tax liabilities	8	1,754	2,172
Restructuring reserves, long-term	15	3	19
Other provisions, long-term	15	422	510
<b>Total long-term liabilities</b>		<b>13,970</b>	<b>15,660</b>
<b>Current liabilities</b>			
Restructuring reserves, current	15	216	177
Other provisions, current	15	1,348	1,537
Interest-bearing current liabilities	19, 20	1,510	1,956
Leasing liabilities, current	11, 19, 20	452	491
Accounts payable	19	2,118	2,398
Contract liabilities	14	2,104	2,464
Current tax liabilities		705	444
Financial instruments, current	19	4	13
Other liabilities	19	1,580	2,046
Accrued expenses and deferred income	16	3,005	3,522
<b>Total current liabilities</b>		<b>13,042</b>	<b>15,047</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>56,505</b>	<b>63,918</b>

Refer to Note 25 Pledged assets and contingent liabilities for information concerning Getinge Group's pledged assets and contingent liabilities.

# Changes in equity for the group

SEK M	Share capital	Other capital provided	Reserves <sup>1</sup>	Retained earnings	Total	Non-controlling interests	Total equity
<b>Opening balance 2025</b>	136	6,789	5,752	20,328	33,005	205	33,210
Comprehensive income for the year	–	–	-4,752	2,378	-2,373	6	-2,367
Dividend	–	–	–	-1,253	-1,253	-14	-1,267
Transactions with non-controlling interests	–	–	–	50	50	-133	-83
<b>Closing balance 2025</b>	136	6,789	1,000	21,504	29,430	64	29,494
<b>Opening balance 2024</b>	136	6,789	3,380	19,861	30,166	237	30,403
Comprehensive income for the year	–	–	2,372	1,665	4,038	28	4,066
Dividend	–	–	–	-1,198	-1,198	-29	-1,228
Transactions with non-controlling interests	–	–	–	–	–	-31	-31
<b>Closing balance 2024</b>	136	6,789	5,752	20,328	33,005	205	33,210

1) Reserves pertain to cash flow hedges, hedges of net investments in foreign operations and translation differences.

## Welcome to Getinge

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

## Financial statements

→ Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

Auditor's report

## Other information

# Consolidated cash flow statement

SEK M	Note	2025	2024
<b>Operating activities</b>			
Operating profit (EBIT)		3,789	2,854
Add-back of amortization, depreciation and write-down		2,250	2,421
Other non-cash items <sup>1</sup>	26	164	808
Add-back of restructuring costs <sup>2</sup>		362	523
Paid restructuring costs		-338	-288
Interest paid and received <sup>3</sup>	26	-490	-517
Other financial items		-26	-24
Taxes paid		-574	-742
<b>Cash flow before changes in working capital</b>		<b>5,137</b>	<b>5,036</b>
<b>Changes in working capital</b>			
Inventories		-465	46
Operating receivables		-218	-712
Operating liabilities <sup>3</sup>		-504	208
<b>Cash flow from operating activities</b>		<b>3,949</b>	<b>4,577</b>
<b>Investing activities</b>			
Acquisition of operations	27	-1,663	-3,256
Investments in intangible assets and tangible assets	9, 10	-1,314	-1,309
Divestment of non-current assets		17	15
<b>Cash flow from investing activities</b>		<b>-2,960</b>	<b>-4,549</b>

SEK M	Note	2025	2024
<b>Financing activities</b>			
Raising of loans		3,259	7,736
Repayment of loans		-2,259	-5,529
Lease payments		-501	-506
Change in long-term receivables		3	31
Dividend paid		-1,267	-1,227
<b>Cash flow from financing activities</b>		<b>-765</b>	<b>504</b>
<b>Cash flow for the year</b>		<b>224</b>	<b>532</b>
Cash and cash equivalents at the beginning of the year		2,961	2,728
Cash flow for the year		224	532
Translation differences		216	-299
<b>Cash and cash equivalents at year-end</b>	26	<b>3,401</b>	<b>2,961</b>

- 1) Provision for field actions for Cardiosave had an impact of SEK 297 M and negotiations with CGU in Brazil had an impact of SEK 482 M in 2024.  
2) Excluding write-downs on fixed assets.  
3) Non-cash financial items were reclassified to operating liabilities for the 2024 comparative figures.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

→ Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**General information**

Getinge AB (publ), which is the Parent Company of Getinge Group, is a limited liability company with its registered offices in Gothenburg, Sweden. A description of the company's operations is included in the Administration Report on page 33. The consolidated financial statements for the fiscal year ending December 31, 2025 were finalized and approved by the Board on March 25, 2026 and will be presented to the AGM on April 21, 2026 for adoption.

**Accounting policies**

*Consolidation*

The consolidated financial statements for Getinge AB (publ) and its subsidiaries have been prepared in accordance with the International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board (IASB), as endorsed by the EU. This Annual Report has been prepared in accordance with IAS 1 Presentation of Financial Statements and the Swedish Annual Accounts Act. In addition, the Swedish Corporate Reporting Board's recommendation RFR 1 Supplementary Accounting Rules for Groups has been applied. Getinge presents the most material accounting policies in each note to provide a deeper understanding of each accounting area.

The consolidated financial statements include Getinge AB (publ) and its subsidiaries which are the companies (including structured entities) over which the Group exercises a controlling influence. The controlling influence is usually transferred at the acquisition date.

The annual report for the parent company has been prepared in accordance with the Swedish Annual Accounts Act (1995:1554) and RFR2, Accounting for Legal Entities. According to RFR2, the parent company must apply all International Financial Reporting Standards (IFRS Accounting Standards) adopted by the EU, as far as possible within the framework of the Annual Accounts Act.

*Translation to SEK on consolidated of subsidiaries that have a different functional currency to the Group*

The Parent Company's functional currency is Swedish kronor (SEK), which is also the Parent Company's and Group's presentation currency. This means that the financial statements are presented in Swedish kronor (SEK). Getinge applies the current rate method, which means that when the consolidated financial statements are prepared, items in the income statements of foreign subsidiaries are translated to SEK at the average exchange rates for the fiscal year. Items in the balance sheet are translated to SEK using the exchange rates at the end of the reporting period (closing day rate). The exchange-rate fluctuations that arise are recognized as a separate component in other comprehensive income and are accumulated in equity. Getinge applies hedge accounting to external loans raised in order to reduce translation effects in exposed currencies. Exchange rate differences for these external loans are recognized directly in other comprehensive income for the Group.

*Receivables and liabilities in foreign currencies*

Each Group company's functional currency is determined based on the primary economic environment in which the company operates. Transactions in foreign currencies are translated to the functional currency of the financial statements according to the exchange rate on the date of the transaction. Receivables and liabilities in currencies other than the functional currency of the reporting company (foreign currencies) are translated to the functional currency using the closing day rate, and unrealized currency gains and losses are included in profit or loss. Exchange-rate fluctuations on operating assets and liabilities are attributed to operating profit, while exchange-rate fluctuations on financial assets and liabilities are attributed to the Group's net financial items, refer to Note 20 Net interest-bearing debt.

Unless otherwise stated, all amounts are given in millions of Swedish kronor (SEK M). For practical reasons, the figures in this Annual Report have not been rounded off, which is why notes and tables may not total correct amounts.

**Significant estimates and assessments**

In order to prepare the financial statements in accordance with IFRS Accounting Standards, management is required to make assessments and assumptions that affect the recognized amounts of assets and liabilities, revenues, expenses, and other information reported during the period. Assumptions, assessments and estimates are reviewed regularly. In the preparation of the financial statements, management has made its best judgment in estimating certain amounts included in the financial statements, with due consideration given to their materiality. The actual outcome may diverge from these assumptions, assessments and estimates.

Getinge presents the most significant estimates and assessments made in each note to provide a deeper understanding.

The Board of Directors and Getinge Executive Team have deemed that the following areas may have a significant impact on Getinge's earnings and financial position in the year ahead:

- Goodwill and intangible assets with an indefinite useful life and capitalized product development costs (Note 9 Intangible assets).
- Provisions for pensions and similar obligations (Note 21 Provisions for pensions and similar obligations).
- Write-down of inventories (Note 12 Inventories).
- Deferred tax (Note 8 Income taxes).
- Disputes and claims for damages (Note 15 Other provisions and Note 26 Pledged assets and contingent liabilities).

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

- Consolidated financial statements
- Group notes
- Parent company financial statements
- Parent company notes
- Auditor's report

**Other information**

Note 1 Accounting policies cont.

**New accounting policies applied by the Group in 2025**

No standards, amendments or interpretations effective from January 1, 2025 had a material impact on the consolidated financial statements.

**New and amended standards and interpretations that have not yet come into effect**

In 2024, the IASB published the new standard IFRS 18 Presentation and Disclosures in Financial Statements. The standard contains requirements for a revised structure of the financial statements as well as new disclosure requirements. Getinge has evaluated the impact on the Group's reporting and predicts certain changes in the presentation of the balance sheet, income statement and cash flow upon implementation of IFRS 18. The standard was adopted by the EU in February 2026 and comes into effect on 1 January 2027.

No other new or amended accounting standards and interpretations that have been published and become effective in 2026 or later are expected to have a material impact on the Getinge Group's financial statements.

**Alternative performance measures and definitions**

In the Annual Report, alternative performance measures are used to facilitate analyses of the Group's operations, and the primary alternative performance measures that are presented are net debt/equity ratio, adjusted earnings per share, gross profit, EBIT, EBITA, EBITDA with add-back of acquisition and restructuring costs as well as other items affecting comparability. For reconciliations of the alternative performance measures and definitions, see pages 205–207 and 211.

**Welcome to Getinge****Market environment****Strategy****Business areas****The Board's Operating Reports****Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**Accounting policies**

Revenue from sales is primarily recognized in accordance with IFRS 15. This includes sales of products and services and is reported net of discounts and excluding indirect taxes. Revenue from operating and finance leases is included in net sales and recognized in accordance with IFRS 16.

Getinge’s customers operate mainly in the healthcare sector and laboratory industry. Getinge’s performance obligations can be divided into two main categories: goods and services. Goods include medical equipment, spare parts, and consumables such as single-use products and detergents. Services primarily consist of service and maintenance, installation, and licenses and software, but also include sales of extended warranties, training, and revenue from rental operations.

Revenue is recognized when control of a good or service has been transferred to the customer, and the customer can use and benefit from the good or service. Within the Group, revenue is mainly recognized at a point in time.

**Revenue recognition at a point in time**

Revenue from standardized products or equipment is generally recognized at a point in time when delivery or installation has occurred and when collection of the receivable is reasonably assured. Upon delivery, the customer has physical possession of the standardized product or equipment, and Getinge typically has a right to payment.

For software licenses, revenue is recognized when the licenses have been made available to the customer, which usually occurs when the software has been accepted and any required training has been completed.

Service and maintenance may be recognized at a point in time if performed as a standalone assignment or if the contract specifies that work is carried out upon the customer’s request. Sales of spare parts are also included in service assignments, and revenue from these is recognized at a point in time.

**Revenue recognition over time**

Revenue recognized over time mainly relates to service and maintenance agreements that often generate revenue over several years. Other revenue recognized over time includes large project assignments where revenue is recognized progressively, revenue from product rentals, and revenue from sales of software and extended warranties.

Revenue from service agreements is adapted based on the structure of the underlying customer contract. Getinge has ongoing service agreements with an unspecified number of service events performed at various times throughout the year, and revenue is then recognized linearly over the contract period. Getinge also has more specified service agreements, where revenue is recognized at a point in time during the period when the specified service has been provided, see Revenue recognition at a point in time.

Revenue relating to leases is allocated evenly over the lease term. Equipment rented out mainly consists of capital goods used within healthcare.

For larger assignments that meet Getinge’s and regulatory criteria for revenue recognition over time, revenue and expenses are recognized in relation to the degree of completion of the assignment at the balance sheet date. Getinge applies stricter criteria for the use of percentage-of-completion than required by regulation. For example, Getinge requires that a specific project stage has been reached, that the contract price of the performance obligation meets a specific threshold, and that the project must be fully customer-specific and extend over at least three months.

**Future revenue**

Expected future revenue from existing customer contracts where revenue is recognized over time amounts to SEK 2.1 billion for 2026 and SEK 0.6 billion for 2027, primarily attributable to multi-year service agreements within Surgical Workflows. Expected revenue for 2028 and beyond from existing customer contracts is not material for the Group.

**Contract assets and liabilities**

For information regarding Getinge’s accounting policies related to performance obligations not yet invoiced or delivered, refer to Note 14 Contract assets and liabilities.

**Significant estimates and assessments**

The classification of contracts in performance obligations and determining when revenue for a performance obligation is recognized depends on a number of underlying factors in the contract, with Getinge considering, for example, time of delivery, the complexity and customization in the installation phase, delivery terms, how customized the entire product or service is, and how the terms for customer acceptance and option for the customer to terminate the contract are designed.

The degree of completion of an assignment to which percentage of completion is applied is established in a ratio between accrued assignment costs for work completed on the closing date and the calculated total assignment costs, except in those instances this does not correspond to the degree of completion. When the outcome of an assignment cannot be calculated in a reliable manner, only the amount corresponding to the accrued assignment costs that will probably be paid by the client is recognized as revenue. Other accrued assignment costs are recognized as costs in the period in which they occur. If it is probable that the total amount of accrued assignment costs will exceed total revenue from the assignment, the expected loss is promptly recognized as a cost in its entirety.

Net sales, SEK M	2025	2024
<b>Capital goods</b>	<b>11,968</b>	<b>12,421</b>
<b>Recurring revenue</b>		
Product sales	16,185	15,588
Service assignments incl. spare parts	6,815	6,750
<b>Total recurring revenue</b>	<b>23,001</b>	<b>22,338</b>
<b>Total</b>	<b>34,969</b>	<b>34,759</b>

Net sales, SEK M	2025	2024
<b>Revenue recognized at one point in time</b>	<b>30,512</b>	<b>30,791</b>
<b>Revenue recognized over time</b>		
Service	3,198	3,025
Ongoing projects	991	676
Other revenue recognized over time	268	267
<b>Total revenue recognized over time</b>	<b>4,457</b>	<b>3,968</b>
<b>Total</b>	<b>34,969</b>	<b>34,759</b>

The leasing income for 2025 is immaterial for the Group. For further information on leasing and details on the portion of net sales attributable to revenue recognized in accordance with IFRS 16, see Note 11 Leasing.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor’s report

**Other information**

**Accounting policies**

Getinge's reporting of operating segments is in line with the internal reporting to the CEO, the chief operating decision maker. The group's operations are controlled and reported primarily by business area. Each segment is consolidated according to the same policies as for the group in its entirety and the earnings of the segments represent their contribution to the group's earnings. Assets in a segment include all operating assets used by the segment and primarily comprise intangible assets, tangible assets, inventories, external accounts receivable, other receivables and prepaid expenses and accrued income. Liabilities in a segment include all operating liabilities utilized by the segment and primarily comprise provisions excluding interest-bearing pension provisions and similar obligations, deferred tax liabilities, external accounts payable, other current liabilities and accrued expenses and deferred income. Non-distributed assets and liabilities include all tax items and all items of a financial interest-bearing nature.

The segment reporting has been prepared in accordance with the same policies as for the group in its entirety. Getinge's operations throughout the world are organized into three business areas – Acute Care Therapies, Life Science and Surgical Workflows. These business areas form the basis for the group's segment information. Business terms and conditions as well as market-regulated pricing apply for delivery of products and services between group companies. No sales are made between the different business areas. The group has no single customer that accounts for 10% or more of the group's sales.

**The reporting segments are active in the following operations**

**Acute Care Therapies** offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care.

**Life Science** offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.

**Surgical Workflows** offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.

SEK M	Acute Care Therapies		Life Science		Surgical Workflows		Undistributed		Total	
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
<b>Net sales</b>	<b>18,675</b>	<b>17,948</b>	<b>4,498</b>	<b>4,552</b>	<b>11,796</b>	<b>12,258</b>	–	–	<b>34,969</b>	<b>34,759</b>
Operating expenses	-15,654	-15,884	-4,029	-4,026	-11,023	-11,556	-474	-440	-31,180	-31,905
<b>Operating profit (EBIT)</b>	<b>3,021</b>	<b>2,065</b>	<b>470</b>	<b>526</b>	<b>773</b>	<b>703</b>	<b>-474</b>	<b>-440</b>	<b>3,789</b>	<b>2,854</b>
Interest income and other similar income	–	–	–	–	–	–	75	107	75	107
Interest expenses and other similar expenses	–	–	–	–	–	–	-719	-678	-719	-678
<b>Profit after financial items</b>	<b>3,021</b>	<b>2,065</b>	<b>470</b>	<b>526</b>	<b>773</b>	<b>703</b>	<b>-1,118</b>	<b>-1,011</b>	<b>3,145</b>	<b>2,282</b>

Other segment information	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
Acquisition and restructuring costs	-293	-715	-22	-35	-59	-91	-24	-57	-397	-898
Write-down of R&D	-28	–	–	–	-107	–	–	–	-135	–
Increased provision for contingent consideration	-179	–	–	–	–	–	–	–	-179	–
Dissolution of provision for contingent consideration	–	–	55	–	–	–	–	–	55	–
Provision for investigations with CGU in Brazil	–	-289	–	–	–	-193	–	–	–	-482
Provision for field actions for Cardiosave	–	-297	–	–	–	–	–	–	–	-297
Other	–	-18	–	–	–	–	–	–	–	-18
<b>Total</b>	<b>-500</b>	<b>-1 319</b>	<b>33</b>	<b>-35</b>	<b>-166</b>	<b>-284</b>	<b>-24</b>	<b>-57</b>	<b>-656</b>	<b>-1,695</b>

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

Note 3 Segment reporting cont.

SEK M	Acute Care Therapies		Life Science		Surgical Workflows		Undistributed		Total	
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
Assets	35,100	39,769	4,271	5,201	12,907	15,169	4,227	3,779	56,505	63,918
Liabilities	7,803	9,762	1,160	1,636	3,032	3,696	15,016	15,614	27,011	30,708
Investments	925	894	104	105	316	309	–	1	1,345	1,309

SEK M	Net sales		Intangible assets, tangible assets and right-of-use assets	
	2025	2024	2025	2024
EMEA	12,340	12,182	11,174	11,814
<i>of which, Sweden</i>	648	617	2,268	2,308
Americas	15,686	15,516	26,596	32,334
<i>of which, USA</i>	14,157	13,929	26,511	32,234
APAC	6,943	7,061	681	791
<b>Total</b>	<b>34,969</b>	<b>34,759</b>	<b>38,452</b>	<b>44,939</b>

Net sales per business area and region, 2025

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
EMEA	4,854	2,235	5,251	12,340
Americas	9,893	1,660	4,133	15,686
APAC	3,928	603	2,412	6,946
<b>Total</b>	<b>18,675</b>	<b>4,498</b>	<b>11,796</b>	<b>34,969</b>

Net sales per business area and revenue type, 2025

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
Capital goods	4,267	1,872	5,829	11,968
Recurring revenue	14,407	2,626	5,967	23,001
<b>Total</b>	<b>18,675</b>	<b>4,498</b>	<b>11,796</b>	<b>34,969</b>

Net sales per business area and revenue stream, 2025

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
Revenue recognized at one point in time	17,499	3,386	9,626	30,512
Revenue recognized over time	1,176	1,112	2,170	4,457
<b>Total</b>	<b>18,675</b>	<b>4,498</b>	<b>11,796</b>	<b>34,969</b>

Secondary reporting segment

Getinge's operations are secondarily reported by geographic area. The US accounted for 41% (40) of the group's sales and was the only country that accounted for more than 10% of total sales. Refer also to page 202 for a list of the group's 20 largest markets. The geographic areas' consolidation is conducted in accordance with the same policies as for the group in its entirety.

Net sales per business area and region, 2024

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
EMEA	4,742	2,057	5,383	12,182
Americas	9,223	1,937	4,356	15,516
APAC	3,983	559	2,519	7,061
<b>Total</b>	<b>17,948</b>	<b>4,552</b>	<b>12,258</b>	<b>34,759</b>

Net sales per business area and revenue type, 2024

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
Capital goods	4,318	1,970	6,133	12,421
Recurring revenue	13,631	2,582	6,125	22,338
<b>Total</b>	<b>17,948</b>	<b>4,552</b>	<b>12,258</b>	<b>34,759</b>

Net sales per business area and revenue stream, 2024

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
Revenue recognized at one point in time	16,808	3,579	10,403	30,791
Revenue recognized over time	1,140	973	1,855	3,968
<b>Total</b>	<b>17,948</b>	<b>4,552</b>	<b>12,258</b>	<b>34,759</b>

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

**NOTE 4** Costs by cost category

<b>Costs by cost category, SEK M</b>	<b>2025</b>	<b>2024</b>
Goods and services	-15,410	-15,918
Salaries and remuneration	-11,044	-11,113
Social security expenses	-1,614	-1,622
Pension expenses	-483	-495
Amortization and write-downs of intangible assets <sup>1</sup>	-1,077	-1,249
Depreciation and write-downs of tangible assets <sup>2</sup>	-650	-639
Depreciation and write-downs of right-of-use assets	-523	-534
Other operating income	604	672
Other operating expenses	-982	-1,008
<b>Total</b>	<b>-31,180</b>	<b>-31,905</b>

1) 2024 figure includes SEK -278 M phasing out of Surgical Perfusion product portfolio reported as restructuring costs in income statement.  
2) 2024 figure includes SEK -46 M phasing out of Surgical Perfusion product portfolio reported as restructuring costs in income statement.

<b>Amortization, depreciation and write-downs, SEK M</b>	<b>2025</b>	<b>2024</b>
Cost of goods sold	-953	-960
Selling expenses	-705	-625
Administrative expenses	-405	-414
Research and development costs	-175	-99
Restructuring costs	-12	-325
<b>Total</b>	<b>-2,250</b>	<b>-2,421</b>

<b>Other operating income, SEK M</b>	<b>2025</b>	<b>2024</b>
Currency gains	454	518
Capital gains	2	1
Other <sup>1</sup>	148	154
<b>Total</b>	<b>604</b>	<b>672</b>

1) 2025 figure includes SEK 55 M dissolution of provision for contingent consideration.

<b>Other operating expenses, SEK M</b>	<b>2025</b>	<b>2024</b>
Currency losses	-731	-461
Capital losses	-13	-10
Other <sup>1</sup>	-238	-538
<b>Total</b>	<b>-982</b>	<b>-1,008</b>

1) 2025 figure includes SEK 179 M increased provision for contingent consideration. 2024 figure includes provisions related to negotiations with CGU in Brazil amounting to SEK 482 M.

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

**NOTE 5** Auditing

Fee to EY, SEK M	2025	2024
Auditing assignment	-34	-
<i>of which Ernst &amp; Young AB</i>	-19	-
Auditing activities other than auditing assignments	-1	-
<i>of which Ernst &amp; Young AB</i>	-	-
Tax consultancy services	0	-
<i>of which Ernst &amp; Young AB</i>	-	-
Other services	-6	-
<i>of which Ernst &amp; Young AB</i>	-6	-
<b>Total</b>	<b>-41</b>	<b>-</b>

Fee to PwC, SEK M	2025	2024
Auditing assignment	-6	-41
<i>of which Öhrlings PricewaterhouseCoopers AB</i>	-2	-15
Auditing activities other than auditing assignments	0	-1
<i>of which Öhrlings PricewaterhouseCoopers AB</i>	-	-1
Tax consultancy services	-3	-6
<i>of which Öhrlings PricewaterhouseCoopers AB</i>	-	-
Other services	-3	-2
<i>of which Öhrlings PricewaterhouseCoopers AB</i>	-3	-1
<b>Total</b>	<b>-11</b>	<b>-50</b>

<b>Total</b>	<b>-52</b>	<b>-50</b>
--------------	------------	------------

EY has the auditing assignment for the entire Group. Auditing assignments refer to auditing of the financial statements and statutory accounts, review of sustainability statement, and other required legal audit. For information on Getinge's election of external auditor, see the Corporate Governance Report page 56.

Auditing activities other than auditing assignments include review of interim reports as well as services in conjunction with the issuance of certificates and audit certificates. Tax consultancy services primarily pertain to general tax matters concerning corporate tax and internal pricing. Other services mainly pertain to services in connection with acquisitions.

**NOTE 6** Exchange-rate differences in income statement

Recognized in income statement within, SEK M	2025	2024
Other operating income and expenses	-278	57
Financial items	-30	-8
<b>Total</b>	<b>-308</b>	<b>49</b>

**NOTE 7** Financial items

**Accounting policies**

Financial income and expenses include interest income on bank deposits and receivables, interest expenses on loans, income from dividends, unrealized and realized profits and losses on financial investments, exchange rate differences and the change in value of derivative instruments used in financial activities. Borrowing costs in conjunction with the raising of loans are recognized as part of the loan to which they pertain and are charged to profit or loss during the term of the loan.

Interest income and other similar income, SEK M	2025	2024
Interest income	73	68
Exchange rate gains	2	39
Other	0	-
<b>Total</b>	<b>75</b>	<b>107</b>

Interest expense and other similar expenses, SEK M	2025	2024
Interest expenses	-426	-410
Interest expenses on lease liabilities <sup>1</sup>	-63	-66
Interest expenses on pension liabilities <sup>2</sup>	-94	-98
Discounting of contingent considerations <sup>3</sup>	-77	-32
Exchange rate losses	-33	-47
Other	-26	-24
<b>Total</b>	<b>-719</b>	<b>-678</b>

1) See Note 11 Leases  
 2) See Note 21 Provisions for pensions and similar obligations  
 3) See Note 19 Financial instruments

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**Accounting policies**

Getinge's income taxes include taxes on Group companies' profits recognized during the accounting period and tax adjustments attributable to earlier periods and changes in deferred taxes. Measurement of all tax liabilities/receivables is conducted at nominal amounts and in accordance with enacted tax regulations and tax rates or those that have been announced and will almost certainly be adopted in the countries where the group companies operate. Tax is recognized directly in equity if the tax is attributable to items that are recognized directly in equity. Deferred tax is calculated to correspond to the tax effect arising when final tax is determined and corresponds to the net effect of tax on all existing differences between fiscal and carrying amounts of assets and liabilities by applying applicable tax rates. Tax loss carryforwards is recognized as an asset only to the extent that it is probable that these loss carryforwards will be matched by future taxable profits. Deferred tax liabilities pertaining to temporary differences that are attributable to investments in subsidiaries and affiliates are not recognized, since the Parent Company, in each instance, can control the point in time of reversal of the temporary differences and a reversal in the foreseeable future has been deemed improbable.

**Significant estimates and assessments**

**Deferred tax**  
Getinge reports deferred tax assets related to loss carryforwards. The reporting of deferred tax assets is based on assessments of future taxable income in various tax jurisdictions, which includes assumptions about whether costs that have not yet been subject to taxation are deductible. The purpose of these assessments is to ensure that it is likely that the Company's future taxable results will enable the utilization of reported loss carryforwards. Additionally, the offsetting possibilities of tax assets and tax liabilities are considered, as well as the fact that a significant portion of the loss carryforwards are attributable to countries with long or unlimited utilization periods.

The Group's tax expense amounted to SEK -869 M (-628), entailing a tax rate of 27.6% (27.5).

<b>Taxes, SEK M</b>	<b>2025</b>	<b>2024</b>
Current tax	-932	-848
Deferred tax	63	219
<b>Total</b>	<b>-869</b>	<b>-628</b>

<b>The relationship between the year's tax expense and the recognized profit before tax, SEK M</b>	<b>2025</b>	<b>2024</b>
<b>Recognized profit before tax</b>	<b>3,145</b>	<b>2,282</b>
Tax according to current tax rate in Sweden	-648	-470
Adjustment for tax rates in foreign subsidiaries	-134	-140
Adjustment of tax expenses from earlier years	-9	18
Other tax effects <sup>1)</sup>	-78	-36
<b>Recognized tax expense</b>	<b>-869</b>	<b>-628</b>

1) Mainly refers to foreign withholding tax and tax effects of non-deductible costs/non-taxable income.

**Deferred tax assets relate to the following temporary differences and loss carryforwards, SEK M**

	<b>2025</b>	<b>2024</b>
Non-current assets	178	391
Leasing liabilities	368	452
Current assets	545	567
Provisions	345	467
Loss carryforwards	710	442
Other	348	408
Offset	-1,702	-1,957
<b>Deferred tax assets</b>	<b>792</b>	<b>770</b>

**Deferred tax liabilities relate to the following temporary differences, SEK M**

	<b>2025</b>	<b>2024</b>
Non-current assets	2,738	3,219
Right-of use assets	366	450
Current assets	59	72
Other	293	388
Offset	-1,702	-1,957
<b>Deferred tax liabilities</b>	<b>1,754</b>	<b>2,172</b>

**Maturity structure for loss carryforwards, SEK M**

	<b>2025</b>	<b>2024</b>
Due within 1 year	-	-
Due within 2 years	-	-
Due within 3 years	-	-
Due within 4 years	-	4
Due within 5 years	-	-
Due after 5 years	10	17
No due date	2,329	1,305
<b>Total</b>	<b>2,339</b>	<b>1,327</b>

At year-end 2025, there were unrecognized deferred tax assets pertaining to loss carryforwards and unutilized interest deductions amounting to SEK 32 M (74).

**OECD global minimum tax model rules**

The Group is subject to the Global Anti-Base Erosion (GloBE) rules. Legislation on global minimum tax has been adopted in Sweden, where Getinge AB (publ) has its registered offices, and came into effect on January 1, 2024. The Group applies the exception to recognizing and disclosing information about deferred tax assets and liabilities related to OECD pillar two income taxes, as stipulated in IAS 12. As of the balance sheet date, the Group has no significant tax exposure regarding Global Anti-Base Erosion rules.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**Accounting policies**

**Goodwill**

Goodwill comprises the portion of a purchase price for an acquisition that exceeds the market value of the identifiable assets, with deductions for liabilities and contingent liabilities, calculated on the acquisition date, on the share of the acquired company's assets acquired by the Group. In a business acquisition whereby the purchase price is less than the net value of acquired assets, assumed liabilities and contingent liabilities, the difference is recognized directly in profit or loss. Goodwill arising in conjunction with the acquisition of a foreign entity is treated as an asset in the foreign entity and translated at the exchange rate on the closing date.

Goodwill is recognized as an intangible asset with an indefinite useful life. For assets with an indefinite useful life such as goodwill, in addition to indications of impairment, an annual assessment of impairment needs is carried out. Goodwill is allocated and tested at the level of cash-generating units, which are identified as the Getinge Group's business areas. If the carrying amount of the tested cash-generating unit exceeds the estimated recoverable value, the difference is recognised as an impairment in the income statement. In 2025, the recoverable value of the Group's operations exceeded the carrying amount of all cash-generating units, thus no impairment has been recognized.

**Other intangible assets**

Other intangible assets comprise capitalized development costs, customer relations, technical know-how, trademarks, agreements and other assets. Intangible assets are recognized at cost with deductions for accumulated amortization and any impairment losses. Amortization is applied proportionally over the asset's anticipated useful life, which usually varies between three and 15 years.

Acquired intangible assets are recognized separately from goodwill if they fulfill the criteria for qualifying as an asset, implying they can be separated or they are based on contractual or other legal rights and that their market value can be established in a reliable manner. Intangible assets that are recognized separately from goodwill in acquisitions of operations include customer relations, technical know-how, trademarks, agreements, etc.

Acquired intangible assets are measured at market value and amortized on a straight-line basis over their anticipated useful life. The useful life can, in certain cases, be indefinite. These intangible assets are not amortized, instead they are tested for impairment every year or more often if there is an indication that there could have been a decrease in value. Costs for development, whereby research results or other knowledge is applied to produce new products, are recognized as an asset in the balance sheet to the extent that these products are expected to generate future financial benefits. These costs are capitalized when management deems that the product is technically and financially viable, which is usually when a product development project has reached a defined milestone in accordance with an established project model. The capitalized value includes expenses for material, direct expenses for salaries and indirect expenses that can be assigned to the asset in a reasonable and consistent manner. In other cases, development costs are expensed as they arise. Research costs are charged to earnings as they arise. Capitalized expenses are amortized on a straight-line basis from the point in time at which the asset is put into commercial operation and during the asset's estimated useful life. The amortization period is determined based on historical data and taking into consideration future changes in technology. For capitalized development costs, the amortization period is five to 15 years and for software three years.

**Depreciation and impairment of intangible assets with determinable useful life**

At the end of each accounting period, the carrying amount of the assets is assessed to determine whether there is any indication that impairment is required. If there is such an indication, the asset's recoverable amount is established. The recoverable amount is deemed to be the higher of the asset's net realizable value and its value in use, for which the impairment loss is recognized as soon as the carrying amount exceeds the recoverable amount. Earlier recognized impairment losses on intangible assets and tangible assets are reversed if the recoverable amount is deemed to have increased, although the impairment losses are not reversed to an amount greater than what the carrying amount would have been if no impairment losses had been recognized in earlier years. Recognized impairments of goodwill are not reversed.

**Significant estimates and assessments**

**Goodwill and intangible assets with an indefinite useful life**

Each year Getinge evaluates whether there is an impairment of goodwill and other intangible assets with an indefinite useful life. In the impairment testing of goodwill and other intangible assets, estimates are made to determine the recoverable value of cash-generating units. The recoverable value for cash-generating units has been determined by calculating the value in use, which is based on management's estimate of future cash flows and is to varying degrees sensitive to changes in assumptions and external factors. Although management considers estimated future cash flows and other assumptions to be reasonable, there are uncertainties, which can significantly affect valuations.

**Capitalized product development costs**

Costs for product development projects are capitalized to the extent that the costs can be expected to generate financial benefits for the company. Capitalization starts when management assess the product to be technically or financially viable. This means that established criteria must be met before a development project is capitalized as an intangible asset. Capitalization ends and amortization of the capitalized development costs starts when the asset is ready for use. Capitalized development costs are tested for impairment when there are indications of a decline in value. Determining the amortization period and testing for impairment require management to make assessments.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

Note 9 Intangible assets cont.

Intangible assets, SEK M	Goodwill	Trademarks	Capitalized development costs <sup>1,2</sup>	Patents & Agreements	Customer relations	Technical know-how	Intangible assets, other	Total
<b>Acquisition cost, Jan 1, 2025</b>	<b>30,831</b>	<b>1,461</b>	<b>9,879</b>	<b>1,154</b>	<b>5,226</b>	<b>4,615</b>	<b>5,809</b>	<b>58,975</b>
Investments	-	-	643	-	-	-	147	791
Acquisitions	-	-	-	-	-	-	-	-
Sales/disposals	-	-	-96	-20	-	-	-226	-342
Reclassifications	-	-	-	-	-	-	1	1
Translation differences	-4,374	-212	-613	-162	-797	-741	-675	-7,573
<b>Accumulated cost, Dec 31, 2025</b>	<b>26,457</b>	<b>1,249</b>	<b>9,813</b>	<b>973</b>	<b>4,430</b>	<b>3,874</b>	<b>5,057</b>	<b>51,852</b>
<b>Amortization and write-downs, Jan 1, 2025</b>	<b>-743</b>	<b>-687</b>	<b>-6,852</b>	<b>-1,140</b>	<b>-3,551</b>	<b>-1,682</b>	<b>-5,078</b>	<b>-19,734</b>
Amortization for the year	-	-4	-381	-2	-121	-250	-211	-970
Write-downs	-	-	-49	-	-	-	-58	-107
Acquisitions	-	-	-	-	-	-	-	-
Sales/disposals	-	-	96	11	-	-	225	332
Reclassifications	-	-	-	-	-	-	-	-
Translation differences	61	104	373	161	540	280	620	2,139
<b>Accumulated amortization and write-downs, Dec 31, 2025</b>	<b>-682</b>	<b>-587</b>	<b>-6,813</b>	<b>-970</b>	<b>-3,132</b>	<b>-1,652</b>	<b>-4,503</b>	<b>-18,339</b>
<b>Closing carrying amount, Dec 31, 2025</b>	<b>25,775</b>	<b>663</b>	<b>3,000</b>	<b>3</b>	<b>1,297</b>	<b>2,221</b>	<b>554</b>	<b>33,513</b>

1) Research and Development cost, gross, amounted to SEK 2,096 M (2,091) whereof SEK 643 M (660) were capitalized.

2) Write-downs of capitalized development costs amounted to SEK -49 M (-309), whereof SEK -49 M (-278) within Acute Care Therapies, SEK - M (-31) within Life Science and SEK - M (-) within Surgical Workflows.

Intangible assets, SEK M	Goodwill	Trademarks	Capitalized development costs <sup>1,2</sup>	Patents & Agreements	Customer relations	Technical know-how	Intangible assets, other	Total
<b>Acquisition cost, Jan 1, 2024</b>	<b>25,579</b>	<b>1,130</b>	<b>9,131</b>	<b>1,146</b>	<b>4,493</b>	<b>1,623</b>	<b>5,886</b>	<b>48,988</b>
Investments	-	-	660	-	-	-	196	856
Acquisitions	3,104	226	-	-	325	2,690	-	6,345
Sales/disposals	-	-	-217	-79	-	-	-643	-939
Reclassifications	-	-	0	-	-	-	0	0
Translation differences	2,148	105	305	88	408	301	370	3,726
<b>Accumulated cost, Dec 31, 2024</b>	<b>30,831</b>	<b>1,461</b>	<b>9,879</b>	<b>1,154</b>	<b>5,226</b>	<b>4,615</b>	<b>5,809</b>	<b>58,975</b>
<b>Amortization and write-downs, Jan 1, 2024</b>	<b>-710</b>	<b>-627</b>	<b>-6,176</b>	<b>-1,126</b>	<b>-3,146</b>	<b>-1,427</b>	<b>-5,106</b>	<b>-18,318</b>
Amortization for the year	0	-4	-398	-7	-134	-121	-275	-939
Write-downs	-	-	-309	-	-	-	0	-309
Acquisitions	-	-	-	0	-	0	-	0
Sales/disposals	-	-	217	79	-	-	639	935
Reclassifications	-	-	0	-	-	-	-	0
Translation differences	-33	-55	-186	-87	-272	-133	-337	-1,102
<b>Accumulated amortization and write-downs, Dec 31, 2024</b>	<b>-743</b>	<b>-687</b>	<b>-6,852</b>	<b>-1,140</b>	<b>-3,551</b>	<b>-1,682</b>	<b>-5,078</b>	<b>-19,734</b>
<b>Closing carrying amount, Dec 31, 2024</b>	<b>30,088</b>	<b>774</b>	<b>3,027</b>	<b>14</b>	<b>1,675</b>	<b>2,932</b>	<b>731</b>	<b>39,242</b>

1) Research and Development cost, gross, amounted to SEK 2,091 M (1,821) whereof SEK 660 M (629) were capitalized.

2) Write-downs of capitalized development costs amounted to SEK -309 M (-133), whereof SEK -278 M (-133) within Acute Care Therapies mainly attributable to the phase out of Surgical Perfusion, SEK -31 M (-) within Life Science and SEK - M (0) within Surgical Workflows.

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

Note 9 Intangible assets cont.

**Impairment testing**

<b>Goodwill, SEK M</b>	<b>2025</b>	<b>2024</b>
Acute Care Therapies	18,519	21,882
Surgical Workflows	5,461	6,161
Life Science	1,795	2,046
<b>Total</b>	<b>25,775</b>	<b>30,088</b>

Goodwill is distributed among the Group's cash generating units (CGUs), which are identified per business area.

Goodwill and other net assets are tested for impairment annually and whenever conditions indicate that impairment may be necessary. The recoverable amount for CGUs is determined based on the calculated value in use. For impairment testing purposes, this has been done at the lowest level where separable cash flows have been identified, which for Getinge is the same as its business areas.

**Assumptions**

The value in use of goodwill and other net assets attributable to Acute Care Therapies, Surgical Workflows and Life Science was calculated based on discounted cash flows, which are based on assumptions regarding sales growth and the cost trend. Cash flows for the first three years are based on a financial plan approved by the Board. Cash flows after this three-year period have been determined using a growth rate corresponding to 2%. This growth is based on reasonable prudence and does not exceed long-term growth for the industry as a whole. A discount rate before tax of 9.5% (9.5) for Acute Care Therapies and 10.3% (10.2) for Surgical Workflows and Life Science, was applied when calculating the value in use. Right-of-use assets are included in the net assets tested for impairment for each business area and future cash flows referring to lease contracts are taken into account when determining the value in use. With the assumptions described above, value in use exceeds the carrying amount for all CGUs.

**Sensitivity analysis**

In connection with the impairment test, sensitivity analyses have been performed regarding changes in growth rate and discount rate, which have a significant impact on the calculation of the discounted cash flows. The sensitivity analyses showed that the negative changes below would not individually generate a need for impairment in any business area:

- Growth rate after year three decreases to 1%
- Discount rate before tax increases by 1 percentage point to 10.5% and 11.3%

**Intangible assets**

Except goodwill, there are within intangible assets also trademarks amounting to SEK 632 M (739) whose useful life has been assessed as indefinite. For these trademarks, no foreseeable time limit have been applied for Getinge's expected future cash flows. The useful life for other intangible assets is three to 15 years. For strategic acquisitions, the useful life exceeds five years.

**NOTE 10** Tangible assets

Tangible assets, SEK M	Buildings and land <sup>1</sup>	Plant and machinery	Equipment, tools, fixtures, fittings	Rental equipment	Construction in progress	Total
<b>Acquisition cost, Jan 1, 2025</b>	<b>4,141</b>	<b>2,388</b>	<b>3,330</b>	<b>624</b>	<b>488</b>	<b>10,971</b>
Investments <sup>2</sup>	41	53	203	1	257	555
Acquisitions	–	–	-6	–	–	-6
Sales/disposals	-160	-76	-217	-23	-3	-477
Reclassifications	26	95	217	42	-232	148
Translation differences	-429	-241	-302	-52	-56	-1,079
<b>Accumulated cost, Dec 31, 2025</b>	<b>3,620</b>	<b>2,219</b>	<b>3,227</b>	<b>592</b>	<b>454</b>	<b>10,111</b>
<b>Depreciation and write-downs, Jan 1, 2025</b>	<b>-2,295</b>	<b>-1,832</b>	<b>-2,498</b>	<b>-444</b>	<b>–</b>	<b>-7,069</b>
Depreciation for the year	-139	-98	-296	-58	–	-591
Write-downs	-15	-67	23	–	–	-59
Acquisitions	–	–	6	–	–	6
Sales/disposals	136	74	203	18	–	431
Reclassifications	0	-4	1	-1	–	-4
Translation differences	208	179	219	38	–	644
<b>Accumulated depreciation and write-downs, Dec 31, 2025</b>	<b>-2,105</b>	<b>-1,747</b>	<b>-2,343</b>	<b>-447</b>	<b>–</b>	<b>-6,642</b>
<b>Closing carrying amount, Dec 31, 2025</b>	<b>1,515</b>	<b>472</b>	<b>883</b>	<b>144</b>	<b>454</b>	<b>3,469</b>

1) Closing carrying amount for land amounted to SEK 159 M (181).  
2) Investments include commitments that have not yet affected cash flow.

Tangible assets, SEK M	Buildings and land <sup>1</sup>	Plant and machinery	Equipment, tools, fixtures, fittings	Rental equipment	Construction in progress	Total
<b>Acquisition cost, Jan 1, 2024</b>	<b>3,689</b>	<b>2,095</b>	<b>3,212</b>	<b>560</b>	<b>654</b>	<b>10,210</b>
Investments	113	56	84	3	196	453
Acquisitions	1	17	19	–	–	38
Sales/disposals	-22	-61	-254	-65	-10	-411
Reclassifications	139	161	139	101	-391	150
Translation differences	221	119	129	24	38	532
<b>Accumulated cost, Dec 31, 2024</b>	<b>4,141</b>	<b>2,388</b>	<b>3,330</b>	<b>624</b>	<b>488</b>	<b>10,971</b>
<b>Depreciation and write-downs, Jan 1, 2024</b>	<b>-2,033</b>	<b>-1,700</b>	<b>-2,381</b>	<b>-372</b>	<b>–</b>	<b>-6,488</b>
Depreciation for the year	-174	-97	-263	-58	–	-591
Write-downs	0	–	-48	–	–	-48
Acquisitions	0	-3	-12	–	–	-15
Sales/disposals	18	59	244	55	–	376
Reclassifications	0	0	54	-52	–	2
Translation differences	-105	-91	-92	-17	–	-305
<b>Accumulated depreciation and write-downs, Dec 31, 2024</b>	<b>-2,295</b>	<b>-1,832</b>	<b>-2,498</b>	<b>-444</b>	<b>–</b>	<b>-7,069</b>
<b>Closing carrying amount, Dec 31, 2024</b>	<b>1,846</b>	<b>556</b>	<b>832</b>	<b>180</b>	<b>488</b>	<b>3,902</b>

1) Closing carrying amount for land amounted to SEK 181 M (170).

**Accounting policies**

Buildings, machinery, equipment and other tangible assets are recognized at acquisition cost, with deductions for accumulated depreciation and any impairment losses. The acquisition cost includes the purchase price and expenses directly attributable to the asset to bring the asset to the site and in the working condition for its intended use. Examples of directly attributable expenses included in the acquisition cost are delivery and handling costs, installation, legal services and consultancy services. Assets provided to the company in conjunction with the acquisition of new subsidiaries are recognized at market value on the acquisition date. Depreciation is conducted straight line. Land is not depreciated since it is deemed to have an infinite economic life, however, the depreciation of other assets is based on the following anticipated useful lives:

Class of assets	Depreciation, number of years
Land improvements	40–50
Buildings	10–50
Machinery	5–25
Equipment	3–10

Tangible assets comprising parts with different useful lives are treated as separate components of tangible assets. Standard maintenance and repair costs are expensed during the periods in which they arise. More extensive repair and upgrading costs are capitalized and depreciated over the item's remaining anticipated useful life. Capital gains/losses are recognized under other operating income/expenses.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**Accounting policies**

*Getinge as a lessee*

The Group's leases mainly comprise right-of-use assets for premises and vehicles. The leases are recognized as a right-of-use asset with a corresponding lease liability when the leased asset is available for use by the Group. Short-term leases and leases for which the underlying asset is of low value are exempted. Each lease payment should be divided between amortization of the lease liability and a financial cost. The financial cost should be allocated over the lease term, so that each reporting period is charged with an amount corresponding to a fixed interest rate for the liability recognized under each period.

The Groups lease liabilities are recognized at the present value of the Group's fixed lease payments. Purchase options are included if it is reasonably certain that Getinge will exercise the option to acquire the underlying asset. Penalties for terminating the lease are included if the lease term reflects that the lessee will exercise an option to cancel the lease.

The Group's right-of-use assets are recognized at acquisition cost, and include initial present value of the lease liability, adjusted for lease payments made at or before the commencement date and any initial direct expenses. Restoration costs are included in the asset if a corresponding provision for restoration costs exists. The right-of-use asset is depreciated on a straight-line basis over the assets useful life and the lease term, whichever is the shortest.

For leases of premises and vehicles, service components are normally a considerable portion of the contracts and are therefore separated. The service components, if these are distinguishable, are recognized as operating expenses and not included in the right of use asset and the lease liability. If a lease contract includes variable lease payments not dependent on an index or rate, or include a low value asset or has a lease term that is twelve months or less, the lease payments are recognized as operating expenses as they occur.

*Getinge as a lessor*

Leases in which Getinge is the lessor are defined in two categories, operating and finance, depending on the financial significance of the agreement. Operating leases are recognized as tangible assets in the category rental equipment. Revenue from operating leases is recognized evenly over the lease term.

Straight-line depreciation is applied to these assets in accordance with the undertakings and the depreciation amount is adjusted to correspond with the estimated realizable value when the undertaking expires. The estimated impairment requirement is immediately charged to profit or loss. The products' estimated realizable value at the expiration of the undertaking is continuously followed up on an individual basis. Finance leases are recognized as long-term or current receivables. Payments received from finance leases are divided between interest income and depreciation of receivables.

**Significant estimates and assessments**

*Getinge as a lessee*

*Measurement of lease liabilities and right-of-use assets*

When entering a lease contract, judgments related to contract scope, lease term and interest rate to be used when discounting future lease payments are made which affect the measurement of the lease liability and the right-of-use asset. Assessment of contract scope includes judgments whether a leased asset is identified in the contract. When determining the lease term of a contract, judgments are also required. Getinge evaluates all agreements with the exception of vehicles, which are evaluated as a portfolio. The lease term includes the non-cancellable period. If Getinge is reasonably certain to use an option to extend the lease, or not to use an option to terminate the lease in advance, this is also considered. The contracts contain a range of different conditions. Extension and termination options are mainly related to real estate leases. Thus, all relevant facts and circumstances that create an economic incentive to include optional periods are evaluated.

The importance of the underlying asset in the operations and its location, significant leasehold improvements and level of rentals in optional periods compared to market rates are examples of factors included in the assessment. Lease terms are negotiated on an individual basis and are reassessed if an option is exercised. Judgments are also required to determine the interest rate when discounting future lease payments and whether the interest rate implicit in the lease can be readily determined and thereby used, or if Getinge's incremental borrowing rate should be used.

*Getinge as a lessor*

*Measurement of lease liabilities and right-of-use assets*

Income from equipment for rental primarily refers to capital goods utilized within the healthcare sector. The typical contract duration ranges from six months to five years. In the period, there have been no material gains or losses recognized from the sale of assets related to the rental operations. The estimated resale value of the rented products at the conclusion of the commitments is continuously monitored on an individual basis. No significant impairments have been recorded against the reported net value of rented products during the year. For further details regarding rental equipment, please refer to Note 10 Tangible assets. Interest income related to lease agreements classified as financial leases is reported within financial items.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

Note 11 Leases cont.

Right-of-use assets, SEK M	Buildings	Cars & other vehicles	Machinery & equipment	Total
<b>Acquisition cost, Jan 1, 2025</b>	<b>2,253</b>	<b>903</b>	<b>24</b>	<b>3,181</b>
Entered into new leasing contracts	144	221	12	377
End of lease contracts	-357	-171	-7	-534
Reassessment/modifications	75	-	1	76
Translation differences	-222	-103	-1	-326
<b>Accumulated cost, Dec 31, 2025</b>	<b>1,893</b>	<b>851</b>	<b>29</b>	<b>2,773</b>
<b>Depreciation and write-downs, Jan 1, 2025</b>	<b>-984</b>	<b>-386</b>	<b>-15</b>	<b>-1,385</b>
Depreciation for the year	-283	-235	-6	-523
End of lease contracts	295	171	7	473
Translation differences	87	45	1	133
<b>Accumulated depreciation and write-downs, Dec 31, 2025</b>	<b>-884</b>	<b>-405</b>	<b>-14</b>	<b>-1,303</b>
<b>Closing carrying amount, Dec 31, 2025</b>	<b>1,009</b>	<b>446</b>	<b>16</b>	<b>1,470</b>

Right-of-use assets, SEK M	Buildings	Cars & other vehicles	Machinery & equipment	Total
<b>Acquisition cost, Jan 1, 2024</b>	<b>1,930</b>	<b>710</b>	<b>23</b>	<b>2,663</b>
Entered into new leasing contracts	369	359	3	731
End of lease contracts	-213	-206	-4	-423
Reassessment/modifications	77	-	1	78
Translation differences	91	40	1	131
<b>Accumulated cost, Dec 31, 2024</b>	<b>2,253</b>	<b>903</b>	<b>24</b>	<b>3,181</b>
<b>Depreciation and write-downs, Jan 1, 2024</b>	<b>-816</b>	<b>-347</b>	<b>-15</b>	<b>-1,177</b>
Depreciation for the year	-303	-227	-4	-534
End of lease contracts	165	206	4	375
Translation differences	-30	-19	-0	-49
<b>Accumulated depreciation and write-downs, Dec 31, 2024</b>	<b>-984</b>	<b>-386</b>	<b>-15</b>	<b>-1,385</b>
<b>Closing carrying amount, Dec 31, 2024</b>	<b>1,270</b>	<b>517</b>	<b>9</b>	<b>1,795</b>

The leasing period for buildings usually amounts to between three to five years, while for cars and other vehicles it is between three to four years. Leasing payments are discounted with the Group's marginal borrowing rate. The Group's weighted average marginal borrowing rate was 3.4% (3.9).

Recognized cost for lease contracts, SEK M	2025	2024
Depreciation on right-of-use assets	-523	-534
Interest expenses on lease liabilities	-63	-66
Cost related to short-term leases	-3	-2
Cost related to low-value leases	-18	-19
<b>Total</b>	<b>-606</b>	<b>-621</b>

Payments for short-term leasing agreements regarding equipment and vehicles and all leasing agreements of low-value are expensed in the income statement. Short-term leasing agreements are agreements with a leasing period of less than 12 months. Low-value contracts include IT equipment and office equipment.

Leasing liabilities, SEK M	2025	2024
Short-term	452	491
Long-term	1,029	1,309
<b>Total</b>	<b>1,480</b>	<b>1,800</b>

The total cash-outflow for leasing contracts amounted to SEK -598 M (-607). For information about Getinge's leasing liabilities undiscounted cash out-flows, see Note 19 Financial instruments.

Getinge as a lessor

Operating leases, SEK M	2025	2024
Leasing income recognized during the year	67	64
<b>Total</b>	<b>67</b>	<b>64</b>

Maturity analysis of undiscounted operating lease receivables

Due within 1 year	44	49
Due within 2 to 5 years	64	68
Due in more than 5 years	17	31
<b>Total</b>	<b>124</b>	<b>148</b>

Financial leases, SEK M	2025	2024
Financial income recognized during the year	1	1
<b>Total</b>	<b>1</b>	<b>1</b>

Maturity analysis of undiscounted finance lease receivables

Due within 1 year	8	5
Due within 2 to 5 years	22	17
Due in more than 5 years	18	9
<b>Total</b>	<b>48</b>	<b>31</b>

**NOTE 12** Inventories

**Accounting policies**  
 Inventories are measured at the lower of cost and production value, according to the first in/first out (FIFO) principle, and net realizable value. The carrying amount of finished products includes raw materials, direct labor, other direct costs and production-related expenses including depreciation.

**Significant estimates and assessments**  
 Assessment of obsolescence in inventories is conducted on an ongoing basis during the year. The value of inventories is adjusted for the estimated decrease in value for products no longer sold, surplus inventories, items under shipping restrictions, physical damage, lead times for inventories, and handling and sales overheads.

Inventories, SEK M	2025	2024
Raw materials	2,194	2,585
Work in progress	888	879
Finished products	2,936	3,126
<b>Total</b>	<b>6,018</b>	<b>6,590</b>

Of the Group’s inventories, SEK 5,777 M (6,382) is measured at cost and SEK 241 M (208) at net realizable value. The write-downs during the year amounted to SEK 719 M (913) and reversed amounts from prior years amounted to SEK 336 M (221) for the Group. The amounts are included in cost of goods sold in the income statement.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

**Financial statements**

- Consolidated financial statements
- Group notes
- Parent company financial statements
- Parent company notes
- Auditor’s report

**Other information**

**NOTE 13** Accounts receivable

**Accounting policies**  
 Accounts receivable belong to the category of financial assets that are measured at amortized cost since the purpose of the holding is to collect contractual cash flows. They are included in current assets with the exception of items that fall due more than 12 months after the end of the reporting period, which are classified as non-current assets. After the acquisition date, they are recognized at amortized cost using the effective interest method. The Group assesses the future expected credit losses related to assets measured at amortized cost and recognizes a reserve for such credit losses (“loss allowance”) on each reporting date. For accounts receivable, the Group applies the simplified approach for loss allowance, meaning that the reserve will correspond to the expected loss for the full lifetime of the receivable. Expected credit losses on accounts receivable are recognized under the item selling expenses in profit or loss. More information on the measurement of accounts receivable and credit losses can be found in Note 18 Financial risk management.

SEK M	2025	2024
Accounts receivable before provisions	6,030	6,556
Provision for doubtful receivables	-247	-209
<b>Total</b>	<b>5,782</b>	<b>6,348</b>

Accounts receivable, after provision for doubtful receivables, theoretically constitutes maximum exposure for the calculated risk of losses. Accordingly, the carrying amount of accounts receivable represents the fair value. It is the Group’s opinion that there is no significant concentration of accounts receivable to any single client. Letters of credit or the equivalent normally cover sales to countries outside the OECD. Confirmed credit losses in relation to net sales amounted to 0.0% (0.1) for the fiscal year 2025.

The provision for doubtful receivables is based on historical credit losses and taking into consideration current and forward-looking information about customers’ payment capacity.

**Maturity analysis of accounts receivable before provision for doubtful receivables, SEK M**

	2025	2024
Not fallen due	4,647	4,961
Fallen due 1–5 days	180	232
Fallen due 6–30 days	403	415
Fallen due 31–60 days	302	346
Fallen due 61–90 days	109	119
Fallen due, more than 90 days	388	483
<b>Total</b>	<b>6,030</b>	<b>6,556</b>

Note 13 Accounts receivable cont.

<b>Maturity analysis of provision for doubtful receivables, SEK M</b>	<b>2025</b>	<b>2024</b>
Not fallen due	-31	-31
Fallen due 1–5 days	-1	-1
Fallen due 6–30 days	-4	-1
Fallen due 31–60 days	-3	-1
Fallen due 61–90 days	-4	-2
Fallen due, more than 90 days	-205	-172
<b>Total</b>	<b>-247</b>	<b>-209</b>

<b>Recognized amounts, by currency, for the Group's accounts receivables, SEK M</b>	<b>2025</b>	<b>2024</b>
USD	2,063	2,523
EUR	1,966	1,845
JPY	367	384
GBP	236	227
SEK	139	147
CNY	123	136
INR	109	133
CAD	104	125
HKD	84	97
AUD	52	85
Other currencies	786	854
<b>Total</b>	<b>6,030</b>	<b>6,556</b>

<b>Changes in provision for doubtful receivables, SEK M</b>	<b>2025</b>	<b>2024</b>
<b>Opening balance</b>	<b>-209</b>	<b>-218</b>
Acquisitions	0	-2
Provision for expected losses	-85	-33
Receivables written off during the year that cannot be recovered	10	24
Recovered doubtful receivables	14	29
Translation differences	22	-9
<b>Closing balance</b>	<b>-247</b>	<b>-209</b>

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**NOTE 14** Contract assets and liabilities

**Accounting policies**

**Contract assets**

A contract asset represents accrued income in projects where performance conditions are met over time. Performance conditions fulfilled over time may occur in the case of sale of service and installation as well as longer projects. Contract assets are reclassified as accounts receivable when invoicing. If, in a specific project, advance payments have been received from the customer, the payment reduces the value of the contract asset in accordance with IFRS 15. A contract asset can also represent the right to compensation for goods and services supplied that have not yet been invoiced.

**Contract liabilities**

A contract liability is recognized where the Group has received compensation from the customer but has not fulfilled its contractual obligations regarding the delivery of goods and services. At Getinge, contract liabilities typically refer to prepaid revenues for service contracts and advances related to projects. If advances have been obtained for a specific project, this has reduced the value of the contract liability in accordance with IFRS 15. Contract liabilities in the form of deferred income and advances from customers in the beginning of the year are essentially recognized in income during the financial year.

<b>Contract assets, SEK M</b>	<b>2025</b>	<b>2024</b>	<b>2023</b>
Service	117	138	112
Projects	691	741	442
Other	41	48	72
<b>Total</b>	<b>850</b>	<b>926</b>	<b>625</b>

<b>Contract liabilities, SEK M</b>	<b>2025</b>	<b>2024</b>	<b>2023</b>
Advances from customers	1,031	1,243	1,380
Service	831	810	810
Other	242	410	262
<b>Total</b>	<b>2,104</b>	<b>2,464</b>	<b>2,453</b>

**NOTE 15** Other provisions

**Accounting policies**

Provisions are recognized when the Group has a legal or informal obligation as a result of past events and it is probable that payment will be required to fulfill the commitment and if a reliable estimation can be made of the amount to be paid. Restructuring measures, guarantee commitments and similar items are recognized as provisions in the balance sheet. Provisions are reviewed at the end of each accounting period.

**Significant estimates and assessments**

*Disputes and claims for damages*

Provisions for disputes and claims for damages represent management's best estimate of the future cash flow required to settle the obligations. The disputes primarily relate to contractual commitments in contracts with customers and suppliers and damages related to product liability. Management's assessment is that the need for a provision or contingent liability depends on the legal processes in the country in question and the course of the proceedings. Comments from external and internal advisors are taken into consideration, as is experience from similar cases. The results of complicated disputes and claims for damages may nevertheless be difficult to predict and disputes could be both time-consuming and costly (see Note 25 Pledged assets and contingent liabilities). Provision for disputes and claims for damages are included under the item other.

In the year 2024, Getinge made a provision of SEK 482 million related to ongoing investigations into anti-competitive practices in the sale of medical technology during the period 2004–2017, primarily to public hospitals in Brazil. By the end of 2025, negotiations with the federal agency for internal control, transparency, and anti-corruption, Comptroller General of the Union (CGU), are still ongoing.

In addition to CGU's investigation, Getinge has previously informed that settlement agreements were reached with the Brazilian federal prosecutor's office (Ministério Público Federal) in 2018 and the competition authority, Administrative Council for Economic Defense (CADE) in 2019, both related to anti-competitive practices in the sale of medical technology. It cannot be ruled out that any further agreements with authorities may have a material impact on the Company's financial results and position, but it is currently impossible to estimate either the amount or timing. Getinge has zero tolerance for violations of these regulations.

During 2025, Getinge has completed the majority of the previously communicated phase-out of the Surgical Perfusion product portfolio, which has resulted in both provisions for and utilization of restructuring reserves.

Note 15 Other provisions cont.

2025, SEK M	Other provision			Total Other provisions	Restructuring reserves
	Guarantee reserve	Personnel	Other		
<b>Opening balance</b>	<b>686</b>	<b>201</b>	<b>1,161</b>	<b>2,048</b>	<b>196</b>
Provisions	443	43	153	639	404
Used amount	-548	-28	-97	-673	-342
Unutilized funds restored	-25	0	-27	-52	-16
Translation differences	-70	-13	-109	-193	-24
<b>Closing balance</b>	<b>486</b>	<b>202</b>	<b>1,081</b>	<b>1,769</b>	<b>219</b>
<i>Of which:</i>					
Short-term	364	51	933	1,348	216
Long-term	122	151	148	422	3
<b>Closing balance</b>	<b>486</b>	<b>202</b>	<b>1,081</b>	<b>1,769</b>	<b>219</b>

**Expected timing of outflow 2025, SEK M**

Within 1 year				1,348	216
Within 3 years				345	3
Within 5 years				17	-
> 5 years				60	-
<b>Closing balance</b>				<b>1,769</b>	<b>219</b>

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

2024, SEK M	Guarantee reserve	Personnel	Other	Total Other provisions	Restructuring reserves
<b>Opening balance</b>	<b>368</b>	<b>204</b>	<b>769</b>	<b>1,341</b>	<b>103</b>
Provisions	536	50	569	1,155	300
Used amount	-211	-55	-132	-399	-186
Unutilized funds restored	-32	-5	-36	-73	-29
Translation differences	25	7	-9	23	8
<b>Closing balance</b>	<b>686</b>	<b>201</b>	<b>1,161</b>	<b>2,048</b>	<b>196</b>
<i>Of which:</i>					
Short-term				1,537	177
Long-term				510	19
<b>Closing balance</b>				<b>2,048</b>	<b>196</b>

**NOTE 16** Prepaid and accrued items

<b>Prepaid expenses and accrued income, SEK M</b>	<b>2025</b>	<b>2024</b>
Insurance expenses	57	50
Commissions	38	43
IT expenses	160	191
Other	141	171
<b>Total</b>	<b>396</b>	<b>455</b>

<b>Accrued expenses and deferred income, SEK M</b>	<b>2025</b>	<b>2024</b>
Salaries	1,804	1,965
Social security expenses	449	476
Commissions	109	180
Interest expenses	48	49
Consultancy fees	66	69
Office related expenses	12	15
Logistics, warehousing and freight expenses	53	72
Other	463	696
<b>Total</b>	<b>3,005</b>	<b>3,522</b>

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**NOTE 17** Supplementary disclosure to equity

**Accounting policies**

*Dividend*

Decision on dividends are made at the Annual General Meeting, or, when applicable, during an Extraordinary General Meeting. After the decision is made, equity is reduced and the dividend is reported as a liability to shareholders in the balance sheet until payment.

**Share capital**

<b>Class of shares</b>	<b>A</b>	<b>B</b>	<b>Total</b>
Quotient value per share, SEK	0.50	0.50	
<i>Number of shares outstanding:</i>			
December 31, 2024	18,217,200	254,152,373	<b>272,369,573</b>
December 31, 2025	18,217,200	254,152,373	<b>272,369,573</b>
<b>Shares' voting rights in %</b>	<b>41,8</b>	<b>58,2</b>	<b>100,0</b>

In accordance with the Articles of Association, the Company's share capital amounts to not less than SEK 75 M and not more than SEK 300 M. Within these limits, the share capital can be raised or lowered without requiring an amendment to the Articles of Association. The maximum number of shares is 600 million. One Class A share carries ten votes and one Class B share carries one vote. Both classes of shares have the same quotient value, which is SEK 0.50. At December 31, 2025, the Company's share capital totaled SEK 136 M (136).

**Dividend**

On April 29, 2025, shareholders were paid a dividend of SEK 4.60 per share (SEK 1,253 M in total) relating to 2024.

The Board and the CEO propose to the Annual General Meeting that a dividend of SEK 4.75 per share, relating to 2025 (SEK 1,294 M in total), to be paid to shareholders. The proposed record date is April 23, 2026. Euroclear is expected to distribute the dividend to shareholders on April 28, 2026.

Getinge's dividend policy is to pay dividends of 30–50% of net profit to shareholders. The Board's dividend proposal for 2025 is a deviation from the policy and is due to the favorable cash flow generated by the operations.

**Earnings per share**

Earnings per share, before and after dilution, amounted to SEK 8.29 (6.01). The calculation of earnings per share relating to the Parent Company's shareholders is based on the following information:

<b>Earnings (numerator), SEK M</b>	<b>2025</b>	<b>2024</b>
Earnings relating to the Parent Company's shareholders, which form the basis for calculation of earnings per share	2,258	1,638
<b>Number of shares (denominator)</b>	<b>2025</b>	<b>2024</b>
Weighted average number of outstanding ordinary shares for calculation of earnings per share	272,369,573	272,369,573

**Financial risks**

Through its global operations, Getinge is exposed to a number of financial risks in the form of currency risks, interest-rate risks, financing risks, and credit and counterparty risks. Risk management is regulated by the finance policy adopted by the board with an associated Treasury directive decided by the Getinge Executive Team and revised yearly. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the finance function. Getinge's financial activities are centralized to benefit from economies of scale, to ensure good internal control and to facilitate monitoring of risk.

**Currency risks**

Currency risks comprise exchange-rate fluctuations, which have an impact on the Group's earnings and equity. Currency exposure occurs in connection with payments in foreign currency (transaction exposure) and when translating foreign subsidiaries' balance sheets and income statements to the presentation currency Swedish kronor (translation exposure).


**Transaction exposure**

*Policy*

The Group's policy states that in the first instance currency exposure is to be reduced by matching inflows and outflows in foreign currency to achieve a "natural hedge" as far as possible. In addition, Getinge's Treasury Directive stipulates that the President and CEO has the mandate to decide to hedge all of the annual forecasted net flow in a foreign currency and half of the flow for the next 13–24 months. Hedging may take place using currency forwards, currency swaps and currency options.

The Group's payment flows in foreign currencies are mainly generated by export sales, with the largest flows in USD, EUR, CNY and JPY. The market value of financial currency derivative instruments that meet the cash flow hedging requirements amounted to SEK 0 M (0) on December 31, 2025.

**Transaction exposure in selected foreign currencies, 2025**



**Translation exposure**

*Policy*

When translating net assets of foreign subsidiaries into Swedish kronor, a translation difference occurs, which can affect consolidated other comprehensive income.

When translating the results of foreign subsidiaries into Swedish kronor, a translation difference also arises, which affects the Group's earnings when exchange rates fluctuate. Getinge's policy is not to hedge this risk.

Although Getinge does not have the specifically stated goal of hedging translation exposure, the Group's borrowing in foreign currency takes place in currencies that limit translation exposure through what is known as "natural hedging".

**Sensitivity analysis of currency exposure**

At a 5% rate movement in all exposure currencies, the impact of revaluation effects on equity is approximately SEK 1,405 M (1,513). The extent to which operating profit is impacted by exchange-rate fluctuations is detailed in the following table, based on the exchange rates specified. The effect of exchange-rate movements on operating profit below is calculated using volumes and operating profit in foreign currency for 2025.

Currency:	Net volume in 2025, millions (local currency)	Impact in SEK M of 5% rate movement <sup>1</sup>
CNY: 1.31	1,508	+/- 99
EUR: 10.80	-195	+/- 105
JPY: 0.059	10,197	+/- 30
USD: 9.17	383	+/- 176

<sup>1</sup>) Excluding foreign-currency revaluation of operating receivables and payables.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements


Parent company notes

Auditor's report

**Other information**


Note 18 Financial risk management cont.

Net assets per functional currency



SEK M	CNY	EUR	GBP	SEK	USD	Other
2025	726	8,784	671	-6,878	23,581	2,610
2024	1,260	9,012	709	-7,621	26,781	3,069

Interest-bearing debt per functional currency<sup>1</sup>



SEK M	EUR	SEK	USD	Other
2025	-540	-6,140	-2,708	-15
2024	-143	-5,253	-3,483	-48

1) Excludes pension provisions and similar obligations and lease liabilities.

Interest-rate risk

Interest-rate risk refers to the risk that changes in market interest rates affect the Group's net interest.

Policy

How quickly interest-rate changes impact net interest depends primarily on the fixed-interest term of the debt portfolio. To mitigate the effect of potential increases in market rates, the Group's finance policy stipulates defined frameworks for decisions on the distribution of debt at fixed and variable interest rates.

Of the total loan portfolio of SEK 9,403 M, SEK 2,732 M was raised at fixed interest or hedged using interest-rate derivative instruments, and all other loans at variable interest. The market value of financial interest-rate derivative instruments that meet the cash flow hedging requirements amounted to SEK 10 M (15) on December 31, 2025. The average interest expense for the Group's liabilities to credit institutions amounted to approximately 4.2% (5.4). If the average interest rate for currencies represented in the variable rate portion of Group's loan portfolio at the end of the year changed by 1 percentage point, this would affect profits by SEK +/- 67 M on an annual basis.

Capital structure

Policy

Getinge monitors its leverage ratio (net debt in relation to adjusted EBITDA). The finance policy stipulates that the leverage ratio is to be kept within a multiple of 2.5x. However, Getinge's leverage ratio may temporarily exceed this level from time to time in order to finance acquisitions or on the basis of short-term effects. Getinge's ambition is to meet credit ratios equivalent to an "investment grade rating".

Net debt/adjusted EBITDA



The financial position remains solid. The Group's leverage ratio (net debt in relation to adjusted EBITDA) was 1.5 (1.6) on December 31, 2025.

According to the terms of the Group's main credit facilities, the net debt/equity ratio (net debt in relation to equity) must be below a certain level. The terms also state that the net debt/equity ratio is to be reported to the counterparty every quarter. As of 31 December 2025, the portion of outstanding interest-bearing debt subject to prescribed covenants amounted SEK 3,369 M (3,884). At year-end, the net debt-to-equity ratio was well below the agreed covenant level. As of the end of the reporting period, there are no circumstances or facts indicating that the company may encounter difficulties in complying with this covenant at future testing dates.

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

**Financing and liquidity risk**


Financing and liquidity risk refers to the risk that costs increase and financing opportunities become limited when loans are refinanced. It also includes the risk of being unable to meet payment obligations due to insufficient liquidity or difficulties in obtaining funding. Financing risk may arise from disruptions in financial markets, for example through decisions on new regulations or the implementation of recently enacted laws.

**Policy**

To reduce financing risks, the Group strives to diversify its sources of funding and debt maturities according to the Group's finance policy.

Group Treasury is responsible for proactively managing and controlling the liquidity risk and for ensuring sufficient liquidity reserves and that committed back-up facilities are available.

**Maturity profile, interest-bearing debt, SEK M<sup>1</sup>**



1) Excludes pension provisions and similar obligations and lease liabilities. Financial liabilities, excluding derivatives, are measured at amortized cost. The difference between the proceeds received, net of transaction costs, and the nominal amount is amortized over the term of the loan using the effective interest method and recognized in the income statement.

The Group's sources of financing primarily consists of equity, cash flow from operating activities and borrowing. Getinge has several borrowing programs, including both committed bank overdraft facilities and capital market funding programs. These provide a high level of contingency for temporary fluctuations in the Group's short-term liquidity requirements, while also ensuring access to long-term financing. In addition to the capital market programs, Getinge also has a back-up revolving credit facility of EUR 470 M with a syndicate of seven banks. This loan agreement falls due in 2030. In 2025, the Group renewed the existing MTN program from 2012 to issue bonds in the Swedish capital market. At year-end 2025, SEK 6,000 M was outstanding under this program. For short-term financing requirements, a Swedish commercial paper program is available. In addition to these credit facilities, the Group has short-term uncommitted credit lines.

At December 31, 2025, the total granted, unused overdraft facilities were SEK 394 M (468). In addition, there were unused short-term credit facilities of SEK 426 M (441) and committed, unused non-current credit facilities of SEK 6,075 M (5,389), which may be utilized without conditions. Of this amount, SEK 1,000 M refers to a confirmed credit facility taken up during the year, which matures in 2026.

The Group's existing credit facilities are currently deemed to be sufficient. As of December 31, 2025, the Group's borrowings were in line with the requirements under the finance policy pertaining to diversification of lenders.

**Credit and counterparty risks**

The Group's financial transactions give rise to credit risk in relation to its financial counterparties. Financial credit risk, or counterparty risk, represents the risk of loss if counterparties fail to fully meet their obligation.

**Policy**

The management of the Group's financial credit risk is regulated in the finance policy through accepting only creditworthy counterparties and fixed limits, which are monitored continuously.

As of December 31, 2025, the total counterparty exposure in derivative instruments was SEK 29 M (15). The Group has signed standard netting agreements (ISDA) with counterparties for currency transactions and interest-rate swaps. These agreements permit relevant financial assets and liabilities to be offset. Transactions take place within established limits and exposures are continuously monitored.

Commercial credit risks are limited by a diversified customer base with a high credit rating. The Group's customers are found primarily in the public sector, which means that its credit risk is generally very low. The credit risk for Getinge's customers in the private sector is also deemed to be low. When deemed necessary, credit risk is managed using letters of credit or export credit-related guarantees. The provision for doubtful accounts receivable at year-end totaled SEK 247 M (209).

The Group's accounts receivable are presented in Note 13, which shows that the share of past due accounts receivable on December 31, 2025 amounted to SEK 1,382 M in relation to the total volume of accounts receivable, which amounted to SEK 6,030 M. For 42% of past due accounts receivable, payment is past due by a maximum of one month.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**Accounting policies**

*Financial instruments – initial recognition*

Financial assets and financial liabilities are recognized when the Group becomes party to the contractual terms of the instrument. Purchases and sales of financial assets are recognized on the transaction date, which is the date on which the Group undertakes to buy or sell the asset. The Group classified its financial assets and liabilities depending on the purpose for which the financial asset or liability was acquired.

*Financial assets measured at amortized cost*

Assets in this category comprise long-term financial receivables, accounts receivable and other current receivables. They are included in current assets with the exception of items that fall due more than 12 months after the end of the reporting period, which are classified as non-current assets.

*Impairment of financial assets measured at amortized cost*

The Group assesses the future expected credit losses related to assets measured at amortized cost and recognizes a reserve for such credit losses (“loss allowance”) on each reporting date. For accounts receivable, the Group applies the simplified approach for loss allowance, meaning that the reserve will correspond to the expected loss for the full lifetime of the receivable. Expected credit losses on accounts receivable are recognized under the item selling expenses in profit or loss.

*Financial liabilities measured at amortized cost*

The Group’s other financial liabilities are initially measured at fair value, net after transaction costs. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Long-term liabilities have an expected term longer than one year while current liabilities have a term of less than 12 months. This category includes liabilities to credit institutions, issued bonds, accounts payable and other current liabilities.

*Cash and cash equivalents*

The major portion of cash and cash equivalents comprises cash funds held at financial institutions, and only a minor portion comprises current liquid investments with a term from the acquisition date of less than three months, which are exposed to only an insignificant risk of value fluctuations. Cash and cash equivalents are recognized at nominal amounts, which are equivalent to fair value.

*Financial assets measured at fair value*

Financial assets in this category comprise derivatives. All derivatives are measured at fair value in the balance sheet. Changes in fair value are recognized as a component of other comprehensive income insofar as they are part of a hedging relationship that qualifies as hedge accounting. They are reversed to profit or loss when the hedged transaction occurs. Derivatives that do not meet the requirements for hedge accounting are measured at fair value through profit or loss.

*Hedge accounting*

For derivative instruments or other financial instruments that meet hedge accounting requirements under the cash flow hedging method or hedging of net investments in foreign operations method, the effective component of the value change is recognized in other comprehensive income. Accumulated value changes from cash flow hedges are reversed from equity to profit or loss at the same time as the hedged item impacts profit or loss. Interest-bearing liabilities in foreign currencies are defined as hedges to handle translation exposure related to net investments in foreign operations. Accumulated value changes from the hedging of net investments in foreign operations are reversed from equity to profit or loss when the foreign operation is divested in full or in part.

*Fair value*

*Derivative instruments*

All derivatives are classified under level 2 of the value hierarchy. Fair value measurements for currency forwards are based on published forward rates in an active market. The fair value of derivative instruments was calculated using the most reliable market prices available. This requires all instruments that are traded in an effective market, such as currency forward contracts, to be measured at market-to-market at current prices. In terms of instruments for which no reliable prices were available, such as interest-rate swaps, cash flows were discounted using deposit and interest-rate swaps for the currency in question. The measurement of interest-rate swaps is based on forward rates as expressed in market yield curves. Translation to Swedish kronor is conducted at the closing day rate.

*Borrowing and other financial instruments*

Loans raised are measured at amortized cost using the effective interest method. For other financial assets and liabilities, fair value is assessed as corresponding to the carrying amount due to the short expected maturity in time.

*Contingent considerations*

Contingent considerations are measured at fair value at Level 3 of the fair value hierarchy. The liabilities for these additional purchase prices are measured at fair value through profit or loss. The future cash flows are discounted if the planned disbursement date exceeds 12 months. Assessments about future cash flows linked to the contingent considerations are regularly reviewed by company management. The discount effect is recognized on an ongoing basis in profit or loss under financial items.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor’s report

**Other information**

**Financial derivatives**

Getinge uses financial derivatives to manage interest and currency exposure arising in its business. The effectiveness of a hedge is assessed when the hedging relationship is entered into. The hedged item and the hedging instrument are continuously assessed to ensure that the relationship meets the hedge accounting requirements. When the Group hedges purchases and sales in foreign currency, a hedging relationship is entered into whereby the critical terms of the hedging instrument match the terms of the hedged item. In this way, a qualitative assessment of the effectiveness of the hedging relationship is performed and the relationship is expected to be effective for the period for which it is valid.

The Group also enters into interest-rate swap agreements that have the same critical terms as the hedged item. Critical terms may be benchmark interest rates, reset dates, currency, maturities and nominal amount. The Group does not hedge 100% of the principal and thus identifies only a portion of the principal outstanding that corresponds to the nominal amount of the swap. The Group applies hedge accounting.

**Contingent considerations**

Getinge signed agreements on contingent considerations in connection with acquisitions of business and subsidiaries. In most cases, the additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the earnings performance of the acquired businesses.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

Contingent considerations, SEK M	2025	2024
<b>Opening balance</b>	<b>3,280</b>	<b>498</b>
Business combinations	–	3,112
Dissolution of provision	-55	-13
Fair value adjustments recognized in profit or loss	184	11
Payments	-1,599	-512
Discount effect	77	32
Translation differences	-443	152
<b>Closing balance</b>	<b>1,444</b>	<b>3,280</b>
<i>Of which:</i>		
Short-term	1,109	1,523
Long-term	335	1,756
<b>Closing balance</b>	<b>1,444</b>	<b>3,280</b>

Contingent considerations are included in other liabilities in the balance sheet.

Regarding the acquisition of Aseptic Solutions LLC, a maximum of approximately SEK 1,507 M (USD 137 M) may be paid in 2025–2030 if contracted results-based milestones are achieved in 2025–2029, and in relation to this, a liability of SEK 396 M (USD 36 M) was recognized in the balance sheet. Based on updated assessments, SEK 55 M of the recognized liability was dissolved in 2025.

Concerning the acquisition of Paragonix Technologies, Inc., completed in 2024, contingent considerations amounting to SEK 1,555 M was paid during 2025 in respect of realized performance-related and regulatory milestones. The company exceeded the performance-related milestones that were reported at the time of the acquisition in 2025, and an additional non-interest-bearing liability of SEK 179 M was recognized in 2025. The revaluation of liabilities relating to contingent considerations has been reported as other operating income and expenses.

The final contingent consideration of SEK 44 M pertaining to the acquisition of Irasun GmbH in 2022 was paid in 2025.

**Cash flow for financial liabilities and derivative instruments**

The table below shows the Group's financial liabilities distributed over the remaining maturity.

The amounts shown in the table are the contractual, undiscounted cash flows.

At December 31, 2025, SEK M	< 1 year	1-2 years	2-5 years	> 5 years
Bank loans and bond loans (including interest)	-1,848	-2,162	-6,340	-
Currency derivatives				
<i>of which outflow</i>	-2,099	-	-	-
<i>of which inflow</i>	2,114	-	-	-
Interest-rate derivatives	-0	2	9	-
Contingent considerations	-1,143	-44	-	-333
Leasing liabilities	-525	-395	-467	-384
Accounts payable	-2,118	-	-	-
<b>Total</b>	<b>-5,619</b>	<b>-2,599</b>	<b>-6,799</b>	<b>-717</b>

**Outstanding derivative instruments**

SEK M	2025		2024	
	Nominal amount	Fair value	Nominal amount	Fair value
Interest-rate derivatives	750	10	750	15
Currency derivatives	2,723	18	2,408	-11
<b>Total</b>	<b>3,473</b>	<b>27</b>	<b>3,158</b>	<b>4</b>

SEK M	2025		2024	
	Asset	Liability	Asset	Liability
Interest-rate derivatives	10	-	15	-
Currency derivatives	22	4	3	13
<b>Total</b>	<b>32</b>	<b>4</b>	<b>17</b>	<b>13</b>
<i>Of which:</i>				
Short-term	22	4	3	13
Long-term	10	-	15	-

Paid and accrued interest on interest-rate derivatives is continuously recognized in profit or loss.

The fair value of derivative instruments is established using valuation techniques based on observable market information.

**Financial instruments by category**

Financial assets, SEK M	Assets at amortized cost		Assets at fair value through profit or loss		Derivatives used for hedging purposes		Total	
	2025	2024	2025	2024	2025	2024	2025	2024
Derivative instruments	-	-	22	3	10	15	32	17
Accounts receivable, financial receivables and other receivables	6,530	7,186	-	-	-	-	6,530	7,186
Cash and cash equivalents	3,401	2,961	-	-	-	-	3,401	2,961
<b>Total</b>	<b>9,931</b>	<b>10,147</b>	<b>22</b>	<b>3</b>	<b>10</b>	<b>15</b>	<b>9,962</b>	<b>10,165</b>

Financial liabilities, SEK M	Liabilities at amortized cost		Liabilities at fair value through profit or loss		Derivatives used for hedging purposes		Total	
	2025	2024	2025	2024	2025	2024	2025	2024
Borrowing	9,403	8,927	-	-	-	-	9,403	8,927
Derivative instruments	-	-	4	13	-	-	4	13
Leasing liabilities	1,480	1,800	-	-	-	-	1,480	1,800
Contingent considerations	-	-	1,444	3,280	-	-	1,444	3,280
Accounts payable and other financial liabilities	2,689	3,055	-	-	-	-	2,689	3,055
<b>Total</b>	<b>13,572</b>	<b>13,783</b>	<b>1,448</b>	<b>3,293</b>	<b>-</b>	<b>-</b>	<b>15,020</b>	<b>17,076</b>

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

The tables refer to net flows.

**Distribution of currency for outstanding derivative instruments in nominal amounts, SEK M**

	2025	2024
CHF	52	–
CNY	–	301
CZK	20	–
DKK	–	58
EUR	1,131	1,190
GBP	72	69
HKD	11	–
JPY	71	0
NOK	–	20
PLN	38	–
SEK	750	750
SGD	11	41
TRY	–	0
USD	1,308	728
ZAR	10	–
<b>Total</b>	<b>3,473</b>	<b>3,158</b>

**Maturity structure for outstanding derivative instruments in 2025, SEK M**

	2026	2027	2028	2029	2030	Total
Interest-rate derivatives	–	–	–	750	–	750
Currency derivatives	2,723	–	–	–	–	2,723
<b>Total</b>	<b>2,723</b>	<b>–</b>	<b>–</b>	<b>750</b>	<b>–</b>	<b>3,473</b>

**Maturity structure for outstanding derivative instruments in 2024, SEK M**

	2025	2026	2027	2028	2029	Total
Interest-rate derivatives	–	–	–	–	750	750
Currency derivatives	2,408	–	–	–	–	2,408
<b>Total</b>	<b>2,408</b>	<b>–</b>	<b>–</b>	<b>–</b>	<b>750</b>	<b>3,158</b>

**Reserve of cash flow hedges**

The table below shows the composition of the Group's reserve of cash flow hedges and the change in each component during the year.

	Currency derivatives	Interest-rate derivatives	Total
<b>Opening balance 2024</b>	<b>3</b>	<b>–</b>	<b>3</b>
Change in fair value of hedging instruments recognized in other comprehensive income	–	15	<b>15</b>
Reclassification to profit or loss	-3	0	<b>-3</b>
Deferred tax	1	-3	<b>-2</b>
<b>Closing balance 2024</b>	<b>0</b>	<b>12</b>	<b>12</b>
<b>Opening balance 2025</b>	<b>–</b>	<b>12</b>	<b>12</b>
Change in fair value of hedging instruments recognized in other comprehensive income	–	-5	<b>-5</b>
Reclassification to profit or loss	–	–	<b>–</b>
Deferred tax	–	1	<b>1</b>
<b>Closing balance 2025</b>	<b>–</b>	<b>8</b>	<b>8</b>

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**Derivative instruments – currency derivatives**

Currency derivatives, in the three largest currency pairs, impact the Group's financial position and earnings as follows:

<b>Derivative instruments – currency derivatives USD/EUR, SEK M</b>	<b>2025</b>	<b>2024</b>
Recognized amount (asset/liability(-))	1	-
Nominal amount USD M	100	-
Maturity	Jan 2026	-
Hedge ratio	1:1	-
Change in discounted forward rates for outstanding hedging instruments since January 1	1	-
Change in value of hedged item to determine effectiveness	-1	-
Weighted average of forward rates at year-end (including forward points)	0.85	-

<b>Derivative instruments – currency derivatives EUR/SEK, SEK M</b>	<b>2025</b>	<b>2024</b>
Recognized amount (asset/liability(-))	3	-1
Nominal amount EUR M	16	104
Maturity	Jan 2026–Oct 2026	Jan 2025–Apr 2025
Hedge ratio	1:1	1:1
Change in discounted forward rates for outstanding hedging instruments since January 1	3	-1
Change in value of hedged item to determine effectiveness	-3	1
Weighted average of forward rates at year-end (including forward points)	10.99	11.48

<b>Derivative instruments – currency derivatives USD/SEK, SEK M</b>	<b>2025</b>	<b>2024</b>
Recognized amount (asset/liability(-))	12	-9
Nominal amount USD M	43	66
Maturity	Jan 2026–Apr 2026	Jan 2025–Apr 2025
Hedge ratio	1:1	1:1
Change in discounted forward rates for outstanding hedging instruments since January 1	12	-9
Change in value of hedged item to determine effectiveness	-12	9
Weighted average of forward rates at year-end (including forward points)	9.42	10.81

**Derivative instruments – interest-rate derivatives**

Interest-rate derivatives impact the Group's financial position and earnings as follows:

<b>SEK M</b>	<b>2025</b>	<b>2024</b>
Recognized amount (asset/liability(-))	10	15
Nominal amount	750	750
Maturity	Sep 2029	Sep 2029
Hedge ratio	1:1	1:1
Change in value of outstanding derivative instruments since January 1	-5	15
Change in value of hedged item to determine effectiveness	5	-15
Weighted average interest rate for outstanding interest-rate derivatives at year-end	2.00 %	2.00 %

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

SEK M	2025	Change	2024
Interest-bearing current liabilities	1,510	-446	1,956
Interest-bearing long-term liabilities	7,893	922	6,971
Provisions for pensions and similar obligations, interest-bearing	2,358	-343	2,700
Leasing liabilities	1,480	-320	1,800
Less cash and cash equivalents	-3,401	-440	-2,961
<b>Total</b>	<b>9,840</b>	<b>-627</b>	<b>10,467</b>

Net interest-bearing debt 2025, SEK M	Cash and cash equivalents	Leasing liabilities	Interest-bearing liabilities	Pension provision, interest-bearing	Total
<b>Opening balance</b>	<b>-2,961</b>	<b>1,800</b>	<b>8,927</b>	<b>2,700</b>	<b>10,467</b>
<b>Cash flow affecting net debt</b>					
- Raising of loans	-	-	3,259	-	3,259
- Amortization	-	-501	-2,207	-53	-2,761
- Changes in cash	-224	-	-	-	-223
<b>Non cash flow changes</b>					
- Changes in lease agreements	-	377	-	-	377
- Actuarial gains/losses pension plans	-	-	-	-165	-165
- Translation differences	-216	-196	-577	-125	-1,114
<b>Closing balance</b>	<b>-3,401</b>	<b>1,480</b>	<b>9,403</b>	<b>2,358</b>	<b>9,840</b>

Net interest-bearing debt 2024, SEK M	Cash and cash equivalents	Leasing liabilities	Interest-bearing liabilities	Pension provision, interest-bearing	Total
<b>Opening balance</b>	<b>-2,728</b>	<b>1,479</b>	<b>6,597</b>	<b>2,664</b>	<b>8,012</b>
<b>Cash flow affecting net debt</b>					
- Raising of loans	-	-	7,736	-	7,736
- Amortization	-	-506	-5,513	-16	-6,035
- Changes in cash	-532	-	-	-	-532
<b>Non cash flow changes</b>					
- Changes in lease agreements	-	745	-	-	745
- Actuarial gains/losses pension plans	-	-	-	-31	-31
- Translation differences	299	83	107	83	572
<b>Closing balance</b>	<b>-2,961</b>	<b>1,800</b>	<b>8,927</b>	<b>2,700</b>	<b>10,467</b>

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

**Accounting policies**

Getinge has both defined-contribution and defined-benefit pension plans, of which some have assets in special funds or similar securities. The plans are usually financed by payments from the respective Group companies and the employees. The Group's Swedish companies are generally covered by the ITP plan, which does not require any payments from employees.

*Defined-contribution plans*

Defined-contribution plans are plans in which Getinge pays fixed fees to an independent legal entity and does not have any legal or informal obligation to pay additional fees. The Group's payments for defined-contribution plans are recognized as expenses during the period in which the employees perform the services that the fee covers.

*Defined-benefit plans*

Some post-employment benefits are fulfilled through so-called defined-benefit plans where the obligations remain within Getinge and are primarily secured by own foundations or similar. Getinge's largest defined-benefit plans are found in subsidiaries in Sweden, Germany and the US. Pension expenses for defined-benefit plans are calculated annually by independent actuaries using the so-called Projected Unit Credit Method, which allocates the expenses over the employees working life. These commitments are measured at the present value of expected future payments, with consideration given to calculated future salary increases, and utilizing a discount rate corresponding to the interest rate of first-class company or government bonds with a remaining term that is almost equivalent to the actual commitments. For the significant pension plans, an assessment is also made quarterly, and if significant assumptions have changed, a revaluation is carried out. The Group's net liabilities for each defined-benefit plan are recognized in the balance sheet and comprises the present value of the obligation less the fair value of the plan assets. If the value of the plan assets exceeds the value of the obligation, a surplus arises, which is recognized as an asset. The recognized asset value is limited to the present value of future repayments from the plan, or reductions in future contributions to the plan. Actuarial gains and losses are recognized in other comprehensive income for the period in which they are incurred.

Costs for defined-benefit pension plans in profit or loss comprise the total costs for service during the current and earlier years and interest on commitments. Costs for service during the current period and previous periods are recognized as employee costs. The interest component of pension expenses is recognized under financial expenses.

**Significant estimates and assessments**

*Pension commitments*

Recognition of the costs of defined-benefit pensions and other applicable retirement benefits is based on actuarial valuations, relying on key assumptions for discount rates, future salary increases and expected inflation. The actuarial assumptions constitute the Company's best assessment of the different variables that determine the costs of providing the benefits. Special assumptions and actuarial calculations are made for each defined-benefit plan. In turn, the discount rate assumptions are based on rates for high-quality fixed-interest investments with durations similar to the pension plans. In Sweden the pension commitments were calculated at a discount rate based on the return on the market rate of Swedish mortgage bonds. These bonds are deemed to be of high quality since they are guaranteed by assets and the mortgage bond market in Sweden is considered to be deep and liquid. In Germany and the US, the discount rate is based on high-quality corporate bonds with a term corresponding to the average remaining term of the commitment.

**Defined-contribution plans**

In several countries, the Group's employees are covered by defined-contribution pension plans. The pension plans are primarily retirement pensions. The premiums are paid continuously throughout the year by each Group company to independent legal entities, such as insurance companies. The size of the premium paid by the employees and Group companies is normally based on a set proportion of the employee's salary and in certain cases the employees pay for a portion of the premiums themselves. The expense for defined-contribution plans amounted to SEK 447 M (455) during 2025.

**Defined-benefit plans**

Getinge has large defined-benefit pension plans mainly in Sweden, Germany and the US. The pension plans primarily comprise retirement pensions. Each employer normally has an obligation to pay a lifelong pension. The pension is earned according to the number of employment years and the employee must be affiliated with the plan for a certain number of years to achieve full retirement pension entitlement.

**Sweden**

Most of the Group's defined-benefit pension commitments in Sweden are so called PRI liabilities. These plans are closed for new employees but remain open for the employees encompassed by the plans. The commitments pertain to lifelong retirement pensions and the benefits are primarily based on the employees' final salary. The average term of the commitments is 14 years.

At year-end, the amount of the Group's defined-benefit pension commitments in Sweden totaled SEK 478 M (511). The Swedish pension commitments decreased year-on-year, mainly due to a higher discount rate. Plan assets exist only to a minor extent and are attributable to a small plan that is not credit insured.

The commitment for retirement pensions and family pensions for salaried employees in Sweden is safeguarded through insurance with Alecta. According to a statement from the Swedish Corporate Reporting Board, UFR 10, this is a multi-employer defined-benefit plan. For the 2025 fiscal year, the

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

Note 21 Provisions for pensions and similar obligations cont.

Company did not have access to such information that makes it possible to recognize this plan as a defined-benefit plan. The pension scheme in accordance with ITP, which is safeguarded through insurance with Alecta, is thus recognized as a defined-contribution scheme. During the year, fees for pension insurance covered by Alecta amounted to SEK 42 M (39). Alecta's surplus can be distributed to the insurers and/or the insured. At year-end 2025, Alecta's surplus in the form of the collective consolidation level was approximately 167% (162). The collective consolidation level comprises the market value of Alecta's assets as a percentage of the insurance commitment calculated in accordance with Alecta's actuarial calculation assumption, which does not correspond with IAS 19.

**Germany**

Some employees in Germany are part of defined-benefit pension plans. These plans are closed for new employees but remain open for the employees encompassed by the plan. The benefits are based on the

employees' final salary and the remaining weighted average term of the total commitment is 12 years. The pension plans are insured in accordance with statutory requirements.

Total defined-benefit pension commitments decreased to SEK 1,769 M (2,011) during the year. The decrease was mainly due to higher discount rate assumptions.

**USA**

The Group's defined-benefit pension commitment in the US is closed for new employees and also to the employees encompassed by the plan, meaning that no new pension rights are vested. The commitment's remaining average term is 10 years.

The total defined-benefit commitment decreased to SEK 912 M (1,081), mainly due to currency rate change.

The value of the plan assets decreased to SEK 836 M (915), mainly due to currency rate change.

Pension and similar commitments, SEK M	2025			2024		
	Present value of commitments	Fair value of plan assets	Net provision in the balance sheet	Present value of commitments	Fair value of plan assets	Net provision in the balance sheet
<b>Opening balance</b>	<b>-3,749</b>	<b>962</b>	<b>-2,787</b>	<b>-3,663</b>	<b>879</b>	<b>-2,784</b>
Costs for service in the current year <sup>1</sup>	-34	–	-34	-37	–	-37
(Interest expenses)/interest income <sup>2</sup>	-140	46	-94	-142	43	-98
Past service costs <sup>1</sup>	-3	–	-3	-3	–	-3
Remeasurements <sup>3</sup> :						
– Return on plan assets	–	38	38	–	-29	-29
– Gains/(losses) attributable to changed demographic assumptions	0	–	0	0	–	0
– Gains/(losses) attributable to changed financial assumptions	110	–	110	89	–	89
– Experience-based gains/(losses)	10	–	10	-42	–	-42
– Special employer's contribution on actuarial assumptions	8	–	8	15	–	15
– Restriction in plan surpluses with regard to asset ceilings	–	-1	-1	–	-1	-1
Translation differences	307	-159	148	-162	80	-81
Contributions paid by employer	0	56	56	-1	60	59
Paid benefits	196	-64	132	204	-70	134
Other changes	-1	–	-1	-7	–	-7
<b>Closing balance</b>	<b>-3,295</b>	<b>878</b>	<b>-2,417</b>	<b>-3,749</b>	<b>962</b>	<b>-2,787</b>
<i>Of which:</i>						
Interest-bearing pension commitments	-3,236	878	-2,358	-3,663	962	-2,700
Non-interest-bearing pension commitments	-60	–	-60	-86	–	-86
<i>Of which:</i>						
Funded pension plans	-927	878	-49	-1,089	962	-127
Unfunded pension plans	-2,368	–	-2,368	-2,660	–	-2,660

1) Costs for service during the current period and previous periods are recognized as employee costs.

2) The interest component of pension expenses is recognized under financial expenses.

3) Actuarial gains and losses are recognized in other comprehensive income for the period in which they are incurred.

Note 21 Provisions for pensions and similar obligations cont.

The defined-benefit pension commitment and composition of plan assets 2025, SEK M	Present value of commitments	Fair value of plan assets	Net provision in the balance sheet
Sweden	-478	23	-455
Germany	-1,769	13	-1,756
USA	-912	836	-76
Other countries	-137	6	-130
<b>Total</b>	<b>-3,295</b>	<b>878</b>	<b>-2,417</b>

The defined-benefit pension commitment and composition of plan assets 2024, SEK M	Present value of commitments	Fair value of plan assets	Net provision in the balance sheet
Sweden	-511	26	-485
Germany	-2,011	15	-1,996
USA	-1,081	915	-166
Other countries	-146	6	-140
<b>Total</b>	<b>-3,749</b>	<b>962</b>	<b>-2,787</b>

Significant actuarial assumptions 2025, %	Sweden	Germany	USA
<i>Weighted average, %</i>			
Discount rate	3.9	4.1	5.1
Expected salary increase rate	2.0	2.5	–
Expected inflation	2.0	2.2	–

Significant actuarial assumptions 2024, %	Sweden	Germany	USA
<i>Weighted average, %</i>			
Discount rate	3.8	3.5	5.4
Expected salary increase rate	2.0	2.5	–
Expected inflation	2.0	2.2	–

Sensitivity of defined-benefit commitments to changes in the significant assumptions 2025, SEK M	Change in assumption	Effect on commitment
Discount rate	+1 percentage point	337
	-1 percentage point	-411
Inflation	+1 percentage point	-259
	-1 percentage point	220
Salary increases	+1 percentage point	-43
	-1 percentage point	31

The sensitivity analyses above covers the significant pension plans in Sweden, Germany and the US and are based on a change in an assumption, while all other assumptions remain constant. It is unlikely that this will happen in practice, and changes in some of the assumptions may correlate. The calculation of sensitivity in the defined-benefit commitments for material actuarial assumptions uses the same method as that used in the calculation of pension liabilities.

Composition of plan assets, SEK M	2025	2024
Equities	106	157
Debt instruments	715	734
Properties	9	13
Cash and cash equivalents and similar assets	16	14
Other	33	44
<b>Total</b>	<b>878</b>	<b>962</b>

The weighted average term of the significant plans' pension commitments amounts to 11 years (13). For the 2026 fiscal year, the expenses for defined-benefit plans are expected to amount to SEK 125 M.

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

SEK M	2025			2024		
	Board and CEO <sup>1</sup>	Other	Total	Board and CEO <sup>1</sup>	Other	Total
Salaries and remuneration	-234	-10,810	-11,044	-253	-10,861	-11,113
Social security expenses	-42	-1,573	-1,614	-40	-1,582	-1,622
Pension expenses	-22	-461	-483	-20	-474	-495
<b>Total</b>	<b>-297</b>	<b>-12,844</b>	<b>-13,141</b>	<b>-313</b>	<b>-12,917</b>	<b>-13,230</b>

1) Refers to the entire Getinge Group.

**Remuneration and other benefits to Senior Executives in 2025**

SEK 000s	Fixed remuneration			Variable remuneration		Pension expenses	Total
	Board fee <sup>2</sup>	Fixed salary <sup>3</sup>	Other benefits <sup>4</sup>	Short-term variable remuneration <sup>5</sup>	Long-term variable remuneration <sup>6</sup>		
Chairman of the Board	-1,879	–	–	–	–	–	-1,879
Board members	-6,719	–	–	–	–	–	-6,719
Mattias Perjos, President & CEO	–	-28,436	-456	-18,761	–	-11,176	-58,829
Other Senior Executives <sup>1</sup>	–	-40,992	-2,802	-27,022	–	-6,547	-77,363
<b>Total</b>	<b>-8,598</b>	<b>-69,428</b>	<b>-3,258</b>	<b>-45,783</b>	<b>–</b>	<b>-17,723</b>	<b>-144,790</b>

**Remuneration and other benefits to Senior Executives in 2024**

SEK 000s	Fixed remuneration			Variable remuneration		Pension expenses	Total
	Board fee <sup>2</sup>	Fixed salary <sup>3</sup>	Other benefits <sup>4</sup>	Short-term variable remuneration	Long-term variable remuneration <sup>6</sup>		
Chairman of the Board	-1,806	–	–	–	–	–	-1,806
Board members	-5,604	–	–	–	–	–	-5,604
Mattias Perjos, President & CEO	–	-27,141	-790	-21,088	–	-10,826	-59,845
Other Senior Executives <sup>1</sup>	–	-38,328	-3,026	-36,902	–	-5,655	-83,911
<b>Total</b>	<b>-7,410</b>	<b>-65,469</b>	<b>-3,816</b>	<b>-57,990</b>	<b>–</b>	<b>-16,481</b>	<b>-151,166</b>

- 1) Other Senior Executives refers to members in the Getinge Executive Team, other than the CEO. Excluding the CEO, the Getinge Executive Team comprised 9 individuals at year-end. Only remuneration that has been received as a member of the Getinge Executive Team is included in the amounts recognized, which includes individuals that joined and left the Getinge Executive Team during the year.
- 2) Also includes fees for work on Board Committees.  
For information on Board fees for each member, refer to pages 62–64.
- 3) Fixed salary pertains base salary including vacation payment.
- 4) Other benefits refer to benefits such as company car, medical insurance etc.
- 5) Short-term variable remuneration refers to bonuses for the 2025 fiscal year, which will be paid in 2026 and other extraordinary variable remuneration, decided with the support of the guidelines for remuneration to senior executives, which were recognized and paid during 2025.
- 6) In 2025, the program for 2023–2025 expired without the performance target being achieved, which means that no long-term variable compensation was earned.

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

Other information

**Remuneration to Senior Executives**

The 2023 Annual General Meeting resolved on guidelines for remuneration to Senior Executives, which are described in pages 47–49. Getinge applied the guidelines adopted by the AGM as follows:

**Principles:** The Annual General Meeting decides on remuneration to the Chairman of the Board and Board members. Employee representatives do not receive Board remuneration. Remuneration to the CEO and other Senior Executives comprises base salary, variable remuneration, other benefits as well as pensions. Other Senior Executives comprise the individuals, who together with the CEO, comprise the Getinge Executive Team. For the Getinge Executive Team structure, see pages 66–67. The allocation between base salary and variable remuneration should be proportionate to the Senior Executive’s responsibility and authority. The CEO’s variable remuneration is maximized to 80% of base salary. For other Senior Executives, the variable remuneration is maximized to between 60 and 90% of the base salary.

**Annual variable remuneration:** The variable remuneration for Senior Executives is based on performance targets set by the Board and in order to promote the company’s development, all members of the Getinge Executive Team have identical targets. For the 2025 fiscal year, the goals were related to earnings, organic growth, tied-up working capital and sustainability.

**Variable long-term remuneration:** In addition to base salary and the above annual variable remuneration, Senior Executives may also receive a variable long-term cash-based bonus (LTI-bonus) that rewards and promotes the Company’s business strategy and long term value creation. The vesting period for this bonus must be at least three fiscal years and the bonus awarded under each three year program shall be limited to a maximum of 33% of the annual base salary. In addition, a limitation rule applies to the CEO regarding the payment of variable long-term remuneration that payment of the annual variable remuneration and variable long-term remuneration together may not exceed 100% of base salary.

**Pensions:** The CEO is entitled to a pension from the age of 62. The pension is premium based and pension expenses amount to 40% of base salary. Variable cash remuneration does not qualify for pension benefits. For other Senior Executives, local regulations apply. All pension benefits are transferable, i.e. not conditional on future employment.

**Severance pay:** The period of notice for the CEO is a minimum of six months. If termination of employment is initiated by the Company, then termination pay of 12 months’ pay will be awarded. Termination pay is not offset against any other income. After the end of the period of notice, severance pay corresponding to one annual salary is paid. The Company is entitled to deduct any income the CEO may receive from other employment or business activities from the severance pay. Upon termination of employment of any other Senior Executives, they have the right to termination pay of a minimum of six months and a maximum of one year.

**Getinge’s total cost for remunerations to the Getinge Executive Team:** The total cost for remunerations to the Getinge Executive Team amounted to SEK 178 M (165) and pertain to base salaries, variable short-term and long-term remuneration, other benefits and pensions. It also includes social security expenses on salaries and benefits and special payroll tax on pensions.

**Drafting and decision-making process:** During the year, the Remuneration Committee gave the Board its recommendations concerning policies for the remuneration to Senior Executives. The Board discussed the Remuneration Committee’s proposals and decided in line with the Remuneration Committee’s recommendations. Remuneration to the CEO for the 2025 fiscal year was decided by the Board taking into account the Remuneration Committee’s recommendations. Remuneration to other Senior Executives was decided by the Remuneration Committee following a recommendation by the CEO and in consultation with the Chairman of the Board.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board’s Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor’s report

**Other information**

**NOTE 23** Average number of employees

By region	2025				2024			
	Men	Women	Unknown	Total	Men	Women	Unknown	Total
EMEA	4,232	2,636	7	6,874	4,213	2,669	7	6,889
<i>of which, Sweden</i>	<i>911</i>	<i>401</i>	<i>3</i>	<i>1,314</i>	<i>900</i>	<i>388</i>	<i>2</i>	<i>1,290</i>
Americas	1,941	1,348	48	3,337	1,859	1,225	215	3,299
<i>of which, USA<sup>1</sup></i>	<i>1,761</i>	<i>1,245</i>	<i>47</i>	<i>3,053</i>	<i>1,679</i>	<i>1,120</i>	<i>214</i>	<i>3,013</i>
APAC	1,091	485	1	1,577	1,098	498	1	1,597
<b>Total</b>	<b>7,264</b>	<b>4,468</b>	<b>55</b>	<b>11,788</b>	<b>7,170</b>	<b>4,392</b>	<b>223</b>	<b>11,785</b>

1) The Unknown category in 2024 mainly related to acquisitions, where all employees had not yet been fully registered. For more information, please refer to pages 114–115 Employee metrics.

**Distribution of Senior Executives and Board members at the closing date, %**

	2025	2024
<b>Women:</b>		
Board members <sup>1</sup> of the Parent Company	27%	20%
Other members of the Company's management, incl. CEO	50%	50%
<b>Men:</b>		
Board members <sup>1</sup> of the Parent Company	73%	80%
Other members of the Company's management, incl. CEO	50%	50%

1) Includes board members elected by the Annual General Meeting and ordinary members appointed by employee organizations. In 2025, the number of female board members increased by one, from two out of ten to three out of eleven board members.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**NOTE 24** Government grants

**Accounting policies**

Government grants are measured at fair value when it is probable that the terms associated with the grants will be met and that the grants will be received. Government grants that apply to costs are recognized in profit or loss as a reduction in costs in the same period as the costs that the grants are intended to cover. If the grants received do not pertain to a specific cost, the grants are recognized as revenue under the item other operating income. Government grants relating to the acquisition of assets reduce the assets' carrying amounts. Such grants affect recognized earnings over the asset's useful life by reducing depreciation.

Government grants received, SEK M	2025	2024
Received	78	60
Repaid	–	–
<b>Total</b>	<b>78</b>	<b>60</b>

Government grants reported in the income statement, SEK M	2025	2024
Other operating income	30	24
Other operating expenses	–	–
Reduction of costs related to the grant	16	17
<b>Total</b>	<b>46</b>	<b>41</b>

During 2025, government grants amounting to SEK 78 M (60) were received, of which SEK 46 M (41) were recognized in the income statement. Grants received that reduced the carrying amount of the assets to which the grants related amounted to SEK 31 M (19). Government grants include contributions related to research and development, which were primarily received in Germany and Sweden. Other grants were mainly received from Chinese and U.S. government agencies.

**NOTE 25** Pledged assets and contingent liabilities

**Accounting policies**  
Contingent liabilities are commitments and other claims for damages not recognized as liabilities/provisions either because it is not certain that an outflow of resources will be required to settle the commitment or because it is not possible to make a reliable estimate of the amount.

**Significant estimates and assessments**  
For significant estimates and assessments regarding disputes and claims for damages, see Note 15 Other provisions.

**Pledged assets, SEK M**

The Group had no pledged assets.

Contingent liabilities, SEK M	2025	2024
Guarantees <sup>1</sup>	618	612
Other	66	90
<b>Total</b>	<b>684</b>	<b>702</b>

1) As of 2025, Guarantees also includes undertakings issued through insurance providers.

**NOTE 26** Supplementary disclosure to cash flow statement

**Accounting policies**  
The cash flow statement is prepared in accordance with IAS 7, the indirect method. The cash flows of foreign Group companies are translated at average rates. Changes in group structure, acquisitions and divestments are reported net excluding cash and cash equivalents, as acquisition of operations or divestment of operations in the investing segment of the cash flow statement.

Cash and cash equivalents, SEK M	2025	2024
Investments	228	26
Cash and bank balances	3,173	2,935
<b>Total</b>	<b>3,401</b>	<b>2,961</b>

Adjustments for items not included in cash flow, SEK M	2025	2024
Gain(-)/loss(+) from divestment/disposal of non-current assets	40	21
Change in provisions, reversed (-)/added (+)	124	782
Other	0	5
<b>Total</b>	<b>164</b>	<b>808</b>

Interest paid and received, SEK M	2025	2024
Interest received	72	68
Interest paid	-563	-585
<b>Total</b>	<b>-490</b>	<b>-517</b>

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

**Accounting policies**

Acquired companies are included in the consolidated accounts from the date of acquisition, which is when Getinge Group can exercise control over the operations in the subsidiary. Acquired companies are consolidated in the financial statements in accordance with the purchase method, which means that the cost of the shares in subsidiaries is eliminated against their equity at the acquisition date. Accordingly, only the portion of the subsidiary's equity that has arisen after the acquisition is included in consolidated equity. Equity in the subsidiaries is thus determined on a market-based value of identifiable assets, liabilities, provisions, and contingent liabilities on the date of the acquisition. If the cost of the shares in the subsidiaries exceeds the value of the acquired net assets, the difference is assigned to goodwill. If the acquisition cost falls below the fair value of the acquired subsidiary's net assets (a bargain purchase), the difference is recognized directly in profit or loss as other operating income. Deferred tax is calculated on the difference between the calculated market values of assets and liabilities and the fiscal residual values. If assets are included in the subsidiary at the time of acquisition – for example, property, participations, or other operations – that will not be retained but sold in the near future, these assets are recognized in the acquisition analysis at the amount expected to be received. Transaction costs in connection with business combinations are expensed in profit or loss when they arise.

Changes in ownership that do not result in a change of controlling influence are reported in equity.

**Significant estimates and assessments**

In conjunction with acquisitions, all identifiable assets and liabilities in the acquired company are measured at fair value, including the value of assets and liabilities previously owned as well as the shares attributable to non-controlling interests.

**Contingent considerations**

Getinge has signed agreements on contingent considerations in connection with acquisitions of business and subsidiaries. The liabilities for these additional purchase prices are measured at fair value through profit or loss. In most cases, the additional purchase prices are contingent on securing government approval for the acquired product development projects and the earnings performance of the acquired businesses. The future cash flows are discounted if the planned disbursement date exceeds 12 months. Assessments about future cash flows linked to the contingent considerations are regularly reviewed by company management and are reported at fair value. The discount effect is recognized on an ongoing basis in profit or loss under financial items. Contingent considerations are included in other non-interest bearing liabilities in the balance sheet, of which SEK 335 M is classified as non-current and SEK 1,109 M is classified as current.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

In 2025, Getinge Group did not make any acquisitions that neither individually nor collectively had a material impact on the financial statements. In September 2024, 100% of the shares in Paragonix Technologies, Inc. were acquired.

In 2025, additional purchase price relating to the acquisition of Paragonix Technologies Inc., of SEK 1,555 M were paid for the achievement of performance-related and regulatory milestones. In addition, the acquisition balance sheet was adjusted, which resulted in a reduced purchase price of SEK 19 M. Additional purchase prices of SEK 44 M were paid for Irasun GmbH in 2025.

During the year, shares were acquired from non-controlling interests in the subsidiary Pulsion Medical Systems SE, after which the Getinge Group owns all of the shares in the company. The acquisition price amounted to SEK 83 M and the transaction was recognized in equity.

Net assets acquired, SEK M	2025	2024
Intangible assets	–	3,241
Tangible assets	–	23
Deferred tax assets	–	25
Inventories	–	93
Accounts receivables	–	142
Other current receivables	–	8
Cash and cash equivalents	–	115
Deferred tax liabilities	–	-755
Accounts payables	–	-32
Other short-term liabilities	–	-57
<b>Identifiable net assets</b>	<b>–</b>	<b>2,802</b>
Goodwill	–	3,103
<b>Total purchase prices</b>	<b>–</b>	<b>5,905</b>
<i>Add/Less:</i>		
Additional purchase prices and other adjustments	1,580	290
Acquisition of shares from non-controlling interests	83	31
Unpaid purchase prices	–	-2,855
Cash and cash equivalents in the acquired operations	–	-115
<b>Impact on the group's cash and cash equivalents</b>	<b>1,663</b>	<b>3,256</b>

In 2025, Paragonix Technologies, Inc. exceeded the performance-related milestones recognized in connection with the acquisition and an additional non-interest-bearing liability of SEK 179 M related to contingent consideration was recognized in the fourth quarter of 2025. Getinge Aseptic Solutions was also acquired in 2024, and updated assessments have resulted in the dissolution in the fourth quarter of SEK 55 M of the contingent consideration that was recognized in connection with the acquisition.

**NOTE 28** Transactions with related parties

Transactions between Getinge AB (publ) and its subsidiaries, which are related companies to Getinge AB (publ), were eliminated in the consolidated financial statements. Business terms and conditions as well as market-regulated pricing apply for delivery of products and services between Group companies. No Board member or Senior Executive has, or has had, any direct or indirect participation in any business transactions, between themselves and the Company, that are or were non-transparent in nature, regarding the applicable terms or conditions.

In addition to the above, there were no significant transactions with related parties. For remuneration and benefits to Senior Executives and Board members, see Note 22 Employee costs.

**NOTE 29** Events after the end of the reporting period

Ongoing geopolitical discussions and shifts in the global landscape are influencing market dynamics. It is too early to draw any conclusions regarding the effects of the geopolitical developments in the Middle East and related circumstances.

**Welcome to Getinge****Market environment****Strategy****Business areas****The Board's Operating Reports****Financial statements**

Consolidated financial statements

→ Group notes

Parent company financial statements

Parent company notes

Auditor's report

**Other information**

# Parent Company's income statement

SEK M	Note	2025	2024
Net sales		348	293
Administrative expenses	2, 14, 15	-397	-328
<b>Operating result</b>		<b>-49</b>	<b>-35</b>
Result from participations in Group companies	4	2,134	1,743
Interest income and other similar income	5	55	37
Interest expenses and other similar expenses	5	-220	-218
<b>Profit after financial items</b>		<b>1,920</b>	<b>1,527</b>
Appropriations	6	60	139
Taxes	7	-24	-39
<b>Net profit for the year</b>		<b>1,956</b>	<b>1,627</b>

# Parent Company's statement of comprehensive income

SEK M	Note	2025	2024
<b>Net profit for the year</b>		<b>1,956</b>	<b>1,627</b>
Other comprehensive income		-	-
<b>Comprehensive income for the year</b>		<b>1,956</b>	<b>1,627</b>

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

Group notes

→ Parent company financial statements

Parent company notes

Auditor's report

Other information

# Parent Company's balance sheet

SEK M	Note	2025	2024
<b>ASSETS</b>			
<b>Non-current assets</b>			
Tangible assets	3	1	2
Participations in Group companies	8	31,572	29,582
Deferred tax assets		97	99
<b>Total non-current assets</b>		<b>31,671</b>	<b>29,683</b>
<b>Current assets</b>			
Accounts receivable		974	1,244
Other receivables		22	2
Prepaid expenses and accrued income		17	16
Cash and cash equivalents	10	2	0
<b>Total current assets</b>		<b>1,016</b>	<b>1,262</b>
<b>TOTAL ASSETS</b>		<b>32,687</b>	<b>30,945</b>

SEK M	Note	2025	2024
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
<i>Restricted equity</i>			
Share capital	16	136	136
Statutory reserve		2,525	2,525
<i>Non-restricted equity</i>			
Share premium reserve		4,264	4,264
Retained earnings		17,491	17,117
Net profit for the year		1,956	1,627
<b>Total equity</b>		<b>26,372</b>	<b>25,668</b>
<b>Long-term liabilities</b>			
Interest-bearing long-term liabilities	9, 10	5,394	3,595
Other provisions, long-term		18	16
<b>Total long-term liabilities</b>		<b>5,411</b>	<b>3,611</b>
<b>Current liabilities</b>			
Interest-bearing short-term liabilities	9	600	1,374
Accounts payable		18	17
Liabilities to Group companies		7	7
Current tax liabilities		14	15
Other liabilities		4	6
Accrued expenses and deferred income	11	261	247
<b>Total current liabilities</b>		<b>903</b>	<b>1,666</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>32,687</b>	<b>30,945</b>

Refer to Note 12 Pledged assets and contingent liabilities for information concerning pledged assets and contingent liabilities.

## Welcome to Getinge

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

## Financial statements

Consolidated financial statements

Group notes

→ Parent company financial statements

Parent company notes

Auditor's report

## Other information

# Changes in Parent Company equity

SEK M	Restricted equity		Non-restricted equity		Total equity
	Share capital <sup>1</sup>	Statutory reserve	Share premium reserve	Retained earnings and net profit for the year	
<b>Opening balance, 2025</b>	<b>136</b>	<b>2,525</b>	<b>4,264</b>	<b>18,743</b>	<b>25,668</b>
Comprehensive income for the year	–	–	–	1,956	1,956
Dividend	–	–	–	-1,253	-1,253
<b>Closing balance, 2025</b>	<b>136</b>	<b>2,525</b>	<b>4,264</b>	<b>19,447</b>	<b>26,372</b>
<b>Opening balance, 2024</b>	<b>136</b>	<b>2,525</b>	<b>4,264</b>	<b>18,314</b>	<b>25,239</b>
Comprehensive income for the year	–	–	–	1,627	1,627
Dividend	–	–	–	-1,198	-1,198
<b>Closing balance, 2024</b>	<b>136</b>	<b>2,525</b>	<b>4,264</b>	<b>18,743</b>	<b>25,668</b>

1) The share capital consists of 18,217,200 Class A shares and 254,152,373 Class B shares. Each share's quotient value is SEK 0.50 and all shares carry equal rights to dividends. One Class A share carries ten votes and one Class B share carries one vote.

## Welcome to Getinge

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

## Financial statements

Consolidated financial statements

Group notes

→ Parent company financial statements

Parent company notes

Auditor's report

## Other information

# Parent Company's cash flow statement

SEK M	Note	2025	2024
<b>Operating activities</b>			
Operating result		-49	-35
Adjustments for items not included in cash flow		1	-
Interest received and similar items		12	5
Dividend received		2,134	1,743
Interest paid and similar items		-174	-191
Taxes paid		-23	-22
<b>Cash flow before changes in working capital</b>		<b>1,902</b>	<b>1,500</b>
<b>Changes in working capital</b>			
Current receivables		170	-133
Current liabilities		10	4
<b>Cash flow from operating activities</b>		<b>2,081</b>	<b>1,371</b>
<b>Investing activities</b>			
Investments in subsidiaries		-1,990	-1,246
Divestment of shares in subsidiaries		-	-
Repayment of shareholders' contribution		-	-
<b>Cash flow from investing activities</b>		<b>-1,990</b>	<b>-1,246</b>
<b>Financing activities</b>			
Raising of loans	10	2,713	2,439
Repayment of loans	10	-1,688	-1,510
Change in long-term receivables		0	-
Dividend paid		-1,253	-1,198
Group contributions received		139	143
<b>Cash flow from financing activities</b>		<b>-89</b>	<b>-126</b>
<b>Cash flow for the year</b>		<b>2</b>	<b>-1</b>
Cash and cash equivalents at the beginning of the year		0	1
Cash flow for the year		2	-1
<b>Cash and cash equivalents at year-end</b>		<b>2</b>	<b>0</b>

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

Group notes

→ Parent company financial statements

Parent company notes

Auditor's report

Other information

**NOTE 1** Parent Company's accounting policies

The Parent Company has prepared its annual report in accordance with the Annual Accounts Act and the Council for Sustainable and Financial Reporting's recommendation RFR 2, Accounting for Legal Entities. The rules in RFR 2 stipulate that the Parent Company, in its annual report for the legal entity, shall apply all EU-approved IFRS Accounting Standards to the extent possible within the framework of the Annual Accounts Act and considering the relationship between accounting and taxation. The recommendation specifies the exceptions to be made from IFRS Accounting Standards. For further information regarding IFRS Accounting Standards, see Note 1 Accounting Principles in the Group's consolidated financial statements. The Parent Company applies the accounting policies detailed for the Group with the exception of the following:

**Revenue recognition**

The recognized net sales in the Parent Company pertain revenues from sale of services to Group companies. Revenue is recognized when the control of the service has been transferred to the Group Company, which is when the Parent Company incurs the associated cost to deliver the service and the receiver can benefit from the use of the delivered services.

**Remuneration to employees**

The Parent Company complies with the Swedish Pension Obligations Vesting Act and directives from the Swedish Financial Supervisory Authority when calculating defined-benefit pension plans.

**Financial derivatives**

For derivatives, the exception in RFR 2 regarding IFRS 9 is applied, i.e., financial instruments are valued and reported based on acquisition values according to the Annual Accounts Act.

The Parent Company applies hedge accounting for its derivatives (interest rate swaps), which means that the derivatives are not continuously reported at fair value. Any interest difference to be received or paid due to an interest rate swap is continuously reported in the income statement.

**Shares and participations**

Subsidiaries are recognized in accordance with the acquisition method, implying that holdings are recognized at cost in the balance sheet less any impairment and with the addition of acquisition costs. Dividends from subsidiaries are recognized as dividend income.

**Group contributions**

Group contributions received and paid are recognized as appropriations according to the alternative rule in RFR 2.

**Operational leases**

All leasing agreements in the Parent Company are recognized as operational leases.

**NOTE 2** Depreciation/amortization according to plan

SEK M	2025	2024
Equipment, tools, fixtures and fittings	-1	-1
Intangible assets	-	-1
<b>Total</b>	<b>-1</b>	<b>-2</b>

**NOTE 3** Tangible assets

Equipment, tools, fixtures and fittings, SEK M	2025	2024
Opening acquisition cost	9	9
<b>Closing accumulated acquisition cost</b>	<b>9</b>	<b>9</b>
Opening depreciation	-7	-7
Depreciation for the year	-1	-1
Reclassifications	-	1
<b>Closing accumulated depreciation</b>	<b>-8</b>	<b>-7</b>
<b>Closing carrying amount</b>	<b>1</b>	<b>2</b>

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

Group notes

Parent company financial statements

→ Parent company notes

Auditor's report

**Other information**

**NOTE 4** Result from participations in Group companies

SEK M	2025	2024
Dividends from Group companies	2,134	1,743
<b>Total</b>	<b>2,134</b>	<b>1,743</b>

**NOTE 5** Financial items

Interest income and other similar income, SEK M	2025	2024
Interest income from Group companies	42	37
Interest income	4	-
Exchange rate gains	8	-
<b>Total</b>	<b>55</b>	<b>37</b>

Interest expenses and other similar expenses, SEK M	2025	2024
Interest expenses	-217	-215
Exchange rate losses	-	-1
Other	-3	-2
<b>Total</b>	<b>-220</b>	<b>-218</b>

**NOTE 6** Appropriations

SEK M	2025	2024
Group contributions received	60	139
<b>Total</b>	<b>60</b>	<b>139</b>

**NOTE 7** Income taxes

Taxes, SEK M	2025	2024
Current tax	-22	-41
Deferred tax	-2	2
<b>Total</b>	<b>-24</b>	<b>-39</b>

**The relationship between the year's tax expense and the recognized profit before tax, SEK M**

	2025	2024
<b>Recognized profit before tax</b>	<b>1,980</b>	<b>1,666</b>
Tax according to current tax rate in Sweden (20.6%)	-408	-343
Tax effect of non-deductible costs	-39	-39
Tax effect of non-taxable income	444	363
Foreign withholding tax <sup>1</sup>	-21	-20
<b>Recognized tax expense</b>	<b>-24</b>	<b>-39</b>

1) Mainly foreign withholding tax.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

Group notes

Parent company financial statements

→ Parent company notes

Auditor's report

**Other information**

Parent Company's holdings	Reg. office	Swedish Corp. Reg. No.	No. of shares	Percentage holding	Carrying amount 2025, SEK M	Carrying amount 2024, SEK M
Getinge Finance Holding AB	Göteborg	556473-1700	23,062,334	100	9,672	9,672
Getinge Sterilization AB	Halmstad	556031-2687	50,000	100	848	848
Getinge Business Support Services AB	Göteborg	556535-6317	1,000	100	1,031	1,031
Getinge Disinfection AB	Halmstad	556042-3393	25,000	100	208	208
Getinge Australia Pty Ltd	Australia		56,975	100	72	72
Getinge Danmark A/S	Denmark		10,000	100	41	41
Getinge IT Solutions ApS	Denmark		533,000	100	27	27
Getinge Infection Control SAS	France		1,666,712	85	698	698
Getinge/Castle International Ltd	Greece		100	100	–	0
Getinge Treasury Ireland DAC	Ireland		2	100	–	–
Neuromedica SA	Spain		40,000	100	3	3
Getinge Shared Services Sp. z o.o.	Poland		60,600	100	22	29
Getinge Holding USA, Inc.	US		10,000	100	18,695	16,697
Getinge Polska Sp. z o.o.	Poland		2,109	35	13	13
Getinge Group Japan KK	Japan		800	100	243	243
<b>Total carrying amount</b>					<b>31,572</b>	<b>29,582</b>

The Parent Company's holding of shares in the subsidiaries constitutes the entire capital of the respective company, which also corresponds to 100% of the voting rights, unless otherwise stated.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

- Consolidated financial statements
- Group notes
- Parent company financial statements
- Parent company notes
- Auditor's report

**Other information**

**Subsidiaries of sub-groups**

Getinge Group, with operations in many countries, is organized into sub-groups in several categories, and accordingly, the legal structure cannot be reflected in a simpler manner in a tabular presentation.

Group companies directly or indirectly owned by Getinge AB (publ) are specified below. The ownership interest is 100% except in cases where the ownership interest is stated in parentheses.

**Sweden**

- Getinge Business Support Services AB, 556535-6317, Göteborg
- Getinge Disinfection AB, 556042-3393, Halmstad
- Getinge Finance Holding AB, 556473-1700, Göteborg
- Getinge Global Sales and Service AB, 559421-7928, Göteborg
- Getinge Logistics AB, 556547-8798, Halmstad
- Getinge Sterilization AB, 556031-2687, Halmstad
- Getinge Sverige AB, 556509-9511, Halmstad
- Getinge Treasury AB, 556535-6309, Göteborg
- Maquet Critical Care AB, 556604-8731, Solna

**Australia**

- Getinge Australia Pty Ltd

**Austria**

- Getinge Österreich GmbH

**Belgium**

- Getinge Belgium NV

**Brazil**

- Getinge do Brasil Equipamentos Médicos Ltda

**Canada**

- Getinge Canada Ltd

**China**

- Getinge (Shanghai) Trading Co., Ltd
- Maquet (Shanghai) Medical Equipment Co., Ltd
- Maquet (Suzhou) Co., Ltd

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

Group notes

Parent company financial statements

→ Parent company notes

Auditor's report

**Other information**

**Colombia**

- Getinge Colombia SAS

**Czech Republic**

- Getinge Czech Republic, s.r.o.

**Denmark**

- Getinge Cetrea A/S
- Getinge Danmark A/S
- Getinge IT Solutions ApS

**Finland**

- Getinge Finland Oy

**France**

- Fluoptics SAS
- Getinge France SAS
- Getinge Infection Control SAS
- Getinge Life Science France SAS
- Intervascular SAS
- LTA Medical
- Maquet SAS

**Germany**

- Getinge Deutschland GmbH
- Getinge Financial Services GmbH
- Getinge Holding B.V. & Co KG
- Getinge Holding GmbH
- Getinge IT Solutions GmbH
- Getinge Vertriebs Holding GmbH
- Irasun GmbH
- Maquet Cardiopulmonary GmbH
- Maquet GmbH
- Maquet Medical Systems AG
- MediKomp GmbH
- Pulsion Medical Systems SE

**Greece**

- Getinge/Castle International Ltd

**Hongkong**

- Getinge Group Hong Kong Ltd

**India**

- Atrium Medical India Pvt Ltd
- Getinge India Pvt Ltd
- Getinge Medical India Pvt Ltd

**Ireland**

- Getinge Ireland Ltd.
- Getinge Treasury Ireland DAC
- Quadralene International Ltd.

**Italy**

- Getinge Italia Srl

**Japan**

- Getinge Group Japan KK

**Mexico**

- Maquet Mexicana, S. de R.L. de C.V.

**Netherlands**

- Applikon Biotechnology B.V.
- Getinge Holding Netherlands B.V.
- Getinge Netherlands B.V.
- Maquet Verwaltungs B.V.

**Norway**

- Getinge Norge AS

**Poland**

- Getinge IC Production Poland Sp. z o.o.
- Getinge Polska Sp. z o.o.
- Getinge Shared Services Sp. z o.o.

**Portugal**

- Getinge Group Portugal Unipessoal Lda

**Russia**

- Maquet LLC

**Saudi Arabia**

- Getinge Regional Headquarter

**Serbia**

- Getinge Group South East Europe d.o.o. Beograd

**Singapore**

- Getinge Singapore Pte. Ltd.
- Getinge South East Asia Pte. Ltd.

**South Africa**

- Maquet Southern Africa (Pty) Ltd

**South Korea**

- Getinge Medical Korea Co., Ltd

**Spain**

- Getinge Group Spain SL
- Neuromedica SA

**Switzerland**

- Getinge Schweiz AG

**Taiwan**

- Getinge Group Taiwan Co., Ltd.

**Thailand**

- Getinge (Thailand) Co., Ltd. (49%)

**Türkiye**

- Maquet Cardiopulmonary Medikal Teknik San. Tic.Ltd.Şti
- Getinge Medikal Sistemler San. Ve Tic. A.Ş.

**Ukraine**

- Maquet Ukraine LLC

**United Arab Emirates**

- Getinge Group Middle East FZ-LLC

**United Kingdom**

- Biocleanse Ltd
- Bioclear Ltd
- Dentisan Ltd
- Getinge Holding Ltd
- Getinge IT Solutions Ltd
- Getinge Ltd
- Quadralene Holdings Ltd
- Quadralene Ltd
- Teknon Ltd

**USA**

- Atrium Medical Corporation
- Datascope Corp.
- Getinge Aseptic Solutions, LLC
- Getinge Group Logistics Americas, LLC
- Getinge Holding USA, Inc.
- Getinge USA Sales, LLC
- Healthmark Industries Co., Inc.
- High Purity New England Inc.
- Lunatron Inc.
- Maquet Cardiovascular LLC
- Maquet Cardiovascular US Sales, LLC
- Paragonix Technologies, Inc.
- Steritec Products Mfg. Co., Inc.
- Talis Clinical LLC
- Transplant Advocates LLC
- Ultra Clean Systems Inc.

**Vietnam**

- Getinge Vietnam Company Ltd

**NOTE 9** Interest-bearing liabilities

Interest-bearing long-term liabilities, SEK M	2025	2024
Bond loans	5,394	3,595
<b>Total</b>	<b>5,394</b>	<b>3,595</b>

All loans fall due for payment within five years.

Interest-bearing short-term liabilities, SEK M	2025	2024
Bond loans	600	1,374
<b>Total</b>	<b>600</b>	<b>1,374</b>

**NOTE 10** Net interest-bearing debt

SEK M	2025	Change	2024
Interest-bearing short-term liabilities	600	-774	1,374
Interest-bearing long-term liabilities	5,394	1,799	3,595
Less cash and cash equivalents	-2	-2	0
<b>Total</b>	<b>5,992</b>	<b>1,023</b>	<b>4,969</b>

Net interest-bearing debt 2025, SEK M	Cash and cash equivalents	Interest-bearing liabilities	Total
<b>Opening balance</b>	<b>0</b>	<b>4,969</b>	<b>4,969</b>
Cash flow affecting net debt	-2	1,025	1,023
<b>Closing balance</b>	<b>-2</b>	<b>5,994</b>	<b>5,992</b>

Net interest-bearing debt 2024, SEK M	Cash and cash equivalents	Interest-bearing liabilities	Total
<b>Opening balance</b>	<b>-1</b>	<b>4,040</b>	<b>4,039</b>
Cash flow affecting net debt	1	929	930
<b>Closing balance</b>	<b>0</b>	<b>4,969</b>	<b>4,969</b>

**NOTE 11** Accrued expenses and deferred income

SEK M	2025	2024
Salaries	68	68
Social security expenses	143	140
Interest expenses	34	30
Other	16	9
<b>Total</b>	<b>261</b>	<b>247</b>

**NOTE 12** Pledged assets and contingent liabilities

**Pledged assets, SEK M**

The Parent Company has no pledged assets.

Contingent liabilities, SEK M	2025	2024
Guarantees FPG/PRI	427	418
Other guarantees	4,624	5,173
<b>Total</b>	<b>5,051</b>	<b>5,591</b>

**NOTE 13** Average number of employees

	2025	2024
Men	36	32
Women	54	45
<b>Total</b>	<b>90</b>	<b>77</b>

Distribution of senior executives at the closing date	2025	2024
<b>Women:</b>		
Board members of the Parent Company	3	2
Other members of the Company's management, incl. CEO	1	1
<b>Men:</b>		
Board members of the Parent Company	8	8
Other members of the Company's management, incl. CEO	2	2

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

Group notes

Parent company financial statements

→ Parent company notes

Auditor's report

Other information

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Consolidated financial statements

Group notes

Parent company financial statements

→ Parent company notes

Auditor's report

Other information

**NOTE 14** Employee costs

2025, SEK M	Board and CEO	Other	Total
Salaries and remuneration	-56	-112	-168
Social security expenses	-20	-43	-63
Pension expenses	-11	-22	-33
<b>Total</b>	<b>-87</b>	<b>-177</b>	<b>-264</b>

2024, SEK M	Board and CEO	Other	Total
Salaries and remuneration	-56	-90	-146
Social security expenses	-20	-46	-66
Pension expenses	-11	-23	-34
<b>Total</b>	<b>-87</b>	<b>-159</b>	<b>-246</b>

**NOTE 15** Auditing

Fee to EY, SEK M	2025	2024
Auditing assignment	-12	-
Auditing activities other than auditing assignment	-	-
Other services	-6	-
<b>Total</b>	<b>-18</b>	<b>-</b>

Fee to PwC, SEK M	2025	2024
Auditing assignment	-2	-12
Auditing activities other than auditing assignment	-	-1
Other services	-2	-1
<b>Total</b>	<b>-4</b>	<b>-14</b>

EY has the auditing assignment for the entire Group. Auditing assignment refer to auditing of the financial statements and statutory accounts, review of the sustainability statement, and other required legal audit. For information on Getinge's appointment of external auditor, see the Corporate Governance Report page 56. Auditing activities other than auditing assignment include review of interim reports as well as services in conjunction with the issuance of certificates and audit certificates. Tax consultancy services primarily pertain to general tax matters concerning corporate tax and internal pricing. Other services mainly pertain to services in connection with acquisitions.

**NOTE 16** Proposed appropriation of profit

The following non-restricted equity in the Parent Company is at the disposal of the Annual General Meeting, SEK M:

Share premium reserve	4,264
Retained earnings	17,491
Net profit for the year	1,956
<b>Total</b>	<b>23,711</b>

The Board and CEO propose that a dividend of SEK 4.75 per share shall be distributed to shareholders	1,294
to be carried forward	22,417
<b>Total</b>	<b>23,711</b>

**NOTE 17** Events after the end of the reporting period

No significant events have occurred after the end of the reporting period.

# Auditor's report

To the general meeting of the shareholders of Getinge AB (publ), corporate identity number 556408-5032

## Report on the annual accounts and consolidated accounts

### Opinions

We have audited the annual accounts and consolidated accounts of Getinge AB (publ) except for the Remuneration report on pages 52–55, Corporate Governance report on pages 56–72 and Sustainability statement on pages 73–137 for the year 2025. The annual accounts and consolidated accounts of the company are included on pages 34–190 in this document.

In our opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of the Parent company as of 31 December 2025 and its financial performance and cash flow for the year then ended in accordance with the Annual Accounts Act. The consolidated accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of the Group as of December 31, 2025 and their financial performance and cash flow for the year then ended in accordance with IFRS Accounting Standards, as adopted by the EU, and the Annual Accounts Act. Our opinions do not cover the Remuneration report on pages 52–55, Corporate Governance report on pages 56–72 and Sustainability statement on pages 73–137. The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the Parent company and the Group.

Our opinions in this report on the annual accounts and consolidated accounts are consistent with the content of the additional report that has been submitted to the Parent company's audit committee in accordance with the Audit Regulation (537/2014) Article 11.

### Basis for Opinions

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the Parent company and the Group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements. This includes that, based on the best of our knowledge and belief, no prohibited services referred to in the Audit Regulation (537/2014) Article 5.1 have been provided to the audited company or, where applicable, its Parent company or its controlled companies within the EU.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

### Other matters

The audit of the annual accounts for 2024 was performed by another auditor who submitted an auditor's report dated 27 March 2025, with unmodified opinions in the Report on the annual accounts.

### Key Audit Matters

Key audit matters of the audit are those matters that, in our professional judgment, were of most significance in our audit of the annual accounts and consolidated accounts of the current period. These matters were addressed in the context of our audit of, and in forming our opinion thereon, the annual accounts and consolidated accounts as a whole, but we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled the responsibilities described in the Auditor's responsibilities for the audit of the financial statements section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying financial statements.

## Welcome to Getinge

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

## Financial statements

Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

→ Auditor's report

## Other information

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

→ Auditor's report

**Other information**

**Description**

**Impairment test of intangible assets with indefinite useful lives**

*With reference to Note 9.*

Goodwill and other intangible assets with indefinite useful lives represent a significant portion of the Group's balance sheet. As of December 31, 2025, goodwill and other intangible assets with indefinite useful lives amount to 26 407 million SEK, corresponding to 47% of the Group's total assets.

The company performs an annual impairment test for these assets, based on discounted future cash flows for the cash-generating units in which goodwill and other intangible assets with indefinite useful lives are recognized. The impairment test is based on a high degree of estimates and assumptions about future cash flows. Note 9 describes how the company has made its assessment, including key assumptions and sensitivity analyses. The company's disclosures indicate that no impairment need has been identified based on the assumptions applied.

Based on the assumptions used to calculate the value in use, we consider the valuation of goodwill and other intangible assets with indefinite useful lives to be a key audit matter in our audit.

**How our audit addressed this key audit matter**

Our audit procedures to evaluate management's impairment testing included, among other things:

- Evaluation of the model and assumptions. The evaluation has included, with the support of our valuation specialists, whether the model is prepared according to accepted valuation techniques and the suitability of applied discount rates and assumptions compared to comparable companies.
- Testing management's sensitivity analysis and performing an independent sensitivity test of significant assumptions to determine whether a reasonably possible change would result in an impairment need.
- Assessing the reasonableness of future cash flows against the approved budget, financial plan, other information obtained from discussions with management, and review of minutes from Board and management meetings.
- Evaluating management's forecasting accuracy by comparing prior forecasts with actual outcomes.
- Assessing whether management has provided the required disclosures in the Annual Report as of December 31, 2025.

**Accounting for contingent liabilities and provisions**

*With reference to Note 15 and 25.*

The Company is subject to legal exposures (material litigation processes, litigations and investigations) with potential exposures to significant claims and cash outflows. Provisions and contingent liabilities are reported based on the company's best assessment of the outcome, applicable rules and practices in the area, history and the stage of the legal process or investigation. The assessments are normally made in consultation with legal advisors. The assessments are usually associated with higher uncertainty and subjectivity and changes in these can have a significant impact on reported provisions or contingent liabilities. Note 15 and note 25 describes how the company has made its assessments of the need for a provision or a contingent liability.

Based on the complexity of the legal processes and investigations, inherent subjectivity and uncertainty about the final outcome, we consider provisions and contingent liabilities for legal exposures to be a key audit matter in our audit.

In our audit, we evaluated the company's process for assessing the outcome of the legal disputes and conducted interviews with management regarding their knowledge of legal exposures.

We reviewed management's calculations and assessments of the legal exposures, reviewed a sample of recorded legal expenses against invoices to identify legal exposures, and obtained statements from external legal advisors in relevant matters.

We assessed the reasonableness of management's judgments regarding the necessary provisions, taking into account the information from the legal advisors.

We also evaluated the accuracy of the disclosures presented in the annual report and reviewed events after the balance sheet date to ensure that all information up to the date of the financial report had been considered in the assessment.

**Other Information than the annual accounts and consolidated accounts**

This document also contains other information than the annual accounts and consolidated accounts and is found on pages 1–33, 73–137 and 198–214. The other information also includes the Remuneration report on pages 52–55. The Board of Directors and the Managing Director are responsible for this other information.

Our opinion on the annual accounts and consolidated accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Responsibilities of the Board of Directors and the Managing Director**

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act and, concerning the consolidated accounts, in accordance with IFRS Accounting Standards as adopted by the EU. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

→ Auditor's report

**Other information**

that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts, The Board of Directors and the Managing Director are responsible for the assessment of the company's and the Group's ability to continue as a going concern. They disclose, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intends to liquidate the company, to cease operations, or has no realistic alternative but to do so.

The Audit Committee shall, without prejudice to the Board of Director's responsibilities and tasks in general, among other things oversee the company's financial reporting process.

**Auditor's responsibility**

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts and consoli-

dated accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of the company's internal control relevant to our audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors and the Managing Director.
- Conclude on the appropriateness of the Board of Directors' and the Managing Director's use of the going concern basis of accounting in preparing the annual accounts and consolidated accounts. We also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's and the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual accounts and consolidated accounts or, if such disclosures are inadequate, to modify our opinion about the annual accounts and consolidated accounts. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause a company and a Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the annual accounts and consolidated accounts, including the disclosures, and whether the annual accounts and consolidated accounts represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the Group audit to obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the consolidated accounts. We are responsible for the direction, supervision and review of the audit work performed for purposes of the Group audit. We remain solely responsible for our opinions.

We must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. We must also inform of significant audit findings during our audit, including any significant deficiencies in internal control that we identified.

We must also provide the Board of Directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or related safeguards applied.

From the matters communicated with the Board of Directors, we determine those matters that were of most significance in the audit of the annual accounts and consolidated accounts, including the most important assessed risks for material misstatement, and are therefore the key audit matters. We describe these matters in the auditor's report unless law or regulation precludes disclosure about the matter.

**Report on other legal and regulatory requirements**

Report on the audit of the administration and the proposed appropriations of the company's profit or loss

**Opinions**

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administration of the Board of Directors and the Managing Director of Getinge AB (publ) for the year 2025 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

**Basis for Opinions**

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the Parent company and the Group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

**Responsibilities of the Board of Directors and the Managing Director**

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's and the Group's type of operations,

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

→ Auditor's report

**Other information**

size and risks place on the size of the Parent company's and the Group's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's and the Group's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

**Auditor's responsibility**

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always

detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, we exercise professional judgment and maintain professional skepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on our professional judgment with starting point in risk and materiality. This means that we focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. We examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to our opinion concerning discharge from liability. As a basis for our opinion on the Board of Directors' proposed appropriations of the company's profit or loss we examined the Board of Directors' reasoned statement and a selection of supporting evidence in order to be able to assess whether the proposal is in accordance with the Companies Act.

*The auditor's examination of the ESEF report*

**Opinion**

In addition to our audit of the annual accounts and consolidated accounts, we have also examined that the Board of Directors and the Managing Director have prepared the annual accounts and consolidated accounts in a format that enables uniform electronic reporting (the Esef report) pursuant to Chapter 16, Section 4(a) of the Swedish Securities Market Act (2007:528) for Getinge AB (publ) for the financial year 2025.

Our examination and our opinion relate only to the statutory requirements.

In our opinion, the Esef report has been prepared in a format that, in all material respects, enables uniform electronic reporting.

**Basis for opinion**

We have performed the examination in accordance with FAR's recommendation RevR 18 Examination of the ESEF report. Our responsibility under this recommendation is described in more detail in the Auditors' responsibility section. We are independent of Getinge AB (publ) in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Responsibilities of the Board of Directors and the Managing Director**

The Board of Directors and the Managing Director are responsible for the preparation of the Esef report in accordance with Chapter 16, Section 4(a) of the Swedish Securities Market Act (2007:528), and for such internal control that the Board of Directors and the Managing Director determine is necessary to prepare the Esef report without material misstatements, whether due to fraud or error.

**Auditor's responsibility**

Our responsibility is to obtain reasonable assurance whether the Esef report is in all material respects prepared in a format that meets the requirements of Chapter 16, Section 4(a) of the Swedish Securities Market Act (2007:528), based on the procedures performed.

RevR 18 requires us to plan and execute procedures to achieve reasonable assurance that the Esef report is prepared in a format that meets these requirements.

Reasonable assurance is a high level of assurance, but it is not a guarantee that an engagement carried out according to RevR 18 and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Esef report.

The audit firm applies ISQM 1 *Quality Management for Firms that Perform Audits or Reviews of Financial Statements, or other Assurance or Related Services Engagements* which requires the firm to design, implement and operate a system of quality management, including policies and procedures regarding compliance with professional ethical requirements, professional standards and applicable legal and regulatory requirements.

The examination involves obtaining evidence, through various procedures, that the Esef report has been prepared in a format that enables uniform electronic reporting of the annual and consolidated accounts. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement in the report, whether due to fraud or error. In carrying out this risk assessment, and in order to design audit procedures that are appropriate in the circumstances, the auditor considers those elements of internal control that are relevant to the preparation of the Esef report by the Board of Directors and the Managing Director, but not for the purpose of expressing an opinion on the effectiveness of those internal controls. The examination also includes an evaluation of the appropriateness and reasonableness of assumptions made by the Board of Directors and the Managing Director.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

→ Auditor's report

**Other information**

The procedures mainly include a validation that the Esef report has been prepared in a valid XHTML format and a reconciliation of the Esef report with the audited annual accounts and consolidated accounts.

Furthermore, the procedures also include an assessment of whether the consolidated statement of financial performance, financial position, changes in equity, cash flow and disclosures in the Esef report have been marked with iXBRL in accordance with what follows from the Esef regulation.

*This is a translation of the Swedish language original. In the event of any differences between this translation and the Swedish language original, the latter shall prevail.*

## The auditor's examination of the corporate governance report

The Board of Directors is responsible for that the corporate governance report on pages 56–72 has been prepared in accordance with the Annual Accounts Act.

Our examination of the corporate governance report is conducted in accordance with FAR's standard RevR 16 The auditor's examination of the corporate governance report. This means that our examination of the corporate governance report is different and substantially less in scope than an audit conducted in accordance with International Standards on Auditing and generally accepted auditing standards in Sweden. We believe that the examination has provided us with sufficient basis for our opinions.

A corporate governance report has been prepared. Disclosures in accordance with chapter 6 section 6 the second paragraph points 2–6 of the Annual Accounts Act and chapter 7 section 31 the second paragraph the same law are consistent with the other parts of the annual accounts and consolidated accounts and are in accordance with the Annual Accounts Act.

Ernst & Young AB, with Fredrik Norrman as principal auditor since 2025, was appointed auditor of Getinge AB by the general meeting of shareholders on April 22, 2025.

Gothenburg, March 25, 2026  
Ernst & Young AB

Fredrik Norrman  
Authorized Public Accountant

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

→ Auditor's report

**Other information**

## Auditor's limited assurance report on Getinge AB (publ)'s sustainability statement

**To the General Meeting of the shareholders Getinge AB (publ), corporate identity number 556408–5032**

**Conclusion**

We have conducted a limited assurance engagement of the sustainability statement prepared by Getinge AB (publ) (the company) for the financial year 2025. The sustainability statement is included on pages 73–137 of this document.

Based on our limited assurance engagement as described in the section Auditor's Responsibility, nothing has come to our attention that causes us to believe that the sustainability statement is not, in all material respects, prepared in accordance with the Swedish Annual Accounts Act, which includes:

- Whether the sustainability statement meets the requirements of ESRS;
- Whether the process carried out by the company to identify reported sustainability information has been conducted as described in the sustainability statement; and
- Compliance with the reporting requirements in Article 8 of the EU's Green Taxonomy Regulation.

**Basis for Conclusion**

We have conducted the limited assurance engagement in accordance with FAR's recommendation RevR 19 – Revisorns översiktliga granskning av den lagstadgade hållbarhetsrapporten. Our responsibility under this recommendation is described in more detail in the section Auditor's Responsibility.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.

**Other Information than the sustainability statement**

This document also contains other information than the sustainability statement, found on pages 1–72 and 138–214, with the exception of pages 52–55. The Board of Directors and the Managing Director are responsible for this other information.

Our conclusion on the sustainability statement does not cover this other information, and we do not express any conclusion with assurance regarding this other information.

In connection with our limited assurance engagement on the sustainability statement, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the sustainability statement. In this procedure we also take into account our knowledge otherwise obtained in the limited assurance engagement and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Other matter**

The sustainability statement for the previous financial year 2024 has not been subject to a limited assurance engagement according to RevR 19 *Revisorns översiktliga granskning av den lagstadgade hållbarhetsrapporten*. Therefore, no limited assurance engagement of comparative figures in the sustainability statement for 2025 has been performed.

**Responsibilities of the Board of directors and Managing Director**

The Board of Directors and the Managing Director are responsible for the preparation of the sustainability statement in accordance with Chapter 6, Sections 12–12f of the Swedish Annual Accounts Act, and for such internal control as the Board of Directors and the Managing Director determine is necessary to enable the preparation of the sustainability statement that is free from material misstatements, whether due to fraud or error.

**Auditor's Responsibility**

Our responsibility is to express a conclusion whether the sustainability statement is prepared in accordance with Chapter 6, Sections 12–12 f of the Swedish Annual Accounts Act based on our limited assurance engagement.

The limited assurance engagement has been conducted in accordance with FAR's recommendation RevR 19 *Revisorns översiktliga granskning av den lagstadgade hållbarhetsrapporten*. This

recommendation requires that we plan and perform our procedures to obtain limited assurance that the sustainability statement is prepared in accordance with these requirements.

The procedures in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed. This means that it is not possible for us to obtain such assurance that we become aware of all significant matters that could have been identified if a reasonable assurance engagement had been performed.

Our firm applies ISQM 1 (International Standard on Quality Management), which requires the firm to design, implement, and manage a quality management system including guidelines or procedures regarding compliance with ethical requirements, standards of professional practice, and applicable laws and regulations.

We are independent of Getinge AB (publ) in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities according to these requirements.

A limited assurance engagement involves performing procedures to obtain evidence to support the sustainability information. The auditor selects

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

Consolidated financial statements

Group notes

Parent company financial statements

Parent company notes

→ Auditor's report

**Other information**

the procedures to be performed, including assessing the risks of material misstatements in the sustainability statement, whether due to fraud or error. In this risk assessment, the auditor considers the parts of the internal control that are relevant to how the Board of Directors and the Managing Director prepares the sustainability statement, in order to design procedures that are appropriate under the circumstances, but not for the purpose of providing a conclusion on the effectiveness of the company's internal control. The review consists of making inquiries, primarily of persons responsible for the preparation of the sustainability statement, performing analytical review, and conducting other limited review procedures.

Our review procedures regarding the sustainability statement included, but were not limited to the following:

- Through inquiries, obtaining a general understanding of the internal control environment, reporting processes, and information systems relevant to the preparation of the information in the sustainability statement.
- Evaluating whether information identified as material through the process the company has undertaken to identify the content of the sustainability statement is also included.
- Evaluating whether the structure and presentation of the sustainability statements are consistent with the requirements of ESRS;
- Conducting inquiries with relevant personnel and analytical review procedures regarding selected disclosures in the sustainability statements;

- Performing substantive review procedures based on a sample of selected disclosures in the sustainability statements;
- Obtain, through inquiries and analytical review procedures, support for the methods used for preparing material estimates and forward-looking information and on how these methods were applied;

Our review procedures regarding the process the company have undertaken to identify sustainability information to report included, but were not limited to the following:

- Obtaining an understanding of the process by:
- Conducting interviews with process owners and stakeholders, and
- Conducting inquiries to understand the sources of the information used by management (e.g., stakeholder dialogues, business plans, and strategy documents), and
- Reviewing the company's internal documentation of its process; and
- Evaluating whether the information obtained from our procedures regarding the process implemented by the company aligns with the description of the process on page 76 in the sustainability statement

Our review procedures regarding the taxonomy disclosures included but was not limited to the following review procedures:

- Obtaining an understanding of the process for identifying economic activities that are covered by and are consistent with the EU Green Taxonomy and the corresponding disclosures in the sustainability statement by:
- Conducting inquiries to relevant personnel and analytical review procedures on the taxonomy disclosures
- Conducting inquiries to understand the sources of the information used in the taxonomy disclosures
- Evaluating whether the presentation of the taxonomy disclosures is consistent with the requirements of the EU Taxonomy Regulation

**Inherent limitations**

In reporting forward-looking information in accordance with ESRS, the board and management of Getinge AB (publ) must prepare forward-looking information based on specified assumptions about events that may occur in the future and possible future activities of Getinge AB (publ). Actual outcomes are likely to differ as expected events often do not occur as anticipated.

Gothenburg, March 25, 2026

Ernst & Young AB

Fredrik Norrman  
Authorized Auditor  
Appointed by the Annual General Meeting to review the sustainability statement

# Other information

The Getinge share	199
Multi-year overview	201
Acquisition history	204
Reconciliation of alternative performance measures	205
Group companies	208
Definitions	211
Annual General Meeting and Nomination Committee	213
Financial information	213
Reading guide and distribution policy	214
Contact	214

# The Getinge share

Getinge’s Class B share has been listed on Nasdaq Stockholm since 1993. The share is included in the Nasdaq Nordic Large Cap segment. On December 31, 2025, the number of shareholders was 57,286. The percentage of foreign-owned shares amounted to 23.4%. Institutional owners accounted for 66.6% of the share capital, of which Swedish institutional owners accounted for 44.9%.

### Share trend and liquidity

At year-end, Getinge’s share was listed at SEK 218.80, which was an increase of 20.5% (-19.1) during the year. The highest price paid in 2025 was SEK 231.60 (October 21) and the lowest was SEK 177.25 (April 9). At year-end, market capitalization amounted to SEK 59.6 billion. During the year, 194.3 million shares (211.9) were traded on Nasdaq. Including trading on alternative trading venues, the total number of shares traded was 627.8 million (692.2).

### Share capital

At year-end 2025, the share capital in Getinge totaled SEK 136,184,786.50 distributed among 272,369,573 shares. All shares carry the same dividend entitlement. One Class A share carries ten votes and one Class B share carries one vote.

### Dividend policy

The Board of Directors of Getinge has adopted a dividend policy entailing that future dividends will be adjusted in line with Getinge’s profit level, financial position and future development potential. The aim is for the dividend to correspond to 30–50% of net income. During the last five years, the dividend payout ratio has been an average of 46.9%, including the proposed dividend.


### Sell-side analysts covering Getinge

ABG Sundal Collier, Bernstein, Danske Bank, DNB Carnegie, Equita, Handelsbanken, J.P. Morgan, Kepler Cheuvreux, Morningstar, Nordea, Pareto Securities, SB1 Markets, Redburn and SEB Enskilda.

### Getinge’s peers

Getinge’s peers consist of the listed companies named in the section for each business area in this Annual Report.

### Performance 2021–2025



SEK 4.75

Proposed dividend per share for the fiscal year 2025

20.50%

Development in Getinge’s share value in 2025

SEK 218.80

Getinge’s share price at year-end 2025

## Welcome to Getinge

## Market environment

## Strategy

## Business areas

## The Board’s Operating Reports

## Financial statements

## Other information

→ The Getinge share

Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Other information

→ The Getinge share

Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

Getinge's largest shareholders on December 31, 2025

	Class A shares	Class B shares	% of capital	% of votes
Carl Bennet AB	18,217,200	36,802,969	20.20%	50.19%
AMF Pension & Fonder		24,242,414	8.90%	5.56%
Fjärde AP-fonden		21,000,000	7.71%	4.81%
Carnegie Fonder		13,656,629	5.01%	3.13%
Swedbank Robur Fonder		10,545,893	3.87%	2.42%
Vanguard		9,415,903	3.46%	2.16%
Handelsbanken Fonder		8,809,837	3.23%	2.02%
Lannebo Kapitalförvaltning		6,597,544	2.42%	1.51%
Incentive AS		6,048,479	2.22%	1.39%
Norges Bank Investment Management		5,709,636	2.10%	1.31%
Other		111,323,069	40.87%	25.51%
<b>Total</b>	<b>18,217,200</b>	<b>254,152,373</b>	<b>100.00%</b>	<b>100.00%</b>

Ownership structure 2025

Shares	No. of shares	% of capital	% of votes	Ownership	Ownership (%)
1 - 100	1,051,955	0.39%	0.24%	31,428	54.86%
101 - 200	1,115,161	0.41%	0.26%	7,346	12.82%
201 - 500	1,088,533	0.40%	0.25%	4,255	7.43%
501 - 1,000	753,705	0.28%	0.17%	2,084	3.64%
1,001 - 2,000	1,001,355	0.37%	0.23%	2,122	3.70%
2,001 - 5,000	3,467,249	1.27%	0.79%	4,685	8.18%
5,001 - 10,000	4,064,565	1.49%	0.93%	2,824	4.93%
10,001 - 20,000	5,045,312	1.85%	1.16%	1,602	2.80%
20,001 - 50,000	3,134,741	1.15%	0.72%	443	0.77%
50,001 - 100,000	3,036,507	1.11%	0.70%	214	0.37%
100,001 - 200,000	3,371,335	1.24%	0.77%	113	0.20%
200,001 - 500,000	3,341,702	1.23%	0.77%	44	0.08%
500,001 - 1,000,000	16,795,359	6.17%	3.85%	76	0.13%
1,000,001 - 2,000,000	13,040,166	4.79%	2.99%	19	0.03%
2,000,001 - 5,000,000	48,242,481	17.71%	11.06%	21	0.04%
5,000,001 - 10,000,000	36,581,399	13.43%	8.38%	5	0.01%
10,000,001 - 20,000,000	24,202,522	8.89%	5.55%	2	0.00%
20,000,001 -	100,262,583	36.81%	60.56%	3	0.01%
Anonymous ownership	2,772,943	1.02%	0.64%	0	0.00%
<b>Total</b>	<b>272,369,573</b>	<b>100.00%</b>	<b>100.00%</b>	<b>57,286</b>	<b>100.00%</b>

Development of share capital

Transaction	No. of shares after transaction	Share capital after transaction, SEK
1990 Formation	500	50,000
1992 Split 50:1, par value SEK 100 to SEK 2	25,000	50,000
1992 Private placement	5,088,400	10,176,800
1993 Private placement	6,928,400	13,856,800
1995 Non-cash issue	15,140,544	30,281,088
1996 Bonus issue 2:1	45,421,632	90,843,264
2001 New issue 1:9 at SEK 100	50,468,480	100,936,960
2003 Split 4:1, par value SEK 2 to SEK 0.50	201,873,920	100,936,960
2008 New issue 1:16 at SEK 120	214,491,404	107,245,520
2009 New issue 1:9 at SEK 83.5	238,323,377	119,161,689
2017 New issue 1:7 at SEK 127	272,369,573	136,184,787


Share capital distribution

	Class A	Class B	Total
No. of shares	18,217,200	254,152,373	272,369,573
No. of votes	182,172,000	254,152,373	436,324,373
% of capital	6.7%	93.3%	100%
% of votes	41.8%	58.2%	100%

Five largest countries – capital, %



Ownership by category – capital, %



Shareholder information

Financial information about Getinge is available on the company's website. Questions regarding this annual report and other financial communications can be directed to the investor relations function at the company, as indicated on the website.

# Multi-year overview

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Other information

The Getinge share

→ Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

Amounts in SEK M unless otherwise stated	2025	2024	2023	2022	2021
<b>Order situation</b>					
Order intake	34,025	34,232	30,894	29,621	28,258
Net sales	34,969	34,759	31,827	28,292	27,049
<i>of which, international sales, %</i>	98.1	98.2	98.0	98.1	98.2
EBITDA	6,039	5,275	5,829	5,653	6,185
Adjusted EBITA	4,880	4,869	3,887	4,281	5,212
Operating profit/loss (EBIT)	3,789	2,854	3,736	3,626	4,371
Net financial items	-644	-571	-393	-154	-183
Profit/loss after financial items	3,145	2,282	3,343	3,472	4,188
Taxes	-869	-628	-915	-956	-1,187
<b>Net profit/loss for the year</b>	<b>2,276</b>	<b>1,654</b>	<b>2,428</b>	<b>2,516</b>	<b>3,000</b>
<b>Margin measures</b>					
EBITDA margin, %	17.3	15.2	18.3	20.0	22.9
Adjusted EBITA margin, %	14.0	14.0	12.2	15.1	19.3
Operating margin (EBIT), %	10.8	8.2	11.7	12.8	16.2
<b>Personnel</b>					
Number of employees, December 31 <sup>1</sup>	11,670	11,791	11,739	11,082	10,729
<b>Balance sheet</b>					
Intangible assets	33,513	39,242	30,670	27,010	24,148
Tangible assets	3,469	3,902	3,723	3,532	3,060
Right-of-use assets	1,470	1,795	1,486	1,336	1,060
Financial assets	826	817	1,061	1,048	1,217
Inventories	6,018	6,590	6,416	6,232	4,767
Other receivables	7,808	8,610	7,503	7,198	6,227
Cash and cash equivalents	3,401	2,961	2,728	5,676	4,076
<b>Total assets</b>	<b>56,505</b>	<b>63,918</b>	<b>53,586</b>	<b>52,032</b>	<b>44,555</b>
Equity	29,494	33,210	30,403	30,453	25,176
Provisions for pensions, interest-bearing	2,358	2,700	2,664	2,454	3,378
Leasing liabilities	1,480	1,800	1,479	1,314	1,036
Other interest-bearing liabilities	9,403	12,207	6,597	4,510	3,270
Other provisions <sup>2</sup>	3,802	4,502	3,245	4,539	3,782
Other non-interest-bearing liabilities <sup>2</sup>	9,969	9,498	9,198	8,761	7,912
<b>Total equity and liabilities</b>	<b>56,505</b>	<b>63,918</b>	<b>53,586</b>	<b>52,032</b>	<b>44,555</b>

Amounts in SEK M unless otherwise stated	2025	2024	2023	2022	2021
Net debt, including pension liabilities	9,840	10,467	8,012	2,602	3,609
Net debt, excluding pension liabilities	7,482	7,766	5,348	148	231
<b>Cash flow</b>					
Cash flow from operating activities	3,949	4,577	2,957	3,367	6,560
Cash flow per share, SEK	14.5	16.8	10.9	12.4	24.1
Net investments in non-current assets	-1,297	-1,294	-1,334	-1,106	-614
<b>Return indicators</b>					
Return on capital employed, %	11.0	11.1	10.2	13.0	17.3
Return on equity, %	7.5	5.2	7.8	8.9	12.9
<b>Financial indicators</b>					
Equity/assets ratio, %	52.2	52.0	56.7	58.5	56.5
Net debt/equity ratio, multiple	0.33	0.32	0.26	0.09	0.14
Capital employed, average	40,934	40,952	35,660	31,510	28,561
Equity December 31	29,494	33,210	30,403	30,453	25,176
<b>Data per share, amounts in SEK unless otherwise stated</b>					
Earnings per share	8.29	6.01	8.86	9.15	10.90
Market price, December 31	218.80	181.55	224.30	216.30	395.10
Dividend	4.75 <sup>3</sup>	4.60	4.40	4.25	4.00
Dividend yield, %	2.17	2.53	1.96	1.96	1.01
Price/earnings ratio	26.39	30.19	25.32	23.64	36.25
Dividend as profit percentage, %	57.29	76.50	49.68	46.45	36.70
Equity per share, SEK	108.28	121.93	111.63	111.81	92.43
Average number of shares (million)	272.4	272.4	272.4	272.4	272.4
Number of shares December 31 (million)	272.4	272.4	272.4	272.4	272.4

1) Number of Full-Time Equivalents (FTE).

2) As from 2024, contingent considerations have been reclassified from Other provisions to Other non-interest-bearing liabilities. Previous years have been restated.

3) Dividend proposed by the Board of Directors.

# Business areas

	2025	2024	2023	2022	2021
<b>ACUTE CARE THERAPIES, SEK M</b>					
<b>Order intake</b>	<b>18,220</b>	<b>17,719</b>	<b>16,375</b>	<b>16,108</b>	<b>15,335</b>
<b>Net sales</b>	<b>18,675</b>	<b>17,948</b>	<b>16,529</b>	<b>15,285</b>	<b>15,527</b>
<b>Adjusted gross profit</b>	<b>10,897</b>	<b>10,417</b>	<b>9,660</b>	<b>9,174</b>	<b>9,596</b>
<i>Margin, %</i>	58.4	58.0	58.4	60.0	61.8
<b>Adjusted EBITDA</b>	<b>4,616</b>	<b>4,474</b>	<b>4,023</b>	<b>4,274</b>	<b>5,272</b>
<i>Margin, %</i>	24.7	24.9	24.3	28.0	34.0
Depreciation, amortization and write-downs of tangible and intangible assets	-853	-920	-905	-872	-828
<b>Adjusted EBITA</b>	<b>3,763</b>	<b>3,554</b>	<b>3,117</b>	<b>3,402</b>	<b>4,444</b>
<i>Margin, %</i>	20.2	19.8	18.9	22.3	28.6
<b>LIFE SCIENCE, SEK M</b>					
<b>Order intake</b>	<b>4,252</b>	<b>4,601</b>	<b>4,148</b>	<b>3,932</b>	<b>4,120</b>
<b>Net sales</b>	<b>4,498</b>	<b>4,552</b>	<b>4,325</b>	<b>4,026</b>	<b>3,558</b>
<b>Adjusted gross profit</b>	<b>1,676</b>	<b>1,808</b>	<b>1,527</b>	<b>1,548</b>	<b>1,492</b>
<i>Margin, %</i>	37.3	39.7	35.3	38.5	41.9
<b>Adjusted EBITDA</b>	<b>712</b>	<b>818</b>	<b>620</b>	<b>801</b>	<b>870</b>
<i>Margin, %</i>	15.8	18.0	14.3	19.9	24.5
Depreciation, amortization and write-downs of tangible and intangible assets	-222	-211	-190	-151	-141
<b>Adjusted EBITA</b>	<b>490</b>	<b>608</b>	<b>430</b>	<b>650</b>	<b>729</b>
<i>Margin, %</i>	10.9	13.4	9.9	16.1	20.5
<b>SURGICAL WORKFLOWS, SEK M</b>					
<b>Order intake</b>	<b>11,553</b>	<b>11,912</b>	<b>10,371</b>	<b>9,581</b>	<b>8,803</b>
<b>Net sales</b>	<b>11,796</b>	<b>12,258</b>	<b>10,974</b>	<b>8,981</b>	<b>7,965</b>
<b>Adjusted gross profit</b>	<b>5,034</b>	<b>5,185</b>	<b>4,346</b>	<b>3,639</b>	<b>3,304</b>
<i>Margin, %</i>	42.7	42.3	39.6	40.5	41.5
<b>Adjusted EBITDA</b>	<b>1,697</b>	<b>1,728</b>	<b>1,304</b>	<b>1,127</b>	<b>949</b>
<i>Margin, %</i>	14.4	14.1	11.9	12.5	11.9
Depreciation, amortization and write-downs of tangible and intangible assets	-619	-638	-583	-577	-559
<b>Adjusted EBITA</b>	<b>1,077</b>	<b>1,090</b>	<b>721</b>	<b>549</b>	<b>390</b>
<i>Margin, %</i>	9.1	8.9	6.6	6.1	4.9

# The group's 20 largest markets

Net sales	2025		2024		2023	
	SEK M	%	SEK M	%	SEK M	%
USA	14,157	40.5%	13,929	40.1%	11,697	36.8%
China	2,708	7.7%	2,844	8.2%	2,836	8.9%
Germany	2,067	5.9%	1,904	5.5%	1,859	5.8%
France	1,513	4.3%	1,611	4.6%	1,483	4.7%
Japan	1,198	3.4%	1,207	3.5%	1,241	3.9%
United Kingdom	1,143	3.3%	1,177	3.4%	1,100	3.5%
Italy	1,105	3.2%	1,041	3.0%	980	3.1%
Canada	794	2.3%	770	2.2%	731	2.3%
Spain	697	2.0%	771	2.2%	738	2.3%
Australia	676	1.9%	715	2.1%	643	2.0%
Sweden	648	1.9%	617	1.8%	632	2.0%
India	605	1.7%	561	1.6%	491	1.5%
Netherlands	498	1.4%	544	1.6%	518	1.6%
Switzerland	453	1.3%	440	1.3%	423	1.3%
Belgium	398	1.1%	363	1.0%	342	1.1%
Denmark	354	1.0%	400	1.2%	345	1.1%
Austria	330	0.9%	302	0.9%	283	0.9%
South Korea	320	0.9%	257	0.7%	304	1.0%
Thailand	318	0.9%	272	0.8%	241	0.8%
Saudi Arabia	318	0.9%	286	0.8%	182	0.6%

## Welcome to Getinge

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

## Financial statements

## Other information

The Getinge share

→ Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# The ten largest markets by business area

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Other information

The Getinge share

→ Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

ACUTE CARE THERAPIES	2025			2024			2023		
	SEK M	%	#	SEK M	%	#	SEK M	%	#
USA	8,962	48.0%	1	8,377	46.7%	1	7,517	45.5%	1
China	1,981	10.6%	2	2,040	11.4%	2	1,830	11.1%	2
Germany	856	4.6%	3	848	4.7%	3	797	4.8%	3
Italy	545	2.9%	4	525	2.9%	5	534	3.2%	5
Japan	534	2.9%	5	541	3.0%	4	578	3.5%	4
France	495	2.6%	6	485	2.7%	6	467	2.8%	6
Canada	494	2.6%	7	454	2.5%	7	421	2.5%	7
Spain	402	2.2%	8	396	2.2%	8	393	2.4%	8
India	375	2.0%	9	372	2.1%	9	314	1.9%	10
United Kingdom	336	1.8%	10	364	2.0%	10	317	1.9%	9

LIFE SCIENCE	2025			2024			2023		
	SEK M	%	#	SEK M	%	#	SEK M	%	#
USA	1,557	34.6%	1	1,738	38.2%	1	1,470	34.0%	1
Germany	422	9.4%	2	290	6.4%	3	291	6.7%	4
France	419	9.3%	3	517	11.3%	2	455	10.5%	2
United Kingdom	260	5.8%	4	275	6.0%	4	219	5.1%	5
China	232	5.2%	5	210	4.6%	5	408	9.4%	3
Italy	199	4.4%	6	115	2.5%	9	96	2.2%	11
Japan	155	3.5%	7	114	2.5%	10	94	2.2%	12
Switzerland	146	3.3%	8	93	2.0%	12	110	2.5%	10
Belgium	133	3.0%	9	129	2.8%	8	125	2.9%	8
Denmark	133	2.9%	10	172	3.8%	6	121	2.8%	9

SURGICAL WORKFLOWS	2025			2024			2023		
	SEK M	%	#	SEK M	%	#	SEK M	%	#
USA	3,639	30.9%	1	3,813	31.1%	1	2,710	24.7%	1
Germany	789	6.7%	2	765	6.2%	2	771	7.0%	2
France	599	5.1%	3	609	5.0%	3	561	5.1%	6
United Kingdom	547	4.6%	4	538	4.4%	6	563	5.1%	5
Japan	509	4.3%	5	552	4.5%	5	569	5.2%	4
China	495	4.2%	6	594	4.8%	4	599	5.5%	3
Australia	437	3.7%	7	456	3.7%	7	388	3.5%	8
Sweden	403	3.4%	8	414	3.4%	8	429	3.9%	7
Italy	361	3.1%	9	401	3.3%	9	350	3.2%	9
Spain	264	2.2%	10	351	2.9%	10	325	3.0%	10

# Acquisition history

Year	Company	Business	Country	Sales
2024	Paragonix Technologies, Inc.	Organ transport products and services	US	SEK 826 M
2024	Technology and intellectual property rights from Intact Solutions LLC	Technology aseptic processing, bioprocessing	US	– –
2023	Healthmark Industries Co. Inc.	Provider of innovative instrument care and infection control consumables	US	SEK 1,321 M
2023	High Purity New England Inc.	Company in the areas of custom single-use solutions for bioprocessing applications	US	SEK 389 M
2023	Ultra Clean Systems Inc.	Manufacturer of ultrasonic cleaning technologies used in hospitals and surgery centers to decontaminate surgical instruments	US	SEK 90 M
2022	Fluoptics SAS	Leader in fluorescence imaging	FR	SEK 45 M
2022	Irasun GmbH	Develops products for venous drainage and temperature control	DE	– –
2021	Talis Clinical LLC	High Acuity cloud-based software solutions	US	SEK 57 M
2021	Development assets from Verrix	Biological indicators	US	– –
2020	Applikon Biotechnology BV	Life Science bioreactor systems	NL	SEK 350 M
2020	Quadralene Holdings Ltd	Disinfection	GB	SEK 75 M
2017	Carus HMS GmbH	Integrated workflow solutions	DE	SEK 20 M
2017	Simm Company and Surgeon Aids	Distributor	TH	SEK 75 M
2016	AccuMed	Production facility for medical textiles	DR	SEK 100 M
2016	1st Call Mobility Ltd	Medical-device solutions for bariatric patients	GB	SEK 100 M
2015	GOA Teknoloji Danismanlik Elektronik	Low temperature sterilization technology	TR	SEK 20 M
2014	Pulsion AG	Systems for hemodynamic monitoring	DE	SEK 300 M
2014	Altrax Group Ltd	Systems for traceability and quality assurance for sterilization	GB	SEK 35 M
2014	Cetrea A/S	Systems for resource planning	DK	SEK 30 M
2014	Austmel Pty Ltd	Sterilization and thermal processes	AU	SEK 80 M
2013	LAAx Inc.	Cardiac and vascular surgery	US	SEK 8 M
2013	Trans Medikal Devices Inc.	Manufacture of sterilizers and distribution of disinfectors	TR	SEK 55 M
2013	STS East LLC	Service	US	SEK 25 M
2012	Product rights from Avalon Laboratories	Cardiopulmonary	US	– –
2012	Eirus Medical	Critical Care	SE	– –
2012	Acare Medical Science Ltd	Healthcare beds	CH	SEK 135 M
2012	USCI	Distributor	JP	SEK 150 M
2012	Tecno Hospitalia	Distributor	CO	SEK 4 M
2012	Therapeutic Support Systems (TSS)	Wound care	US	SEK 1,600 M
2012	Steritec Products Mfg Inc.	Consumables	US	SEK 70 M
2011	Blanchet Medical Service	Service	FR	SEK 3 M
2011	Atrium Medical Inc	Products for the cardiovascular market	US	USD 200 M
2011	Combimobil AB	Rehabilitation aids	SE	SEK 2 M
2011	Fumedica	Distributor	CH	SEK 70 M
2011	IDS Medical Equipment	Distributor	SG	SEK 25 M
2011	Mak Saglik	Distributor	TR	SEK 20 M
2011	STS Holding West	Service	US	SEK 20 M
2010	Odelga	Service	AT	SEK 25 M
2008	Datascope	Cardiac assist and vascular surgery	US	USD 231 M
2008	Cardio Research Pty Ltd.	Distributor	AU	AUD 5.1 M
2008	Subtil Crepieux	Service	FR	EUR 8 M
2008	Getus Services Ltd	Service	NZ	NZD 1.1 M
2008	Olmed AB	Distributor	SE	SEK 70 M

Year	Company	Business	Country	Sales
2008	Boston Scientific's Cardiac and Vascular surgery divisions	Endoscopic vessel harvesting (EVH), anastomosis, stabilizers and instruments for surgery on beating hearts and vascular implants	US	SEK 1,733 M
2007	NS Nielsen Equipment A/S	Distributor	DK	– –
2006	Huntleigh Technology	Special mattresses for pressure-ulcer treatment, beds for intensive, specialist and elderly care vein thrombosis prophylaxis and equipment for fetal and vascular diagnostics.	UK	SEK 2,675 M
2006	Comercio E Industria Medicia	Consumables for open-heart surgery	BR	SEK 25 M
2006	OTY GmbH	Telemedicine specializing in products and solutions for hospitals' IT infrastructure focused on the operating room.	DE	SEK 20 M
2006	Getinge Czech Republic	Distributor	CZ	SEK 10 M
2005	Lancer UK	Distributor	UK	SEK 104 M
2005	La Cahléne	Isolator technology and electron sterilization technology	FR	EUR 40 M
2004	Dynamed	Distributor	CA	SEK 85 M
2004	BHM Medical Inc.	Patient management products for the care and elderly care segments	CA	SEK 206 M
2003	MAQUET AG	Distributor	CH	CHF 4.9 M
2003	Siemens LSS	Ventilators and anesthesia equipment for the hospital market	SE	EUR 230 M
2003	Jostra GmbH	Equipment and consumables for cardiac surgery	DE	EUR 90 M
2003	Copharm B.V.	Distributor	NL	EUR 10 M
2002	Heraeus Medical	Surgical lamps, ceiling service units and therapy accessories and gas distribution for operating rooms	DE	EUR 52 M
2001	ALM	Surgical lamps	FR	FRF 490 M
2000	Maquet	Surgical tables	DE	EUR 155 M
2000	Parker Bath	Bathing systems for the semi-institutional care market	UK	SEK 150 M
2000	Lenken Healthcare	Distributor	IE	SEK 65 M
2000	Gestion Techno-Medic	Patient lifting systems	CA	SEK 22 M
1999	Lunatronics Aps	Comprehensive IT solutions for the maintenance of sterilization departments	DK	DKK 15 M
1999	MPT Corp.	Washer disinfectors for the life science market	US	SEK 35 M
1998	Egerton Hospital Equipment	Specialist beds and anti-decubitus mattresses for hospitals and care facilities	UK	SEK 45 M
1998	Royal Linden B.V.	Infection control	NL	SEK 60 M
1998	Medibo	Patient lifting and pressure-ulcer treatments	BE	SEK 28 M
1998	OMASA	Infection control	IT	SEK 100 M
1998	SMI/BBC	Infection control	FR	SEK 75 M
1998	Kemitem	Water distillers pure-steam generators for pharmaceutical industry	DK	DKK 25 M
1998	Pegasus	Anti-decubitus products for hospitals and elderly care	UK	SEK 350 M
1996	MDT/Castle	Infection control	US	– –
1996	Van Dijk Medizintechnik GmbH	Infection control	DE	SEK 30 M
1995	Arjo	Products for aging care related to hygiene and patient management	SE	SEK 1,538 M
1994	Lancer	Disinfection products	FR	FRF 70 M

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Other information

The Getinge share

Multi-year overview

→ Acquisition history

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# Reconciliation of alternative performance measures

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

The Getinge share

Multi-year overview

Acquisition history

→ Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. The alternative performance measures are not to be considered a substitute for, but rather a supplement to, the financial statements prepared in accordance with IFRS.

The alternative performance measures recognized are not calculated in accordance with IFRS but are provided since Getinge believes that they are important to investors' assessments of the Group and the Getinge share. These performance measures are widely used by investors, securities analysts and other stakeholders as supplementary measures of the earnings trend and financial position. Getinge's performance measures that are not defined in accordance with IFRS are not necessary comparable with similar measures presented by other companies and have certain limitations as analysis tools.

**THE GROUP'S PRIMARY PERFORMANCE MEASURES**

Calculation of organic net sales, SEK M	2025	2024
<b>Net sales</b>	<b>34,969</b>	<b>34,759</b>
<i>Add-back of:</i>		
Currency translation	2,216	423
Acquired operations	-735	-1,794
<b>Net sales, organic</b>	<b>36,451</b>	<b>33,387</b>

Adjusted gross profit, SEK M	2025	2024
<b>Gross profit</b>	<b>16,654</b>	<b>16,153</b>
<i>Add-back of:</i>		
Depreciation, amortization and write-downs of tangible and non-acquired intangible assets	953	960
Other items affecting comparability	-	297
Adjustment for write-downs included in other items affecting comparability	-	-
<b>Adjusted gross profit</b>	<b>17,607</b>	<b>17,409</b>

Adjusted EBITDA, SEK M	2025	2024
<b>Operating profit/loss (EBIT)</b>	<b>3,789</b>	<b>2,854</b>
<i>Add-back of:</i>		
Depreciation, amortization and write-downs of tangible and non-acquired intangible assets	1,864	1,823
Amortization and write-down of acquired intangible assets	386	320
Other items affecting comparability	307	797
Acquisition and restructuring costs	397	898
Adjustment for write-downs included in other items affecting comparability and restructuring costs	-162	-46
<b>Adjusted EBITDA</b>	<b>6,581</b>	<b>6,646</b>

EBITA, SEK M	2025	2024
<b>Operating profit/loss (EBIT)</b>	<b>3,789</b>	<b>2,854</b>
<i>Add-back of:</i>		
Amortization and write-down of acquired intangible assets	386	320
<b>EBITA</b>	<b>4,175</b>	<b>3,174</b>

Adjusted EBITA, SEK M	2025	2024
<b>Operating profit/loss (EBIT)</b>	<b>3,789</b>	<b>2,854</b>
<i>Add-back of:</i>		
Amortization and write-down of acquired intangible assets	386	320
Other items affecting comparability	307	797
Acquisition and restructuring costs	397	898
<b>Adjusted EBITA</b>	<b>4,880</b>	<b>4,869</b>

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Other information

The Getinge share

Multi-year overview

Acquisition history

→ Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

Adjusted EBIT, SEK M	2025	2024
<b>Operating profit/loss (EBIT)</b>	<b>3,789</b>	<b>2,854</b>
<i>Add-back of:</i>		
Other items affecting comparability	307	797
Acquisition and restructuring costs	397	898
<b>Adjusted EBIT</b>	<b>4,494</b>	<b>4,549</b>

Adjusted net profit for the year, SEK M	2025	2024
<b>Net profit for the year</b>	<b>2,276</b>	<b>1,654</b>
<i>Add-back of:</i>		
Amortization and write-down of acquired intangible assets	386	320
Other items affecting comparability	307	797
Acquisition and restructuring costs	397	898
Tax items affecting comparability	-	-
Tax on add-back items	-273	-459
<b>Adjusted net profit for the year</b>	<b>3,093</b>	<b>3,211</b>

The calculation of adjusted earnings per share, before and after dilution, attributable to the Parent Company's shareholders, is based on the following information:

Earnings (numerator), SEK M	2025	2024
<b>Adjusted net profit for the year</b>	<b>3,093</b>	<b>3,211</b>
Adjusted net profit for the year attributable to non-controlling interest	-17	-16
<b>Adjusted net profit for the year attributable to the Parent Company shareholders, which form the basis for calculation of adjusted earnings per share</b>	<b>3,076</b>	<b>3,195</b>
<b>Number of shares (denominator)</b>		
Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands)	272,370	272,370
<b>Adjusted earnings per share, SEK</b>	<b>11.29</b>	<b>11.73</b>

Net debt/equity ratio, multiple	2025	2024
Net interest-bearing debt, SEK M	9,840	10,467
Equity, SEK M	29,494	33,210
<b>Net debt/equity ratio<sup>1)</sup></b>	<b>0.33</b>	<b>0.32</b>

1) Net interest-bearing debt in relation to equity.

**Adjusted EBITA per segment**

	Acute Care Therapies	Life Science	Surgical Workflows	Group functions and other	Total
<b>Adjusted EBITA, 2025, SEK M</b>					
<b>Operating profit (EBIT)</b>	<b>3,021</b>	<b>470</b>	<b>773</b>	<b>-474</b>	<b>3,789</b>
<i>Add back of:</i>					
Amortization and write-down of acquired intangible assets	243	53	90	–	386
Other items affecting comparability	207	-55	155	–	307
Acquisition and restructuring costs	293	22	59	24	397
<b>Adjusted EBITA</b>	<b>3,763</b>	<b>490</b>	<b>1,077</b>	<b>-450</b>	<b>4,880</b>

	Acute Care Therapies	Life Science	Surgical Workflows	Group functions and other	Total
<b>Adjusted EBITA, 2024, SEK M</b>					
<b>Operating profit (EBIT)</b>	<b>2,065</b>	<b>526</b>	<b>703</b>	<b>-440</b>	<b>2,854</b>
<i>Add back of:</i>					
Amortization and write-down of acquired intangible assets	170	46	104	–	320
Other items affecting comparability	604	–	193	–	797
Acquisition and restructuring costs	715	35	91	57	898
<b>Adjusted EBITA</b>	<b>3,554</b>	<b>608</b>	<b>1,090</b>	<b>-383</b>	<b>4,869</b>

	Acute Care Therapies	Life Science	Surgical Workflows	Group functions and other	Total
<b>Other items affecting comparability, 2025, SEK M</b>					
Write-down of R&D, Acute Care Therapies	28	–	–	–	28
Write-down of R&D, Surgical Workflows	–	–	107	–	107
Increased provision for contingent consideration, Acute Care Therapies	179	–	–	–	179
Dissolution of provision for contingent consideration, Life Science	–	-55	–	–	-55
Write-down of acquired intangible assets, Surgical Workflows	–	–	48	–	48
<b>Total</b>	<b>207</b>	<b>-55</b>	<b>155</b>	<b>–</b>	<b>307</b>

	Acute Care Therapies	Life Science	Surgical Workflows	Group functions and other	Total
<b>Other items affecting comparability, 2024, SEK M</b>					
Provision for investigations with CGU in Brazil, Acute Care Therapies	289	–	–	–	289
Provision for investigations with CGU in Brazil, Surgical Workflows	–	–	193	–	193
Provision for field actions for Cardiosave, Acute Care Therapies	297	–	–	–	297
Other	18	–	–	–	18
<b>Total</b>	<b>604</b>	<b>–</b>	<b>193</b>	<b>–</b>	<b>797</b>

Welcome to Getinge

Market environment

Strategy

Business areas

The Board's Operating Reports

Financial statements

Other information

The Getinge share

Multi-year overview

Acquisition history

→ Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

# Group companies

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

The Getinge share

Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

→ Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

**HEAD OFFICE**

**GETINGE AB (PUBL)**

Lindholmospiren 7A  
SE-417 56 Göteborg  
Tel: +46 10 335 0000  
President: Mattias Perjos

**AUSTRALIA**

**Getinge Australia Pty Ltd**

Suite 701, Level 7, 11 Help St  
AU-Chatswood, NSW 2067  
Tel: +61 18 0043 8464  
President: Kartik Natarajan

**AUSTRIA**

**Getinge Österreich GmbH**

Lemböckgasse 49 Haus 2, Stiege E, EG  
AT-1230 Wien  
Tel: +43 1 8651 4870  
President: Raghed Hanna

**BELGIUM**

**Getinge Belgium NV**

Alfons Gossetlaan 17  
BE-1702 Groot-Bijgaarden  
Tel: +32 24 67 8585  
President: Raghed Hanna

**BRAZIL**

**Getinge do Brasil Equipamentos Médicos Ltda**

Avenida Manuel Bandeira, 291 – Bloco B –  
Conjunto 33 e 34  
BR-05317-020 São Paulo  
Tel: +55 11 2608 7400  
President: Aurélio Carmona

**CANADA**

**Getinge Canada Ltd**

90 Matheson Blvd W, Suite 300  
CA-L5R 3R3, Mississauga, ON  
Tel: +1 905 752 3300  
President: Patricia Fitch

**CHINA**

**Maquet (Shanghai) Medical Equipment Co., Ltd**

20F, Building 1, 188 Ruby Road, Changning District  
CN-201 103 Shanghai  
Tel: +86 21 6197 3999  
President: Echo Mao

**Maquet (Suzhou) Co., Ltd**

No 158 Fangzhou Road, SIP  
CN-215 024 Suzhou  
Tel: +86 512 6283 9880  
President: Shukun Liu

**COLOMBIA**

**Getinge Colombia SAS**

Carrera 16 # 95 70  
CO-110221 Bogotá, D.C.  
Tel: +571 743 8124  
President: Rodrigo Aurelio García

**CZECH REPUBLIC**

**Getinge Czech Republic, s.r.o.**

Na Strzi 1702/65  
CZ-140 00 Praha 4-Nusle  
Tel: +420 225 092 302  
President: Jiri Lacina

**DENMARK**

**Getinge Cetrea A/S**

Brendstrupgårdsvej 21 F  
DK-8200 Aarhus N  
Tel: +45 26 397 990  
President: Charlotte Enlund

**Getinge Danmark A/S**

Tonsbakken 16-18  
DK-2740 Skovlunde  
Tel: +45 45 932 727  
President: Magnus Back

**Getinge IT Solutions ApS**

Dampfærgevej 21, 2.  
DK-2100 Copenhagen  
Tel: +45 33 338 855  
President: Charlotte Enlund

**FINLAND**

**Maquet Finland Oy**

Vuoritontuntie 22  
FI-02200 Espoo  
Tel: +358 9 6824 120  
President: Magnus Back

**FRANCE**

**Fluoptics SAS**

44 Rue des Berges  
FR-38000 Grenoble  
Tel: +33 485 870 660  
President: Olivier Pacaud

**Getinge France SAS**

Carnot Plaza, 14/16 avenue Carnot  
FR-91300 Massy  
Tel: +33 238 258 888  
President: Sylvain Touron

**Getinge Infection Control SAS**

30 Boulevard De L'Industrie  
FR-31170 Tournefeuille  
Tel: +33 561 151 111  
President: Sébastien Blanche

**Getinge Life Science France SAS**

1 Rue Comte Donegal  
FR-41100 Vendôme  
Tel: +33 561 151 111  
President: Michael Raphael & Patrick Boivin

**Intervascular SAS**

270 Voie Ariane - ZI Athélie 1  
FR-13600 La Ciotat  
Tel: +33 442 084 646  
President: Jocelyn Lebrun

**LTA Medical**

27 rue Albert Einstein  
FR- 93 000 Bobigny  
Tel: +33 766 152 048  
President: Jérôme Polenne

**Maquet SAS**

Parc de Limère – Avenue de la Pomme de Pin  
FR-45074 Orléans  
Tel: +33 238 258 888  
President: Jérôme Baron

**GERMANY**

**Getinge Deutschland GmbH**

Kehler Straße 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Raghed Hanna

**Getinge Holding B.V. & Co KG**

Kehler Straße 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Matthias Gelsok

**Getinge IT Solutions GmbH**

Südportal 5  
DE-22848 Norderstedt  
Tel: +49 4051 435 0  
President: Dr. Matthias Rath

**Irasun GmbH**

Lichtenbergstraße 8  
DE-85748 Garching bei München  
Tel: +49 1764 3666 346  
President: Florian Altinger & Fabian König

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

The Getinge share

Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

→ Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

**Maquet Cardiopulmonary GmbH**

Kehler Straße 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Dr. Dieter Engel

**Maquet GmbH**

Kehler Straße 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Sebastian Hügli

**MediKomp GmbH**

Kehler Straße 31  
DE-76437 Rastatt  
Tel: +49 7222 932 0  
President: Özgür Yildiz

**Pulsion Medical Systems SE**

Hans-Riedl-straße 21  
DE-85622 Feldkirchen  
Tel: +49 8945 991 40  
President: Stephan Haft

**HONG KONG**

**Getinge Group Hong Kong Ltd**

26/F, Port 33, 33 Tseuk Luk Street, San Po Kong, Kowloon  
HK Hong Kong  
Tel: +852 2207 6111  
President: CM Leung

**INDIA**

**Getinge India Pvt Ltd**

9th Floor, E Wing, Times Square, Mathurdas VasANJI Road, Marol Village IN-400 059 Mumbai  
Tel: +91-7400094775  
President: Sunil Joshi

**Getinge Medical India Pvt Ltd**

9th Floor, E Wing, Time Square, Mathurdas VasANJI Road, Marol Village IN-400059 Mumbai  
Tel: +91 22 6233 2100  
President: Aruna Nayak

**IRELAND**

**Getinge Ireland Ltd.**

B6 Calmount Park, Ballymount, Dublin 12  
IE-D12NA03 Dublin  
Tel: +353 1 426 0032  
President: Amy Rothwell

**ITALY**

**Getinge Italia Srl**

Via Guido Gozzando, 14  
IT-20092 Cinisello Balsamo (MI)  
Tel: +39 02 611 135 1  
President: Roberto Chareun

**JAPAN**

**Getinge Group Japan KK**

Sphere Tower Tennoz 7F, 2-2-8 Higashi-shinagawa, Shinagawa-ku  
JP-140-0002 Tokyo  
Tel: +81 3 5463 8310  
President: Yuko Nagasawa

**MEXICO**

**Maquet Mexicana, S. de R.L. de C.V.**

Montecito 38, piso 10 ofna 33, Col Nápoles, Alcaldía Benito Juárez  
MX-03810 Mexico City  
Tel: +52 55 9000 8970  
President: Rodrigo Aurelio García

**NETHERLANDS**

**Applikon Biotechnology B.V.**

Heertjeslaan 2  
NL-2629 JG Delft  
Tel: +31 10 208 3555  
President: Eric Goossens

**Getinge Netherlands B.V.**

Olympia 4  
NL-1213 NT Hilversum  
Tel: +31 35 303 5000  
President: Raghed Hanna

**NEW ZEALAND**

**Maquet New Zealand Pty Ltd (Branch)**

Level 2, Building B, 600 Great South Road  
NZ-Auckland 1051  
Tel: +61 1800 438 464  
President: Kartik Natarajan

**NORWAY**

**Getinge Norge AS**

Enebakkveien 150  
NO-0680 Oslo  
Tel: +47 230 35 200  
President: Magnus Back

**POLAND**

**Getinge IC Production Poland Sp. z o.o.**

ul. Szkolna 30  
PL-62-064 Plewiska  
Tel: +48 61 630 99 00  
President: Jakub Cegięła

**Getinge Polska Sp. z o.o.**

ul. Żwirki i Wigury 18  
PL-02-092 Warszawa  
Tel: +48 22 882 06 44  
President: Szymon Kawałko

**Getinge Shared Service Sp. z o.o.**

Powstańców Wielkopolskich 13 F ( Budynek D)  
PL-30-707 Kraków  
Tel: +48 12 385 42 22  
President: Agnieszka Obuchowska

**PORTUGAL**

**Getinge Group Portugal Unipessoal Lda**

Edifício Zenith, Rua Dr. Antonio Loureiro Borges nº 9/9ª - 3º andar  
PT-1495-131 Alges Miraflores  
Tel: +351 214 189 815  
President: Marcio Mazon

**RUSSIA**

**Maquet LLC**

Office Park Comcity, 22nd km Kievskoe highway, 6, bld.1  
RU-108811 Moscow  
Tel: +7 495 514 0055  
President: Anna Mednikova

**SAUDI ARABIA**

**Getinge Regional Headquarter**

Building No: 7793, West Umm Al Hamam District SA 12329, Riyadh  
Tel: +966 563 333 417  
President: Georges El Obeid

**SERBIA**

**Getinge Group South East Europe d.o.o. Beograd**

Bulevar Vojvode Bojovica 6-8  
RS-11000 Belgrade  
Tel: +420 225 092 302  
President: Jiri Lacina

**SINGAPORE**

**Getinge Singapore Pte. Ltd.**

20 Bendemeer Rd #06-02 BS Bendemeer Centre  
SG-339914 Singapore  
Tel: +65 6 296 1992  
President: Marimuthu Anbuhezian

**Getinge South East Asia Pte. Ltd.**

20 Bendemeer Rd #06-01/02 BS Bendemeer Centre  
SG-339914 Singapore  
Tel: +65 6 296 1992  
President: Teodor Johansson

**SOUTH KOREA**

**Getinge Medical Korea Co., Ltd.**

13F KeumKang Building, 304, Bongeunsa-ro, Gangnam-gu  
KR-06143 Seoul  
Tel: +82 25 58 2271  
President: Hyun Dong Kim

**SPAIN**

**Getinge Group Spain SL**

C/Marie Curie 5, edificio Alfa Planta 6 Of 6.2  
ES-28521 Rivas Vacia Madrid  
Tel: +34 91 678 1652  
President: Marcio Mazon

**SWEDEN**

**Getinge AB**

Lindholmspiren 7A  
SE-417 56 Göteborg  
Tel: +46 10 335 0000  
President: Mattias Perjos

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

The Getinge share

Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

→ Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

**Getinge Business Support Services AB**

Lindholmospiren 7 A  
SE-417 56 Göteborg  
Tel: +46 10 335 0000  
President: Pelle Nilsson

**Getinge Disinfection AB**

Ljungadalsgatan 11  
SE-352 46 Växjö  
Tel: +46 10 335 9800  
President: Jacek Hupalo

**Getinge Logistics AB**

Ekebergsvägen 26  
SE-305 75 Getinge  
Tel: +46 10 335 0000  
President: Christian Svensson Lambrant

**Getinge Sterilization AB**

Ekebergsvägen 26  
SE-305 75 Getinge  
Tel: +46 10 335 0000  
President: Maria Ek

**Getinge Sverige AB**

Ekebergsvägen 26  
SE-305 75 Getinge  
Tel: +46 10 335 0000  
President: Magnus Back

**Getinge Treasury AB**

Lindholmospiren 7A  
SE-417 56 Göteborg  
Tel: +46 10 335 0000  
President: Mimmi Lykken Ljungdahl

**Maquet Critical Care AB**

Röntgenvägen 2  
SE-171 54 Solna  
Tel: +46 10 335 7300  
President: Cecilia Sjöstedt

**SWITZERLAND**

**Getinge Schweiz AG**  
Quellenstraße 41b  
CH-4310 Rheinfelden  
Tel: +41 61 836 47 70  
President: Raghed Hanna

**TAIWAN**

**Getinge Group Taiwan Co., Ltd.**  
Rm. 08, 6F., No. 288, Sec. 6, Civic Blvd., Xinyi Dist.  
TW- 110417 Taipei City  
Tel: +886 2 8161 6588  
President: Tina Wang

**THAILAND**

**Getinge (Thailand) Co., Ltd.**  
5 Soi Krungthepkreetha 4 (B.Grimm) Huamark,  
Bangkapi  
TH-10240 Bangkok  
Tel: +66 02 704 4388  
President: Kulissara Tunyong

**TURKEY**

**Getinge Medikal Sistemler San. Ve Tic. A.Ş.**  
Allianz Plaza Küçükbakkalköy Mah. Kayışdağı Cad.  
No:1 Kapı no:96  
TR-34752 Ataşehir / Istanbul  
Tel: +90 216 444 66 78  
President: Vecihe Özek

**Maquet Cardiopulmonary Medikal Teknik San.Tic.Ltd.Şti**

Serbest Bölge R Ada,108/1,109/1,110/1,111/1  
Parseller 1 Cadde Dış Kapı No:8  
TR-07070 Antalya  
Tel: +90 242 249 90 30  
President: Murat Calik

**UNITED ARAB EMIRATES**

**Getinge Group Middle East FZ-LLC**  
19th Floor, Units 1905–1909, (DSP) Towers-North,  
Dubai Science Park  
AE-214742 Dubai  
Tel: +971 4 447 0963  
President: Salah Malek

**UNITED KINGDOM**

**Getinge Ltd**  
Unit 3 Indurent Park, Andresseway Way  
DE61 6YH Derby  
Tel: +44 1773 814730  
President: Amy Rothwell

**Quadralene Ltd**

Unit 3, Indurent Park, Andresseway Way  
GB-DE21 6YH Derby  
Tel: +44 1332 292500  
President: Ross Tustain

**US**

**Atrium Medical Corporation**  
40 Continental Blvd.  
US-03054, Merrimack, NH  
Tel: +1 603 880 1433  
President: Chad Carlton

**Datascope Corp.**

45 Barbour Pond Drive  
US-07470 Wayne, NJ  
Tel: +1 888 627 8383  
President: Gerald Zukowski

**Getinge Aseptic Solutions, LLC**

201 Housatonic Avenue  
06776 Milford CT  
Tel: +1 860 350 1900  
President: Benoit Portier

**Getinge Group Logistics Americas, LLC**

45 Barbour Pond Drive  
US-07470 Wayne, NJ  
Tel: +1 551 427 1052  
President: Jennifer Bone

**Getinge USA Sales, LLC**

45 Barbour Pond Rd  
US-07470 Wayne, NJ  
Tel: +1 973 709 7000  
President: Patricia Fitch

**Healthmark Industries Co., Inc.**

18600 Maylyn Blvd.  
48026-3496 Fraser, MI  
Tel: +1 800 521 6224  
President: Daniel Basile

**High Purity New England Inc.,**

2 Thurber Blvd.  
02917 Smithfield, RI  
Tel: +1 401 349 4477  
President: Sean Herdlein

**Maquet Cardiovascular LLC**

45 Barbour Pond Drive  
US-07470 Wayne, NJ  
Tel: +1 973 709 7000  
President: Cynthia Hougum

**Paragonix Technologies, Inc.**

950 Winter Street, 2nd Floor  
US-02451 Waltham, MA  
Tel: +1 781 428 4153  
President: Lisa Anderson

**Steritec Products Mfg. Co., Inc.**

74 Inverness Drive East  
US-80112 Englewood, CO  
Tel: +1 303 660 4201  
President: Bryan Leo

**Talis Clinical LLC**

650 Mondial Parkway  
US-44241 Streetsboro, OH  
Tel: +1 234 284 2400  
President: Gary Colister

**Ultra Clean Systems Inc.**

110 Douglas Road East  
US-34677 Oldsmar, FL  
Tel: +1 727 512 9576  
President: Christopher Devlin

**VIETNAM**

**Getinge Vietnam Company Ltd**

Floor 6, Yoco Building, 41 Nguyen Thi Minh Khai,  
Saigon Ward, District 1  
VN-Ho Chi Minh City  
Tel: +84 28 3824 3391  
President: Teodor Johansson

# Definitions

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

The Getinge share

Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

Group companies

→ Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

**FINANCIAL TERMS**

**Adjusted earnings per share:** Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

**Adjusted EBIT:** Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.

**Adjusted EBITA:** EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

**Adjusted EBITDA:** EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

**Adjusted gross profit:** Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

**Adjusted net profit for the period:** Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income statement items.

**Adjusted profit before tax:** Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

**Capital employed:** Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

**Capital goods:** Durable products that are not consumed when used.

**Cash flow per share:** Cash flow from operating activities divided by the average number of outstanding shares.

**Currency transaction effect:** Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

**Dividend yield:** Dividend in relation to the market share price on December 31.

**Earnings per share:** Net profit attributable to Parent Company shareholders in relation to average number of shares.

**EBIT:** Operating profit.

**EBITA margin:** EBITA in relation to net sales.

**EBITA:** Operating profit (EBIT) before add-back of amortization and write-down of acquired intangible assets.

**EBITDA margin:** EBITDA in relation to net sales.

**EBITDA:** Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.

**Equity per share:** Equity in relation to the number of shares at the end of the period.

**Equity/assets ratio:** Equity in relation to total assets.

**Free cash flow:** Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.

**Gross margin:** Gross profit in relation to net sales.

**Interest-coverage ratio:** Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.

**Items affecting comparability:** Acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

**Net debt/equity ratio:** Net interest-bearing debt in relation to equity.

**Operating liabilities:** Accounts payable, other provisions and other non-interest-bearing liabilities (contract liabilities, non-interest-bearing provisions for pensions and similar obligations, accrued expenses and deferred income as well as other liabilities).

**Operating margin:** Operating profit (EBIT) in relation to net sales.

**Operating receivables:** Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables).

**Organic change:** A financial change adjusted for currency, acquisitions and divestments of operations.

**Adjusted to following from first quarter of 2026:** A financial change adjusted for currency, acquisitions and divestments of operations and phase-out of product categories.

**P/E ratio:** Share price (final price) in relation to earnings per share.

**Recurring revenue:** Revenue from sales of products that are continuously consumed as well as service, spare parts and similar items.

**Return on capital employed:** Rolling 12 months' adjusted EBIT in relation to capital employed.

**Return on equity:** Rolling 12 months' profit after tax in relation to average equity.

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

The Getinge share

Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

Group companies

→ Definitions

Annual General Meeting and Nomination Committee

Financial information

Reading guide and distribution policy

Contact

**SUSTAINABILITY TERMS**

**Double materiality assessment:** The process of identifying an organization's impacts on people and the environment and the sustainability-related financial risks and opportunities for the organization. The results are also used to determine whether a sustainability topic is to be included in the company's sustainability statement.

**Employee engagement:** The engagement score in Getinge's employee survey.

**ESRS:** European Sustainability Reporting Standards.

**Online customer training:** The number of training courses held for customers. The total number of times a customer has completed an e-learning course or participated in a training webinar.

**I-REC (International Renewable Energy Certificates):** Used to certify that electricity was generated from renewable sources.

**Scope 1 & 2:** Carbon emissions from production (in ton CO<sub>2</sub> equivalents). Scope 1 includes emissions from oil and gas consumption. Emissions from Getinge's vehicle fleet are excluded in the interim report but the amounts for the full-year are presented in the Sustainability statement. Scope 2 includes emissions from electricity, heating and cooling. Emissions from leased premises are excluded in the interim report but the amounts for the full-year are presented in the Sustainability statement.

**Scope 3:** Includes other indirect emissions, both upstream and downstream in the value chain, arising from activities such as freight transport, purchased goods and services, as well as emissions from the use of products sold.

**WRAR (Work Related Accident Rate):** The number of work related accidents divided by the number of hours worked, normalized by multiplying by 200,000 hours or 1,000,000 hours, respectively.

**MEDICAL TERMS**

**Cardiopulmonary:** Pertaining or belonging to both heart and lung.

**Cardiovascular:** Pertaining or belonging to both heart and blood vessels.

**DPTE®-BetaBag:** Bag that ensures contamination-free transfer of components.

**ECMO:** Extracorporeal membrane oxygenation (ECMO), meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.

**Endoscope:** Equipment for visual examination of the body's cavities, such as the stomach.

**Endovascular:** Vascular treatment using catheter technologies.

**EVH:** Endoscopic Vessel Harvesting is a minimally invasive technique for removing blood vessels, for example during coronary artery bypass surgery.

**Extracorporeal life support (ECLS):** Oxygenation of the patient's blood outside the body (extracorporeal) using advanced medical technology.

**Grafts:** Artificial vascular implants.

**Hemodynamic monitoring:** Monitoring the balance between blood pressure and blood flow.

**Low-temperature sterilization:** A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery.

**NAVA:** Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that activates the diaphragm and using these signals adapts the ventilation to the patient's respiratory rhythm.

**Perfusionist:** A healthcare professional who operates the heart-lung machine during surgery.

**Stent:** A tube for endovascular widening of blood vessels.

**Sterilizer:** A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

**Vascular intervention:** A medical procedure conducted through vascular puncturing instead of using an open surgery method.

**Ventilator:** Medical device to help patients breathe.

**Vessel harvesting:** The name of the process for removing blood vessels from the body.

**WIS:** The product category of washers, isolators and sterilizers.

**GEOGRAPHIC AREAS**

**Americas:** North, South and Central America.

**APAC:** Asia and Pacific (excluding Middle East).

**EMEA:** Europe, Middle East and Africa.

# Annual General Meeting and Nomination Committee

# Financial information

**Welcome to Getinge**

**Market environment**

**Strategy**

**Business areas**

**The Board's Operating Reports**

**Financial statements**

**Other information**

The Getinge share

Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

Group companies

Definitions

→ Annual General Meeting and Nomination Committee

→ Financial information

Reading guide and distribution policy

Contact

**Annual General Meeting**

The Annual General Meeting will be held on April 21, 2026, in Kongresshallen at Hotel Tylösand, Halmstad, Sweden. Detailed information about participation and postal voting is available on the company's website, <https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2026/>

**Registration**

Shareholders wishing to participate at the Annual General Meeting must:

- be recorded in the share register kept by Euroclear Sweden AB on April 13, 2026, and
- notify the company of their intention to participate not later than April 15, 2026

Shareholders who wish to participate in person may register in the following ways:

- On Getinge's website: [www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2026/](https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2026/)
- By post to:  
Getinge AB (publ) "AGM 2026"  
c/o Euroclear Sweden AB, PO Box 191,  
SE-101 23 Stockholm, Sweden
- By telephone: +46 (0) 10 335 08 18  
(weekdays between 9:00 a.m.–4:00 p.m.)

Shareholders who wish to participate in the Annual General Meeting by postal vote should cast their postal vote in accordance with instructions available on Getinge's website, <https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2026/>.

**Nominee-registered shares**

Shareholders whose shares are registered in the name of a nominee through a bank or other nominee must be entered in their own name in the share register maintained by Euroclear Sweden AB on April 13, 2026 in order to be entitled to participate in the AGM. Shareholder must inform the nominee well in advance of this date.

For shareholders represented by proxy, power of attorney must be issued, which should be sent before the AGM. A proxy form can be downloaded from <https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2026/>.

Anyone representing a legal entity must show a certified copy of the registration certificate or equivalent authorization documents stating the authorized signatory.

**Nomination Committee**

Getinge AB's interim report for the third quarter of 2025 contained instructions for shareholders on how to proceed to submit proposals to Getinge's Nomination Committee and how to propose motions to be addressed at the Annual General Meeting.

**Dividend**

The Board of Directors and CEO propose that a dividend of SEK 4.75 (4.60) per share, a combined total of SEK 1,294 M (1,253), shall be paid for 2025.

The proposed record date is April 23, 2026. Euroclear Sweden AB expects to distribute the dividend to shareholders on April 28, 2026.

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website [www.getinge.com](http://www.getinge.com).

The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at [www.getinge.com](http://www.getinge.com). A printed copy of the Annual Report can also be ordered at [www.getinge.com](http://www.getinge.com).

**Financial information**

Preliminary dates for financial information are as follows:

- April 21, 2026: Q1 Report 2026
- April 21, 2026: Annual General Meeting
- July 17, 2026: Q2 Report 2026
- October 20, 2026: Q3 Report 2026
- January 26, 2026: Q4 Report 2026
- March 2027: 2026 Annual Report

# Reading guide and distribution policy

# Contact

## Welcome to Getinge

## Market environment

## Strategy

## Business areas

## The Board's Operating Reports

## Financial statements

## Other information

The Getinge share

Multi-year overview

Acquisition history

Reconciliation of alternative performance measures

Group companies

Definitions

Annual General Meeting and Nomination Committee

Financial information

→ Reading guide and distribution policy

→ Contact

### Reading guide

- The Getinge Group is referred to as Getinge in the Annual Report.
- Figures in parentheses pertain to operations in 2024, unless otherwise specified.
- Swedish kronor (SEK) is used throughout (sometimes abbreviated as SEK or kr).
- Millions of Swedish kronor are abbreviated SEK M.
- All figures pertain to SEK M, unless otherwise specified.
- For practical reasons, numbers are rounded off in the Annual Report, therefore it can occur that notes and tables do not sum up.
- Information provided in the Annual Report concerning markets, competition and future growth constitutes Getinge's assessment based on both external information and material compiled internally.

### Distribution policy

The Annual Report is available for download at [www.getinge.com](http://www.getinge.com).

A printed version of the report can also be ordered from the website. The decision not to automatically send a printed version to the company's shareholders is based on the ambition to reduce Getinge's negative impact on the environment.

Getinge AB (publ)  
Lindholmospiren 7A  
P.O Box 8861  
SE-402 72, Gothenburg  
Sweden

Tel: +46 (0)10-335 00 00  
E-mail: [info@getinge.com](mailto:info@getinge.com)  
[www.getinge.com](http://www.getinge.com)



Getinge AB (publ)  
Lindholmspiren 7A  
P.O. Box 8861  
SE-402 72, Gothenburg  
Sweden

Tel: +46 (0)10 335 00 00  
E-mail: [info@getinge.com](mailto:info@getinge.com)  
[www.getinge.com](http://www.getinge.com)